
<html lang="en"     class="pb-page"  data-request-id="d99ea413-5a5d-4e71-9811-cbc533785645"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2018.61.issue-18;article:article:10.1021/acs.jmedchem.8b00838;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer" /></meta><meta name="dc.Creator" content="Benjamin&#xA;J.  Buckley" /></meta><meta name="dc.Creator" content="Ashraf  Aboelela" /></meta><meta name="dc.Creator" content="Elahe  Minaei" /></meta><meta name="dc.Creator" content="Longguang X.  Jiang" /></meta><meta name="dc.Creator" content="Zhihong  Xu" /></meta><meta name="dc.Creator" content="Umar  Ali" /></meta><meta name="dc.Creator" content="Karen  Fildes" /></meta><meta name="dc.Creator" content="Chen-Yi  Cheung" /></meta><meta name="dc.Creator" content="Simon M.  Cook" /></meta><meta name="dc.Creator" content="Darren C.  Johnson" /></meta><meta name="dc.Creator" content="Daniel A.  Bachovchin" /></meta><meta name="dc.Creator" content="Gregory M.  Cook" /></meta><meta name="dc.Creator" content="Minoti  Apte" /></meta><meta name="dc.Creator" content="Mingdong  Huang" /></meta><meta name="dc.Creator" content="Marie  Ranson" /></meta><meta name="dc.Creator" content="Michael J.  Kelso" /></meta><meta name="dc.Description" content="Metastasis is the cause of death in the majority (∼90%) of malignant cancers. The oral potassium-sparing diuretic amiloride and its 5-substituted derivative 5-N,N-(hexamethylene)amiloride (HMA) rep..." /></meta><meta name="Description" content="Metastasis is the cause of death in the majority (∼90%) of malignant cancers. The oral potassium-sparing diuretic amiloride and its 5-substituted derivative 5-N,N-(hexamethylene)amiloride (HMA) rep..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 21, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00838" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00838" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00838" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00838" /></link>
        
    
    

<title>6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00838" /></meta><meta property="og:title" content="6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0022.jpeg" /></meta><meta property="og:description" content="Metastasis is the cause of death in the majority (∼90%) of malignant cancers. The oral potassium-sparing diuretic amiloride and its 5-substituted derivative 5-N,N-(hexamethylene)amiloride (HMA) reportedly show robust antitumor/metastasis effects in multiple in vitro and animal models. These effects are likely due, at least in part, to inhibition of the urokinase plasminogen activator (uPA), a key protease determinant of cell invasiveness and metastasis. This study reports the discovery of 6-substituted HMA analogs that show nanomolar potency against uPA, high selectivity over related trypsin-like serine proteases, and minimal inhibitory effects against epithelial sodium channels (ENaC), the diuretic and antikaliuretic target of amiloride. Reductions in lung metastases were demonstrated for two analogs in a late-stage experimental mouse metastasis model, and one analog completely inhibited formation of liver metastases in an orthotopic xenograft mouse model of pancreatic cancer. The results support further evaluation of 6-substituted HMA derivatives as uPA-targeting anticancer drugs." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00838"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00838">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00838&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00838&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00838&amp;href=/doi/10.1021/acs.jmedchem.8b00838" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 8299-8320</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00835" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00862" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Benjamin J. Buckley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Benjamin J. Buckley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Horizons and School of Chemistry & Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia</div><div class="loa-info-affiliations-info">Illawarra Health & Medical Research Institute, Wollongong, NSW 2522, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Benjamin%0AJ.++Buckley">Benjamin J. Buckley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ashraf Aboelela</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ashraf Aboelela</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Horizons and School of Chemistry & Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia</div><div class="loa-info-affiliations-info">Illawarra Health & Medical Research Institute, Wollongong, NSW 2522, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ashraf++Aboelela">Ashraf Aboelela</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elahe Minaei</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elahe Minaei</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Horizons and School of Chemistry & Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia</div><div class="loa-info-affiliations-info">Illawarra Health & Medical Research Institute, Wollongong, NSW 2522, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elahe++Minaei">Elahe Minaei</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Longguang X. Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Longguang X. Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Joint Biomedical Engineering Research Centre on Photodynamic Technologies, Fuzhou University, Fujian 350116, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Longguang+X.++Jiang">Longguang X. Jiang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4734-3778" title="Orcid link">http://orcid.org/0000-0002-4734-3778</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhihong Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhihong Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pancreatic Research Group, South Western Sydney Clinical School, University of New South Wales, and Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhihong++Xu">Zhihong Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Umar Ali</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Umar Ali</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Horizons and School of Chemistry & Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia</div><div class="loa-info-affiliations-info">Illawarra Health & Medical Research Institute, Wollongong, NSW 2522, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Umar++Ali">Umar Ali</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karen Fildes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karen Fildes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Illawarra Health & Medical Research Institute, Wollongong, NSW 2522, Australia</div><div class="loa-info-affiliations-info">Graduate School of Medicine, University of Wollongong, Wollongong, NSW 2522, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karen++Fildes">Karen Fildes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chen-Yi Cheung</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chen-Yi Cheung</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology and Immunology, University of Otago, Otago 9016, New Zealand</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chen-Yi++Cheung">Chen-Yi Cheung</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simon M. Cook</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simon M. Cook</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Illawarra Health & Medical Research Institute, Wollongong, NSW 2522, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simon+M.++Cook">Simon M. Cook</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Darren C. Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Darren C. Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Darren+C.++Johnson">Darren C. Johnson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel A. Bachovchin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel A. Bachovchin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States</div><div class="loa-info-affiliations-info">Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+A.++Bachovchin">Daniel A. Bachovchin</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8210-1662" title="Orcid link">http://orcid.org/0000-0001-8210-1662</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gregory M. Cook</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gregory M. Cook</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology and Immunology, University of Otago, Otago 9016, New Zealand</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gregory+M.++Cook">Gregory M. Cook</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Minoti Apte</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Minoti Apte</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pancreatic Research Group, South Western Sydney Clinical School, University of New South Wales, and Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Minoti++Apte">Minoti Apte</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mingdong Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mingdong Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Joint Biomedical Engineering Research Centre on Photodynamic Technologies, Fuzhou University, Fujian 350116, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mingdong++Huang">Mingdong Huang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1377-6786" title="Orcid link">http://orcid.org/0000-0002-1377-6786</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marie Ranson</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marie Ranson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Horizons and School of Chemistry & Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia</div><div class="loa-info-affiliations-info">Illawarra Health & Medical Research Institute, Wollongong, NSW 2522, Australia</div></div><span class="conrtib-corresp"><strong>*</strong>M.R.: e-mail, <a href="/cdn-cgi/l/email-protection#d3bea1b2bda0bcbd93a6bca4fdb6b7a6fdb2a6"><span class="__cf_email__" data-cfemail="ddb0afbcb3aeb2b39da8b2aaf3b8b9a8f3bca8">[email protected]</span></a>; phone, +61 2 4221 3291.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marie++Ranson">Marie Ranson</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Michael J. Kelso</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael J. Kelso</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Horizons and School of Chemistry & Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia</div><div class="loa-info-affiliations-info">Illawarra Health & Medical Research Institute, Wollongong, NSW 2522, Australia</div></div><span class="conrtib-corresp"><strong>*</strong>M.J.K.: e-mail, <a href="/cdn-cgi/l/email-protection#462b2d232a35290633293168232233682733"><span class="__cf_email__" data-cfemail="deb3b5bbb2adb19eabb1a9f0bbbaabf0bfab">[email protected]</span></a>; phone, +61 2 4221 5085.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Kelso">Michael J. Kelso</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7809-6637" title="Orcid link">http://orcid.org/0000-0001-7809-6637</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00838&amp;href=/doi/10.1021%2Facs.jmedchem.8b00838" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 8299–8320</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 21, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 May 2018</li><li><span class="item_label"><b>Published</b> online</span>21 August 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 September 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00838" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00838</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8299%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBenjamin%250AJ.%2BBuckley%252C%2BAshraf%2BAboelela%252C%2BElahe%2BMinaei%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D18%26contentID%3Dacs.jmedchem.8b00838%26title%3D6-Substituted%2BHexamethylene%2BAmiloride%2B%2528HMA%2529%2BDerivatives%2Bas%2BPotent%2Band%2BSelective%2BInhibitors%2Bof%2Bthe%2BHuman%2BUrokinase%2BPlasminogen%2BActivator%2Bfor%2BUse%2Bin%2BCancer%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8320%26publicationDate%3DSeptember%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00838"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2010</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">19</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00838" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Benjamin\nJ.&quot;,&quot;last_name&quot;:&quot;Buckley&quot;},{&quot;first_name&quot;:&quot;Ashraf&quot;,&quot;last_name&quot;:&quot;Aboelela&quot;},{&quot;first_name&quot;:&quot;Elahe&quot;,&quot;last_name&quot;:&quot;Minaei&quot;},{&quot;first_name&quot;:&quot;Longguang&quot;,&quot;last_name&quot;:&quot;X. Jiang&quot;},{&quot;first_name&quot;:&quot;Zhihong&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Umar&quot;,&quot;last_name&quot;:&quot;Ali&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;Fildes&quot;},{&quot;first_name&quot;:&quot;Chen-Yi&quot;,&quot;last_name&quot;:&quot;Cheung&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;M. Cook&quot;},{&quot;first_name&quot;:&quot;Darren&quot;,&quot;last_name&quot;:&quot;C. Johnson&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;A. Bachovchin&quot;},{&quot;first_name&quot;:&quot;Gregory&quot;,&quot;last_name&quot;:&quot;M. Cook&quot;},{&quot;first_name&quot;:&quot;Minoti&quot;,&quot;last_name&quot;:&quot;Apte&quot;},{&quot;first_name&quot;:&quot;Mingdong&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Marie&quot;,&quot;last_name&quot;:&quot;Ranson&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Kelso&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;21&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;8299-8320&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00838&quot;},&quot;abstract&quot;:&quot;Metastasis is the cause of death in the majority (∼90%) of malignant cancers. The oral potassium-sparing diuretic amiloride and its 5-substituted derivative 5-N,N-(hexamethylene)amiloride (HMA) reportedly show robust antitumor/metastasis effects in multiple in vitro and animal models. These effects are likely due, at least in part, to inhibition of the urokinase plasminogen activator (uPA), a key protease determinant of cell invasiveness and metastasis. This study reports the discovery of 6-substituted HMA analogs that show nanomolar potency against uPA, high selectivity over related trypsin-like serine proteases, and minimal inhibitory effects against epithelial sodium channels (ENaC), the diuretic and antikaliuretic target of amiloride. Reductions in lung metastases were demonstrated for two analogs in a late-stage experimental mouse metastasis model, and one analog completely inhibited formation of liver metastases in an orthotopic xenograft mouse model of pancreatic cancer. The results support further eva&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00838&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00838" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00838&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00838" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00838&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00838" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00838&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00838&amp;href=/doi/10.1021/acs.jmedchem.8b00838" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00838" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00838" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (14 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00838%26sid%3Dliteratum%253Aachs%26pmid%3D30130401%26genre%3Darticle%26aulast%3DBuckley%26date%3D2018%26atitle%3D6-Substituted%2BHexamethylene%2BAmiloride%2B%2528HMA%2529%2BDerivatives%2Bas%2BPotent%2Band%2BSelective%2BInhibitors%2Bof%2Bthe%2BHuman%2BUrokinase%2BPlasminogen%2BActivator%2Bfor%2BUse%2Bin%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D18%26spage%3D8299%26epage%3D8320%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/jmcmar.2018.61.issue-18/20180927/jmcmar.2018.61.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Metastasis is the cause of death in the majority (∼90%) of malignant cancers. The oral potassium-sparing diuretic amiloride and its 5-substituted derivative 5<i>-N</i>,<i>N</i>-(hexamethylene)amiloride (HMA) reportedly show robust antitumor/metastasis effects in multiple in vitro and animal models. These effects are likely due, at least in part, to inhibition of the urokinase plasminogen activator (uPA), a key protease determinant of cell invasiveness and metastasis. This study reports the discovery of 6-substituted HMA analogs that show nanomolar potency against uPA, high selectivity over related trypsin-like serine proteases, and minimal inhibitory effects against epithelial sodium channels (ENaC), the diuretic and antikaliuretic target of amiloride. Reductions in lung metastases were demonstrated for two analogs in a late-stage experimental mouse metastasis model, and one analog completely inhibited formation of liver metastases in an orthotopic xenograft mouse model of pancreatic cancer. The results support further evaluation of 6-substituted HMA derivatives as uPA-targeting anticancer drugs.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16258" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16258" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The urokinase plasminogen activator (uPA) is a trypsin-like serine protease (TLSP) that has been implicated in the invasive spread and metastatic dissemination of transformed cells in several aggressive cancers, including triple-negative breast, pancreatic, gastric, colorectal, and prostate cancers.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1−5)</a> Clinically, uPA expression provides the highest level of evidence (level 1)<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> for predicting poor patient prognosis in breast cancer and it is one of the strongest predictors of progression-free survival and overall survival.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a></div><div class="NLM_p">uPA binds to cell surfaces via a specific interaction with its cognate receptor urokinase plasminogen activator receptor (uPAR), which is expressed on cancer cells and the supporting stroma, often at the invasive front of tumors.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10−12)</a> uPAR-bound uPA activates colocalized plasminogen to yield the broad spectrum TLSP plasmin,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> a key mediator of directed pericellular proteolysis that activates multiple downstream proteases (e.g., matrix metalloproteinases and cathepsins), ultimately leading to degradation of the extracellular matrix and basement membrane components that confine primary tumors.<a onclick="showRef(event, 'ref3 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref3 ref14 ref15">(3,14,15)</a> The uPA-initiated proteolytic cascade is thus a key determinant of local invasion and metastatic spread via the lymphatic and circulatory systems.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a></div><div class="NLM_p">uPA attracted much interest in the 1990s and early 2000s as an anticancer target in academic and industry laboratories (reviewed by Ngo et al.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and Tyndall et al.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a>). For example, efforts from Abbott Laboratories led to highly potent naphthamidine-based inhibitors, e.g., <b>1</b>.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26">(20−23)</a> X-ray cocrystal structures of these and other inhibitors uncovered a novel subsite, termed S1β, adjacent to the S1 binding pocket in uPA. Targeting of this site afforded potency gains in a variety of arylamidine-based inhibitors.<a onclick="showRef(event, 'ref23 ref20'); return false;" href="javascript:void(0);" class="ref ref23 ref20">(20,24)</a> The poor drug properties of arylamidines ultimately proved to be a major stumbling block, however, and compounds were not advanced to the clinic.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(25)</a> Astex Therapeutics were able to repurpose the oral antiarrhythmic drug mexiletine into a potent, orally active non-amidine-containing uPA inhibitor <b>2</b>,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(26)</a> but no clinical studies have been reported to date.</div><div class="NLM_p"><b>3a</b> and its oral hydroxyamidine prodrug <b>3b</b> (Heidelberg Pharma AG; formerly WILEX AG) are, to the best of our knowledge, the only uPA inhibitors to have undergone clinical evaluation in cancer.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(27)</a> Phase II studies of oral <b>3b</b> in combination with gemcitabine showed a 17% increase in 1-year survival in patients with locally advanced, nonresectable pancreatic cancers compared to patients treated with gemcitabine alone.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(28)</a> In a separate phase II study, patients with HER2-negative metastatic breast cancers who had received adjuvant chemotherapy following primary diagnosis and were subsequently treated with <b>3b</b> in combination with capecitabine showed an increase in median progression-free survival (8.3 months) compared to patients receiving capecitabine alone (4.3 months).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(29)</a></div><div class="NLM_p">Amiloride <b>4</b> is an oral potassium-sparing diuretic that has been used for over 4 decades in the treatment of hypokalemia, hypertension, and cirrhosis.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(30,31)</a> The diuretic and antikaliuretic properties of amiloride arise through inhibition of renal epithelial sodium channels (ENaCs).<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(32,33)</a> Several groups have reported that the compound also shows anticancer side-activities in multiple in vitro and rodent models (reviewed by Matthews et al.).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In one study, high doses of amiloride (200 mg/kg in drinking water ad libitum) caused complete remission in a prostate xenograft mouse model.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(34)</a> It has been suggested that the anticancer effects of amiloride observed at the high doses used in this and other animal studies likely arise, at least in part, from inhibition of uPA proteolytic activity (IC<sub>50</sub> = 7 μM).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(35)</a> Amiloride is unsuitable for use clinically as an anticancer drug, however, due to its low maximum daily dose ceiling (20 mg/day), where overdose risks hyperkalemia and associated cardiac events.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(36)</a> Nevertheless, the demonstrable in vivo anticancer side-activities of amiloride, combined with excellent drug-like properties (inferred from decades of oral clinical use) and low micromolar potency against uPA, suggest it as an attractive starting scaffold for repurposing using the selective optimization of side-activity (SOSA) approach<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(37)</a> into a high potency uPA inhibitor for treating uPA-driven cancers.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Moreover, the reduced basicity of the acyl guanidine group relative to arylamidines potentially offers a solution to the poor drug properties of earlier inhibitors.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(25)</a> We propose that effective dosing of an analog suitably optimized for high uPA potency that lacks the diuretic and antikaliuretic effects of amiloride may safely and effectively recapitulate in humans the anticancer activities observed with high doses of amiloride in animals.</div><div class="NLM_p">Our preliminary structure–activity exploration of amiloride analogs as uPA inhibitors focused on the effects of varying substituents at the 5-NH<sub>2</sub> group.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(38)</a> Relatively flat SAR trends were observed, with multiple analogs carrying diverse 5-substituents returning IC<sub>50</sub> values in the range 1–50 μM. Large increases in potency relative to amiloride were not realized, with the most active compound (5-<i>N</i>,<i>N</i>′-dimethylethylenediamine amiloride) showing only a ∼2-fold increase (IC<sub>50</sub> = 3 μM). A key finding, however, was that 5<i>-N</i>,<i>N</i>-(hexamethylene)amiloride <b>5</b> (HMA, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) retained potency against uPA (IC<sub>50</sub> = 6 μM).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of reported uPA inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">HMA has a long history of use as a pharmacological tool<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(39)</a> and, like amiloride, reportedly shows in vitro and in vivo anticancer activities.<a onclick="showRef(event, 'ref42 ref43 ref44 ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref42 ref43 ref44 ref45 ref46 ref47">(40−45)</a> For example, HMA has been shown to delay primary tumor growth and increase thermosensitivity of SCK mammary carcinoma cells in a mouse allograft model,<a onclick="showRef(event, 'ref42 ref48'); return false;" href="javascript:void(0);" class="ref ref42 ref48">(40,46)</a> and it was recently shown to suppress sorafenib-resistant engraftment of FLT3-ITD+ acute myeloid leukemia primary cells in mice, with total suppression observed in combination with sorafenib.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(43)</a> Importantly, alkyl substitution of the 5-NH<sub>2</sub> group of amiloride (as in HMA) appears to reduce inhibitory effects against ENaCs.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(46,47)</a> On the basis of this, HMA <b>5</b> was selected as the starting point for SOSA optimization.</div><div class="NLM_p last">There have been many structure–activity studies exploring the effects of substitution at various positions around the pyrazine core of amiloride,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(46)</a> but there is a surprising lack of reports on analogs carrying variations at the 6-position of amiloride, HMA, or any other 5-substituted amilorides.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(48)</a> This study reports the synthesis, uPA structure–activity relationships, and in vivo anticancer properties of HMA analogs carrying (hetero)aryl substituents at the 6-position.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83616" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83616" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">The reported X-ray cocrystal structure of amiloride bound to uPA<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(49)</a> indicated that the 6-Cl group projects toward the S1β subsite, suggesting that other groups attached here might better occupy the site and increase potency. A diverse series of 6-(hetero)aryl substituted HMA analogs was produced from the common 5<i>-N</i>,<i>N</i>-(hexamethylene)amiloride methyl ester intermediate <b>7</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Ester <b>7</b> was obtained via nucleophilic aromatic substitution of the commercially available 3-amino-5,6-dichloropyrazine-2-methyl ester <b>6</b> with hexamethyleneimine. The reported method for preparing <b>7</b>,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(38)</a> which involves heating <b>6</b> with hexamethyleneimine in DMF at 100 °C for 1 h, requires multiple column chromatography steps to obtain pure <b>7</b> (65% yield). We found that when the reaction was instead performed at reflux in 2-propanol in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), an excellent yield of <b>7</b> (86%) was obtained after only 2 h. The improved procedure could be performed on multigram scale in an open flask with the pure <b>7</b> crystallizing from the reaction mixture and isolated by simple filtration.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 6-(Hetero)aryl HMA Analogs <b>9</b>–<b>32</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (CH<sub>2</sub>)<sub>6</sub>NH, DIPEA, <i><sup>i</sup></i>PrOH, reflux, 2 h, 86%; (b) R-B(OH)<sub>2</sub> or R-B(pin), Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, toluene/MeOH (4:1), reflux, 0.5–18 h; (c) guanidine (2 M in MeOH), DMF, rt, 18 h.</p></p></figure><div class="NLM_p">Direct attachment of (hetero)aryl substituents to the 6-position of <b>7</b> was achieved using standard Suzuki–Miyaura cross-coupling conditions with commercial arylboronic acids (or pinacol boronates), Pd(PPh<sub>3</sub>)<sub>4</sub>, and K<sub>2</sub>CO<sub>3</sub> in toluene/MeOH (4:1) at reflux. A total of twenty-three 6-(hetero)aryl methyl esters <b>9a</b>–<b>32a</b> were produced in yields ranging from 34 to 93%. The methyl esters were converted to their respective acylguanidines <b>9</b>–<b>32</b> in 2–92% by treatment with guanidine. Low guanidinylation yields were initially obtained using the reported method<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(38)</a> leading us to search for an improved procedure. Treating the methyl esters in DMF with a 2 M stock solution of guanidine in MeOH was found to give much higher yields, with most reactions proceeding to completion at room temperature and no major side products forming. The revised procedure was simple to carry out and allowed multiple guanidinylation reactions to be performed in parallel, and the 2 M guanidine solution could be stored under N<sub>2</sub> in a refrigerator for up to 2 weeks.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(50)</a></div><div class="NLM_p">6-(2-(Alkylamino)pyrimidin-5-yl) HMA analogs <b>33</b>–<b>35</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) were obtained from 6-(2-chloropyrimidin-5-yl) methyl ester intermediate <b>8</b>. Compound <b>8</b> was synthesized in 64% yield by Suzuki–Miyaura coupling of <b>7</b> with (2-chloropyrimidin-5-yl)boronic acid. Nucleophilic aromatic substitution of the 2-chloro group with the requisite amines yielded esters <b>33a</b>–<b>35a</b> in 83–87% yields, which were converted to acyl guanidines <b>33</b>–<b>35</b> in 85–89% yields using the new guanidinylation procedure.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 6-(2-(Alkylamino)pyrimidin-5-yl) Analogs <b>33</b>–<b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (2-chloropyrimidin-5-yl)boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, toluene/MeOH (4:1), reflux, 18 h, 64%; (b) (i) R-NH<sub>2</sub>, DIPEA, DMF, rt, 2 d or (ii) R-NH<sub>2</sub>, DIPEA, <i>i</i>-PrOH, reflux, 4 h, 83–87%; (c) guanidine (2 M in MeOH), DMF, rt, 18 h, 85–89%.</p></p></figure><div class="NLM_p">Previous reports describing napthamidine-based inhibitors<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(20,21)</a> identified that the 2-aminopyrimidine group shows favorable binding in the uPA S<sub>1</sub>β pocket. On the basis of this, 2-aminopyrimidinyl derivative <b>41</b> was synthesized using the route outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. The 3-NH<sub>2</sub> group of methyl ester <b>7</b> was di-Boc protected using Boc-anhydride to give <b>36</b> in 85% yield. Halogen exchange from the 6-chloro group to 6-bromo in preparation for Buchwald–Hartwig amination was carried out over two steps. Hydrodechlorination using 1 atm of hydrogen in the presence of Pd/C and MgO was successful, although it was accompanied by loss of one Boc-group giving mono-Boc derivative <b>37</b> in 92% yield. Introduction of the 6-bromo substituent using <i>N</i>-bromosuccinimide (NBS) gave <b>38</b> (60% yield), and Buchwald–Hartwig amination of <b>38</b> with 2-aminopyrimidine using Pd<sub>2</sub>(dba)<sub>3</sub>/Xantphos afforded the 6-substituted pyrazine methyl ester <b>39</b> in 30% yield. Removal of the remaining Boc-group with trifluoroacetic acid (98% yield) followed by guanidinylation delivered <b>41</b> (35% yield).</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 2-Aminopyrimidinyl Derivative <b>41</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (Boc)<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, DIPEA, DMAP, rt, 16 h, 85%; (b) Pd/C, H<sub>2</sub> (1 atm), MgO, MeOH, rt, 48 h, 92%; (c) <i>N</i>-bromosuccinimide, CH<sub>2</sub>Cl<sub>2</sub>, rt, 5 h, 60%; (d) 2-aminopyrimidine, Pd<sub>2</sub>(dba)<sub>3</sub>/Xantphos, 1,4-dioxane, Cs<sub>2</sub>CO<sub>3</sub>, 100 °C, 18 h, 30%; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 98%; (f) guanidine (2 M in MeOH), DMF, rt, 35%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Inhibition of uPA and Structure–Activity Relationships</h3><div class="NLM_p">Inhibition of catalytically active, low molecular weight human uPA by <b>9</b>–<b>35</b> and <b>41</b> was determined using a fluorometric enzyme activity assay.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(51)</a> Concentration–response curves for representative analogs <b>18</b> and <b>27</b> are provided in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, and calculated <i>K</i><sub>i</sub> values are presented in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Inhibition of low molecular weight human uPA by <b>18</b> (black) and <b>27</b> (red). Data points represent the mean ± SEM (<i>n</i> = 3) from a single representative experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibition of uPA by 6-Substituted HMA Analogs<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0015.gif" alt="" id="GRAPHIC-d7e1012-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0016.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">For compounds where <i>n</i> > 1, values represent the mean ± SEM from identical repeat assays conducted on different days. <i>K</i><sub>i</sub> values were calculated from experimentally determined IC<sub>50</sub> values according to the methods of Cheng and Prussof.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></p></div></div><div></div></div><div class="NLM_p">Amiloride <b>4</b> and HMA <b>5</b> returned <i>K</i><sub>i</sub> values of 2433 nM and 1356 nM, respectively, under the assay conditions. Replacing the 6-Cl group of HMA with a phenyl substituent <b>9</b> led to ∼3.7-fold decrease in potency. Substitution of the phenyl ring at the <i>para</i>-position (<b>10</b> and <b>11</b>) did not improve potency, while conversion to the 3,4-methylenedioxy derivative <b>12</b> provided a slight increase relative to HMA (<i>K</i><sub>i</sub> = 934 nM). Appending an isoquinolyl group <b>13</b> reduced activity nearly 3-fold relative to HMA. <i>N</i>-Methylpyrazole derivative <b>14</b> showed a ∼2.7-fold increase (<i>K</i><sub>i</sub> = 508 nM). Extension of the <i>N</i>-methyl group of <b>14</b> to <i>N</i>-ethylmorpholino <b>15</b> had only a minor effect (<i>K</i><sub>i</sub> = 658 nM). Surprisingly, while 2-indolyl <b>16</b> and 2-benzothiophenyl substituents <b>17</b> showed reduced activity, the single atom change to 2-benzofuranyl derivative <b>18</b> afforded a significant boost in potency (<i>K</i><sub>i</sub> = 183 nM), which increased 2-fold upon addition of a fluorine atom at the benzofuran 4-position (<b>19</b>, <i>K</i><sub>i</sub> = 88 nM). The preference for oxygen in the heteroaryl ring was also seen with the 2- and 3-furanyl derivatives <b>22</b> and <b>23</b>, respectively, which both showed nM potency, whereas 2- and 3-thiophene derivatives <b>20</b> and <b>21</b> were micromolar inhibitors.</div><div class="NLM_p last">2-Fluoropyridine substitution (<b>24</b><i>K</i><sub>i</sub> = 1778 nM) afforded similar activity to HMA <b>5</b>, while addition of a 5-pyrimidinyl group <b>25</b> (<i>K</i><sub>i</sub> = 108 nM) gave a ∼12.6-fold increase. Addition of a methoxy group to the pyrimidine 2-position yielded the first sub-100 nM inhibitor <b>26</b> (<i>K</i><sub>i</sub> = 53 nM), and adding a second methoxy group to the pyrimidine 4-position <b>27</b> (<i>K</i><sub>i</sub> = 42 nM) gave a further increase. The favorable binding of the pyrimidine group was evident from the significant losses in potency observed with dimethoxypyridine <b>28</b> and dimethoxyphenyl derivatives <b>29</b> and <b>30</b>. Loss of potency with the dimethoxypyridazine <b>31</b> was less dramatic (<i>K</i><sub>i</sub> = 315 nM). An additional 2-fold gain in potency was achieved upon addition of an amine to the pyrimidine 2-position, yielding the most potent inhibitor in the study (<b>32</b><i>K</i><sub>i</sub> = 21 nM). Further gains in potency were not obtained through <i>N</i>-alkyl substitution, with <i>N-</i>methyl <b>33</b>, <i>N</i>-isopropyl <b>34</b>, and <i>N</i>-hydroxyethyl <b>35</b> derivatives showing activity similar to <b>26</b>. The 2-aminopyrimidine derivative <b>41</b> obtained using Buchwald–Hartwig chemistry showed lower potency (<i>K</i><sub>i</sub> = 228 nM).</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> X-ray Crystallography</h3><div class="NLM_p">An X-ray cocrystal structure was obtained for HMA <b>5</b> bound to the catalytic domain of human uPA (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The binding orientation and interactions observed in the HMA:uPA structure mirrored those previously observed with amiloride <b>4</b>.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(49)</a> The key salt bridge interaction was present between the acylguanidine of HMA and the Asp189 side chain carboxylate located at the base of the S1 binding pocket. H-bonds were present between the backbone carbonyl of Gly219 and the terminal NH and amide NH groups of the acyl guanidine. The second terminal guanidine-NH formed an H-bond to the side chain hydroxyl of Ser190, and the exocyclic NH<sub>2</sub> group at C3 formed an H-bond to the side chain hydroxyl of Ser195. A bridging H-bond network was observed between a surface-bound water molecule, the acyl guanidine carbonyl oxygen, Ser190 side chain hydroxyl, and a guanidine NH group. A sulfate ion from the crystallization buffer was observed in the oxyanion hole of both structures.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray cocrystal structures of (a) amiloride <b>4</b><a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(49)</a> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1F5L">1F5L</a>) and (b) HMA <b>5</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZA7">5ZA7</a>, 1.7 Å resolution) bound to uPA. Blue wire basket = 2<i>mF</i><sub>o</sub> – <i>DF</i><sub>C</sub> map contoured at 1.5σ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">X-ray cocrystal structures were similarly obtained for benzofuran (<b>18</b>, <b>19</b>), furan (<b>22</b>, <b>23</b>), pyrimidine <b>25</b>, 2-methoxypyrimidine <b>26</b>, 2,4-dimethoxypyrimidine <b>27</b>, and <i>N</i>-methylpyrazole <b>14</b> analogs (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>. X-ray refinement statistics are provided in <a href="/doi/suppl/10.1021/acs.jmedchem.8b00838/suppl_file/jm8b00838_si_001.pdf" class="ext-link">Supporting Information, Table S1</a>). H-bonding networks reminiscent of those seen in the HMA:uPA structure were observed in all complexes. The seven-membered hexamethylene ring appeared to sample multiple conformations, as evidenced by low electron density in all structures. Replacement of the 6-Cl group with (hetero)aryl substituents did not significantly alter the binding positions or orientation of the pyrazine core or acylguanidines relative to HMA <b>5</b>. The 6-substituent occupied S1β in all cases, and sulfate ion occupied the oxyanion hole in some complexes.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray cocrystal structures of: (a) <b>22</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAE">5ZAE</a>, 1.7 Å), (b) <b>23</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAF">5ZAF</a>, 1.7 Å), (c) <b>18</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZA9">5ZA9</a>, 1.6 Å), and (d) <b>19</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZC5">5ZC5</a>, 1.9 Å) bound to uPA. Blue wire baskets represent 2<i>mF</i><sub>o</sub> – <i>DF</i><sub>C</sub> maps contoured at 1.5σ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray cocrystal structures of (a) <b>25</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAG">5ZAG</a>, 2.0 Å), (b) <b>26</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAH">5ZAH</a>, 3.0 Å), (c) <b>27</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAJ">5ZAJ</a>, 1.7 Å), and (d) <b>14</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZA8">5ZA8</a>, 1.9 Å) bound to uPA. Blue wire baskets represent 2<i>mF</i><sub>o</sub> – <i>DF</i><sub>C</sub> maps contoured at 1.5σ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The structure obtained with 2-furanyl analog <b>22</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a) revealed that the ∼8.7-fold increase in potency relative to HMA <b>5</b> may arise from new H-bonds formed between the furanyl O, a bridging water molecule, and the amide NH of Gly219. Favorable van der Waals contacts between the furan ring and Gly219, the Cys191-Cys220 disulfide, Ser146 backbone carbonyl, and the side chain Cβ and Cγ of Gln192 were also apparent. Changing to the 3-furanyl substituent <b>23</b> had little effect on uPA activity despite the furanyl oxygen no longer making the water-bridged H-bond interaction with Gly219 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b). Flexibility of the Arg217 side chain was noted in this structure, where it had shifted toward S1β to participate in the Gly219-bridging water H-bond network. Relative to <b>22</b>, the plane of the furan ring in <b>23</b> was tilted 11°, a pose that promoted van der Waals interactions with Cys220. Interactions with S1β residues Cys191-Cys220, Ser146, and the Gln192 side chain were preserved, and there appeared to be a dipolar interaction between the side chain carbonyl of Gln192 and the polarized furan 2-CH group.</div><div class="NLM_p">Ring fusion to give benzofuran <b>18</b> led to a slight decrease in potency (<i>K</i><sub>i</sub> = 183 nM) relative to <b>22</b> despite this group extending further into S1β and almost completely occupying the subsite (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>c). The plane of the benzofuran ring was essentially perpendicular to the pyrazine core, but the ring oxygen had flipped 180° relative to the furanyl oxygen of <b>22</b>. This orientation allowed the benzofuran 7-CH group to fill a small, hydrophobic dimple formed by Lys143, Gln192, and Ser146. Additional hydrophobic contacts were seen between the benzofuran 3- and 4-position CH groups and Gly219. Similar to what was observed in the HMA <b>5</b> and <b>22</b> structures, the side chain of Arg217 adopted a conformation well away from S1β. The structure with <b>19</b> suggested that the 2-fold increase in potency obtained after fluorine substitution at the benzofuran 4-position (<b>19</b><i>K</i><sub>i</sub> = 88 nM) arose from favorable interactions between the 4-fluoro group and the side chain guanidine of Arg217 (possibly an H-bond), which had shifted back toward S1β in this complex. The interaction with Arg217 also appeared to cause a slight twisting about the benzofuran–pyrazine axis away from perpendicular, with the 78° dihedral angle in <b>18</b> reducing to 68° in <b>19</b>.</div><div class="NLM_p">The 5-pyrimidine substituent of <b>25</b> was found to partially occupy S1β (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a), making van der Waals interactions with the Cys191-Cys220 disulfide, Ser146, and Gln192 residues. A dipole interaction between the polarized 4-CH group of the pyrimidine and the Gln192 side chain carbonyl appeared to be present, along with an H-bond between the amide NH of Gly219 and the lone pair of electrons on a pyrimidine nitrogen. The polarized 6-CH on the pyrimidine appeared to interact with the Gly219 carbonyl group.</div><div class="NLM_p">Addition of a methoxy group to the pyrimidine 2-position <b>26</b> led to a ∼2-fold increase in potency, but it did not appear to make any specific interactions with the protein, instead orienting toward bulk solvent (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b). The side chain of Arg217 had flipped back toward S1β driven by a polar interaction with the pyrimidine nitrogen (possibly an H-bond).</div><div class="NLM_p">Introduction of a second methoxy substituent onto the pyrimidine ring <b>27</b> resulted in a small increase in potency relative to <b>26</b>. The pyrimidine and pyrazine rings were almost perpendicular (dihedral angle 80°), allowing for increased occupancy of S1β and projection of a methoxy group toward the small hydrophobic dimple formed by Lys143, Gln192, and Ser146 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>c). The second methoxy substituent was projected toward bulk solvent. In contrast to <b>25</b> and <b>26</b>, the Arg217 side chain was positioned well away from S1β, apparently to avoid a steric clash with the pyrimidine 2-OCH<sub>3</sub> group of <b>27</b>.</div><div class="NLM_p last">The <i>N</i>-methylpyrazole substituent of <b>14</b> adopted a coplanar arrangement with the pyrazine reducing its penetration into S1β (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>d). Interactions were observed between the pyrazole 3-CH and 5-CH groups and the backbone of Gly219 and the side chain of Gln192, respectively. The surface water molecule bound to Gly219 in the furanyl structures <b>22</b> and <b>23</b> was observed but did not appear to interact with the pyrazole.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Inhibition of Trypsin-like Serine Proteases</h3><div class="NLM_p">HMA <b>5</b> and 6-substituted analogs <b>18</b>, <b>19</b>, and <b>26</b> were screened against a panel of trypsin-like serine proteases (TLSPs) using chromogenic assays (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). In agreement with earlier reports showing that occupancy of uPA’s S1β subsite confers high selectivity over other TLSPs,<a onclick="showRef(event, 'ref23 ref20 ref55'); return false;" href="javascript:void(0);" class="ref ref23 ref20 ref55">(20,24,53)</a> each of the compounds showed 20–100+ fold selectivity for uPA.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. uPA Selectivity versus Related Trypsin-like Serine Proteases of HMA <b>5</b> and 6-Substituted Analogs <b>18</b>, <b>19</b>, and <b>26</b><a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0017.gif" alt="" id="GRAPHIC-d7e1592-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0018.gif" alt="" id="gr16" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup><sup>a</sup></sup><p class="last">Values were obtained using chromogenic enzyme inhibition assays.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(38)</a> N/D = not determined.</p></div></div><div></div></div><div class="NLM_p">To further probe uPA selectivity, superfamily wide screening against 85 serine hydrolases was performed in situ using the recently described EnPlex activity-based protein profiling (ABPP) assay.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(54)</a> In this approach, individual serine hydrolases are conjugated to differently colored Luminex beads and the ability of inhibitory compounds to outcompete a biotinylated serine-reactive/streptavidin-phycoerythrin probe at the active site of each enzyme provides a rapid and semiquantitative readout of enzyme inhibition. Results from the Enplex screen with amiloride <b>4</b>, HMA <b>5</b>, and 6-substituted analogs <b>18</b>, <b>25</b>, and <b>26</b> are shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. EnPlex<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(54)</a> screening of amiloride <b>4</b>, HMA <b>5</b> and analogs <b>18</b>, <b>25</b>, and <b>26</b> for inhibition of 85 serine hydrolases. Gray boxes indicate wells in which no fluorescence was observed. The singular readouts suggesting activity of <b>4</b> and <b>26</b> against LIPE are artifacts. Black arrows indicate decreasing compound concentration from 33.3 μM to 10 nM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Amiloride showed slight activity against only a few serine hydrolases (C1r, C1s, DDHD1, factor VIIa, and LACTB), consistent with its reported high selectivity for uPA.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(35)</a> HMA <b>5</b> showed activity against the highly homologous S28 protease family members dipeptidyl peptidase 2 (DPP7) and prolylcarboxypeptidase (PRCP).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(55)</a> Surprisingly, inhibitory activity against uPA was not observed for HMA under these assay conditions. 2-Benzofuranyl analog <b>18</b> showed the least selectivity among the tested compounds, inhibiting plasma kallikrein (KLKb1) and trypsin. 5-Pyrimidinyl analog <b>25</b> showed remarkable selectivity for uPA, with slight inhibition of trypsin being the only off-target TLSP activity observed. 2-Methoxypyrimidinyl analog <b>26</b> showed slight activity against C1s, plasma kallikrein, plasmin, prolylcarboxy peptidase, trypsin, and transmembrane protease serine 11D (TMPRSS11d).</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Human Cell Cytotoxicity</h3><div class="NLM_p">HMA <b>5</b> and representative analogs <b>18</b>, <b>19</b>, <b>25</b>, and <b>26</b> were tested for cytotoxicity against four human cell lines (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). HMA <b>5</b> showed toxicity in the low micromolar range against all cell lines, with HEK-293 embryonic kidney and HT-1080 fibrosarcoma cells being most sensitive. In general, the cell lines were more sensitive to <b>18</b>, suggesting the benzofuran group may contribute to cytotoxic effects. MDA-MB-231 cells were ∼3-fold more sensitive to the 4-fluorinated benzofuran <b>19</b>, but the compound was less toxic than <b>18</b> toward the other three cell types. Cytotoxicity was not a general feature of 6-substituted HMA analogs since pyrimidine analogs <b>25</b> and <b>26</b> showed much lower activity against all cells. The lower log <i>D</i><sub>7.4</sub> of the pyrimidines (i.e., 2.8 and 3.4, respectively) relative to benzofuran <b>18</b> (i.e., log <i>D</i><sub>7.4</sub> = 5.1) and HMA (log <i>D</i><sub>7.4</sub> = 3.8) suggests lipophilicity may be a contributor to cytotoxicity.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Effect of HMA and Selected Analogs on Human Cell Viability</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0019.gif" alt="" id="GRAPHIC-d7e1745-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0020.gif" alt="" id="gr17" /></img><div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Off-Target Activity against GPCRs</h3><div class="NLM_p">Amiloride and related analogs are known to bind to G-protein-coupled receptors (GPCRs).<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(56,57)</a> For example, amiloride is a known antagonist of the adenosine 2A receptor (A<sub>2A</sub>).<a onclick="showRef(event, 'ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref60 ref61 ref62">(58−60)</a> Recent work describing the effects of substitution at the amiloride 5-position on A<sub>2A</sub> antagonism identified analogs with increased potency, including HMA <b>5</b>.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(61)</a> In the current study, a representative selection of 6-substituted HMA analogs were evaluated alongside HMA <b>5</b> for A<sub>2A</sub> antagonism using a radiolabeled ligand displacement assay (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). In all cases, the presence of the 6-substituent diminished antagonist effects relative to HMA, with the majority of compounds showing poor A<sub>2A</sub> binding.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Single concentration screening (10 μM) of HMA <b>5</b> and 6-substituted HMA analogs as antagonists of the human adenosine A<sub>2A</sub> receptor (hA<sub>2A</sub>AR-WT). Radioligand [<sup>3</sup>H]ZM241385 was present at 2.5 nM. Total binding (TB, 100%) of [<sup>3</sup>H]ZM241385 was determined in the absence of inhibitors. Nonspecific binding (NSB, 0%) was determined in the presence of 100 μM A<sub>2A</sub> agonist 5′-(<i>N</i>-ethylcarboxamido)adenosine (NECA). Data represent the mean ± SEM from at least three independent experiments conducted in duplicate. Methods were as described in ref <a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(61)</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Development of active site-directed uPA inhibitors has been complicated by the observation that compounds optimized for high affinity against human uPA often show reduced potency against the homologous mouse enzyme.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(62)</a> This species selectivity can confound interpretation of data from mouse models as the decreased affinity for mouse uPA may lead to an underestimation of compound efficacy. To explore this issue in the 6-substituted HMA class, we measured the activities of <b>4</b>, <b>5</b>, <b>18</b>, and <b>26</b> against mouse uPA (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Activities of Compounds <b>4</b>, <b>5</b>, <b>18</b>, and <b>26</b> against Human and Mouse uPA</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0021.gif" alt="" id="gr18" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Experimental replicates were performed as described in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Value is the average of two independent experiments.</p></div></div><div></div></div><div class="NLM_p last">Amiloride <b>4</b> was essentially equipotent against mouse and human uPA. Addition of the 5-hexamethylene ring in <b>5</b> decreased affinity for mouse uPA by almost 7-fold, while compounds <b>18</b> and <b>26</b> showed larger (10- to 30-fold) reductions. These findings align with reported trends for compounds bearing substituents that target uPA’s S1β subsite.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(62)</a> The lower potency against mouse uPA was a key consideration in dose selection for in vivo studies with <b>18</b> and <b>26</b> (see below).</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Diuretic and Antikaliuretic Effects</h3><div class="NLM_p">The potassium-sparing activity of amiloride arises from inhibition of epithelial sodium channels (ENaCs) in the kidneys, leading to reduced urinary excretion of K<sup>+</sup>.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(32)</a> In cases of overdose, the potassium-sparing effects can lead to hyperkalemia and cardiac arrhythmias.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(63)</a> As such, removal of ENaC activity is essential for development of a 6-substituted HMA analog suitable for use in cancer. Early work from the Cragoe group at Merck established that alkyl substitution of the 5-NH<sub>2</sub> group of amiloride reduces ENaC activity<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(47)</a> and showed that HMA produces >80-fold lower inhibition than amiloride in a deoxycorticosterone acetate (DOCA) induced K<sup>+</sup> excretion model in adrenalectomized rats.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(47)</a> 6-Substituted HMA analogs were thus expected to show similarly low activity against ENaCs. To confirm this, a representative selection of analogs was tested against recombinant HEK-293 cells that overexpress the α, β, and γ subunits of human ENaCs (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). In line with expectations, amiloride <b>4</b> produced a strong effect (68% inhibition of ENaC at 10 μM), whereas HMA <b>5</b> showed greatly reduced activity and 6-substituted analogs <b>11</b>, <b>18</b>, <b>25</b>, and <b>26</b> showed similar or lower inhibition than HMA.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inhibition of ENaC activity by amiloride <b>4</b>, HMA <b>5</b> and 6-substituted analogs <b>11</b>, <b>18</b>, <b>25</b>, and <b>26</b> in transfected HEK-293 cells. All compounds were present at 10 μM. Data represent the mean ± SD (<i>n</i> = 4).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Amiloride <b>4</b>, HMA <b>5</b>, and analogs <b>18</b> and <b>26</b> were next tested in a rat model of diuresis to confirm that loss of ENaC inhibitory potency corresponded to an absence of diuretic and antikaliuretic effects in vivo (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). With the exception of vehicle controls, all animals were dosed with 25 mg/kg acetazolamide to induce diuresis<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(64)</a> prior to receiving 1.5 mg/kg of amiloride <b>4</b>, HMA <b>5</b>, <b>18</b>, or <b>26</b>. Urine was collected over a 6 h period following dosing. Consistent with previous reports, amiloride <b>4</b> showed potent diuretic and antikaliuretic effects, increasing urine volume and sodium excretion by 34% and 159%, respectively, while decreasing potassium excretion by 92% relative to acetazolamide-treated controls (Na<sup>+</sup>/K<sup>+</sup> excretion ratio = 63, <i>p</i> < 0.0001 for all measurements).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(64)</a> Compound <b>18</b> did not significantly decrease K<sup>+</sup> excretion, while HMA <b>5</b> and 2-methoxypyrimidine analog <b>26</b> showed a very slight potassium-sparing effect (24% reduction, <i>p</i> < 0.001). HMA <b>5</b>, <b>18</b>, and <b>26</b> did not alter Na<sup>+</sup> excretion or urine volume, and the Na<sup>+</sup>/K<sup>+</sup> excretion ratios for the three compounds were no different to acetazolamide treated controls (range = 2.44–2.68).</div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Effects of amiloride <b>4</b>, HMA <b>5</b>, and 6-substituted analogs <b>18</b> and <b>26</b> on urine flow and excretion of Na<sup>+</sup> and K<sup>+</sup> in Sprague Dawley rats. Rats were dosed with 25 mg/kg acetazolamide prior to administering 1.5 mg/kg of test compound. Data represent the mean ± SEM (<i>n</i> = 8): (∗∗) <i>p</i> < 0.001, (∗∗∗∗) <i>p</i> < 0.0001 relative to acetazolamide control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Experimental Lung Metastasis Model</h3><div class="NLM_p">Two analogs were advanced to anticancer pilot studies to establish efficacy in vivo. Compounds <b>18</b> and <b>26</b> were selected as representative examples showing different potency and polarity (<b>18</b> log <i>D</i><sub>7.4</sub> = 5.1, <b>26</b> log <i>D</i><sub>7.4</sub> = 3.4). In the first study, amiloride <b>4</b> and 6-substituted HMA analogs <b>18</b> and <b>26</b> were examined for antimetastasis effects in an experimental mouse model of late-stage lung metastasis. Luciferase-tagged HT-1080 human fibrosarcoma cells were used in the model after confirming cell surface expression of uPA/uPAR (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00838/suppl_file/jm8b00838_si_001.pdf" class="ext-link">Supporting Information Figure S1</a>). Assays of lung homogenates following organ harvest at end point were used to quantitate lung tumor burden and response to treatment. Animals received 2.5 × 10<sup>5</sup> HT-1080 cells via lateral tail vein injection on day 0 and were weighed and scored for clinical signs (scoresheet <a href="/doi/suppl/10.1021/acs.jmedchem.8b00838/suppl_file/jm8b00838_si_001.pdf" class="ext-link">Supporting Information Figure S2</a>) over 21 days. Animals received 7.5 mg kg<sup>–1</sup> day<sup>–1</sup> of compound (or vehicle) via ip injection from day −1 to day 20. This dose was selected based on extensive in vivo pharmacokinetic profiling and represented a compromise between tolerability and attempting to demonstrate efficacy with compounds that show reduced potency against murine uPA.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(65)</a></div><div class="NLM_p">Amiloride <b>4</b> did not significantly inhibit metastasis in this model at the concentration tested. Benzofuranyl analog <b>18</b> decreased metastasis by 21% (<i>p</i> = 0.0297) relative to control, but there was no statistically significant difference between amiloride and <b>18</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). 2-Methoxypyrimidine analog <b>26</b> significantly decreased lung metastasis (33%, <i>p</i> = 0.0007).</div><figure id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Effects of amiloride <b>4</b>, <b>18</b>, and <b>26</b> in experimental mouse model of late-stage lung metastasis. All compounds were administered once daily at 7.5 mg kg<sup>–1</sup> day<sup>–1</sup> for 21 days. Lung metastasis was quantified by end point luciferase assay of lung homogenates. Data represent the mean ± SEM (<b>18</b> and <b>26</b><i>n</i> = 6; vehicle and <b>4</b><i>n</i> = 4): (∗) <i>p</i> < 0.03; (∗∗∗) <i>p</i> < 0.001 relative to vehicle control, (∧) <i>p</i> < 0.03 relative to <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Orthotopic Model of Pancreatic Cancer</h3><div class="NLM_p">The in vivo antitumor and antimetastasis effects of <b>18</b> and <b>26</b> were evaluated alongside the standard of care drug gemcitabine in an orthotopic xenograft mouse model of pancreatic cancer (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). Briefly, female athymic nude mice (BALBc nu/nu, 8–11 weeks of age) were anesthetized, an incision was made in the left flank, and the spleen and tail of the pancreas were externalized. A mixture of human pancreatic cancer cells (AsPC-1) 1 × 10<sup>6</sup> and human pancreatic stellate cells (hPSCs) 1 × 10<sup>6</sup> in 50 μL of PBS was injected into the tail of the pancreas. uPA expression was confirmed in both cell lines by Western blot analysis (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00838/suppl_file/jm8b00838_si_001.pdf" class="ext-link">Supporting Information Figure S3</a>).<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(66)</a> The pancreas and spleen were then reinternalized, and the wound was closed. Seven days after cell implantation, mice were randomized to receive treatment with gemcitabine (75 mg/kg po twice weekly), <b>18</b>, or <b>26</b> (10 mg/kg ip daily) for 28 days (<i>n</i> = 4 mice/group). The higher dose (relative to the lung metastasis model) was chosen to increase the likelihood of observing efficacy. In line with previous observations in this model, gemcitabine showed only modest inhibitory effects on the primary tumor.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(67)</a> Measurement of tumor volume at end point revealed that <b>18</b> and <b>26</b> produced similar reductions to gemcitabine on the primary mass (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A). Notably, liver metastases (key site in this model) were reduced in mice treated with compounds <b>18</b> and <b>26</b> compared to those treated with gemcitabine, with no macroscopic metastatic lesions observed in any mice that received <b>26</b> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B). The absence of liver metastases in all animals treated with <b>26</b> was confirmed by histology (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00838/suppl_file/jm8b00838_si_001.pdf" class="ext-link">Supporting Information Figure S4</a>).</div><figure id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Effects of gemcitabine (Gem), <b>18</b>, and <b>26</b> on end point primary tumor volume in an orthotopic xenograft pancreatic cancer model. Mice received oral gemcitabine 75 mg/kg twice weekly or daily intraperitoneal injections of <b>18</b> or <b>26</b> (10 mg/kg) for 28 days. Data represent the mean ± SEM (<i>n</i> = 4 per group). (B) Number of mice with histologically confirmed liver metastases after receiving gemcitabine, <b>18</b>, and <b>26</b> (<i>n</i> = 4 per group): (∗) <i>p</i> = 0.0285 vs vehicle, χ<sup>2</sup> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87673" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87673" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">This study reveals that 6-substituted HMA derivatives are potent inhibitors of human uPA with potential for development into a new class of anticancer drugs. Access to a diverse series of 6-(hetero)aryl analogs was afforded via a simple two step Suzuki–Miyaura/acyl guanidinylation approach using commercial boronic acids/esters and a common 6-chloropyrazine intermediate <b>7</b>. The key intermediate was easily synthesized on multigram scale in a single step from commercial reagents. Buchwald–Hartwig chemistry was established on a related 6-bromopyrazine scaffold to access 6-aminopyrimidine HMA derivative <b>41</b>. Given the general reactivity of halopyrazines in transition-metal-catalyzed cross-coupling reactions,<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(68)</a> it is likely that a great many other substituents could be appended at the 6-position of HMA using this chemistry. Screening of such a library against proteins that reportedly bind to HMA (e.g., P2X<sub>7</sub>,<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(69)</a> NHE1,<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(70)</a> HIV-1 Vpu,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(71)</a> influenza A M2,<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(72)</a> GnRHR,<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(73)</a> GABA-A ρ-1,<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(74)</a> ASIC1a,<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(75)</a> and GIRK)<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(76)</a> could help to identify more potent and selective probes for these targets, and possibly therapeutic leads.</div><div class="NLM_p last">Leading compounds from the study showed uPA inhibitory potencies more than 10-fold higher than HMA, with X-ray crystallography revealing that the gains arose from interactions formed between the appended 6-substituents and uPA’s S1β pocket. High target selectivity was demonstrated across the serine hydrolase superfamily, and selected analogs showed no activity against ENaCs in vitro or K<sup>+</sup>-sparing/diuretic effects in vivo. Analogs carrying 2-benzofuranyl and 5-pyrimidinyl substituents emerged as distinct lead classes with differing physicochemical properties and human cell cytotoxicity profiles. Examples from each class were found to inhibit formation of lung metastases in a mouse experimental metastasis model, and 2-methoxypyrimidine analog <b>26</b> completely inhibited formation of liver macrometastases in a mouse pancreatic cancer model. In summary, this work reports the successful repurposing of the diuretic amiloride into potent uPA inhibitors with attractive pharmacological properties for further evaluation as a novel class as anticancer agents for treating uPA-driven malignancies.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51353" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51353" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Chemistry: General</h3><div class="NLM_p last">All solvents and chemicals were purchased and used without further purification except <sup><i>i</i></sup>PrOH, which was distilled from BaO and stored over 4 Å molecular sieves under Ar. Progress of reactions was monitored using Merck silica gel 60 F<sub>254</sub> TLC plates with EtOAc/pet. spirit mixtures as eluent. Compound spots on TLC plates were visualized under UV light at 254 nm. Column chromatography was performed using Merck silica gel 60 (230–400 mesh). Melting points (mp) were measured in open capillaries using a Griffin analog melting point apparatus (Thermo-Fisher Scientific, Waltham, MA, USA) and are uncorrected. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded using a Varian Inova 500 or Varian Premium Shielded 500 (499.74 MHz for <sup>1</sup>H; 125.66 MHz for <sup>13</sup>C) in deuterated solvents. Chemical shifts are reported in parts per million (δ ppm) relative to TMS for <sup>1</sup>H or the solvent peak for <sup>13</sup>C. High-resolution mass spectrometry (HRMS) analysis was performed using a Waters XEVO QToF mass spectrometer (Waters Corporation, Milford, MA, USA) with leucine encephalin as internal standard. Purity of all final compounds was confirmed at >95% using high performance liquid chromatography (HPLC). HPLC analyses were performed using a Shimadzu CLASS-VP LC10 analytical HPLC system (Shimadzu Corporation, Kyoto, Japan) with detection at 254 nm. Gradient elutions were performed using mixtures of solvent 100% H<sub>2</sub>O/0.1% TFA and 100% CH<sub>3</sub>CN/0.1% TFA on a Waters VisionHT 3 μm C18 column (150 mm × 4.6 mm) at a flow rate of 0.5 mL.min<sup>–1</sup>. Column temperature was not controlled. Only one previous 6-substituted HMA analog (6-phenyl HMA) has been reported, but no characterization or uPA inhibition data were described.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(77)</a></div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Chemistry: Experimental Procedures and Compound Characterization. Synthesis of Methyl 3-Amino-6-chloro-5-hexamethyleneimine-2-pyrazinecarboxylate (<b>7</b>)</h3><div class="NLM_p last">To a suspension of methyl 3-amino-5,6-dichloro-2-pyrazinecarboxylate (5.55 g, 25.0 mmol) in 2-propanol (50 mL) was added hexamethyleneimine (2.73 g, 3.10 mL, 27.5 mmol). DIPEA (3.55 g, 4.79 mL, 27.5 mmol) was added, and the reaction mixture was heated at reflux for 2 h. The reaction mixture was allowed to cool to room temperature, which caused the product to crystallize. The solid product was collected by vacuum filtration and washed with cold 2-propanol (2 × 10 mL) and then diethyl ether (10 mL). After drying, the pure product was obtained as pink crystals (6.1 g, 86%). Mp 109–111 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 6.13 (br s, 2H), 3.89 (s, 3H), 3.82 (t, <i>J</i> = 6.0 Hz, 4H), 1.84 (s, 4H), 1.58 (s, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 166.4, 153.7, 153.1, 120.3, 111.3, 52.0, 51.1, 28.4, 26.7. MS (ESI): <i>m</i>/<i>z</i> 285 (M + H)<sup>+</sup>, 307 (M + Na)<sup>+</sup>. HRMS (ESI<sup>+</sup>) Anal. for C<sub>12</sub>H<sub>17</sub>N<sub>4</sub>NaO<sub>2</sub><sup>+</sup>: calcd mass 307.0932, found 307.0938.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> General Method A: Suzuki–Miyaura Coupling Reactions</h3><div class="NLM_p last">Methyl 3-amino-6-chloro-5-hexamethyleneimine-2-pyrazinecarboxylate <b>7</b> (1 equiv) was combined with K<sub>2</sub>CO<sub>3</sub> (10 equiv), the appropriate boronic acid (1.5 equiv), and Pd(PPh<sub>3</sub>)<sub>4</sub> (5 mol %) in a two-neck round-bottom flask. The flask was connected to a condenser and purged with nitrogen. A 4:1 dry toluene/MeOH mixture (60 mL) was added via syringe, and the reaction mixture was heated at reflux for 0.5–18 h. The mixture was allowed to cool to room temperature and filtered through Celite (10 × 3 cm, eluting with 3 × 20 mL of EtOAc). The filtrate was evaporated to dryness and the residue purified by silica gel flash column chromatography using EtOAc/pet. spirit.</div></div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Methyl 3-Amino-5-(azepan-1-yl)-6-(4-(methylthio)phenyl)pyrazine-2-carboxylate (<b>10a</b>)</h3><div class="NLM_p last">General method A using 4-(methylthio)phenylboronic acid (93 mg, 0.545 mmol) afforded <b>10a</b> as a yellow solid; yield 77% (104 mg, 0.279 mmol). Mp 132–134 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.42 (d, <i>J</i> = 8.1 Hz, 2H), 7.25 (d, <i>J</i> = 8.1 Hz, 2H), 6.20 (bs, 2H), 3.88 (s, 3H), 3.36 (t, <i>J</i> = 5.5 Hz, 4H,), 2.48 (s, 3H), 1.62 (s, 4H), 1.43 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl3) δ 167.4, 154.8, 153.4, 137.8, 137.5, 131.2, 128.3, 126.8, 112.5, 51.9, 51.0, 28.0, 27.1, 16.1. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>19</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub>S: calcd mass, 373.1698. Found: 373.1688. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 36.1 min).</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Methyl 3-Amino-5-(azepan-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrazine-2-carboxylate (<b>11a</b>)</h3><div class="NLM_p last">General method A using 4-(trifluoromethyl)phenylboronic acid (570 mg, 3.0 mmol) afforded <b>11a</b> as a white solid; yield 64% (505 mg, 1.28 mmol). Mp 158–160 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.63 (s, 4H), 6.13 (br s, 2H, NH<sub>2</sub>), 3.89 (s, 3H), 3.34 (s, 4H), 1.65 (s, 4H), 1.45 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 167.4, 154.9, 153.7, 144.6, 129.9, 129.3, 128.2, 125.6, 125.1, 113.2, 52.1, 51.3, 28.1, 27.3. HRESI-MS <i>m</i>/<i>z</i> (M + Na<sup>+</sup>) Anal. for C<sub>19</sub>H<sub>21</sub>F<sub>3</sub>N<sub>4</sub>NaO<sub>2</sub>: calcd mass 417.1526. Found 417.1514. Anal.-HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 29.3 min).</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Methyl 3-Amino-5-(azepan-1-yl)-6-(benzo[<i>d</i>][1,3]dioxol-5-yl)pyrazine-2-carboxylate (<b>12a</b>)</h3><div class="NLM_p last">General method A using benzo[<i>d</i>][1,3]dioxol-5-ylboronic acid (85 mg, 0.515 mmol) afforded <b>12a</b> as a yellow solid; yield 51% (66 mg, 0.178 mmol). Mp 156–158 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.02 (s, 1H), 6.93 (d, <i>J</i> = 8.0 Hz, 1H), 6.80 (d, <i>J</i> = 8.0 Hz, 1H), 5.96 (s, 2H), 3.88 (s, 4H), 3.38 (s, 4H), 1.63 (s, 4H), 1.44 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.6, 154.9, 153.5, 147.9, 147.1, 134.9, 131.5, 121.7, 112.2, 108.7, 108.3, 101.1, 51.9, 51.0, 28.1, 27.1. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>19</sub>H<sub>23</sub>N<sub>4</sub>O<sub>4</sub>: calcd mass 371.1719. Found 371.1734. Anal. HPLC (100 H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 31.8 min).</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Methyl 3-Amino-5-(azepan-1-yl)-6-(isoquinolin-4-yl)pyrazine-2-carboxylate (<b>13a</b>)</h3><div class="NLM_p last">General method A using isoquinolin-4-ylboronic acid (271 mg, 1.06 mmol) afforded <b>13a</b> as a brown solid; yield 58% (156 mg, 0.413 mmol). Mp 140–142 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 9.23 (s, 1H), 8.58 (s, 1H), 8.00 (d, <i>J</i> = 8.0 Hz, 1H), 7.81 (d, <i>J</i> = 8.0 Hz, 1H), 7.68 (t, <i>J</i> = 7.5 Hz, 1H), 7.62 (t, <i>J</i> = 7.5 Hz, 1H), 3.86 (s, 3H), 3.21 (t, <i>J</i> = 5.5 Hz, 4H), 1.47 (s, 4H), 1.38 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.3, 155.8, 154.0, 152.1, 143.0, 134.3, 131.8, 130.8, 128.4, 128.0, 127.4, 126.7, 124.5, 112.9, 52.0, 50.4, 27.8, 26.8. HRESI-MS <i>m</i>/<i>z</i> (M + Na<sup>+</sup>) 400, Anal. for C<sub>21</sub>H<sub>24</sub>N<sub>5</sub>NaO<sub>2</sub>: calcd mass 400.1749. Found 400.1747. Anal. HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 22.3 min).</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Methyl 3-Amino-5-(azepan-1-yl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrazine-2-carboxylate (<b>14a</b>)</h3><div class="NLM_p last">General method A using 1-methyl-1<i>H</i>-pyrazol-4-ylboronic acid (110 mg, 0.526 mmol) afforded <b>14a</b> as a yellow solid; yield 77% (89 mg, 0.269 mmol). Mp 134–136 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.64 (s, 1H), 7.57 (s, 1H), 6.17 (bs, 2H), 3.91 (s, 3H), 3.89 (s, 3H), 3.47 (t, <i>J</i> = 6 Hz, 4H), 1.66 (s, 4H), 1.47 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.4, 155.5, 153.4, 138.7, 129.1, 125.3, 122.6, 112.4, 52.1, 51.2, 39.0, 28.0, 27.2. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) 331, Anal. for C<sub>16</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub>: calcd mass 331.1882. Found 331.1894. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 25.2 min).</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Methyl 3-Amino-5-(azepan-1-yl)-6-(1-(2-morpholinoethyl)-1<i>H</i>-pyrazol-4-yl)pyrazine-2-carboxylate (<b>15a</b>)</h3><div class="NLM_p last">General method A using 1-(2-morpholinoethyl)-1<i>H</i>-pyrazol-4-ylboronic acid (165 mg, 0.536 mmol) afforded <b>15a</b> as a yellow solid; yield 80% (119 mg, 0.277 mmol). Mp 132–134 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.70 (s, 1H), 7.61 (s, 1H), 6.24 (bs, 2H), 4.25 (s, 2H), 3.89 (s, 3H), 3.69 (s, 4H), 3.46 (s, 4H), 2.84 (s, 2H), 2.50 (s, 4H), 1.65 (s, 4H), 1.47 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.2, 155.5, 153.3, 138.6, 128.7, 125.2, 122.1 112.4, 66.9, 58.2, 53.7, 51.9, 51.1, 49.6, 27.9 27.0. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>), Anal. for C<sub>22</sub>H<sub>36</sub>N<sub>7</sub>O<sub>3</sub>: calcd mass 430.2567. Found 430.2553. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA →100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 21.6 min).</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Methyl 3-Amino-5-(azepan-1-yl)-6-(1<i>H</i>-indol-2-yl)pyrazine-2-carboxylate (<b>16a</b>)</h3><div class="NLM_p last">General method A using 1<i>H</i>-indol-2-ylboronic acid (278 mg, 1.73 mmol) afforded <b>16a</b> as an orange solid; yield 34% (87.5 mg, 0.239 mmol). Mp 152–154 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 9.14 (s, 1H), 7.57 (d, 1H), 7.37 (d, 1H, <i>J</i> = 7.7 Hz), 7.16 (t, 1H, <i>J</i> = 7.0 Hz), 7.08 (t, 1H, <i>J</i> = 7.0 Hz), 6.52 (s, 1H), 3.93 (s, 3H), 3.58 (t, <i>J</i> = 5.75 Hz, 4H), 1.70 (s,4H), 1.50 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.2, 155.1, 153.2, 136.0, 135.7, 129.0, 124.5, 122.4, 120.7, 119.90, 112.70, 111.0, 102.0, 52.1, 51.7, 28.1, 27.5. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) 388, Anal. for C<sub>20</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub>: calcd mass 388.1730. Found 388.1731. Anal. HPLC (100 H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 29.8 min).</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Methyl 3-Amino-5-(azepan-1-yl)-6-(benzo[<i>b</i>]thiophen-2-yl)pyrazine-2-carboxylate (<b>17a</b>)</h3><div class="NLM_p last">General method A using benzo[<i>b</i>]thiophen-2-ylboronic acid (534 mg, 3.0 mmol) afforded <b>17a</b> as a yellow solid; yield 78% (600 mg). Mp 146–148 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 1.48 (s, 4H), 1.69 (s, 4H), 3.51 (s, 4H), 3.91 (s, 3H), 6.13 (br s, 2H, NH2), 7.22 (s, 1H), 7.21 (m, 2H), 7.71 (d, <i>J</i> = 6.9 Hz, 1H), 7.80 (d, <i>J</i> = 7.0 Hz, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 167.3, 155.3, 153.6, 143.3, 140.2, 140.1, 125.4, 124.5, 124.4, 123.6, 122.3, 122.0, 113.2, 52.3, 51.3, 28.2, 27.4. HRESI-MS <i>m</i>/<i>z</i> (M + K<sup>+</sup>) Anal. for C<sub>20</sub>H<sub>22</sub>KN<sub>4</sub>O<sub>3</sub> calcd mass 405.1394. Found 405.1361. Anal.-HPLC (100 H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 31.9 min).</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Methyl 3-Amino-5-(azepan-1-yl)-6-(benzofuran-2-yl)pyrazine-2-carboxylate (<b>18a</b>)</h3><div class="NLM_p last">General method A using benzofuran-2-ylboronic acid (486 mg, 3.0 mmol) afforded <b>18a</b> as a yellow solid; yield 57% (420 mg). Mp 121–123 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 1.46 (s, 4H), 1.66 (s, 4H), 3.45 (t, <i>J</i> = 5.8 Hz, 4H), 3.90 (s, 3H), 6.13 (br s, 2H, NH2), 6.93 (s, 1H), 7.21 (t, <i>J</i> = 7.3 Hz, 1H), 7.25 (t, <i>J</i> = 7.2 Hz, 1H), 7.47 (d, <i>J</i> = 7.9 Hz, 1H), 7.56 (d, <i>J</i> = 7.5 Hz, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 167.2, 164.9, 154.8, 154.6, 129.2, 124.4, 123.1, 121.4, 121.2, 112.9, 111.5, 105.1, 52.2, 50.2, 28.2, 27.3. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>20</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub>: calcd mass 367.1831. Found. 367.1770. Anal.-HPLC (70:30 H<sub>2</sub>O/0.1% CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 29.5 min).</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Methyl 3-Amino-5-(azepan-1-yl)-6-(4-fluorobenzofuran-2-yl)pyrazine-2-carboxylate (<b>19a</b>)</h3><div class="NLM_p last">General method A using 4-fluorobenzofuran-2-ylboronic acid (95 mg, 0.531 mmol) afforded <b>19a</b> as a yellow solid; yield 58% (80 mg, 0.210 mmol). Mp 108–110 °C. <sup>1</sup>H NMR (126 MHz, CDCl<sub>3</sub>): 7.27 (d, 1H), 7.20 (m, 1H), 6.99 (s, 1H), 6.93 (t, 1H, <i>J</i> = 8.5 Hz), 3.91 (s, 3H), 3.46 (s, 4H), 1.69 (s, 4H), 1.49 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.0, 156.9, 156.2, 154.7, 154.0, 138.3, 124.6, 120.5, 118.0, 115.9, 110.4, 108.6, 107.6, 52.2, 50.0, 28.0, 27.1. HRESI-MS <i>m</i>/<i>z</i> (M + Na<sup>+</sup>) Anal. for C<sub>20</sub>H<sub>21</sub>FN<sub>6</sub>NaO<sub>4</sub>: calcd mass 407.1495. Found 407.1504. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 21.2 min).</div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Methyl-3-amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(thiophen-2-yl)pyrazine-2-carboxamide (<b>20a</b>)</h3><div class="NLM_p last">General method A using thiophen-2-ylboronic acid (70 mg, 0.549 mmol) afforded <b>20a</b> as a light yellow solid; yield 85% (99 mg, 0.299 mmol). Mp 118–120 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.27 (d, <i>J</i> = 5 Hz, 1H), 7.03 (d, <i>J</i> = 3 Hz, 1H), 6.98 (m, 1H), 3.89 (s, 3H), 3.43 (t, <i>J</i> = 5.7 Hz, 4H), 1.67 (s, 4H), 1.47 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.3, 155.2, 153.5, 142.8, 126.9, 126.0, 125.8, 125.5, 112.7, 52.1, 51.1, 28.2, 27.3. HRESI-MS <i>m</i>/<i>z</i> (M + Na<sup>+</sup>) Anal. for C<sub>16</sub>H<sub>20</sub>N<sub>4</sub>NaO<sub>2</sub>: calcd mass 355.1205. Found 355.1193. Anal. HPLC (100 H<sub>2</sub>O/0.1% TFA →100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 28.8 min).</div></div><div id="sec4_3_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Methyl 3-Amino-5-(azepan-1-yl)-6-(thiophen-3-yl)pyrazine-2-carboxylate (<b>21a</b>)</h3><div class="NLM_p last">General method A using thiophen-3-ylboronic acid (75 mg, 0.584 mmol) afforded <b>21a</b> as a white solid; yield 85% (100 mg, 0.302 mmol). Mp 118–120 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.38 (s, 1H), 7.29 (m, 1H), 7.25 (d, <i>J</i> = 5 Hz, 1H), 3.88 (s, 3H), 3.38 (t, <i>J</i> = 5.8 Hz, 4H), 1.63 (s, 4H), 1.44 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.4, 155.3, 153.5, 141.3, 128.1, 127.9, 125.4, 122.8, 112.2, 52.0, 50.9, 28.0, 27.1. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>16</sub>H<sub>21</sub>N<sub>4</sub>NaO<sub>2</sub>S: calcd mass 355.1205. Found 355.1197. Anal. HPLC (100 H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 28.3 min).</div></div><div id="sec4_3_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Methyl 3-Amino-5-(azepan-1-yl)-6-(furan-2-yl)pyrazine-2-carboxylate (<b>22a</b>)</h3><div class="NLM_p last">General method A using furan-2-ylboronic acid (59 mg, 0.526 mmol) afforded <b>22a</b> as an off white solid; yield 98% (111 mg, 0.352 mmol). Mp 116–118 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.41 (s, 1H), 6.54 (d, <i>J</i> = 2.3 Hz, 1H), 6.45 (s, 1H), 6.13 (br s, 2H, NH<sub>2</sub>), 3.89 (s, 3H), 3.37 (t, <i>J</i> = 5.5 Hz, 4H), 1.66 (s, 4H), 1.47 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 167.1, 154.8, 154.0, 152.2, 141.4, 122.0, 112.1, 111.6, 108.6, 52.0, 50.0, 28.0, 26.9. HRESI-MS <i>m</i>/<i>z</i> (M + Na<sup>+</sup>) Anal. for C<sub>16</sub>H<sub>21</sub>N<sub>4</sub>NaO<sub>3</sub>: calcd mass 339.1418. Found 339.1433. Anal.-HPLC (100 H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 27.1 min).</div></div><div id="sec4_3_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Methyl 3-Amino-5-(azepan-1-yl)-6-(furan-3-yl)pyrazine-2-carboxylate (<b>23a</b>)</h3><div class="NLM_p last">General method A using furan-3-ylboronic acid (107 mg, 0.389 mmol) afforded <b>23a</b> as a yellow solid; yield 93% (114 mg, 0.360 mmol). Mp 122–124 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.64 (s, 1H), 7.41 (s, 1H), 6.61 (s, 1H), 6.20 (bs, 2H), 3.89 (s, 3H), 3.48 (t, <i>J</i> = 5 Hz, 4H), 1.66 (s, 4H), 1.47 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.3, 155.6, 153.6, 142.6, 140.6, 125.8, 124.8, 112.6, 111.2, 52.0, 51.0, 28.0, 27.1. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>16</sub>H<sub>21</sub>N<sub>4</sub>O<sub>3</sub>: calcd mass 316.1614. Found 316.1604. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 30.9 min).</div></div><div id="sec4_3_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Methyl 3-Amino-5-(azepan-1-yl)-6-(2-fluoropyridin-3-yl)pyrazine-2-carboxylate (<b>24a</b>)</h3><div class="NLM_p last">General method A using 2-fluoropyridin-3-ylboronic acid (75 mg, 0.529 mmol) afforded <b>24a</b> as a brown solid; yield 76% (92 mg, 0.266 mmol). Mp 156–158 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.17 (d, <i>J</i> = 4.3 Hz, 1H), 8.06 (m, 1H), 7.29 (t, <i>J</i> = 5.5 Hz, 1H), 3.89 (s, 3H), 3.36 (s, <i>J</i> = 5.7 Hz, 4H), 1.63 (s, 4H), 1.46 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.2, 161.3, 155.2, 154.1, 146.8, 141.1, 124.5, 123.8, 122.2, 113.3, 52.3, 50.3, 28.1, 27.3. HRESI-MS <i>m</i>/<i>z</i> (M + Na<sup>+</sup>) Anal. for C<sub>17</sub>H<sub>20</sub>FN<sub>5</sub>NaO<sub>2</sub>: calcd mass 368.1499. Found 368.1489. Anal. HPLC (100 H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 26.3 min).</div></div><div id="sec4_3_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Methyl 3-Amino-5-(azepan-1-yl)-6-(pyrimidin-5-yl)pyrazine-2-carboxylate (<b>25a</b>)</h3><div class="NLM_p last">General method A using pyrimidin-5-ylboronic acid (279 mg, 2.25 mmol) afforded <b>25a</b> as a yellow solid; yield 91% (450 mg). Mp 176–178 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 9.13 (s, 1H), 8.89 (s, 2H), 6.13 (br s, 2H, NH2), 3.91 (s, 3H), 3.52 (t, <i>J</i> = 6.0 Hz, 4H), 1.68 (s, 4H), 1.48 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 167.1, 157.1, 155.7, 155.3, 153.9, 134.9, 124.5, 114.5, 52.3, 51.5, 28.0, 27.4. HRESI-MS <i>m</i>/<i>z</i> (M + Na<sup>+</sup>) Anal. for C<sub>16</sub>H<sub>20</sub>N<sub>6</sub>NaO<sub>2</sub>: calcd mass 351.1545. Found. 351.1535. Anal.-HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 23.4 min).</div></div><div id="sec4_3_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Methyl 3-Amino-5-(azepan-1-yl)-6-(2-methoxypyrimidin-5-yl)pyrazine-2-carboxylate (<b>26a</b>)</h3><div class="NLM_p last">General method A using 2-methoxypyrimidin-5-ylboronic acid (79 mg, 0.513 mmol) afforded <b>26a</b> as a yellow solid; yield 88% (111 mg, 0.310 mmol). Mp 168–170 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): 8.66 (s, 2H), 6.13 (br s, 2H, NH<sub>2</sub>), 4.05 (s, 3H), 3.90 (s, 3H), 3.38 (t, <i>J</i> = 5.5 Hz, 4H), 1.68 (s, 4H), δ 1.48 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 166.4, 164.7, 158.3, 155.3, 153.8, 128.8, 125.2, 113.9, 55.2, 52.2, 51.4, 28.0, 27.3. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>17</sub>H<sub>22</sub>N<sub>6</sub>O<sub>3</sub>: calcd mass 359.1832. Found 359.1848. Anal.-HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>tr</i> = 28.0 min).</div></div><div id="sec4_3_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Methyl 3-Amino-5-(azepan-1-yl)-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxylate (<b>27a</b>)</h3><div class="NLM_p last">General method A using 2,4-dimethoxypyrimidin-5-ylboronic acid (79 mg, 0.350 mmol) afforded <b>27a</b> as a yellow solid; yield 91% (124 mg, 0.319 mmol). Mp 150–152 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.36 (s, 1H), 4.03 (s, 3H), 3.94 (s, 3H), 3.87 (s, 3H), 3.39 (s, 4H), 1.60 (s, 4H,), 1.46 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 168.3, 167.2, 164.8, 158.1, 155.3, 154.1, 123.8, 117.1, 112.6, 55.0, 54.1, 52.0, 50.0, 28.0, 27.0. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>18</sub>H<sub>25</sub>N<sub>6</sub>O<sub>4</sub> calcd mass 389.1937. Found389.1929. Anal.-HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 27.1 min).</div></div><div id="sec4_3_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Methyl 3-Amino-5-(azepan-1-yl)-6-(2,6-dimethoxypyridin-3-yl)pyrazine-2-carboxylate (<b>28a</b>)</h3><div class="NLM_p last">General method A using 2,6-dimethoxypyridin-3-ylboronic acid (200 mg, 0.703 mmol) afforded <b>28a</b> as a yellow solid; yield 42% (115 mg, 0.297 mmol). Mp 134–136 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.66 (d, <i>J</i> = 8.0 Hz, 1H), 6.38 (d, <i>J</i> = 8.0 Hz, 1H), 3.92 (s, 3H), 3.87 (s, 3H), 3.86 (s, 3H), 3.45 (bs, 2H), 3.31 (bs, 2H), 1.57 (s, 4H), 1.44 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.5, 162.8, 159.7, 155.3, 153.9, 141.5, 127.6, 116.2, 112.2, 101.3, 53.7, 53.5, 51.9, 50.1, 28.1, 27.1. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>), Anal. for C<sub>19</sub>H<sub>25</sub>N<sub>5</sub>O<sub>4</sub>: calcd mass 388.1985. Found 388.1983. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 31.6 min).</div></div><div id="sec4_3_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Methyl 3-Amino-5-(azepan-1-yl)-6-(2,4-dimethoxyphenyl)pyrazine-2-carboxylate (<b>29a</b>)</h3><div class="NLM_p last">General method A using 2,4-dimethoxyphenylboronic acid (128 mg, 0.702 mmol) afforded <b>29a</b> as a yellow solid; yield 53% (143 mg, 0.371 mmol). Mp 106–108 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.33 (d, <i>J</i> = 8.3 Hz, 1H), 6.54 (dd, <i>J</i> = 8.3 Hz, <i>J</i> = 2.1 Hz 1H), 6.42 (d, <i>J</i> = 2.1 Hz, 1H), 3.85 (s, 3H), 3.82 (s, 3H), 3.70 (s, 3H), 3.44 (s, 2H), 3.26 (s, 2H), 1.58 (s, 2H), 1.53 (s, 2H), 1.46 (s, 2H), 1.39 (s, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.0, 160.9, 158.2, 155.4, 154.0, 131.1, 129.2, 123.7, 111.8, 105.1, 98.7, 55.7, 55.7, 52.0, 50.6, 27.8, 26.9. HRESI-MS <i>m</i>/<i>z</i> (M + Na<sup>+</sup>), Anal. for C<sub>20</sub>H<sub>27</sub>N<sub>4</sub>NaO<sub>4</sub>: calcd mass 409.1852. Found 409.1866. Anal. HPLC (100 H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 28.6 min).</div></div><div id="sec4_3_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Methyl 3-Amino-5-(azepan-1-yl)-6-(3,5-dimethoxyphenyl)pyrazine-2-carboxylate (<b>30a</b>)</h3><div class="NLM_p last">General method A using 3,5-dimethoxyphenylboronic acid (128 mg, 0.702 mmol) afforded <b>30a</b> as a yellow solid; 62% (166 mg, 0.430 mmol). Mp 96–98 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 6.64 (s, 2H), 6.40 (s, 1H), 3.88 (s, 3H), 3.81 (s, 6H), 3.38 (t, <i>J</i> = 6.0 Hz, 4H), 1.64 (s, 4H), 1.44 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.5, 161.0, 154.7, 153.7, 142.8, 131.6, 112.0, 106.3, 100.0, 55.6, 52.0, 50.9, 28.1, 27.1. HRESI-MS <i>m</i>/<i>z</i> (M + Na<sup>+</sup>), Anal. for C<sub>20</sub>H<sub>26</sub>N<sub>4</sub>NaO<sub>4</sub>: calcd mass 409.1852. Found 409.1867. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 30.0 min).</div></div><div id="sec4_3_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Methyl 3-Amino-5-(azepan-1-yl)-6-(3,6-dimethoxypyridazin-4-yl)pyrazine-2-carboxylate (<b>31a</b>)</h3><div class="NLM_p last">General method A using 3,6-dimethoxypyridazin-4-ylboronic acid (97 mg, 0.526 mmol) afforded <b>31a</b> as a yellow solid; yield 68% (94 mg, 0.242 mmol). Mp 152–154 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.17 (s, 1H), 4.08 (s, 3H), 4.00 (s, 3H), 3.88 (s, 3H), 3.43 (s, 2H), 3.29 (s, 2H), 1.63 (s, 4H), 1.44 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.00, 162.8, 159.6, 154.7, 154.1, 135.1, 122.9, 119.4, 113.1, 54.8, 54.6, 52.1, 49.7, 28.0, 27.2. HRESI-MS <i>m</i>/<i>z</i> (M + Na<sup>+</sup>), Anal. for C<sub>18</sub>H<sub>24</sub>N<sub>6</sub>NaO<sub>4</sub>: calcd mass 411.1757. Found 411.1762. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 21.2 min).</div></div><div id="sec4_3_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Methyl 3-Amino-6-(2-aminopyrimidin-5-yl)-5-(azepan-1-yl)pyrazine-2-carboxylate (<b>32a</b>)</h3><div class="NLM_p last">General method A using 2-aminopyrimidin-5-ylboronic acid (208 mg, 1.5 mmol) afforded <b>32a</b> as a yellow solid; yield 83% (285 mg). Mp 216–218 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.27 (s, 2H), 7.04 (br s, 2H, NH<sub>2</sub>), 6.76 (br s, 2H, NH<sub>2</sub>), 3.74 (s, 3H), 3.41 (t, <i>J</i> = 5.9 Hz, 4H), 1.59 (s, 4H), 1.41 (s, 4H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 27.0, 27.9, 51.0, 51.9, 112.3, 123.9, 126.5, 154.2, 155.1, 157.4, 163.0, 167.3, 163.0, 157.4, 155.1, 154.2, 126.5, 123.9, 112.3, 51.9, 51.0, 27.9, 27.0. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>), Anal. for C<sub>16</sub>H<sub>22</sub>N<sub>7</sub>O<sub>2</sub>: calcd mass 344.1835. Found 344.1833. Anal. HPLC (100 H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 14.2 min).</div></div><div id="sec4_3_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Methyl 3-Amino-5-(azepan-1-yl)-6-(2-chloropyrimidin-5-yl)pyrazine-2-carboxylate (<b>8</b>)</h3><div class="NLM_p last">General method A using (2-chloropyrimidin-5-yl)boronic acid (475 mg, 3 mmol) afforded <b>8</b> as a yellow solid (460 mg, 64%). Mp 168–170 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.76 (s, 2H), 6.13 (br s, 2H, NH<sub>2</sub>), 3.91 (s, 3H), 3.35 (t, <i>J</i> = 5.8 Hz, 4H), 1.71 (s, 4H), 1.49 (s, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 27.3, 27.8, 51.4, 52.2, 114.6, 122.8, 133.3, 153.7, 155.0, 158.0, 159.2, 166.8. MS (ESI): <i>m</i>/<i>z</i> 363 (M + H)<sup>+</sup>, 385 (M + H)<sup>+</sup>. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>), Anal. for C<sub>16</sub>H<sub>20</sub>ClN<sub>6</sub>O<sub>2</sub>: calcd mass 363.1336. Found 363.1347. Anal. HPLC (100 H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 17.6 min).</div></div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> General Method B. Synthesis of Methyl 3-Amino-5-(azepan-1-yl)-6-(2-(substituted amino)pyrimidin-5-yl)pyrazine-2-carboxylates <b>33a</b> and <b>34a</b></h3><div class="NLM_p last">To a solution of methyl 3-amino-5-(azepan-1-yl)-6-(2-chloropyrimidin-5-yl)pyrazine-2-carboxylate <b>8</b> (0.25 mmol) in DMF (2 mL) at room temperature was added the appropriate amine (0.75 mmol). DIPEA (0.75 mmol) was then added, and the reaction mixture was stirred at room temperature for 2 days. The mixture was extracted with EtOAc (3 × 10 mL), and the combined organic layer was washed with brine, dried (MgSO<sub>4</sub>), and evaporated. The residue was purified by silica gel flash column chromatography using EtOAc/pet. spirit.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Methyl 3-Amino-5-(azepan-1-yl)-6-(2-(methylamino)pyrimidin-5-yl)pyrazine-2-carboxylate (<b>33a</b>)</h3><div class="NLM_p last">General method B using <b>8</b> (91 mg, 0.25 mmol) and methylamine (2 M in MeOH, 0.375 mL, 0.75 mmol) gave <b>33a</b> as a yellow solid; yield 87% (78.0 mg). Mp 158–160 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.45 (s, 2H), 6.22 (br s, 2H, NH<sub>2</sub>), 5.28 (q, <i>J</i> = 4.9 Hz, 1H, NH), 3.90 (s, 3H), 3.42 (t, <i>J</i> = 5.9 Hz, 4H), 3.04 (d, <i>J</i> = 5.1 Hz, 3H), 1.67 (s, 4H), δ 1.47 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 167.4, 162.0, 157.2, 155.3, 153.7, 126.9, 124.2, 113.3, 52.3, 51.3, 28.8, 28.0, 27.3. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>), Anal. for C<sub>17</sub>H<sub>24</sub>N<sub>7</sub>O<sub>2</sub> 358.1991, found 358.2001. Anal. HPLC (100 H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 14.8 min).</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Methyl 3-Amino-5-(azepan-1-yl)-6-(2-(isopropylamino)pyrimidin-5-yl)pyrazine-2-carboxylate (<b>34a</b>)</h3><div class="NLM_p last">General method B using <b>8</b> (91 mg, 0.25 mmol) and isopropylamine (45 mg, 0.75 mmol) gave <b>34a</b> as a yellow solid; yield 83% (80 mg). Mp 155–157 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.43 (s, 2H), 6.25 (br s, 2H), 5.10 (d, <i>J</i> = 7.8 Hz, 1H), 4.16 (septet, <i>J</i> = 6.8 Hz, 1H), 3.89 (s, 3H), 3.43 (t, <i>J</i> = 5.9 Hz, 4H), 1.67 (s, 4H), 1.47 (s, 4H), 1.25 (d, <i>J</i> = 7.0 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 167.2, 157.0, 155.1, 153.5, 126.8, 123.8, 113.1, 52.0, 51.1, 43.0, 27.8, 27.1, 22.9. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>), Anal. for for C<sub>19</sub>H<sub>28</sub>N<sub>7</sub>O<sub>2</sub> 386.2304, found 386.2318. Anal. HPLC (100 H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 16.1 min).</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Methyl 3-Amino-5-(azepan-1-yl)-6-(2-(2-hydroxyethyl)amino)pyrimidin-5-yl)pyrazine-2-carboxylate (<b>35a</b>)</h3><div class="NLM_p last">To a solution of methyl 3-amino-5-(azepan-1-yl)-6-(2-chloropyrimidin-5-yl)pyrazine-2-carboxylate <b>8</b> (91 mg, 0.25 mmol) in 2-propanol (5 mL) was added ethanolamine (16.8 mg, 0.017 mL, 0.275 mmol). DIPEA (35.5 mg, 0.048 mL, 0.275 mmol) was then added, and the reaction mixture was heated at reflux for 2 h. After cooling to room temperature, additional equivalents of ethanolamine (0.275 mmol) and DIPEA (0.275 mmol) were added, and the reaction mixture was heated for a further 2 h. The mixture was allowed to cool to room temperature overnight, which caused the product to crystallize. The solid product was collected by vacuum filtration and washed with cold 2-propanol (2 × 2 mL) and diethyl ether (2 mL). After drying, the pure product was obtained as light yellow crystals (82 mg, 84%). Mp 164–166 °C <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ, 8.44 (s, 2H), 6.23 (br s, 2H), 5.64 (t, <i>J</i> = 5.5 Hz, 1H), 3.90 (s, 3H), 3.85 (t, <i>J</i> = 4.4 Hz, 2H), 3.62 (q, <i>J</i> = 4.9 Hz, 2H), 3.42 (t, <i>J</i> = 5.6 Hz, 4H), 1.68 (s, 4H), 1.48 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 167.1, 161.7, 156.9, 155.1, 153.5, 126.2, 124.6, 113.3, 63.6, 52.1, 51.1, 44.9, 27.8, 27.1. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>), Anal. for C<sub>18</sub>H<sub>26</sub>N<sub>7</sub>O<sub>3</sub> 388.2097, found 388.2088. Anal. HPLC (100 H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 14.4 min).</div></div><div id="sec4_5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> General Method C. Synthesis of Acyl Guanidines Using the Reported Method<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(38)</a></h3><div class="NLM_p last">Free guanidine was generated via neutralization of guanidine·HCl with Na<sup>+</sup> <sup><i>i</i></sup>PrO<sup>–</sup> in <sup><i>i</i></sup>PrOH to create a 2-fold molar excess relative to the 6-substituted pyrazinoyl methyl ester. A stock solution of <sup><i>i</i></sup>PrO<sup>–</sup> was prepared by adding Na (typically 30–70 mg) in anhydrous <sup><i>i</i></sup>PrOH under N<sub>2</sub> and heated at 70 °C for 30 min. From this stock solution an amount of <sup><i>i</i></sup>PrO<sup>–</sup> was removed via syringe and made up to 10 mL in anhydrous <sup><i>i</i></sup>PrOH. To this solution was added a stoichiometric amount of guanidine hydrochloride, and the mixture was stirred at 70 °C for 30 min. This solution was gravity filtered onto the neat 6-substituted pyrazinoyl methyl ester. Once filtration was complete, the mixture was heated to reflux and allowed to react for 1–6 h. The reactions were monitored by MS and TLC and terminated by removal of solvent under reduced pressure. Final products were isolated by rp-HPLC. All compounds were isolated as TFA salts and exchanged to their respective HCl salts by stirring with quaternary ammonium Cl<sup>–</sup> anion exchange resin in MeOH prior to biological evaluation.</div></div><div id="sec4_6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> General Method D. Improved Synthesis of Acyl Guanidines</h3><div class="NLM_p">Dry CH<sub>3</sub>OH (50 mL) was slowly added with stirring to small pieces of sodium (2.3 g, 0.1 mol) cooled on ice under nitrogen. After complete dissolution of the sodium, guanidine hydrochloride (9.55 g, 0.1 mol) was added and the resulting mixture was stirred at room temperature for 1.5 h. Filtration of the white precipitate gave a 2 M solution of free guanidine in methanol, which was collected in a sealed dry flask under nitrogen and stored in a refrigerator.</div><div class="NLM_p last">To a suspension of the requisite methyl ester (1 equiv, 0.2–0.5 mmol) in DMF (5 mL) was added 2 M guanidine in methanol (10 equiv, 2–5 mmol), and the resulting mixture was stirred at room temperature overnight. Brine (20 mL) was added and the mixture extracted with EtOAc (3 × 30 mL). The organic layer was washed with 10% NaCl (2 × 30 mL), dried (MgSO<sub>4</sub>), and concentrated under reduced pressure. The crude mixture was dissolved in 5 mL of 30% CH<sub>3</sub>CN/70% H<sub>2</sub>O and 0.1% acetic acid and loaded onto a reverse phase silica gel chromatography column. Isocratic elution was performed with CH<sub>3</sub>CN/H<sub>2</sub>O mixtures containing 0.1% acetic acid. The pooled fractions containing pure compound by TLC analysis were concentrated under reduced pressure and neutralized with solid NaHCO<sub>3</sub>. The aqueous mixture was extracted with EtOAc (3 × 30 mL), and the combined organic layer was washed with brine, dried (MgSO<sub>4</sub>), and evaporated to give the free acylguanidine.</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(4-(methylthio)phenyl)pyrazine-2-carboxamide (<b>10</b>)</h3><div class="NLM_p last">General method C using <b>10a</b> (70 mg, 0.214 mmol) gave <b>10</b> as a yellow solid; yield 5% (6 mg, 0.015 mmol). Mp 152–154 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 10.31 (s, 1H), 9.44 (s, 2H), 8.47 (s, 2H), 7.44 (d, <i>J</i> = 8.1 Hz, 2H), 7.28 (d, <i>J</i> = 8.1 Hz, 2H), 3.40 (t, <i>J</i> = 5.5 Hz, 4H) 1.60 (s, 4H), 1.46 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.0, 156.6, 155.7, 153.6, 139.0, 136.4, 131.2, 128.1, 126.6, 111.0, 51.5, 27.9, 27.1, 15.5. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>19</sub>H<sub>26</sub>N<sub>7</sub>OS: calcd mass 400.1920. Found 400.1935. Anal. HPLC. (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 28.4 min).</div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(4-(trifluoromethyl)phenyl)pyrazine-2-carboxamide (<b>11</b>)</h3><div class="NLM_p last">General method D using <b>11a</b> (394 mg, 1.0 mmol) gave <b>11</b> as a yellow solid; yield 92% (385 mg). Mp 172–175 °C. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.68 (d, <i>J</i> = 8.0 Hz, 2H), 7.65 (d, <i>J</i> = 8.0 Hz, 2H), 3.38 (t, <i>J</i> = 5.0 Hz, 4H), 1.65 (s, 4H), 1.46 (s, 4H). <sup>13</sup>C NMR (CD<sub>3</sub>OD): δ 167.9, 160.2, 155.8, 155.0, 145.6, 130.1, 130.0 (d, <i>J</i> = 32 Hz), 129.2, 125.8 (d, <i>J</i> = 2.7 Hz), 124.3 (d, <i>J</i> = 170), 112.9, 51.6, 28.6, 27.6. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>19</sub>H<sub>23</sub>F<sub>3</sub>N<sub>7</sub>O: calcd mass 422.1916. Found 422.1911. Anal. HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> 27.9 min).</div></div><div id="sec4_6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 3-Amino-5-(azepan-1-yl)-6-(benzo[<i>d</i>][1,3]dioxol-5-yl)-<i>N</i>-carbamimidoylpyrazine-2-carboxamide (<b>12</b>)</h3><div class="NLM_p last">General method C using <b>12a</b> (54 mg, 0.146 mmol) gave <b>12</b> as a yellow oil; yield 9% (6 mg, 0.015 mmol). Mp 154–156 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.39 (s, 1H), 8.71 (s, 2H), 8.27 (s, 2H), 7.31 (s, 1H), 6.96 (m, 2H), 6.08 (s, 2H), 3.40 (<i>t</i>, <i>J</i> = 5.75 Hz, 4H), 1.60 (s, 2H), 1.39 (s, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.2, 155.2, 154.8, 153.6, 147.26, 146.7, 133.4, 130.3, 121.4, 112.7, 108.5, 108.0, 101.2, 50.4, 27.2, 26.1. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>19</sub>H<sub>24</sub>N<sub>7</sub>O<sub>3</sub>: calcd mass 398.1941. Found 398.1929. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 26.4 min).</div></div><div id="sec4_6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(isoquinolin-4-yl)pyrazine-2-carboxamide (<b>13</b>)</h3><div class="NLM_p last">General method C using <b>13a</b> (156 mg, 0.413 mmol) gave <b>13</b> as an orange solid; yield 15% (32 mg, 0.079 mmol). Mp 158–160 °C. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 10.47 (s, exchange with solvent), 9.57 (bs, 1H), 9.19 (s, exchange with solvent), 9.09 (s, exchange with solvent) 8.69 (bs, 1H), 8.40 (d, <i>J</i> = 8.2 Hz, 1H), 8.01 (t, <i>J</i> = 7.5 Hz, 1H), 7.91 (t, <i>J</i> = 7.5 Hz, 1H), 7.81 (d, <i>J</i> = 8.2 Hz, 1H), 3.37 (s, 2H), 3.23 (s, 2H), 1.53 (s, 4H), 1.44 (s, 4H). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD) δ 167.5, 157.7, 156.9, 156.4, 149.7, 137.6, 136.9, 136.9, 136.8, 131.6, 131.4, 129.0, 125.7, 124.7, 113.0, 51.6, 29.0, 27.8. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>20</sub>H<sub>24</sub>N<sub>7</sub>OS: calcd mass 410.1763. Found 410.1758. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 22.7 min).</div></div><div id="sec4_6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrazine-2-carboxamide (<b>14</b>)</h3><div class="NLM_p last">General method C using <b>14a</b> (69 mg, 0.207 mmol) gave <b>14</b> as a yellow oil; yield 38% (32 mg, 0.193 mmol). Mp 150–152 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 10.49 (s, 1H), 8.83 (s, 2H), 8.52 (s, 2H), 8.00 (s, 1H), 7.57 (s, 1H), 5.49 (bs, 2H), 3.93 (s, 3H), 3.50 (t, <i>J</i> = 5.75 Hz, 4H), 1.69 (s, 4H), 1.49 (s, 4H).<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.6, 156.4, 156.1, 153.4, 137.4, 130.7, 125.1, 121.7, 111.1, 51.5, 38.7, 27.9, 27.3. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>16</sub>H<sub>24</sub>N<sub>9</sub>O: calcd mass 358.2104. Found 358.2118. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 21.0 min).</div></div><div id="sec4_6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(1-(2-morpholinoethyl)-1<i>H</i>-pyrazol-4-yl)pyrazine-2-carboxamide (<b>15</b>)</h3><div class="NLM_p last">General method C using <b>15a</b> (99 mg, 0.229 mmol) gave <b>15</b> as an orange oil; yield 20% (22 mg, 0.048 mmol). Mp 157–159 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 10.48 (s, 1H), 8.86 (s, 2H), 8.65 (s, 2H), 7.89 (s, 1H), 7.56 (s, 1H), 4.67 (s, 2H), 3.93 (s, 4H), 3.69 (s, 2H,), 3.47 (s, 4H), 3.42 (bs, 2H), 3.05 (bs, 2H,) 1.67 (s, 4H), 1.49 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.6, 156.4, 156.1, 153.6, 140.0, 130.6, 124.1, 122.9, 111.3, 63.8, 57.2, 53.3, 51.4, 46.4, 27.9, 27.2. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>21</sub>H<sub>33</sub>N<sub>10</sub>O<sub>2</sub>: calcd mass 457.2788. Found 457.2796. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 19.0 min).</div></div><div id="sec4_6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(1<i>H</i>-indol-2-yl)pyrazine-2-carboxamide (<b>16</b>)</h3><div class="NLM_p last">General method C using <b>16a</b> (76 mg, 0.209 mmol) gave <b>16</b> as an orange solid; yield 31% (29 mg, 0.074 mmol). Mp 152–154 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 11.09 (s, 1H), 10.82 (s, 1H), 8.82 (s, 2H), 7.92 (s, 2H), 7.55 (d, 1H, <i>J</i> = 7.7 Hz), 7.41 (d, 1H, <i>J</i> = 7.7 Hz), 7.12 (t, 1H, <i>J</i> = 7 Hz), 7.03 (t, 1H), 6.44 (s, 1H), 3.64 (t, <i>J</i> = 5.0 Hz, 4H), 1.73 (s, 4H), 1.50 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.7, 156.2, 155.7, 153.0, 136.6, 134.9, 128.3, 125.7, 122.7, 120.5, 119.8, 111.7, 110.8, 102.3, 52.1, 27.9, 27.6. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>20</sub>H<sub>28</sub>N<sub>7</sub>O<sub>3</sub>: calcd mass 393.2151. Found 393.2159. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 24.4 min).</div></div><div id="sec4_6_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 3-Amino-5-(azepan-1-yl)-6-(benzo[<i>b</i>]thiophen-2-yl)-<i>N</i>-carbamimidoylpyrazine-2-carboxamide (<b>17</b>)</h3><div class="NLM_p last">General method D using <b>17a</b> (383 mg, 1.0 mmol) gave <b>17</b> as a yellow solid; yield 78% (320 mg). Mp 220–224 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 10.48 (s, 1H), 8.92 (s, 2H), 8.76 (s, 2H), 7.60 (d, <i>J</i> = 7.5 Hz, 1H), 7.43 (d, <i>J</i> = 7.5 Hz, 1H), 7.31 (t, <i>J</i> = 7.5 Hz, 1H), 7.26 (t, <i>J</i> = 7.5 Hz, 1H), 7.20 (s, 1H), 3.50 (t, <i>J</i> = 5.75 Hz, 4H), 1.69 (s, 4H), 1.49 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 168.2. 164.9, 160.7, 156.5, 155.4, 144.1, 141.3, 141.2, 125.8, 125.5, 124.7, 123.5, 123.0, 113.5, 52.0, 29.2, 28.1. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) C<sub>20</sub>H<sub>24</sub>N<sub>7</sub>OS: calcd mass 410.1763. Found 410.1758. Anal. HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 27.5 min).</div></div><div id="sec4_6_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 3-Amino-5-(azepan-1-yl)-6-(benzofuran-2-yl)-<i>N</i>-carbamimidoylpyrazine-2-carboxamide (<b>18</b>)</h3><div class="NLM_p last">General method D using <b>18a</b> (366 mg, 1.0 mmol) gave <b>18</b> as a yellow solid; yield 86% (338 mg). Mp 130–132 °C ; <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.64 (d, <i>J</i> = 7.5 Hz, 1H), 7.50 (d, <i>J</i> = 8.0 Hz, 1H), 7.31 (t, <i>J</i> = 8.0 Hz, 1H), 7.26 (t, <i>J</i> = 7.5 Hz, 1H), 7.05 (s, 1H), 3.51 (t, <i>J</i> = 5.0 Hz, 4H), 1.71 (s, 4H), 1.54 (s, 4H). <sup>13</sup>C NMR (CD<sub>3</sub>OD): δ 167.4, 164.3, 154.6, 154.5, 154.4, 154.1, 129.7, 124.9, 123.7, 121.6, 121.1, 112.4, 111.5, 105.6, 50.3, 28.6, 27.3. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>20</sub>H<sub>24</sub>N<sub>7</sub>O<sub>2</sub>: calcd mass 394.1991. Found 394.1986. Anal. HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 27.5 min).</div></div><div id="sec4_6_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(4-fluorobenzofuran-2-yl)pyrazine-2-carboxamide (<b>19</b>)</h3><div class="NLM_p last">General method C using <b>19a</b> (54 mg, 0.139 mmol) gave <b>19</b> as an orange solid; yield 26% (15 mg, 0.036 mmol). Mp 132–136 °C. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 10.47 (s, exchange with solvent), 8.98 (s, exchange with solvent), 8.33 (s, exchange with solvent), 7.36 (t, <i>J</i> = 8.7 Hz, 1H), 7.32 (q, <i>J</i> = 5.5 Hz, 1H), 7.22 (s, 1H), 7.02 (t, <i>J</i> = 8.7 Hz, 1H), 3.44 (t, <i>J</i> = 5.8 Hz, 4H) 1.72 (s, 4H), 1.51 (s, 4H). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD) δ 167.3, 158.2, 157.4, 157.0, 156.9, 156.2, 156.2, 155.7, 126.6, 121.2, 112.2, 109.8, 108.7, 102.4, 51.1, 29.0, 27.9. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>20</sub>H<sub>22</sub>FN<sub>7</sub>O<sub>2</sub>,: calcd mass 412.1897. Found 412.1909. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 25.6 min).</div></div><div id="sec4_6_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(thiophen-2-yl)pyrazine-2-carboxamide (<b>20</b>)</h3><div class="NLM_p last">General method C using <b>20a</b> (99 mg, 0.298 mmol) gave <b>20</b> as a yellow oil; yield 2% (2 mg, 0.006 mmol). Mp 136–138 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 10.10 (s, 1H), 10.04 (bs, 2H), 8.08 (bs, 2H), 7.26 (d, <i>J</i> = 5 Hz, 1H), 7.03 (d, <i>J</i> = 3 Hz, 1H), 3.47 (t, <i>J</i> = 5.75 Hz, 4H), 1.68 (m, 4H), 1.49 (m, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.0, 156.3, 156.1, 153.4, 139.9, 128.4, 128.2, 125.2, 124.5, 111.0, 51.0, 27.8, 27.1. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>16</sub>H<sub>21</sub>N<sub>7</sub>O: calcd mass 360.1607. Found 360.1610. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 24.2 min).</div></div><div id="sec4_6_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(thiophen-3-yl)pyrazine-2-carboxamide (<b>21</b>)</h3><div class="NLM_p last">General method C using <b>21a</b> (103 mg, 0.309 mmol) gave <b>21</b> as an orange oil; yield 17% (24 mg, 0.067 mmol). Mp 138–140 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 10.31 (s, 1H), 8.62 (bs, 2H), 8.29, (bs, 2H), 7.78 (m, 3H), 7.64 (dd, <i>J</i> = 8.5, 1.5 Hz, 1H,), 7.44 (m, 2H), 6.23 (bs, 2H), 3.38 (t, <i>J</i> = 5.75, 4H), 1.59 (s, 4H), 1.42 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.7, 156.2, 156.0, 153.6, 140.1, 128.4, 127.8, 125.9, 123.6, 110.7, 51.3, 27.9, 27.1. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>16</sub>H<sub>21</sub>N<sub>7</sub>O: calcd mass 360.1607. Found 360.1611. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 25.2 min).</div></div><div id="sec4_6_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide (<b>22</b>)</h3><div class="NLM_p last">General method D using <b>22a</b> (316 mg, 1.0 mmol) gave <b>22</b> as a yellow solid; yield 91% (310 mg). Mp 143–146 °C. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.50 (s, 1H), 6.55 (d, <i>J</i> = 3.0 Hz, 1H), 6.50 (s, 1H), 3.37 (t, <i>J</i> = 6.0 Hz, 4H), 1.64 (s, 4H), 1.47 (s, 4H). <sup>13</sup>C NMR (CD<sub>3</sub>OD): δ 168.1, 160.7, 156.3, 156.0, 153.4, 142.8, 122.4, 112.6, 112.4, 109.9, 50.9, 29.2, 27.8. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>16</sub>H<sub>22</sub>N<sub>7</sub>O<sub>2</sub>: calcd mass 344.1835. Found 344.1830. Anal. HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 24.3 min).</div></div><div id="sec4_6_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(furan-3-yl)pyrazine-2-carboxamide (<b>23</b>)</h3><div class="NLM_p last">General method C using <b>23a</b> (90 mg, 0.285 mmol) gave <b>23</b> as a yellow solid; yield 35% (41 mg, 0.119 mmol). Mp 146–148 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 10.42 (s, 1H), 8.54 (s, 4H), 7.63 (s, 1H), 7.42 (s, 1H), 6.63 (s, 1H), 5.35 (bs, 2H), 3.52 (t, <i>J</i> = 5.75 Hz, 4H), 1.68 (s, 4H), 1.49 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.4, 156.3, 155.8, 153.6, 143.2, 141.1, 125.3, 124.9, 110.8, 110.7, 51.4, 27.9, 27.1. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>16</sub>H<sub>22</sub>N<sub>7</sub>O<sub>2</sub>: calcd mass 344.1835. Found 344.1837. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 25.5 min).</div></div><div id="sec4_6_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(2-fluoropyridin-3-yl)pyrazine-2-carboxamide (<b>24</b>)</h3><div class="NLM_p last">General method C using <b>24a</b> (100 mg, 0.290 mmol) gave <b>24</b> as a yellow solid; yield 13% (18 mg, 0.048 mmol). Mp 160–162 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 10.42 (s, 1H), 8.59 (bs, 4H), 8.17 (m, 2H), 7.29 (t, <i>J</i> = 5.4 Hz) 5.13 (bs, 2H), 3.38 (s, 4H), 1.64 (s, 4H), 1.47 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.5, 160.7, 158.8, 156.0, 155.9, 154.0, 146.9, 141.4, 124.2, 123.4, 122.5, 111.8, 50.4, 27.9, 27.2. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>17</sub>H<sub>22</sub>FN<sub>8</sub>O: calcd mass 373.1901. Found 373.1916. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 22.2 min).</div></div><div id="sec4_6_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(pyrimidin-5-yl)pyrazine-2-carboxamide (<b>25</b>)</h3><div class="NLM_p last">General method D using <b>25a</b> (328 mg, 1.0 mmol) gave <b>25</b> as a yellow solid; yield 87% (305 mg). Mp 188–190 °C. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 8.98 (s, 1H), 8.97 (s, 2H), 3.35 (t, <i>J</i> = 5.5 Hz, 4H), 1.67 (s, 4H), 1.47 (s, 4H). <sup>13</sup>C NMR (CD<sub>3</sub>OD): δ 162.2, 156.5, 156.3, 155.7, 155.5, 154.0, 153.5, 135.2, 122.2, 51.0, 28.0, 27.1. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>). Anal. for C<sub>16</sub>H<sub>22</sub>N<sub>9</sub>O: calcd mass 356.1947. Found 356.1942. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 20.1 min).</div></div><div id="sec4_6_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(2-methoxypyrimidin-5-yl)pyrazine-2-carboxamide (<b>26</b>)</h3><div class="NLM_p last">General method D using <b>26a</b> (358 mg, 1.0 mmol) gave <b>26</b> as a yellow solid; yield 90% (345 mg). Mp 148–150 °C. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 8.77 (s, 2H), 4.08 (s, 3H), 3.46 (t, <i>J</i> = 5.5 Hz, 4H), 1.72 (s, 4H), 1.54 (s, 4H). <sup>13</sup>C NMR (CD<sub>3</sub>OD): δ 166.7, 164.1, 163.4, 158.1, 154.8, 153.6, 128.6, 124.2, 112.8, 54.3, 27.7, 26.7. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>17</sub>H<sub>24</sub>N<sub>9</sub>O<sub>2</sub>: calcd mass 386.2053. Found 386.2048. Anal. HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 20.7 min).</div></div><div id="sec4_6_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide (<b>27</b>)</h3><div class="NLM_p last">General method C using <b>27a</b> (104 mg, 0.267 mmol) gave <b>27</b> as a yellow solid; yield 54% (65 mg, 0.156 mmol). Mp 184–186 °C. <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 10.76 (s, 1H), 9.27 (s, 2H), 8.51 (s, 2H), 8.48 (s, 2H), 4.08 (s, 3H), 3.35 (t, <i>J</i> = 5.75 Hz, 4H), 1.66 (s, 4H), 1.46 (s, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.6, 164.0, 157.8, 156.1, 153.9, 127.8, 124.7, 112.5, 55.6, 51.6, 27.8, 27.1. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>18</sub>H<sub>26</sub>N<sub>9</sub>O<sub>3</sub>: calcd mass 416.2159. Found 416.2158. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 21.4 min).</div></div><div id="sec4_6_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(2,6-dimethoxypyridin-3-yl)pyrazine-2-carboxamide (<b>28</b>)</h3><div class="NLM_p last">General method C using <b>28a</b> (98 mg, 0.253 mmol) gave <b>28</b> as a yellow solid; yield 13% (15 mg, 0.036 mmol). Mp 152–154 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 10.28 (s, 1H), 8.77 (s, 2H), 8.14 (s, 2H), 7.61 (d, <i>J</i> = 8.0 Hz), 6.39 (d, <i>J</i> = 8.0 Hz, 1H), 3.94 (s, 3H), 3.87 (s, 3H), 3.52 (s, 2H), 3.35 (s, 2H), 1.60 (s, 4H), 1.51 (s, 2H), 1.44 (s, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.0, 163.2, 159.2, 155.4, 153.5, 141.1, 128.0, 114.6, 110.2, 101.3, 53.8, 53.5, 50.4, 27.7, 26.81. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>19</sub>H<sub>27</sub>N<sub>8</sub>O<sub>3</sub>: calcd mass 415.2206. Found 415.2191. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 26.1 min).</div></div><div id="sec4_6_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(2,4-dimethoxyphenyl)pyrazine-2-carboxamide (<b>29</b>)</h3><div class="NLM_p last">General method C using <b>29a</b> (123 mg, 0.317 mmol) gave <b>29</b> as a yellow solid; yield 8% (12 mg, 0.029 mmol). Mp 156–158 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 10.19 (s, 1H), 9.10 (bs, 2H), 7.79 (bs, 2H), 7.23 (d, <i>J</i> = 8.1 Hz), 6.58 (d, <i>J</i> = 8.1 Hz), 6.48 (s, 1H) 3.86 (s, 3H), 3.74 (s, 3H), 3.51 (s, 2H), 3.36 (s, 2H), 1.59 (s, 4H), 1.50 (s, 2H), 1.45 (s, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 166.0, 161.5, 157.8, 155.7, 155.4, 153.8, 130.6, 129.6, 122.1, 109.8, 105.0, 98.7, 55.7, 55.6, 50.6, 27.8, 26.9. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>20</sub>H<sub>28</sub>N<sub>7</sub>O<sub>3</sub>: calcd mass 414.2254. Found 414.2269. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 26.7 min).</div></div><div id="sec4_6_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(3,5-dimethoxyphenyl)pyrazine-2-carboxamide (<b>30</b>)</h3><div class="NLM_p last">General method C using <b>30a</b> (147 mg, 0.381 mmol) gave <b>30</b> as a yellow solid; yield 26% (44 mg, 0.116 mmol). Mp 138–140 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 10.75 (s, 1H), 8.81 (bs, 2H), 8.60 (bs, 2H), 6.73 (d, <i>J</i> = 2.2 Hz), 6.58 (t, <i>J</i> = 2.2 Hz, 1H), 3.84 (s, 6H), 3.38 (s, 2H), 1.64 (s, 4H), 1.45 (s, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.0, 160.1, 156.4, 155.6, 153.8, 141.6, 132.9, 110.9, 106.5, 100.3, 55.9, 51.0, 28.0, 27.1. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>20</sub>H<sub>28</sub>N<sub>7</sub>O<sub>3</sub>: calcd mass 414.2254. Found 414.2244. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 25.8 min).</div></div><div id="sec4_6_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(3,6-dimethoxypyridazin-4-yl)pyrazine-2-carboxamide (<b>31</b>)</h3><div class="NLM_p last">General method C using 31a (94 mg, 0.243 mmol) gave <b>31</b> as a yellow solid; yield 17% (21 mg, 0.051 mmol). Mp 202–204 °C. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 10.38 (s, exchange with solvent), 8.77 (s, exchange with solvent), 8.21 (s, exchange with solvent), 7.35 (s, 1H), 4.06 (s, 3H), 3.99 (s, 3H), 3.35 (s, 4H), 1.66 (s, 4H), 1.55 (s, 2H), 1.45 (s, 2H). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD) δ 167.3, 164.1, 160.9, 156.9, 156.8, 156.1, 136.3, 124.0, 121.4, 112.2, 55.4, 55.3, 51.0, 28.9, 27.9. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>18</sub>H<sub>26</sub>N<sub>9</sub>O<sub>3</sub>: calcd mass 416.2159. Found 416.2150. Anal. HPLC (70:30 H<sub>2</sub>O/0.1% TFA/CH<sub>3</sub>CN/0.1% TFA → 00% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 19.0 min).</div></div><div id="sec4_6_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 3-Amino-6-(2-aminopyrimidin-5-yl)-5-(azepan-1-yl)-<i>N</i>-carbamimidoylpyrazine-2-carboxamide (<b>32</b>)</h3><div class="NLM_p last">General method D using <b>32a</b> (86 mg, 0.25 mmol) gave <b>32</b> as a yellow solid; yield 78% (72 mg). Mp 225–228; <sup>1</sup>H NMR (DMSO-<i>d6</i>): δ 1.41 (s, 4H), 1.60 (s, 4H), 3.38 (t, <i>J</i> = 5.9 Hz, 4H), 6.73 (br s, 2H), 7.25 (br s, 1H), 8.40 (s, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>): δ 167.5, 162.9, 159.1, 157.5, 154.9, 153.7, 126.0, 123.6, 112.9, 51.1, 28.0, 27.0. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>), Anal. for C<sub>16</sub>H<sub>23</sub>N<sub>10</sub>O<sub>3</sub>: calcd mass 371.2056. Found 371.2067. Anal. HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 10.2 min).</div></div><div id="sec4_6_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(2-(methylamino)pyrimidin-5-yl)pyrazine-2-carboxamide (<b>33</b>)</h3><div class="NLM_p last">General method D using <b>33a</b> (39 mg, 0.11 mmol) gave <b>33</b> as a yellow solid; yield 85% (36 mg). Mp 168–170; <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 8.47 (s, 2H), 3.48 (t, <i>J</i> = 5.6 Hz, 4H), 2.97 (s, 3H), 1.69 (s, 4H), 1.51 (s, 4H). <sup>13</sup>C NMR (CD<sub>3</sub>OD): δ 28.0, 28.5, 29.0, 52.0, 113.5, 124.4, 127.3, 155.4, 156.7, 158.3, 158.5, 162.9, 168.3, 162.9, 158.5, 158.3, 156.7, 155.4, 127.3, 124.4, 113.5, 52.0, 29.0, 28.5, 28.0. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>17</sub>H<sub>25</sub>N<sub>10</sub>O: calcd mass 385.2213. Found 385.2195. Anal. HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 14.8 min).</div></div><div id="sec4_6_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(2-(isopropylamino)pyrimidin-5-yl)pyrazine-2-carboxamide (<b>34</b>)</h3><div class="NLM_p last">General method D using <b>34a</b> (35 mg, 0.09 mmol) gave <b>34</b> as a yellow solid; yield 89% (32 mg). Mp 172–175 °C. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 8.46 (s, 2H), 4.14 (septet, <i>J</i> = 6.8 Hz, 1H), 3.47 (t, <i>J</i> = 5.6 Hz, 4H), 1.69 (s, 4H), 1.51 (s, 4H), 1.25 (d, <i>J</i> = 6.5 Hz, 6H). <sup>13</sup>C NMR (CD<sub>3</sub>OD): δ 21.6, 26.8, 27.8, 42.8, 50.9, 112.3, 123.2, 126.2, 154.2, 155.5, 157.1, 158.8, 160.6, 167.1, 160.6, 158.8, 157.1, 155.5, 154.2, 126.2, 123.3, 112.3, 50.9, 42.8, 27.8, 26.8, 21.6. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>19</sub>H<sub>29</sub>N<sub>10</sub>O: calcd mass 413.2526. Found 413.2525. Anal. HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 16.1 min).</div></div><div id="sec4_6_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(2-((2-hydroxyethyl)amino)pyrimidin-5-yl)pyrazine-2-carboxamide (<b>35</b>)</h3><div class="NLM_p last">General method D using <b>35a</b> (50 mg, 0.13 mmol) gave <b>35</b> as a Yellow solid: yield 86% (46 mg). Mp 188–191 °C. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 8.48 (s, 2H), 3.72 (t, <i>J</i> = 5.6 Hz, 2H),), 3.54 (t, <i>J</i> = 5.6 Hz, 2H), 3.45 (t, <i>J</i> = 5.8 Hz, 4H), 1.68 (s, 4H), 1.50 (s, 4H). <sup>13</sup>C NMR (CD<sub>3</sub>OD): δ 167.1, 162.3, 160.8, 158.2, 156.3, 154.9, 126.5, 124.7, 117.5, 61.7, 51.9, 44.6, 28.9, 27.8.. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>18</sub>H<sub>27</sub>N<sub>10</sub>O<sub>2</sub>: calcd mass 415.2318. Found 415.2324. Anal. HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 14.4 min).</div></div><div id="sec4_6_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Methyl 3-((Di-<i>tert</i>-butyloxycarbonyl)amino)-5-(azepan-1-yl)-6-chloro-2-pyrazinecarboxylate (<b>36</b>)</h3><div class="NLM_p last">To a stirred solution of <b>7</b> (2.85 g, 10 mmol) and DMAP (61 mg, 0.5 mmol) in 1,2-dichloroethane (40 mL) was added a solution of di-<i>tert</i>-butyl dicarbonate (6.57 g, 30 mmol) in 1,2-dichloroethane (20 mL) at rt. The reaction mixture was heated at 70 °C for 18 h. After cooling to room temperature, additional equivalents of di-<i>tert</i>-butyl dicarbonate (3.28 g, 15 mmol) and DIPEA (10 mL) were added and the reaction mixture was heated for a further 18 h. Solvents were evaporated and the residue was partitioned between EtOAc (100 mL) and water (100 mL). The aqueous layer was extracted with EtOAc (3 × 75 mL), and the combined organic layer was washed with brine, dried (MgSO<sub>4</sub>), and concentrated. The residue was purified by silica gel flash column chromatography using EtOAc/pet. spirit (10–15%) to give <b>36</b> (4.10 g, 85%) as a white solid. Mp 116–118 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 3.89 (s, 3H), 3.88 (t, <i>J</i> = 6.1 Hz, 4H), 1.55 (s, 4H), 1.84 (s, 4H), 1.41 (s, 18H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 163.0, 152.3, 150.4, 145.4, 128.6, 126.1, 83.3, 52.8, 51.6, 28.1, 28.1, 26.7. MS (ESI): <i>m</i>/<i>z</i> 507 (M + Na)<sup>+</sup>. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>22</sub>H<sub>33</sub>ClN<sub>4</sub>O<sub>6</sub>Na: calcd mass 507.1986. Found 507.2000. Anal. HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min).</div></div><div id="sec4_6_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Methyl 5-(Azepan-1-yl)-3-((<i>tert</i>-butoxycarbonyl)amino)pyrazine-2-carboxylate (<b>37</b>)</h3><div class="NLM_p last">To a mixture of chloropyrazine <b>36</b> (3.30 g, 6.8 mmol), Pd/C (476 mg, 10 mol %), and MgO (408 mg, 10.2 mmol) was added dry MeOH (50 mL). The flask was charged with H<sub>2</sub> (1 atm), and the reaction mixture was stirred at rt for 2 days. The solvent was evaporated and the residue redissolved in EtOAc and filtered through Celite, eluting with EtOAc. The organic layer was washed with brine, dried (MgSO<sub>4</sub>), and evaporated to give the crude mono Boc-protected product <b>37</b> as a white solid (2.22 g, 92%). Crude product showed sufficient purity and was used in the next step with further purification. Mp 97–100 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.28 (s, 1H), 7.68 (s, 1H), 3.94 (s, 3H), 3.62 (br s, 4H), 1.58 (br s, 4H), 1.53 (s, 9H), 1.84 (br s, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 167.3, 153.8, 150.6, 150.3, 122.4, 113.5, 80.7, 52.3, 47.9, 28.3, 27.4, 26.6. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>17</sub>H<sub>27</sub>N<sub>4</sub>O<sub>4</sub>: 351.2032. Found 351.2032. Anal. HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min).</div></div><div id="sec4_6_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Methyl 5-(Azepan-1-yl)-6-bromo-3-((<i>tert</i>-butoxycarbonyl)amino)pyrazine-2-carboxylate (<b>38</b>)</h3><div class="NLM_p last">To a solution of pyrazine methyl ester <b>37</b> (2.10 g, 6.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (90 mL) was added <i>N</i>-bromosuccinimide (1.18 g, 6.6 mmol), and the reaction mixture was stirred at rt for 5 h. The mixture was treated with water (50 mL) and stirred for 10 min. The organic layer was separated, washed with sodium bicarbonate solution (2 × 50 mL) and brine (50 mL), dried (MgSO<sub>4</sub>), and concentrated. The residue was purified by silica gel flash column chromatography using EtOAc/pet. spirit (10–15%) to give <b>38</b> (1.56 g, 60%) as a white solid. Mp 114–115 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 10.04 (s, 1H), 3.95 (t, <i>J</i> = 6.0 Hz, 4H), 3.92 (s, 3H), 1.89 (br s, 4H), 1.60 (t, <i>J</i> = 3.1 Hz, 4H), 1.52 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 166.3, 153.0, 150.0, 147.7, 114.8, 111.9, 81.0, 52.5, 51.4, 28.2, 28.2, 26.8. MS (ESI): <i>m</i>/<i>z</i> 429 (M + H)<sup>+</sup>. HRESI-MS <i>m</i>/<i>z</i> (M + Na<sup>+</sup>) Anal. for C<sub>17</sub>H<sub>25</sub>BrN<sub>4</sub>O<sub>4</sub>Na: calcd mass 451.0957. Found 451.0959. Anal. HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min).</div></div><div id="sec4_6_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Methyl 5-(Azepan-1-yl)-3-((<i>tert</i>-butoxycarbonyl)amino)-6-(pyrimidin-2-ylamino)pyrazine-2-carboxylate (<b>39</b>)</h3><div class="NLM_p last">A resealable Schlenk tube was charged with bromopyrazine <b>38</b> (429 mg, 1.0 mmol), 2-aminopyrimidine (135 mg, 1.4 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (10 mg, 0.011 mmol, 1 mol % Pd), Xantphos (13 mg, 0.022 mmol), Cs<sub>2</sub>CO<sub>3</sub> (426 mg, 1.4 mmol), and degassed dioxane (5 mL). The Schlenk tube was capped and carefully subjected to three cycles of evacuation–backfilling with N<sub>2</sub>. It was then sealed and the reaction mixture heated at 100 °C for 20 h. The mixture was cooled to rt, diluted with THF (20 mL), filtered through Celite, and concentrated. The residue was purified by silica gel flash column chromatography using EtOAc/pet. spirit (50–60%) to give <b>39</b> (130 mg, 30%) as a white solid. Mp 168–170 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 10.16 (s, 1H), 8.35 (d, <i>J</i> = 4.8 Hz, 2H), 7.23 (s, 1H), 6.71 (t, <i>J</i> = 4.8 Hz, 1H), 3.90 (s, 3H), 3.77 (t, <i>J</i> = 6.0 Hz, 4H), 1.73 (br s, 4H), 1.53 (s, 9H), 1.48 (br s, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 166.8, 161.3, 158.3, 152.3, 150.2, 147.9, 126.6, 113.2, 111.5, 80.5, 52.4, 50.5, 28.3, 28.0, 26.8. MS (ESI): <i>m</i>/<i>z</i> 444 (M + H)<sup>+</sup>. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>21</sub>H<sub>30</sub>N<sub>7</sub>O<sub>4</sub>: calcd mass 444.2359. Found 444.2374. Anal. HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min).</div></div><div id="sec4_6_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Methyl 3-Amino-5-(azepan-1-yl)-6-(pyrimidin-2-ylamino)pyrazine-2-carboxylate (<b>40</b>)</h3><div class="NLM_p last">To a solution of Boc-protected pyrazine <b>39</b> (60 mg, 0.135 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) at 0 °C was added TFA (0.1 mL), and the mixture was stirred at room temperature overnight. The mixture was concentrated in vacuo and the residue partitioned between CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and saturated NaHCO<sub>3</sub> solution (20 mL). The organic layer was dried (MgSO<sub>4</sub>) and concentrated and the residue purified by silica gel flash column chromatography using EtOAc/pet. spirit (60–70%) to give <b>40</b> (45 mg, 98%) as a gray solid. Mp 194–196 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.34 (d, <i>J</i> = 4.8 Hz, 2H), 7.04 (s, 1H), 6.67 (t, <i>J</i> = 4.8 Hz, 1H), 6.20 (br s, 2H, NH<sub>2</sub>), 3.87 (s, 3H), 3.67 (t, <i>J</i> = 6.0 Hz, 4H), 1.69 (br s, 4H), 1.48 (t, <i>J</i> = 3.2 Hz, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 166.8, 161.8, 158.4, 154.2, 153.5, 124.3, 112.8, 109.4, 52.0, 50.6, 50.3, 28.2, 26.7. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>16</sub>H<sub>22</sub>N<sub>7</sub>O<sub>2</sub>: calcd mass 344.1835. Found 344.1848. Anal. HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min).</div></div><div id="sec4_6_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> 3-Amino-5-(azepan-1-yl)-<i>N</i>-carbamimidoyl-6-(pyrimidin-2-ylamino)pyrazine-2-carboxamide (<b>41</b>)</h3><div class="NLM_p last">General method D using <b>40</b> (35 mg, 0.1 mmol) gave <b>41</b> (30 mg, 81%) as a yellow solid. Mp 210–212 °C. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 8.25 (d, <i>J</i> = 4.9 Hz, 2H), 6.70 (t, <i>J</i> = 4.9 Hz, 1H), 3.70 (t, <i>J</i> = 6.0 Hz, 4H), 1.63 (br s, 4H), 1.43 (t, <i>J</i> = 3.1 Hz, 4H). <sup>13</sup>C NMR (CD<sub>3</sub>OD): δ 165.7, 162.2, 158.3, 155.6, 154.9, 154.8, 124.1, 112.3, 108.0, 50.4, 27.8, 26.2. MS (ESI): <i>m</i>/<i>z</i> 371 (M + H)<sup>+</sup>. HRESI-MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) Anal. for C<sub>16</sub>H<sub>23</sub>N<sub>10</sub>O: calcd mass 371.2056. Found 371.2057. Anal. HPLC (100% H<sub>2</sub>O/0.1% TFA → 100% CH<sub>3</sub>CN/0.1% TFA over 30 min, <i>t</i><sub>R</sub> = 14.3 min).</div></div><div id="sec4_6_33_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> Cell Culture Conditions</h3><div class="NLM_p last">ATCC certified cell lines were used for all experiments. Cells were cultured at 37 °C, 95% humidity, and 5% (v/v) CO<sub>2</sub> in a ThermoScientific Heracell 150i CO<sub>2</sub> incubator (ThermoScientific) and maintained in DMEM/Hi glucose culture medium supplemented with 10% heat-inactivated FCS. Adherent cells were passaged via the addition of trypsin/0.05% EDTA solution (GIBCO), followed by centrifugation and resuspension in fresh media using a 5 mL Luerlock syringe fitted with an 18-gauge needle (Terumo, Tokyo, Japan). All cell lines were routinely tested for the presence of mycoplasma infection.</div></div><div id="sec4_6_33_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Fluorometric uPA Activity Assay</h3><div class="NLM_p last">Urokinase from human kidney cells (catalog no. U4010, Sigma-Aldrich, St. Louis, MO, USA) was diluted to 900 nM, aliquoted, and stored at −80 °C until use in experiments (typically 4–5 plates assayed on the same day). Thawed enzyme stocks were maintained at −20 °C between during assays using a Nalgene Labtop Cooler Jr (catalog no. 5115-0012, Thermo-Fisher Scientific, Waltham, MA, USA). A 5 mM stock solution of urokinase fluorescent substrate III (Z-Gly-Gly-Arg-AMC, Calbiochem catalog no. 672159, Merck Millipore, MA, USA, human uPA <i>K</i><sub>m</sub> = 400 μM) was prepared in dH<sub>2</sub>O/10% DMSO and aliquoted with storage at −20 °C. Assay buffer (20 mM HEPES, pH 7.4, 100 mM NaCl, 0.5 mM EDTA, 0.01% v/v Tween-20) was prepared and used within 7 days with storage at 4 °C. On the day of assay, compound stocks (20–50 mM in anhydrous DMSO) were serially diluted in assay buffer in a clear Greiner CELLSTAR 96-well plate on ice (Greiner Bio-One GmBH, Kremsmünster, Austria) to give each dilution at 2× the final assayed concentration. In a separate black Greiner CELLSTAR 96-well plate (Greiner Bio-One GmBH, Kremsmünster, Austria), residual volumes of assay buffer were added via multichannel pipet to compound fluorescence blanks and inhibited enzyme control wells, as appropriate. Next, 90 μL of dilute fluor (250 μM final) was added to all wells, followed by 100 μL of 2× compound dilution to appropriate wells. Immediately prior to assay, 900 nM uPA stock was diluted to 15 nM and 10 μL of this dilution was added to all relevant wells, initiating the reaction. Reaction progress was monitored using a POLARStar OMEGA fluorescence plate reader (fluorescence intensity mode, top-optic, ex 355 nm, em 450 nm, 20 flashes per well, double orbital shaking for 3 s prior to every read, cycle time 60 s, 45–60 cycles, incubation at 37 °C, BMG-Labtech, Ortenberg, Germany). Changes in fluorescence over a 15 min period from the linear portion of the reaction progress curve were used to determine IC<sub>50</sub> values by fitting log-transformed data to a sigmoidal dose–response curve in GraphPad Prism v7.0 (GraphPad Software, La Jolla, CA, USA). Experiments with Mouse uPA (active mouse urokinase, HMW, Molecular Innovations Inc., MI, USA) were performed as above with a final enzyme concentration of 20 nM (<i>K</i><sub>m</sub> = 580 μM). <i>K</i><sub>i</sub> values were calculated according to the methods of Cheng and Prussof.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_6_33_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Chromogenic Trypsin-like Serine Protease (TLSP) Activity Assays</h3><div class="NLM_p last">For experiments using uPA (catalog no. U4010, Sigma-Aldrich, St. Louis, MO, USA), trypsin, tPA, thrombin, plasmin, and factor Xa, concentrated stocks were prepared in deionized H<sub>2</sub>O and stored at −80 °C until thawed for use. Thawed enzyme stocks were maintained at −20 °C between assays using a Nalgene Labtop Cooler Jr (catalog no. 5115-0012, Thermo-Fisher Scientific, Waltham, MA, USA). A 312.5 μM stock solution of S-2288 chromogenic substrate (H-<span class="smallcaps smallerCapital">d</span>-Ile-<span class="smallcaps smallerCapital">l</span>-Pro-<span class="smallcaps smallerCapital">l</span>-Arg-<i>p</i>-nitoraniline, Chromogenix, MA, USA, uPA <i>K</i><sub>m</sub> = 200 μM, trypsin <i>K</i><sub>m</sub> = 28 μM, tPA <i>K</i><sub>m</sub> = 300 μM, thrombin <i>K</i><sub>m</sub> = 3 μM, plasmin <i>K</i><sub>m</sub> = 9 mM) was prepared in deionized H<sub>2</sub>O and aliquoted with storage at −20 °C. Assay buffer (10 mM HEPES, 150 mM NaCl, 0.01% v/v Tween-20, pH 7.4) was prepared and used within 7 days with storage at 4 °C. On the day of assay, compound stocks (20–50 mM in DMSO) were serially diluted in assay buffer in a clear Greiner CELLSTAR 96-well plate on ice (Greiner Bio-One GmBH, Kremsmünster, Austria) to give each dilution at 10× the final assay concentration. In a separate Greiner CELLSTAR 96-well plate (Greiner Bio-One GmBH, Kremsmünster, Austria) residual volumes of assay buffer were added via multichannel pipet to compound fluorescence blanks and inhibited enzyme control wells, as appropriate. Next, 80 μL of dilute substrate (250 μM final) was added to all wells, followed by 10 μL of 10× compound dilution to appropriate wells. Immediately prior to assay, concentrated enzyme stocks were diluted to 100 nM and 10 μL of this dilution was added to all relevant wells, initiating the reaction (final enzyme concentration = 10 nM). DMSO was present at a final concentration of 1% v/v. Change in absorbance over time at 405 nm was measured at 37 °C using a Molecular Devices SpectraMax Plus 384-well plate reader (Molecular Devices LLC, Sunnyvale, CA, USA). IC<sub>50</sub> values were determined by plotting percentage of residual activity (V0) versus log drug concentration and fitted to sigmoidal dose response curves using GraphPad Prism v7.0 (GraphPad Software, La Jolla, CA, USA). The following chromogenic substrates and final enzyme concentrations were used for experiments with other TLSPs. S-2366, <span class="smallcaps smallerCapital">l</span>-pyroGlu-<span class="smallcaps smallerCapital">l</span>-Pro-<span class="smallcaps smallerCapital">l</span>-Arg-<i>p</i>-nitroaniline, Chromogenix, MA, USA, [human plasma kallikrein] = 23.5 nM, <i>K</i><sub>m</sub> = 430 μM, [factor XIa] = 2 nM, <i>K</i><sub>m</sub> = 400 μM, [activated protein C] = 10 nM, <i>K</i><sub>m</sub> = 200 μM.</div></div><div id="sec4_6_33_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Crystallization and X-ray Data Collection</h3><div class="NLM_p last">Expression and purification of recombinant human uPA protease domain were performed as previously described.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(78)</a> Crystals were grown by the sitting drop vapor diffusion method and were obtained by equilibrating against a reservoir solution containing 50 mM sodium citrate (pH 4.6) and 2.0 M ammonium sulfate supplemented with 5% PEG400 at room temperature for a period of 3 days. For uPA:inhibitor cocomplexes at pH 7.4, the crystals were soaked for 1 week in new soaking buffer (40% PEG4000, 100 mM Tris-HCl, pH 7.4) containing 100 μM compound. Prior to X-ray data collection, crystals were soaked in a cryoprotectant solution containing 20% glycerol and snap-frozen in liquid N<sub>2</sub>. X-ray diffraction data of the crystals were collected at the BL17U beamline, Shanghai Synchrotron Radiation Facility (SSRF). The diffraction data were indexed and integrated using the HKL2000 program package.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(79)</a> Structures were solved by molecular replacement<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(80)</a> using the uPA structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DVA">4DVA</a>)<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(81)</a> as the search model. The electron density for the compound was clearly visible in the uPA active sites and was modeled based on the <i>F</i><sub>o</sub> – <i>F</i><sub>c</sub> difference map. The structures were refined using the CCP4 program package<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(79)</a> and manually adjusted using the molecular graphics program COOT<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(82)</a> iteratively until convergence. Solvent molecules were added using a <i>F</i><sub>o</sub> – <i>F</i><sub>c</sub> Fourier difference map at 2.5σ in the final refinement step. Statistics for data collection and final model refinement are summarized in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00838/suppl_file/jm8b00838_si_001.pdf" class="ext-link">Supporting Information Table S1</a>.</div></div><div id="sec4_6_33_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> EnPlex Assays</h3><div class="NLM_p last">Enplex superfamily wide serine hydrolase activity screening was performed as described in ref <a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(54)</a>.</div></div><div id="sec4_6_33_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> Cytotoxicity Assays</h3><div class="NLM_p last">Subconfluent cells (∼70–80% confluence) were harvested and dissociated into a single cell suspension. Cells were seeded at a density of 5000 cells/well (final volume 90 μL) into a Greiner CELLSTAR 96-well plate (Greiner Bio-One GmBH, Kremsmünster, Austria) via multichannel pipet and incubated for 18h prior to the addition of compounds. Compounds were serially diluted from 20 to 50 mM DMSO stocks in culture media in a separate 96-well plate under sterile conditions to give 10× stocks (10 nM to 1 mM) on the day of compound addition. 10 μL of the 10× compound/media stocks or matched vehicle/media solutions (for vehicle controls; final vehicle concentration was equal to 0.2%) were transferred via multichannel pipet into the assay plate containing 90 μL of cell suspension via multichannel pipet to give the treated assay plate at the final 1× drug concentrations (1 nM to 100 μM, <i>n</i> = 4 wells at each concentration). Drug blanks or vehicle media blanks were included as appropriate at each concentration to correct for intrinsic color of the compounds and the phenol red containing media. 200 μL media was added to outside wells to decrease evaporation but was not used in the assay itself. Compound-treated plates were incubated for 48 h prior to development. After 48 h, plates were removed from the incubator and 20 μL of CellTiter 96 Aqueous One solution cell proliferation assay (catalog no. G3581, Promega Corporation, Fitchburg, WI, USA) was added to each well. Plates were incubated for a further 2 h prior to reading at 490 nm using a SpectraMax Plus 384-well plate reader (Molecular Devices LLC, Sunnyvale, CA, USA). IC<sub>50</sub> values (defined as the concentration of each treatment causing 50% inhibition of maximal cell viability) were determined using a logarithmic sigmoidal dose–response curve using the variable slope parameter to determine IC<sub>50</sub> using GraphPad Prism v7.0 (GraphPad Software, La Jolla, CA, USA).</div></div><div id="sec4_6_33_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> ENaC Inhibition Assays</h3><div class="NLM_p last">HEK-293 cells were cultured in Dulbecco’s modified Eagle medium/nutrient mixture F-12 (D-MEM/F-12) supplemented with 10% fetal bovine serum, 100 U/mL penicillin G sodium, 100 μg/mL streptomycin sulfate, and appropriate selection antibiotics. Semiconfluent cells were transfected with cDNA for ENaC α, β, and γ subunits (genes SCNN1A, SCNN1B, and SCNN1G) prior to experimentation. Cells were plated at a density of 20 000 cells/well in a 384-well black wall, flat clear bottom microtiter plates (type: BD Biocoat poly-<span class="smallcaps smallerCapital">d</span>-lysine multiwell cell culture plate) and incubated at 37 °C overnight. Following manufacturer instructions, cells were loaded with 20 μL of membrane potential dye solution for 30 min at 37 °C from the FLIPR membrane potential red dye fluorescence assay kit (Molecular Devices, Sunnyvale, CA, USA). This assay uses fluorometric detection of changes in membrane potential following modulation of transmembrane ion channel/exchanger activity, i.e., antagonism of stimulated ENaC activity in this case. Drug, vehicle, and control solutions were prepared from frozen stocks in DMSO on the day of experimentation through dilution into HEPES-buffered physiological salt solution (NaCl 137 mM, KCl 4 mM, CaCl<sub>2</sub> 1.8 mM, MgCl<sub>2</sub> 1 mM, HEPES 10 mM, glucose 10 mM, DMSO 0.3% v/v, pH 7.4) in a 384-well microtiter plate ready for addition to the assay plate by the FLIPR<sup>TETRA</sup> instrument. All analogs were tested at 8 concentrations (<i>n</i> = 4 wells at each concentration). Positive control cells were stimulated with 1 μM S-3969 (ENaC agonist, <i>n</i> = 4 wells).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(83)</a> Negative control cells were first stimulated with 1 μM S-3969 and then treated with 30 μM benzamil (potent ENaC antagonist, <i>n</i> = 4 wells). Following dye loading, cells were preincubated with 5 μL of drug, vehicle, or control solutions for 5 min. Next 5 μL of S-3939 solution (final [S-3969] = 1 μM) was added to stimulate ENaC activity. All data were normalized to agonist-treated positive and antagonist-treated negative controls such that the agonist-treated signal corresponded to 100% activity and antagonist-treated signal corresponded to 0% activity. Normalized data were used to determine IC<sub>50</sub> values for each analog using the log[inhibitor]-normalized response variable slope algorithm in GraphPad Prism v7.0 (GraphPad Software, La Jolla, CA, USA). These experiments were performed under contract by Charles River Laboratories, Cleveland, OH, USA.</div></div><div id="sec4_6_33_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> Rat Diuresis and Kaliuresis Model</h3><div class="NLM_p last">Sixty-four male 21 week old Sprague-Dawley rats were randomized into 8 groups of 8 animals. All test animals received one intraperitoneal (ip) injection of either vehicle or 25 mg/kg acetazolamide followed by one intravenous (iv) injection of vehicle, 1.5 mg/kg amiloride or 1.5 mg/kg amiloride derivative. Acetazolamide was administered at an injection volume of 1 mL/kg and concentration of 25 mg/mL. Amiloride, HMA, <b>18</b>, and <b>26</b> were administered at an injection volume of 1 mL/kg and concentration of 1.5 mg/mL. Monosodium acetazolamide was formulated in 0.9% saline. Amiloride and HMA were formulated in 50 mM acetate buffer (pH 5.5)/5% v/v DMSO, and <b>18</b> and <b>26</b> were formulated in 50 mM acetate buffer (pH 5.5)/5% v/v DMSO/0.5% v/v Tween-80. Immediately following dosing, all animals were placed into metabolic cages and total urine was collected over 6 h. A control group receiving ip and iv administrations of vehicle was also included for comparison. Urine Na<sup>+</sup> and K<sup>+</sup> levels were quantitated using a Konelab 20 XTi biochemistry analyzer (LLQ = 20 mM). This experiment was approved by the Austin Health Animal Ethics Committee (A2016/05420) and was conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, seventh edition, 2004. Statistical analyses were performed using a one-way ANOVA with Dunnett’s post hoc test in GraphPad Prism v7.0 (GraphPad Software, La Jolla, CA, USA).</div></div><div id="sec4_6_33_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> Mouse Lung Metastasis Model</h3><div class="NLM_p last">All animal studies were approved by the Institutional Animal Care and Use Committee at the University of Wollongong (AE1708). Male and female NOD.Cg-Prkdc<scid>IL2rg<tm1Wjl>SzJAusb mice (Australian BioResources, Moss Vale, NSW, Australia) at 7–8 weeks of age were randomized into treatment groups (<i>n</i> = 4–6/treatment group). Treatments commenced 1 day prior to tail vein administration of 2.5 × 10<sup>5</sup> luciferase-tagged HT-1080 human fibrosarcoma cells (BioWare Brite HT-1080-Red-Fluc) in an injection volume of 100 μL of PBS [except sham control (<i>n</i> = 1)]. Daily ip injections continued to day 20 with 7.5 mg/kg amiloride, <b>18</b>, <b>26</b>, or vehicle (50 mM acetate buffer, pH 5.5, 7.5% v/v DMSO, 0.75% Tween-80). Animals were weighed and assessed for clinical signs daily. Humane end points of >15% acute weight loss (from previous 7 day maximum individual weight) or >20% chronic weight loss (from all-time individual maximum weight) or a body condition score >3 was employed. On day 21, all remaining animals were euthanized via slow CO<sub>2</sub> asphyxiation, weighed, necropsied, and had their lungs removed. Lungs were snap frozen in liquid N<sub>2</sub> and stored at −80 °C until homogenization. Lungs were homogenized on ice using a PRO Scientific Bio-Gen PRO200 homogenizer in cell lysis buffer (150 mM NaCl, 10 mM Tris base, 1% Triton X100 v/v, pH 8.0) and centrifuged twice at 4 °C and 1000 rpm for 15 min to remove cell debris. Homogenates were prepared to approximately 50 mg/mL protein based on individual wet lung weights. Luciferase activity was quantified according to the manufacturer’s instructions using the Molecular Diagnostics SpectraMax Glo Steady-Luc report assay kit. Luciferase assays were conducted in clear-bottomed white walled 96-well plates (Nunc) using a BMG Labtech PolarSTAR multimode plate reader. Data were analyzed using GraphPad Prism v7.0, and statistical significance was determined using the one-way ANOVA with Dunnett’s post hoc test.</div></div><div id="sec4_6_33_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> Orthotopic Model of Pancreatic Cancer</h3><div class="NLM_p">The orthotopic model has been described in detail previously.<a onclick="showRef(event, 'ref69 ref85'); return false;" href="javascript:void(0);" class="ref ref69 ref85">(67,84)</a> In brief, 6- to 8-week-old female athymic nude mice (BALB/c nu/nu) were anesthetized and an incision was made in the left flank, followed by exteriorization of the spleen and tail of the pancreas. A mixture of human PC cells (AsPC-1) 1 × 10<sup>6</sup> + human PSCs (hPSCs) 1 × 10<sup>6</sup> in 50 μL of PBS was injected into the tail of the pancreas. AsPC-1 cells were chosen for their high implantation rate (100% in our hands) and high reproducibility of tumor growth rates and metastasis. After intrapancreatic injection, organs were reinternalized and the abdomen was surgically closed. Mice receiving treatment were randomized into subgroups (<i>n</i> = 4 mice per group) on postsurgical day 7. These mice were treated as follows for 4 weeks: gemcitabine (75 mg/kg BIW oral gavage); <b>18</b> or <b>26</b> (10 mg/kg/day ip or vehicle (daily ip, BIW oral gavage). Compounds were formulated for ip injection in 50 mM sodium acetate buffer (pH 5.5)/10% (v/v) DMSO/1% (w/v/) Kolliphor HS-15 and filtered through 0.22 μm PVDF syringe-driven filters under sterile conditions. Pancreatic tumor growth was monitored by palpation. Mice were killed at 4 weeks after first ip injection. Tumors were resected and assessed for size and volume by two separate observers (tumor volume was calculated to two decimal points, according to an established formula (<sup>1</sup>/<sub>2</sub>(length × breadth × width) using digital Vernier calipers (Intech Tools, Thomas Town, VIC, Australia).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(84)</a> The abdominal cavity, mesentery, spleen, liver, and lungs were examined and scored according to the presence or absence of visible macrometastatic nodules. These organs were then excised and fixed in 10% neutral buffered formalin overnight and processed using the Leica Peloris dual retort tissue processor (Germany). Histological staining was performed on 4 μm sections deparaffinised in xylene and rehydrated using graded ethanol washes. Haematoxylin and eosin staining were performed on a Leica autostainer XL.</div><div class="NLM_p last">This experiment was approved by the University of New South Wales Animal Care and Ethics Committee (Approval Number 15/106A) and was conducted in accordance with ARRIVE Guidelines.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i97"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00838" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66506" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66506" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00838" class="ext-link">10.1021/acs.jmedchem.8b00838</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">X-ray crystallography refinement data and statistics, HT-1080 uPA and uPAR expression data, experimental late-stage metastasis model clinical score sheet (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00838/suppl_file/jm8b00838_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of all compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00838/suppl_file/jm8b00838_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00838/suppl_file/jm8b00838_si_001.pdf">jm8b00838_si_001.pdf (1.38 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00838/suppl_file/jm8b00838_si_002.csv">jm8b00838_si_002.csv (4.43 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00838" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64161" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64161" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marie Ranson</span> - <span class="hlFld-Affiliation affiliation">Molecular
Horizons and School of Chemistry & Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">Illawarra
Health & Medical Research Institute, Wollongong, NSW 2522, Australia</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ec819e8d829f8382ac99839bc2898899c28d99"><span class="__cf_email__" data-cfemail="c3aeb1a2adb0acad83b6acb4eda6a7b6eda2b6">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Kelso</span> - <span class="hlFld-Affiliation affiliation">Molecular
Horizons and School of Chemistry & Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">Illawarra
Health & Medical Research Institute, Wollongong, NSW 2522, Australia</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7809-6637" title="Orcid link">http://orcid.org/0000-0001-7809-6637</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#96fbfdf3fae5f9d6e3f9e1b8f3f2e3b8f7e3"><span class="__cf_email__" data-cfemail="5b36303e3728341b2e342c753e3f2e753a2e">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benjamin
J. Buckley</span> - <span class="hlFld-Affiliation affiliation">Molecular
Horizons and School of Chemistry & Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">Illawarra
Health & Medical Research Institute, Wollongong, NSW 2522, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ashraf Aboelela</span> - <span class="hlFld-Affiliation affiliation">Molecular
Horizons and School of Chemistry & Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">Illawarra
Health & Medical Research Institute, Wollongong, NSW 2522, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elahe Minaei</span> - <span class="hlFld-Affiliation affiliation">Molecular
Horizons and School of Chemistry & Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">Illawarra
Health & Medical Research Institute, Wollongong, NSW 2522, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Longguang X. Jiang</span> - <span class="hlFld-Affiliation affiliation">National
Joint Biomedical Engineering Research Centre on Photodynamic Technologies, Fuzhou University, Fujian 350116, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4734-3778" title="Orcid link">http://orcid.org/0000-0002-4734-3778</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhihong Xu</span> - <span class="hlFld-Affiliation affiliation">Pancreatic
Research Group, South Western Sydney Clinical School, University of New South Wales, and Ingham Institute for Applied Medical
Research, Liverpool, NSW 2170, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Umar Ali</span> - <span class="hlFld-Affiliation affiliation">Molecular
Horizons and School of Chemistry & Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">Illawarra
Health & Medical Research Institute, Wollongong, NSW 2522, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen Fildes</span> - <span class="hlFld-Affiliation affiliation">Illawarra
Health & Medical Research Institute, Wollongong, NSW 2522, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">Graduate
School of Medicine, University of Wollongong, Wollongong, NSW 2522, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chen-Yi Cheung</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology and Immunology, University
of Otago, Otago 9016, New Zealand</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon M. Cook</span> - <span class="hlFld-Affiliation affiliation">Illawarra
Health & Medical Research Institute, Wollongong, NSW 2522, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Darren C. Johnson</span> - <span class="hlFld-Affiliation affiliation">Tri-Institutional
PhD Program in Chemical Biology, Memorial
Sloan Kettering Cancer Center, New York, New York 10065, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel A. Bachovchin</span> - <span class="hlFld-Affiliation affiliation">Tri-Institutional
PhD Program in Chemical Biology, Memorial
Sloan Kettering Cancer Center, New York, New York 10065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Chemical
Biology Program, Memorial Sloan Kettering
Cancer Center, New York, New York 10065, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8210-1662" title="Orcid link">http://orcid.org/0000-0001-8210-1662</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregory M. Cook</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology and Immunology, University
of Otago, Otago 9016, New Zealand</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minoti Apte</span> - <span class="hlFld-Affiliation affiliation">Pancreatic
Research Group, South Western Sydney Clinical School, University of New South Wales, and Ingham Institute for Applied Medical
Research, Liverpool, NSW 2170, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingdong Huang</span> - <span class="hlFld-Affiliation affiliation">National
Joint Biomedical Engineering Research Centre on Photodynamic Technologies, Fuzhou University, Fujian 350116, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1377-6786" title="Orcid link">http://orcid.org/0000-0002-1377-6786</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i98">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15448" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15448" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was funded by the Australian National Health and Medical Research Council (NHMRC, Project Grant APP1100432). The authors gratefully acknowledge Dr. Arnault Massink, Mrs Corine van Veen and Prof Ad P. Ijzerman, Leiden Academic Centre for Drug Research, Leiden University, for A<sub>2A</sub> activity screening. D.C.J. acknowledges funding from an NIH T32 GM115327-Tan training grant. D.A.B and D.C.J. acknowledge funding from a MSKCC Core Grant P30 (Grant CA008748).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ABPP</td><td class="NLM_def"><p class="first last">activity-based protein profiling</p></td></tr><tr><td class="NLM_term">ASIC1a</td><td class="NLM_def"><p class="first last">acid-sensing ion channel 1a</p></td></tr><tr><td class="NLM_term">C1r</td><td class="NLM_def"><p class="first last">complement C1r subcomponent</p></td></tr><tr><td class="NLM_term">C1s</td><td class="NLM_def"><p class="first last">complement component 1s</p></td></tr><tr><td class="NLM_term">DDHD1</td><td class="NLM_def"><p class="first last">phosphatidic acid-preferring phospholipase A1</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DOCA</td><td class="NLM_def"><p class="first last">deoxycorticosterone acetate</p></td></tr><tr><td class="NLM_term">DPP7</td><td class="NLM_def"><p class="first last">dipeptidyl peptidase 2</p></td></tr><tr><td class="NLM_term">ENaC</td><td class="NLM_def"><p class="first last">epithelial sodium channel</p></td></tr><tr><td class="NLM_term">FLT3-ITD+</td><td class="NLM_def"><p class="first last">Fms-like tyrosine kinase internal tandem duplication positive</p></td></tr><tr><td class="NLM_term">GABA-A</td><td class="NLM_def"><p class="first last">γ-aminobutyric acid<sub>A</sub> receptor</p></td></tr><tr><td class="NLM_term">Gem</td><td class="NLM_def"><p class="first last">gemcitabine</p></td></tr><tr><td class="NLM_term">GIRK</td><td class="NLM_def"><p class="first last">G-protein-coupled inwardly rectifying potassium channel</p></td></tr><tr><td class="NLM_term">GnRHR</td><td class="NLM_def"><p class="first last">gonadotropin-releasing hormone receptor</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">hA<sub>2A</sub>AR-WT</td><td class="NLM_def"><p class="first last">human adenosine A<sub>2A</sub> receptor</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">HIV-1</td><td class="NLM_def"><p class="first last">human immunodeficiency virus 1</p></td></tr><tr><td class="NLM_term">HMA</td><td class="NLM_def"><p class="first last">5-(<i>N</i>,<i>N</i>-hexamethylene)amiloride</p></td></tr><tr><td class="NLM_term">Hpsc</td><td class="NLM_def"><p class="first last">human pancreatic stellate cells</p></td></tr><tr><td class="NLM_term">KLKb1</td><td class="NLM_def"><p class="first last">plasma kallikrein</p></td></tr><tr><td class="NLM_term">LACTB</td><td class="NLM_def"><p class="first last">serine β-lactamase-like protein</p></td></tr><tr><td class="NLM_term">NECA</td><td class="NLM_def"><p class="first last">5′-(<i>N</i>-ethylcarboxamido)adenosine</p></td></tr><tr><td class="NLM_term">NHE1</td><td class="NLM_def"><p class="first last">sodium hydrogen exchanger isoform 1</p></td></tr><tr><td class="NLM_term">NSB</td><td class="NLM_def"><p class="first last">nonspecific binding</p></td></tr><tr><td class="NLM_term">P2X<sub>7</sub></td><td class="NLM_def"><p class="first last">P2X purinoreceptor</p></td></tr><tr><td class="NLM_term">PRCP</td><td class="NLM_def"><p class="first last">prolylcarboxypeptidase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SOSA</td><td class="NLM_def"><p class="first last">selective optimization of side activity</p></td></tr><tr><td class="NLM_term">TB</td><td class="NLM_def"><p class="first last">total binding</p></td></tr><tr><td class="NLM_term">TLSP</td><td class="NLM_def"><p class="first last">trypsin-like serine protease</p></td></tr><tr><td class="NLM_term">TMPRSS11d</td><td class="NLM_def"><p class="first last">trypsin and transmembrane protease serine 11D</p></td></tr><tr><td class="NLM_term">uPA</td><td class="NLM_def"><p class="first last">urokinase plasminogen activator</p></td></tr><tr><td class="NLM_term">uPAR</td><td class="NLM_def"><p class="first last">urokinase plasminogen activator receptor</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i100">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00542" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00542" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 84 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ulisse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrenti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Armiento, M.</span></span> <span> </span><span class="NLM_article-title">The urokinase plasminogen activator system: a target for anti-cancer therapy</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.2174/156800909787314002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.2174%2F156800909787314002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=19200050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1Wjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=32-71&issue=1&author=S.+Ulisseauthor=E.+Baldiniauthor=S.+Sorrentiauthor=M.+D%E2%80%99Armiento&title=The+urokinase+plasminogen+activator+system%3A+a+target+for+anti-cancer+therapy&doi=10.2174%2F156800909787314002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The urokinase plasminogen activator system: a target for anti-cancer therapy</span></div><div class="casAuthors">Ulisse, Salvatore; Baldini, Enke; Sorrenti, Salvatore; D'Armiento, Massimino</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-71</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The urokinase plasminogen activator (uPA) system (uPAS) consists of the uPA, its cognate receptor (uPAR) and two specific inhibitors, the plasminogen activator inhibitor 1 (PAI-1) and 2 (PAI-2).  The uPA converts the proenzyme plasminogen in the serine protease plasmin, involved in a no. of physiopathol. processes requiring basement membrane (BM) and/or extracellular matrix (ECM) remodelling, including tumor progression and metastasis.  Data accumulated over the past years have made increasingly clear that the uPAS has a multifunctional task in the neoplastic evolution, affecting tumor angiogenesis, malignant cell proliferation, adhesion and migration, intravasation and growth at the metastatic site.  In agreement with their role in cancer progression and metastasis, an increased expression of uPA, uPAR, and PAI-1 has been documented in several malignant tumors, and a pos. correlation between the levels of one or more uPAS members and a poor prognosis has been frequently reported.  This is particularly evident in breast cancer, for which uPA has been demonstrated to be the most potent independent prognostic factor described to date.  The involvement of the uPAS in cancer progression identifies its components as suitable targets for anti-cancer therapy.  Several therapeutical approaches aimed at inhibiting the uPA/uPAR functions have been shown to possess anti-tumor effects in xenograft models, including selective inhibitors of uPA activity, antagonist peptides, monoclonal antibodies able to prevent uPA binding to uPAR and gene therapy techniques silencing uPA/uPAR expression.  All these strategies, however, although promising, need definitive confirmation in humans as, up to now, only few uPA inhibitors entered clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra2dQsy6IUN7Vg90H21EOLACvtfcHk0lh_NyUnpNz_4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1Wjsr8%253D&md5=7fb917600d9bc1b0ec5751822c401e59</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F156800909787314002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156800909787314002%26sid%3Dliteratum%253Aachs%26aulast%3DUlisse%26aufirst%3DS.%26aulast%3DBaldini%26aufirst%3DE.%26aulast%3DSorrenti%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Armiento%26aufirst%3DM.%26atitle%3DThe%2520urokinase%2520plasminogen%2520activator%2520system%253A%2520a%2520target%2520for%2520anti-cancer%2520therapy%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2009%26volume%3D9%26issue%3D1%26spage%3D32%26epage%3D71%26doi%3D10.2174%2F156800909787314002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brungs, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghmesheh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vine, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carolan, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span> <span> </span><span class="NLM_article-title">The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">23099</span>– <span class="NLM_lpage">23109</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.15485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.18632%2Foncotarget.15485" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=23099-23109&issue=14&author=D.+Brungsauthor=J.+Chenauthor=M.+Aghmeshehauthor=K.+L.+Vineauthor=T.+M.+Beckerauthor=M.+G.+Carolanauthor=M.+Ranson&title=The+urokinase+plasminogen+activation+system+in+gastroesophageal+cancer%3A+A+systematic+review+and+meta-analysis&doi=10.18632%2Foncotarget.15485"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.15485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.15485%26sid%3Dliteratum%253Aachs%26aulast%3DBrungs%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DAghmesheh%26aufirst%3DM.%26aulast%3DVine%26aufirst%3DK.%2BL.%26aulast%3DBecker%26aufirst%3DT.%2BM.%26aulast%3DCarolan%26aufirst%3DM.%2BG.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DThe%2520urokinase%2520plasminogen%2520activation%2520system%2520in%2520gastroesophageal%2520cancer%253A%2520A%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D14%26spage%3D23099%26epage%3D23109%26doi%3D10.18632%2Foncotarget.15485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Croucher, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span> <span> </span><span class="NLM_article-title">Revisiting the biological roles of PAI2 (SERPINB2) in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1038/nrc2400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1038%2Fnrc2400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=18548086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFOkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=535-545&issue=7&author=D.+R.+Croucherauthor=D.+N.+Saundersauthor=S.+Lobovauthor=M.+Ranson&title=Revisiting+the+biological+roles+of+PAI2+%28SERPINB2%29+in+cancer&doi=10.1038%2Fnrc2400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting the biological roles of PAI2 (SERPINB2) in cancer</span></div><div class="casAuthors">Croucher, David R.; Saunders, Darren N.; Lobov, Sergei; Ranson, Marie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">535-545</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor expression of the urokinase plasminogen activator correlates with invasive capacity.  Consequently, inhibition of this serine protease by physiol. inhibitors should decrease invasion and metastasis.  However, of the two main urokinase inhibitors, high tumor levels of the type 1 inhibitor actually promote tumor progression, whereas high levels of the type 2 inhibitor decrease tumor growth and metastasis.  We propose that the basis of this apparently paradoxical action of two similar serine protease inhibitors lies in key structural differences controlling interactions with components of the extracellular matrix and endocytosis-signaling co-receptors.  Of the two main urokinase plasminogen activator inhibitors, high tumor levels of the type 1 inhibitor promote tumor progression, whereas high levels of the type 2 inhibitor decrease tumor growth and metastasis.  What might be the basis of this paradoxical action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi0c6ydaFqRrVg90H21EOLACvtfcHk0lh_NyUnpNz_4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFOkt7o%253D&md5=3e6a3c1e8760dc75f203540ba87f69f4</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2400%26sid%3Dliteratum%253Aachs%26aulast%3DCroucher%26aufirst%3DD.%2BR.%26aulast%3DSaunders%26aufirst%3DD.%2BN.%26aulast%3DLobov%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DRevisiting%2520the%2520biological%2520roles%2520of%2520PAI2%2520%2528SERPINB2%2529%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26issue%3D7%26spage%3D535%26epage%3D545%26doi%3D10.1038%2Fnrc2400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, N. L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vennin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, J. R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vine, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shearer, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allam, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pajic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, J. P.</span></span>; <span class="NLM_contrib-group">Australian Pancreatic Cancer Genome Initiative</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biankin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timpson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D. N.</span></span> <span> </span><span class="NLM_article-title">SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">4288</span>– <span class="NLM_lpage">4298</span>, <span class="refDoi"> DOI: 10.1038/onc.2017.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1038%2Fonc.2017.63" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=4288-4298&issue=30&author=N.+L.+E.+Harrisauthor=C.+Venninauthor=J.+R.+W.+Conwayauthor=K.+L.+Vineauthor=M.+Pineseauthor=M.+J.+Cowleyauthor=R.+F.+Shearerauthor=M.+C.+Lucasauthor=D.+Herrmannauthor=A.+H.+Allamauthor=M.+Pajicauthor=J.+P.+Mortonauthor=Australian+Pancreatic+Cancer+Genome+Initiativeauthor=A.+V.+Biankinauthor=M.+Ransonauthor=P.+Timpsonauthor=D.+N.+Saunders&title=SerpinB2+regulates+stromal+remodelling+and+local+invasion+in+pancreatic+cancer&doi=10.1038%2Fonc.2017.63"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fonc.2017.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2017.63%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DN.%2BL.%2BE.%26aulast%3DVennin%26aufirst%3DC.%26aulast%3DConway%26aufirst%3DJ.%2BR.%2BW.%26aulast%3DVine%26aufirst%3DK.%2BL.%26aulast%3DPinese%26aufirst%3DM.%26aulast%3DCowley%26aufirst%3DM.%2BJ.%26aulast%3DShearer%26aufirst%3DR.%2BF.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DHerrmann%26aufirst%3DD.%26aulast%3DAllam%26aufirst%3DA.%2BH.%26aulast%3DPajic%26aufirst%3DM.%26aulast%3DMorton%26aufirst%3DJ.%2BP.%26aulast%3D%26aulast%3DBiankin%26aufirst%3DA.%2BV.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DTimpson%26aufirst%3DP.%26aulast%3DSaunders%26aufirst%3DD.%2BN.%26atitle%3DSerpinB2%2520regulates%2520stromal%2520remodelling%2520and%2520local%2520invasion%2520in%2520pancreatic%2520cancer%26jtitle%3DOncogene%26date%3D2017%26volume%3D36%26issue%3D30%26spage%3D4288%26epage%3D4298%26doi%3D10.1038%2Fonc.2017.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seetoo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berney, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ham, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, P. J.</span></span> <span> </span><span class="NLM_article-title">Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1002/1097-0215(20000920)89:5<431::AID-IJC6>3.0.CO;2-V</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1002%2F1097-0215%2820000920%2989%3A5%3C431%3A%3AAID-IJC6%3E3.0.CO%3B2-V" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=11008205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnsFWmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2000&pages=431-439&issue=5&author=J.+L.+Yangauthor=D.+Seetooauthor=Y.+Wangauthor=M.+Ransonauthor=C.+R.+Berneyauthor=J.+M.+Hamauthor=P.+J.+Russellauthor=P.+J.+Crowe&title=Urokinase-type+plasminogen+activator+and+its+receptor+in+colorectal+cancer%3A+independent+prognostic+factors+of+metastasis+and+cancer-specific+survival+and+potential+therapeutic+targets&doi=10.1002%2F1097-0215%2820000920%2989%3A5%3C431%3A%3AAID-IJC6%3E3.0.CO%3B2-V"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets</span></div><div class="casAuthors">Yang, Jia-Lin; Seetoo, Da-qiang; Wang, Yao; Ranson, Marie; Berney, Christophe R.; Ham, John M.; Russell, Pamela J.; Crowe, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">431-439</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Urokinase-type plasminogen activator (uPA) and its receptor (uPAR), plasminogen (Plg), and plasminogen activator inhibitors-1 and -2 (PAI-1 and PAI-2) were obsd. in many cancers and may contribute to progression and metastasis.  In this study, the authors examd. the expression of the 5 proteins by immunohistochem. in 59 consecutive primary colorectal cancers (CRC) and correlated the protein expression with patient outcome.  In addn., the authors detd. the effect of down-regulation of uPAR on the invasive/metastatic capability of CRC cells, by measuring antisense-uPAR transfected HCT116 and control cell lines, in terms of uPAR expression, uPA-binding activity, invasiveness through Matrigel in vitro and metastasis after cecal orthotopic implantation in nude mice in vivo.  The authors found that higher expression of uPA or uPAR in primary tumor tissues was pos. correlated with distant metastasis of CRC (Mann-Whitney, p < 0.02) and neg. correlated with both patient overall survival (OS) and cancer-specific survival (CSS; Cox model, p < 0.04).  The prognostic value of uPA and uPAR for both OS and CSS was independent of other variables (multivariate Cox model, p < 0.007).  Antisense-uPAR transfected HCT116 cells, which expressed significantly lower levels of total cellular and cell surface uPAR proteins and uPA-binding activity compared with either wild-type or cells transfected with vector alone (Bonferroni, p < 0.05/3), consistently showed decreased invasiveness through Matrigel (Bonferroni, p < 0.05/3) and decreased metastasis formation in nude mice (Fisher, p < 0.05).  These data suggest that uPAR and uPA are independent prognostic factors in CRC; anti-uPAR treatment, which affects both uPAR and uPA levels, may have potential for new treatment of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBhJJx-EBpm7Vg90H21EOLACvtfcHk0lh66iVNCMg7CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnsFWmsrY%253D&md5=be98ec0cf73d21ec4744bca274a02364</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2F1097-0215%2820000920%2989%3A5%3C431%3A%3AAID-IJC6%3E3.0.CO%3B2-V&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0215%252820000920%252989%253A5%253C431%253A%253AAID-IJC6%253E3.0.CO%253B2-V%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%2BL.%26aulast%3DSeetoo%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DBerney%26aufirst%3DC.%2BR.%26aulast%3DHam%26aufirst%3DJ.%2BM.%26aulast%3DRussell%26aufirst%3DP.%2BJ.%26aulast%3DCrowe%26aufirst%3DP.%2BJ.%26atitle%3DUrokinase-type%2520plasminogen%2520activator%2520and%2520its%2520receptor%2520in%2520colorectal%2520cancer%253A%2520independent%2520prognostic%2520factors%2520of%2520metastasis%2520and%2520cancer-specific%2520survival%2520and%2520potential%2520therapeutic%2520targets%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2000%26volume%3D89%26issue%3D5%26spage%3D431%26epage%3D439%26doi%3D10.1002%2F1097-0215%2820000920%2989%3A5%3C431%3A%3AAID-IJC6%3E3.0.CO%3B2-V" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsche, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravdin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somerfield, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bast, R. C.,  Jr.</span></span> <span> </span><span class="NLM_article-title">American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">33</span>),  <span class="NLM_fpage">5287</span>– <span class="NLM_lpage">5312</span>, <span class="refDoi"> DOI: 10.1200/JCO.2007.14.2364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1200%2FJCO.2007.14.2364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=17954709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKnsbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=5287-5312&issue=33&author=L.+Harrisauthor=H.+Fritscheauthor=R.+Mennelauthor=L.+Nortonauthor=P.+Ravdinauthor=S.+Taubeauthor=M.+R.+Somerfieldauthor=D.+F.+Hayesauthor=R.+C.+Bast&title=American+society+of+clinical+oncology+2007+update+of+recommendations+for+the+use+of+tumor+markers+in+breast+cancer&doi=10.1200%2FJCO.2007.14.2364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer</span></div><div class="casAuthors">Harris, Lyndsay; Fritsche, Herbert; Mennel, Robert; Norton, Larry; Ravdin, Peter; Taube, Sheila; Somerfield, Mark R.; Hayes, Daniel F.; Bast, Robert C., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5287-5312</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Purpose: To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer.  Methods: For the 2007 update, an Update Committee composed of members from the full Panel was formed to complete the review and anal. of data published since 1999.  Computerized literature searches of MEDLINE and the Cochrane Collaboration Library were performed.  The Update Committee's literature review focused attention on available systematic reviews and meta analyses of published tumor marker studies.  In general, significant health outcomes (overall survival, disease-free survival, quality of life, lesser toxicity, and cost-effectiveness) were used for making recommendations.  Recommendations and Conclusions: Thirteen categories of breast tumor markers were considered, six of which were new for the guideline.  The following categories showed evidence of clin. utility and were recommended for use in practice: CA 15-3, CA 27.29, carcinoembryonic antigen, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, urokinase plasminogen activator, plasminogen activator inhibitor 1, and certain multiparameter gene expression assays.  Not all applications for these markers were supported, however.  The following categories demonstrated insufficient evidence to support routine use in clin. practice: DNA/ploidy by flow cytometry, p53, cathepsin D, cyclin E, proteomics, certain multiparameter assays, detection of bone marrow micrometastases, and circulating tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJw2_N7FeeLrVg90H21EOLACvtfcHk0lh66iVNCMg7CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKnsbzK&md5=194b8cd7564003cb9519cb7df2c54818</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.14.2364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.14.2364%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DL.%26aulast%3DFritsche%26aufirst%3DH.%26aulast%3DMennel%26aufirst%3DR.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DRavdin%26aufirst%3DP.%26aulast%3DTaube%26aufirst%3DS.%26aulast%3DSomerfield%26aufirst%3DM.%2BR.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DBast%26aufirst%3DR.%2BC.%26atitle%3DAmerican%2520society%2520of%2520clinical%2520oncology%25202007%2520update%2520of%2520recommendations%2520for%2520the%2520use%2520of%2520tumor%2520markers%2520in%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26issue%3D33%26spage%3D5287%26epage%3D5312%26doi%3D10.1200%2FJCO.2007.14.2364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Look, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Putten, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbeck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomssen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kates, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyratos, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eppenberger-Castori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweep, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrat, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magdelenat, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisboa, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendahl, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quillien, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricolleau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer-van Gelder, M.
E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manders, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiets, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blankenstein, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daxenbichler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windbichler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cufer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borstnar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kueng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beex, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klijn, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Higgins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eppenberger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janicke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foekens, J. A.</span></span> <span> </span><span class="NLM_article-title">Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients</span>. <i>J. Natl. Cancer. Inst.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1093/jnci/94.2.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1093%2Fjnci%2F94.2.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=11792750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD38Xit1amt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2002&pages=116-128&issue=2&author=M.+P.+Lookauthor=W.+L.+van+Puttenauthor=M.+J.+Duffyauthor=N.+Harbeckauthor=I.+J.+Christensenauthor=C.+Thomssenauthor=R.+Katesauthor=F.+Spyratosauthor=M.+Fernoauthor=S.+Eppenberger-Castoriauthor=C.+G.+Sweepauthor=K.+Ulmauthor=J.+P.+Peyratauthor=P.+M.+Martinauthor=H.+Magdelenatauthor=N.+Brunnerauthor=C.+Dugganauthor=B.+W.+Lisboaauthor=P.+O.+Bendahlauthor=V.+Quillienauthor=A.+Daverauthor=G.+Ricolleauauthor=M.%0AE.+Meijer-van+Gelderauthor=P.+Mandersauthor=W.+E.+Fietsauthor=M.+A.+Blankensteinauthor=P.+Broetauthor=S.+Romainauthor=G.+Daxenbichlerauthor=G.+Windbichlerauthor=T.+Cuferauthor=S.+Borstnarauthor=W.+Kuengauthor=L.+V.+Beexauthor=J.+G.+Klijnauthor=N.+O%E2%80%99Higginsauthor=U.+Eppenbergerauthor=F.+Janickeauthor=M.+Schmittauthor=J.+A.+Foekens&title=Pooled+analysis+of+prognostic+impact+of+urokinase-type+plasminogen+activator+and+its+inhibitor+PAI-1+in+8377+breast+cancer+patients&doi=10.1093%2Fjnci%2F94.2.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients</span></div><div class="casAuthors">Look, Maxime P.; van Putten, Wim L. J.; Duffy, Michael J.; Harbeck, Nadia; Christensen, Ib Jarle; Thomssen, Christoph; Kates, Ronald; Spyratos, Frederique; Ferno, Marten; Eppenberger-Castori, Serenella; Sweep, C. G. J.; Ulm, Kurt; Peyrat, Jean-Philippe; Martin, Pierre-Marie; Magdelenat, Henri; Brunner, Nils; Duggan, Catherine; Lisboa, Bjorn W.; Bendahl, Par-Ola; Quillien, Veronique; Daver, Alain; Ricolleau, Gabriel; Meijer-van Gelder, Marion E.; Manders, Peggy; Fiets, W. Edward; Blankenstein, Marinus A.; Broet, Philippe; Romain, Sylvie; Daxenbichler, Gunter; Windbichler, Gudrun; Cufer, Tanja; Borstnar, Simona; Kueng, Willy; Beex, Louk V. A. M.; Klijn, Jan G. M.; O'Higgins, Niall; Eppenberger, Urs; Janicke, Fritz; Schmitt, Manfred; Foekens, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-128</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) play essential roles in tumor invasion and metastasis.  High levels of both uPA and PAI-1 are assocd. with poor prognosis in breast cancer patients.  To confirm the prognostic value of uPA and PAI-1 in primary breast cancer, the authors reanalyzed individual patient data provided by members of the European Organization for Research and Treatment of Cancer-Receptor and Biomarker Group (EORTC-RBG).  The study included 18 datasets involving 8377 breast cancer patients.  During follow-up (median 79 mo), 35% of the patients relapsed and 27% died.  Levels of uPA and PAI-1 in tumor tissue exts. were detd. by different immunoassays; values were ranked within each dataset and divided by the no. of patients in that dataset to produce fractional ranks that could be compared directly across datasets.  Assocns. of ranks of uPA and PAI-1 levels with relapse-free survival (RFS) and overall survival (OS) were analyzed by Cox multivariable regression anal. stratified by dataset, including the following traditional prognostic variables: age, menopausal status, lymph node status, tumor size, histol. grade, and steroid hormone-receptor status.  All P values were two-sided.  Apart from lymph node status, high levels of uPA and PAI-1 were the strongest predictors of both poor RFS and poor OS in the analyses of all patients.  Moreover, in both lymph node-pos. and lymph node-neg. patients, higher uPA and PAI-1 values were independently assocd. with poor RFS and poor OS.  For (untreated) lymph node-neg. patients in particular, uPA and PAI-1 included together showed strong prognostic ability (all P<.001).  This pooled anal. of the EORTC-RBG datasets confirmed the strong and independent prognostic value of uPA and PAI-1 in primary breast cancer.  For patients with lymph node-neg. breast cancer, uPA and PAI-1 measurements in primary tumors may be esp. useful for designing individualized treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUHv67JMd3wbVg90H21EOLACvtfcHk0lhFh-A9D3HOfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xit1amt7s%253D&md5=4a607778acf517db8947cf683122d741</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F94.2.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F94.2.116%26sid%3Dliteratum%253Aachs%26aulast%3DLook%26aufirst%3DM.%2BP.%26aulast%3Dvan%2BPutten%26aufirst%3DW.%2BL.%26aulast%3DDuffy%26aufirst%3DM.%2BJ.%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DChristensen%26aufirst%3DI.%2BJ.%26aulast%3DThomssen%26aufirst%3DC.%26aulast%3DKates%26aufirst%3DR.%26aulast%3DSpyratos%26aufirst%3DF.%26aulast%3DFerno%26aufirst%3DM.%26aulast%3DEppenberger-Castori%26aufirst%3DS.%26aulast%3DSweep%26aufirst%3DC.%2BG.%26aulast%3DUlm%26aufirst%3DK.%26aulast%3DPeyrat%26aufirst%3DJ.%2BP.%26aulast%3DMartin%26aufirst%3DP.%2BM.%26aulast%3DMagdelenat%26aufirst%3DH.%26aulast%3DBrunner%26aufirst%3DN.%26aulast%3DDuggan%26aufirst%3DC.%26aulast%3DLisboa%26aufirst%3DB.%2BW.%26aulast%3DBendahl%26aufirst%3DP.%2BO.%26aulast%3DQuillien%26aufirst%3DV.%26aulast%3DDaver%26aufirst%3DA.%26aulast%3DRicolleau%26aufirst%3DG.%26aulast%3DMeijer-van%2BGelder%26aufirst%3DM.%2BE.%26aulast%3DManders%26aufirst%3DP.%26aulast%3DFiets%26aufirst%3DW.%2BE.%26aulast%3DBlankenstein%26aufirst%3DM.%2BA.%26aulast%3DBroet%26aufirst%3DP.%26aulast%3DRomain%26aufirst%3DS.%26aulast%3DDaxenbichler%26aufirst%3DG.%26aulast%3DWindbichler%26aufirst%3DG.%26aulast%3DCufer%26aufirst%3DT.%26aulast%3DBorstnar%26aufirst%3DS.%26aulast%3DKueng%26aufirst%3DW.%26aulast%3DBeex%26aufirst%3DL.%2BV.%26aulast%3DKlijn%26aufirst%3DJ.%2BG.%26aulast%3DO%25E2%2580%2599Higgins%26aufirst%3DN.%26aulast%3DEppenberger%26aufirst%3DU.%26aulast%3DJanicke%26aufirst%3DF.%26aulast%3DSchmitt%26aufirst%3DM.%26aulast%3DFoekens%26aufirst%3DJ.%2BA.%26atitle%3DPooled%2520analysis%2520of%2520prognostic%2520impact%2520of%2520urokinase-type%2520plasminogen%2520activator%2520and%2520its%2520inhibitor%2520PAI-1%2520in%25208377%2520breast%2520cancer%2520patients%26jtitle%3DJ.%2520Natl.%2520Cancer.%2520Inst.%26date%3D2002%26volume%3D94%26issue%3D2%26spage%3D116%26epage%3D128%26doi%3D10.1093%2Fjnci%2F94.2.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foekens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portengen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janicke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer-van Gelder, M.
E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henzen-Logmans, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Putten, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klijn, J. G.</span></span> <span> </span><span class="NLM_article-title">The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients</span>. <i>Cancer. Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">636</span>– <span class="NLM_lpage">643</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10676647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht1GmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=636-643&issue=3&author=J.+A.+Foekensauthor=H.+A.+Petersauthor=M.+P.+Lookauthor=H.+Portengenauthor=M.+Schmittauthor=M.+D.+Kramerauthor=N.+Brunnerauthor=F.+Janickeauthor=M.%0AE.+Meijer-van+Gelderauthor=S.+C.+Henzen-Logmansauthor=W.+L.+van+Puttenauthor=J.+G.+Klijn&title=The+urokinase+system+of+plasminogen+activation+and+prognosis+in+2780+breast+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients</span></div><div class="casAuthors">Foekens, John A.; Peters, Harry A.; Look, Maxime P.; Portengen, Henk; Schmitt, Manfred; Kramer, Michael D.; Brunner, Nils; Janicke, Fritz; Gelder, Marion E. Meijer-Van; Henzen-Logmans, Sonja C.; Van Putten, Wim L. J.; Klijn, Jan G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">636-643</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">The antigen levels of components of the urokinase-type plasminogen activator (uPA) system of plasminogen activation are correlated with prognosis in several types of cancers, including breast cancer.  In the present study involving 2780 patients with primary invasive breast cancer, we have evaluated the prognostic importance of the four major components of the uPA system [uPA, the receptor uPAR (CD87), and the inhibitors PAI-1 and PAI-2].  The antigen levels were detd. by ELISA in cytosols prepd. from primary breast tumors.  The levels of the four factors significantly correlated with each other; the Spearman rank correlation coeffs. (rs) ranged from 0.32 (between PAI-2 and PAI-1 or uPAR) to 0.59 (between uPA and PAI-1).  The median duration of follow-up of patients still alive was 88 mo.  In the multivariate analyses for relapse-free survival (RFS) and overall survival (OS), we defined a basic model including age, menopausal status, tumor size and grade, lymph node status, adjuvant therapy, and steroid hormone receptor status.  UPA, uPAR, PAI-1, and PAI-2 were considered as categorical variables, each with two cut points that were established by isotonic regression anal.  Compared with tumors with low levels, those with intermediate and high levels showed a relative hazard rate (RHR) and 95% confidence interval (95% CI) of 1.22 (1.02-1.45) and 1.69 (1.39-2.05) for uPA, and 1.32 (1.14-1.54) and 2.17 (1.74-2.70) for PAI-1, resp., in multivariate anal. for RFS in all patients.  Compared with tumors with high PAI-2 levels, those with intermediate and low levels showed a poor RFS with a RHR (95% CI) of 1.30 (1.14-1.48) and 1.76 (1.38-2.24), resp.  Similar results were obtained in the multivariate anal. for OS in all patients.  Furthermore, uPA and PAI-1 were independent predictive factors of a poor RFS and OS in node-neg. and node-pos. patients.  PAI-2 also added to the multivariate models for RFS in node-neg. and node-pos. patients, and in the anal. for OS in node-neg. patients.  UPAR did not further contribute to any of the multivariate models.  A prognostic score was calcd. based on the ests. from the final multivariate model for RFS.  Using this score, the difference between the highest and lowest 10% risk groups was 66% in the anal. for RFS at 10 yr and 61% in the anal. for OS.  Moreover, sep. prognostic scores were calcd. for node-neg. and node-pos. patients.  In the 10% highest risk groups, the proportion of disease-free patients was only 27±6% and 9±3% at 10 yr for node-neg. and node-pos. patients, resp.  These proportions were 86±4% and 61±6% for the corresponding 10% lowest risk groups of relapse.  We conclude that several components of the uPA system are potential predictors of RFS and OS in patients with primary invasive breast cancer.  Knowledge of these factors could be helpful to assess the individual risk of patients, to select various types of adjuvant treatment and to identify patients who may benefit from targeted therapies that are currently being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLtE82O-8T47Vg90H21EOLACvtfcHk0lhFh-A9D3HOfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht1GmtLk%253D&md5=ee7094ecddd28d8f0f0cf13efe9dbd9c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFoekens%26aufirst%3DJ.%2BA.%26aulast%3DPeters%26aufirst%3DH.%2BA.%26aulast%3DLook%26aufirst%3DM.%2BP.%26aulast%3DPortengen%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DM.%26aulast%3DKramer%26aufirst%3DM.%2BD.%26aulast%3DBrunner%26aufirst%3DN.%26aulast%3DJanicke%26aufirst%3DF.%26aulast%3DMeijer-van%2BGelder%26aufirst%3DM.%2BE.%26aulast%3DHenzen-Logmans%26aufirst%3DS.%2BC.%26aulast%3Dvan%2BPutten%26aufirst%3DW.%2BL.%26aulast%3DKlijn%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520urokinase%2520system%2520of%2520plasminogen%2520activation%2520and%2520prognosis%2520in%25202780%2520breast%2520cancer%2520patients%26jtitle%3DCancer.%2520Res.%26date%3D2000%26volume%3D60%26issue%3D3%26spage%3D636%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Grady, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devaney, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Siorain, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennelly, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lijnen, H. J.</span></span> <span> </span><span class="NLM_article-title">Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1002%2F1097-0142%2819880801%2962%3A3%3C531%3A%3AAID-CNCR2820620315%3E3.0.CO%3B2-B" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1988&pages=531-533&issue=3&author=M.+J.+Duffyauthor=P.+O%E2%80%99Gradyauthor=D.+Devaneyauthor=L.+O%E2%80%99Siorainauthor=J.+J.+Fennellyauthor=H.+J.+Lijnen&title=Urokinase-plasminogen+activator%2C+a+marker+for+aggressive+breast+carcinomas.+Preliminary+report&doi=10.1002%2F1097-0142%2819880801%2962%3A3%3C531%3A%3AAID-CNCR2820620315%3E3.0.CO%3B2-B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2F1097-0142%2819880801%2962%3A3%3C531%3A%3AAID-CNCR2820620315%3E3.0.CO%3B2-B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0142%252819880801%252962%253A3%253C531%253A%253AAID-CNCR2820620315%253E3.0.CO%253B2-B%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DM.%2BJ.%26aulast%3DO%25E2%2580%2599Grady%26aufirst%3DP.%26aulast%3DDevaney%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Siorain%26aufirst%3DL.%26aulast%3DFennelly%26aufirst%3DJ.%2BJ.%26aulast%3DLijnen%26aufirst%3DH.%2BJ.%26atitle%3DUrokinase-plasminogen%2520activator%252C%2520a%2520marker%2520for%2520aggressive%2520breast%2520carcinomas.%2520Preliminary%2520report%26jtitle%3DCancer%26date%3D1988%26volume%3D62%26issue%3D3%26spage%3D531%26epage%3D533%26doi%3D10.1002%2F1097-0142%2819880801%2962%3A3%3C531%3A%3AAID-CNCR2820620315%3E3.0.CO%3B2-B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Estreicher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhlhauser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpentier, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassalli, J. D.</span></span> <span> </span><span class="NLM_article-title">The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1083/jcb.111.2.783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1083%2Fjcb.111.2.783" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1990&pages=783-792&issue=2&author=A.+Estreicherauthor=J.+Muhlhauserauthor=J.+L.+Carpentierauthor=L.+Orciauthor=J.+D.+Vassalli&title=The+receptor+for+urokinase+type+plasminogen+activator+polarizes+expression+of+the+protease+to+the+leading+edge+of+migrating+monocytes+and+promotes+degradation+of+enzyme+inhibitor+complexes&doi=10.1083%2Fjcb.111.2.783"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1083%2Fjcb.111.2.783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.111.2.783%26sid%3Dliteratum%253Aachs%26aulast%3DEstreicher%26aufirst%3DA.%26aulast%3DMuhlhauser%26aufirst%3DJ.%26aulast%3DCarpentier%26aufirst%3DJ.%2BL.%26aulast%3DOrci%26aufirst%3DL.%26aulast%3DVassalli%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520receptor%2520for%2520urokinase%2520type%2520plasminogen%2520activator%2520polarizes%2520expression%2520of%2520the%2520protease%2520to%2520the%2520leading%2520edge%2520of%2520migrating%2520monocytes%2520and%2520promotes%2520degradation%2520of%2520enzyme%2520inhibitor%2520complexes%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1990%26volume%3D111%26issue%3D2%26spage%3D783%26epage%3D792%26doi%3D10.1083%2Fjcb.111.2.783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lund, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurison, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer-Hansen, G.</span></span> <span> </span><span class="NLM_article-title">uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1744</span>– <span class="NLM_lpage">1760</span>, <span class="refDoi"> DOI: 10.2174/138945011797635902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.2174%2F138945011797635902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=21707477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVSrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=1744-1760&issue=12&author=I.+K.+Lundauthor=M.+Illemannauthor=T.+Thurisonauthor=I.+J.+Christensenauthor=G.+Hoyer-Hansen&title=uPAR+as+anti-cancer+target%3A+evaluation+of+biomarker+potential%2C+histological+localization%2C+and+antibody-based+therapy&doi=10.2174%2F138945011797635902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy</span></div><div class="casAuthors">Lund, Ida K.; Illemann, Martin; Thurison, Tine; Christensen, Ib J.; Hoeyer-Hansen, Gunilla</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1744-1760</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Degrdn. of proteins in the extracellular matrix is crucial for the multistep process of cancer invasion and metastasis.  Compelling evidence has demonstrated the urokinase receptor (uPAR) and its cognate ligand, the urokinase plasminogen activator (uPA), to play crit. roles in the concerted action of several proteolytic systems in generation of a high proteolytic potential required for tissue remodeling processes.  UPAR is addnl. cleaved by uPA on the cell surface, liberating domain I, resulting in abrogated pericellular proteolysis.  The expression of both uPAR and uPA is significantly up-regulated during cancer progression and is primarily confined to the tumor-assocd. stromal compartment.  Furthermore, both uPAR and uPA have proven to be prognostic markers in several types of cancer; high levels indicating poor survival.  The cleaved forms of uPAR are also prognostic markers, and a potential diagnostic and predictive impact of the different uPAR forms has been reported.  Hence, pericellular proteolysis seems to be a suitable target for anti-cancer therapy and numerous approaches have been pursued.  Targeting of this process may be achieved by preventing the binding of uPA to uPAR on the cell surface and/or by direct inhibition of the catalytic activity of uPA.  Both strategies have been pursued and inhibition of these functions has shown effect in xenogenic cancer models.  Pericellular proteolysis has also been inhibited in vivo in mouse models of wound healing and hepatic fibrinolysis using mouse monoclonal antibodies (mAbs) against mouse uPA or uPAR.  These reagents will target uPA and uPAR in both stromal cells and cancer cells, and their therapeutic potential can now be assessed in syngenic mouse cancer models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-yFaxesgDvLVg90H21EOLACvtfcHk0liHF8okX5cgig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVSrtbo%253D&md5=07724bde3e8c999edff87d6c1d332c9a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F138945011797635902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945011797635902%26sid%3Dliteratum%253Aachs%26aulast%3DLund%26aufirst%3DI.%2BK.%26aulast%3DIllemann%26aufirst%3DM.%26aulast%3DThurison%26aufirst%3DT.%26aulast%3DChristensen%26aufirst%3DI.%2BJ.%26aulast%3DHoyer-Hansen%26aufirst%3DG.%26atitle%3DuPAR%2520as%2520anti-cancer%2520target%253A%2520evaluation%2520of%2520biomarker%2520potential%252C%2520histological%2520localization%252C%2520and%2520antibody-based%2520therapy%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2011%26volume%3D12%26issue%3D12%26spage%3D1744%26epage%3D1760%26doi%3D10.2174%2F138945011797635902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dohn, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Høyer-Hansen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hostmark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litlekalsoy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von der Maase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappot, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laerum, O. D.</span></span> <span> </span><span class="NLM_article-title">Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder</span>. <i>Urol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">165.e15</span>– <span class="NLM_lpage">165.e24</span>, <span class="refDoi"> DOI: 10.1016/j.urolonc.2014.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.urolonc.2014.12.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=165.e15-165.e24&issue=4&author=L.+H.+Dohnauthor=M.+Illemannauthor=G.+H%C3%B8yer-Hansenauthor=I.+J.+Christensenauthor=J.+Hostmarkauthor=J.+Litlekalsoyauthor=H.+von+der+Maaseauthor=H.+Pappotauthor=O.+D.+Laerum&title=Urokinase-type+plasminogen+activator+receptor+%28uPAR%29+expression+is+associated+with+T-stage+and+survival+in+urothelial+carcinoma+of+the+bladder&doi=10.1016%2Fj.urolonc.2014.12.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.urolonc.2014.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.urolonc.2014.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DDohn%26aufirst%3DL.%2BH.%26aulast%3DIllemann%26aufirst%3DM.%26aulast%3DH%25C3%25B8yer-Hansen%26aufirst%3DG.%26aulast%3DChristensen%26aufirst%3DI.%2BJ.%26aulast%3DHostmark%26aufirst%3DJ.%26aulast%3DLitlekalsoy%26aufirst%3DJ.%26aulast%3Dvon%2Bder%2BMaase%26aufirst%3DH.%26aulast%3DPappot%26aufirst%3DH.%26aulast%3DLaerum%26aufirst%3DO.%2BD.%26atitle%3DUrokinase-type%2520plasminogen%2520activator%2520receptor%2520%2528uPAR%2529%2520expression%2520is%2520associated%2520with%2520T-stage%2520and%2520survival%2520in%2520urothelial%2520carcinoma%2520of%2520the%2520bladder%26jtitle%3DUrol.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3D4%26spage%3D165.e15%26epage%3D165.e24%26doi%3D10.1016%2Fj.urolonc.2014.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ploug, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, V.</span></span> <span> </span><span class="NLM_article-title">Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>349</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1016/0014-5793(94)00674-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2F0014-5793%2894%2900674-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=8050560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaK2cXlvF2jsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=1994&pages=163-168&issue=2&author=M.+Plougauthor=V.+Ellis&title=Structure-function+relationships+in+the+receptor+for+urokinase-type+plasminogen+activator.+Comparison+to+other+members+of+the+Ly-6+family+and+snake+venom+alpha-neurotoxins&doi=10.1016%2F0014-5793%2894%2900674-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom α-neurotoxins</span></div><div class="casAuthors">Ploug, Michael; Ellis, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-8</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    </div><div class="casAbstract">A review with 50 refs. Plasminogen activation is regulated by the interaction between urokinase-type plasminogen activator (uPA) and its specific glycolipid-anchored cell surface receptor (uPAR).  UPAR is composed of three homologous domains and is the only multi-domain member of the Ly-6 family of glycolipid-anchored membrane proteins.  Recent evidence has highlighted similarities between the individual domains of uPAR and the large family of secreted, single domain snake venom α-neurotoxins, suggesting that uPAR may adopt the same gross folding pattern as these structurally well characterized proteins.  Structural aspects of the binding between α-neurotoxins and the acetylcholine receptor may have a major influence on future studies of the interaction between uPA and uPAR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaboUKtl143LVg90H21EOLACvtfcHk0liHF8okX5cgig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlvF2jsL0%253D&md5=4c56931f332e53a5cae9836b7e97bf32</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2894%2900674-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252894%252900674-1%26sid%3Dliteratum%253Aachs%26aulast%3DPloug%26aufirst%3DM.%26aulast%3DEllis%26aufirst%3DV.%26atitle%3DStructure-function%2520relationships%2520in%2520the%2520receptor%2520for%2520urokinase-type%2520plasminogen%2520activator.%2520Comparison%2520to%2520other%2520members%2520of%2520the%2520Ly-6%2520family%2520and%2520snake%2520venom%2520alpha-neurotoxins%26jtitle%3DFEBS%2520Lett.%26date%3D1994%26volume%3D349%26issue%3D2%26spage%3D163%26epage%3D168%26doi%3D10.1016%2F0014-5793%2894%2900674-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, C.</span></span> <span> </span><span class="NLM_article-title">The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer</span>. <i>Clin. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1016/j.clinbiochem.2004.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.clinbiochem.2004.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=15234235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltl2gtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2004&pages=541-548&issue=7&author=M.+J.+Duffyauthor=C.+Duggan&title=The+urokinase+plasminogen+activator+system%3A+a+rich+source+of+tumour+markers+for+the+individualised+management+of+patients+with+cancer&doi=10.1016%2Fj.clinbiochem.2004.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The urokinase plasminogen activator system: a rich source of tumor markers for the individualised management of patients with cancer</span></div><div class="casAuthors">Duffy, M. J.; Duggan, C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">541-548</span>CODEN:
                <span class="NLM_cas:coden">CLBIAS</span>;
        ISSN:<span class="NLM_cas:issn">0009-9120</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The urokinase plasminogen activator (uPA) system consists of the serine protease uPA, the glycolipid-anchored receptor, uPAR, and the 2 serpin inhibitors, plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2).  Recent findings suggest that uPA, uPAR and PAI-1 play a crit. role in cancer invasion and metastasis.  Consistent with their role in cancer dissemination, high levels of uPA, PAI-1 and uPAR in multiple cancer types correlate with adverse patient outcome.  The prognostic value of uPA/PAI-1 in axillary node-neg. breast cancer patients was recently validated using both a prospective randomized trial and a pooled anal.  Assay of uPA and PAI-1 may thus help identify low-risk node-neg. patients for whom adjuvant chemotherapy is unnecessary.  Finally, emerging data suggest that high levels of uPA and PAI-1 in breast cancer are assocd. with a preferential response to adjuvant chemotherapy but relative resistance to hormone therapy.  The measurement of uPA components, esp. in breast cancer, thus has the potential to help with individualised patient management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSGX_RwBqQxLVg90H21EOLACvtfcHk0liPfRG0PkXzPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltl2gtb4%253D&md5=69b7627e184196fa2fac01785e496df2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.clinbiochem.2004.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinbiochem.2004.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DM.%2BJ.%26aulast%3DDuggan%26aufirst%3DC.%26atitle%3DThe%2520urokinase%2520plasminogen%2520activator%2520system%253A%2520a%2520rich%2520source%2520of%2520tumour%2520markers%2520for%2520the%2520individualised%2520management%2520of%2520patients%2520with%2520cancer%26jtitle%3DClin.%2520Biochem.%26date%3D2004%26volume%3D37%26issue%3D7%26spage%3D541%26epage%3D548%26doi%3D10.1016%2Fj.clinbiochem.2004.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S. J.</span></span> <span> </span><span class="NLM_article-title">Navigating ECM barriers at the invasive front: the cancer cell-stroma interface</span>. <i>Annu. Rev. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1146/annurev.cellbio.24.110707.175315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1146%2Fannurev.cellbio.24.110707.175315" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2009&pages=567-595&author=R.+G.+Roweauthor=S.+J.+Weiss&title=Navigating+ECM+barriers+at+the+invasive+front%3A+the+cancer+cell-stroma+interface&doi=10.1146%2Fannurev.cellbio.24.110707.175315"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1146%2Fannurev.cellbio.24.110707.175315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.cellbio.24.110707.175315%26sid%3Dliteratum%253Aachs%26aulast%3DRowe%26aufirst%3DR.%2BG.%26aulast%3DWeiss%26aufirst%3DS.%2BJ.%26atitle%3DNavigating%2520ECM%2520barriers%2520at%2520the%2520invasive%2520front%253A%2520the%2520cancer%2520cell-stroma%2520interface%26jtitle%3DAnnu.%2520Rev.%2520Cell%2520Dev.%2520Biol.%26date%3D2009%26volume%3D25%26spage%3D567%26epage%3D595%26doi%3D10.1146%2Fannurev.cellbio.24.110707.175315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelso, M. J.</span></span> <span> </span><span class="NLM_article-title">Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2061</span>, <span class="refDoi"> DOI: 10.1002/ijc.26156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1002%2Fijc.26156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=21544803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSjsb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=2051-2061&issue=9&author=H.+Matthewsauthor=M.+Ransonauthor=M.+J.+Kelso&title=Anti-tumour%2Fmetastasis+effects+of+the+potassium-sparing+diuretic+amiloride%3A+an+orally+active+anti-cancer+drug+waiting+for+its+call-of-duty%3F&doi=10.1002%2Fijc.26156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor/metastasis effects of the potassium-sparing diuretic amiloride: An orally active anti-cancer drug waiting for its call-of-duty?</span></div><div class="casAuthors">Matthews, Hayden; Ranson, Marie; Kelso, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2051-2061</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Amiloride.HCl is clin. used as an oral potassium-sparing diuretic, but multiple studies in biochem., cellular and animal models have shown that the drug also possesses anti-tumor and anti-metastasis activities.  The addnl. effects appear to arise through inhibition of two discrete targets: (i) the sodium-hydrogen exchanger 1 (NHE1), a membrane protein responsible for the characteristically low extracellular pH of tumors and (ii) the urokinase-type plasminogen activator (uPA), a serine protease mediator of cell migration, invasion and metastasis and well-known marker of poor prognosis in cancer.  This mini-review summarizes for the first time the reported anti-tumor/metastasis effects of amiloride in exptl. models, discusses the putative mol. mechanisms responsible for these effects and concludes by commenting on the pros and cons of trialling amiloride or one of its structural analogs as potential new anti-tumor/metastasis drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohvJl1aiKpW7Vg90H21EOLACvtfcHk0liPfRG0PkXzPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSjsb%252FK&md5=97a98cebb32a4052f03c0f7d8391b1c6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fijc.26156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.26156%26sid%3Dliteratum%253Aachs%26aulast%3DMatthews%26aufirst%3DH.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DKelso%26aufirst%3DM.%2BJ.%26atitle%3DAnti-tumour%252Fmetastasis%2520effects%2520of%2520the%2520potassium-sparing%2520diuretic%2520amiloride%253A%2520an%2520orally%2520active%2520anti-cancer%2520drug%2520waiting%2520for%2520its%2520call-of-duty%253F%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26issue%3D9%26spage%3D2051%26epage%3D2061%26doi%3D10.1002%2Fijc.26156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andronicos, N. M.</span></span> <span> </span><span class="NLM_article-title">Plasminogen binding and cancer: promises and pitfalls</span>. <i>Front. Biosci., Landmark Ed.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">s294</span>– <span class="NLM_lpage">304</span>, <span class="refDoi"> DOI: 10.2741/1044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.2741%2F1044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=12700073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvVenurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=s294-304&author=M.+Ransonauthor=N.+M.+Andronicos&title=Plasminogen+binding+and+cancer%3A+promises+and+pitfalls&doi=10.2741%2F1044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Plasminogen binding and cancer: promises and pitfalls</span></div><div class="casAuthors">Ranson, Marie; Andronicos, Nicholas M.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">S294-S304</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  The urokinase plasminogen activation system is a key modulator of the tissue remodeling processes required for tumor cell invasion and metastasis.  Malignant progression is characterized by inappropriately high cell surface levels of receptor-bound active urokinase.  This enhances the rate of plasminogen activation resulting in markedly increased levels of cell surface plasmin.  The repercussions of this are significant and include the activation of growth factors and signaling pathways, and the degrdn. of extracellular matrixes, either directly or indirectly, via the activation of matrix metalloproteinases.  Native, circulating plasminogen binds in a lysine- and/or carbohydrate-dependent manner to tumor and endothelial cells with low affinity but high capacity and a heterogeneous group of plasminogen receptors have been identified.  This heterogeneity underscores the complexity of the mechanisms responsible for the regulation of cell-surface plasminogen binding.  This review summarizes the literature on known plasminogen receptor candidates and shows that they can be subdivided into three classes based on their mode of interaction with plasminogen.  We also aim to emphasize the notion that in the tumor environment the known intrinsic functional relationship between plasminogen conformation and activation is essentially connected to cellular binding.  This allows plasminogen to be co-localized in an activation-susceptible form with the enhanced uPA levels seen in malignancy and together furnishes tumor cells with elevated tissue remodeling capacity.  In addn., some of the pitfalls and strategies encountered when conducting plasminogen receptor expts. are also addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjGwsfozeOFrVg90H21EOLACvtfcHk0liPfRG0PkXzPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvVenurc%253D&md5=f99ad18e97eeb71b4a6b9311849a3cb9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2741%2F1044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F1044%26sid%3Dliteratum%253Aachs%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DAndronicos%26aufirst%3DN.%2BM.%26atitle%3DPlasminogen%2520binding%2520and%2520cancer%253A%2520promises%2520and%2520pitfalls%26jtitle%3DFront.%2520Biosci.%252C%2520Landmark%2520Ed.%26date%3D2003%26volume%3D8%26spage%3Ds294%26epage%3D304%26doi%3D10.2741%2F1044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, J. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span> <span> </span><span class="NLM_article-title">Structural basis for therapeutic intervention of uPA/uPAR system</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1729</span>– <span class="NLM_lpage">1743</span>, <span class="refDoi"> DOI: 10.2174/138945011797635911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.2174%2F138945011797635911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=21707478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVSrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=1729-1743&issue=12&author=J.+C.+K.+Ngoauthor=L.+Jiangauthor=Z.+Linauthor=C.+Yuanauthor=Z.+Chenauthor=X.+Zhangauthor=H.+Yuauthor=J.+Wangauthor=L.+Linauthor=M.+Huang&title=Structural+basis+for+therapeutic+intervention+of+uPA%2FuPAR+system&doi=10.2174%2F138945011797635911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for therapeutic intervention of uPA/uPAR system</span></div><div class="casAuthors">Ngo, Jacky Chi Ki; Jiang, Longguang; Lin, Zhonghui; Yuan, Cai; Chen, Zhuo; Zhang, Xu; Yu, Haiyang; Wang, Jundong; Lin, Lin; Huang, Mingdong</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1729-1743</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Urokinase-type plasminogen activator (uPA) is one of the two physiol. serine proteases responsible for the activation of plasminongen to plasmin.  UPA activity is regulated by its inhibitors (PAI-1 and PAI-2) and its receptor (uPAR), and an expanding list of their interacting proteins.  In addn. to plasminogen activation, this system also plays important roles in the regulation of many cellular processes including cell proliferation, adhesion and migration.  It is beyond reasonable doubt that this enzyme system plays a central role in tumor biol. and represents a high potential target for therapeutic intervention of tumor growth and metastasis.  During the past fifteen years, crystal structures of uPA and its inhibitors have facilitated the development of uPA inhibitors.  Many crystal structures of proteins in the uPA/uPAR system have also been reported recently, esp. a series of structures of uPAR and its complexes with vitronectin and uPA, facilitating the development and evaluation of uPAR inhibitors.  Recent progress on uPA inhibitors will be summarized in this article.  The unique structural features and the druggable potentials of these new structures will also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqxQduyMhtsbVg90H21EOLACvtfcHk0lhm3ABiWo_jaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVSrtb0%253D&md5=d3f068f16db2bc1582af43cdd7977049</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F138945011797635911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945011797635911%26sid%3Dliteratum%253Aachs%26aulast%3DNgo%26aufirst%3DJ.%2BC.%2BK.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DM.%26atitle%3DStructural%2520basis%2520for%2520therapeutic%2520intervention%2520of%2520uPA%252FuPAR%2520system%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2011%26volume%3D12%26issue%3D12%26spage%3D1729%26epage%3D1743%26doi%3D10.2174%2F138945011797635911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tyndall, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelso, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clingan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span> <span> </span><span class="NLM_article-title">Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancer</span>. <i>Recent Pat. Anti-Cancer Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.2174/157489208783478711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.2174%2F157489208783478711" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1-13&issue=1&author=J.+D.+Tyndallauthor=M.+J.+Kelsoauthor=P.+Clinganauthor=M.+Ranson&title=Peptides+and+small+molecules+targeting+the+plasminogen+activation+system%3A+towards+prophylactic+anti-metastasis+drugs+for+breast+cancer&doi=10.2174%2F157489208783478711"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F157489208783478711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157489208783478711%26sid%3Dliteratum%253Aachs%26aulast%3DTyndall%26aufirst%3DJ.%2BD.%26aulast%3DKelso%26aufirst%3DM.%2BJ.%26aulast%3DClingan%26aufirst%3DP.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DPeptides%2520and%2520small%2520molecules%2520targeting%2520the%2520plasminogen%2520activation%2520system%253A%2520towards%2520prophylactic%2520anti-metastasis%2520drugs%2520for%2520breast%2520cancer%26jtitle%3DRecent%2520Pat.%2520Anti-Cancer%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26issue%3D1%26spage%3D1%26epage%3D13%26doi%3D10.2174%2F157489208783478711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nienaber, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edalji, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinghofer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magdalinos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockway, T.</span></span> <span> </span><span class="NLM_article-title">Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">563</span>, <span class="refDoi"> DOI: 10.1016/S0969-2126(00)00136-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2FS0969-2126%2800%2900136-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2000&pages=553-563&issue=5&author=V.+L.+Nienaberauthor=D.+Davidsonauthor=R.+Edaljiauthor=V.+L.+Girandaauthor=V.+Klinghoferauthor=J.+Henkinauthor=P.+Magdalinosauthor=R.+Manteiauthor=S.+Merrickauthor=J.+M.+Severinauthor=R.+A.+Smithauthor=K.+Stewartauthor=K.+Walterauthor=J.+Wangauthor=M.+Wendtauthor=M.+Weitzbergauthor=X.+Zhaoauthor=T.+Rockway&title=Structure-directed+discovery+of+potent+non-peptidic+inhibitors+of+human+urokinase+that+access+a+novel+binding+subsite&doi=10.1016%2FS0969-2126%2800%2900136-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2800%2900136-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252800%252900136-2%26sid%3Dliteratum%253Aachs%26aulast%3DNienaber%26aufirst%3DV.%2BL.%26aulast%3DDavidson%26aufirst%3DD.%26aulast%3DEdalji%26aufirst%3DR.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DHenkin%26aufirst%3DJ.%26aulast%3DMagdalinos%26aufirst%3DP.%26aulast%3DMantei%26aufirst%3DR.%26aulast%3DMerrick%26aufirst%3DS.%26aulast%3DSeverin%26aufirst%3DJ.%2BM.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DWalter%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWendt%26aufirst%3DM.%26aulast%3DWeitzberg%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DRockway%26aufirst%3DT.%26atitle%3DStructure-directed%2520discovery%2520of%2520potent%2520non-peptidic%2520inhibitors%2520of%2520human%2520urokinase%2520that%2520access%2520a%2520novel%2520binding%2520subsite%26jtitle%3DStructure%26date%3D2000%26volume%3D8%26issue%3D5%26spage%3D553%26epage%3D563%26doi%3D10.1016%2FS0969-2126%2800%2900136-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClellan, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockway, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nienaber, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinghofer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span> <span> </span><span class="NLM_article-title">Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3063</span>– <span class="NLM_lpage">3068</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.bmcl.2004.04.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=3063-3068&issue=12&author=M.+D.+Wendtauthor=A.+Geyerauthor=W.+J.+McClellanauthor=T.+W.+Rockwayauthor=M.+Weitzbergauthor=X.+Zhaoauthor=R.+Manteiauthor=K.+Stewartauthor=V.+Nienaberauthor=V.+Klinghoferauthor=V.+L.+Giranda&title=Interaction+with+the+S1+beta-pocket+of+urokinase%3A+8-heterocycle+substituted+and+6%2C8-disubstituted+2-naphthamidine+urokinase+inhibitors&doi=10.1016%2Fj.bmcl.2004.04.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DGeyer%26aufirst%3DA.%26aulast%3DMcClellan%26aufirst%3DW.%2BJ.%26aulast%3DRockway%26aufirst%3DT.%2BW.%26aulast%3DWeitzberg%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DMantei%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DNienaber%26aufirst%3DV.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DInteraction%2520with%2520the%2520S1%2520beta-pocket%2520of%2520urokinase%253A%25208-heterocycle%2520substituted%2520and%25206%252C8-disubstituted%25202-naphthamidine%2520urokinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26issue%3D12%26spage%3D3063%26epage%3D3068%26doi%3D10.1016%2Fj.bmcl.2004.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockway, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClellan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nienaber, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinghofer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span> <span> </span><span class="NLM_article-title">Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1021/jm0300072</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0300072" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=303-324&issue=2&author=M.+D.+Wendtauthor=T.+W.+Rockwayauthor=A.+Geyerauthor=W.+McClellanauthor=M.+Weitzbergauthor=X.+Zhaoauthor=R.+Manteiauthor=V.+L.+Nienaberauthor=K.+Stewartauthor=V.+Klinghoferauthor=V.+L.+Giranda&title=Identification+of+novel+binding+interactions+in+the+development+of+potent%2C+selective+2-naphthamidine+inhibitors+of+urokinase.+Synthesis%2C+structural+analysis%2C+and+SAR+of+N-phenyl+amide+6-substitution&doi=10.1021%2Fjm0300072"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm0300072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0300072%26sid%3Dliteratum%253Aachs%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DRockway%26aufirst%3DT.%2BW.%26aulast%3DGeyer%26aufirst%3DA.%26aulast%3DMcClellan%26aufirst%3DW.%26aulast%3DWeitzberg%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DMantei%26aufirst%3DR.%26aulast%3DNienaber%26aufirst%3DV.%2BL.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DIdentification%2520of%2520novel%2520binding%2520interactions%2520in%2520the%2520development%2520of%2520potent%252C%2520selective%25202-naphthamidine%2520inhibitors%2520of%2520urokinase.%2520Synthesis%252C%2520structural%2520analysis%252C%2520and%2520SAR%2520of%2520N-phenyl%2520amide%25206-substitution%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D2%26spage%3D303%26epage%3D324%26doi%3D10.1021%2Fjm0300072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruncko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClellan, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellaria, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nienaber, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinghofer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockway, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span> <span> </span><span class="NLM_article-title">Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.bmcl.2004.10.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=93-98&issue=1&author=M.+Brunckoauthor=W.+J.+McClellanauthor=M.+D.+Wendtauthor=D.+R.+Sauerauthor=A.+Geyerauthor=C.+R.+Daltonauthor=M.+A.+Kaminskiauthor=M.+Weitzbergauthor=J.+Gongauthor=J.+F.+Dellariaauthor=R.+Manteiauthor=X.+Zhaoauthor=V.+L.+Nienaberauthor=K.+Stewartauthor=V.+Klinghoferauthor=J.+Bouskaauthor=T.+W.+Rockwayauthor=V.+L.+Giranda&title=Naphthamidine+urokinase+plasminogen+activator+inhibitors+with+improved+pharmacokinetic+properties&doi=10.1016%2Fj.bmcl.2004.10.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DBruncko%26aufirst%3DM.%26aulast%3DMcClellan%26aufirst%3DW.%2BJ.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DSauer%26aufirst%3DD.%2BR.%26aulast%3DGeyer%26aufirst%3DA.%26aulast%3DDalton%26aufirst%3DC.%2BR.%26aulast%3DKaminski%26aufirst%3DM.%2BA.%26aulast%3DWeitzberg%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DDellaria%26aufirst%3DJ.%2BF.%26aulast%3DMantei%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DNienaber%26aufirst%3DV.%2BL.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%26aulast%3DRockway%26aufirst%3DT.%2BW.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DNaphthamidine%2520urokinase%2520plasminogen%2520activator%2520inhibitors%2520with%2520improved%2520pharmacokinetic%2520properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26issue%3D1%26spage%3D93%26epage%3D98%26doi%3D10.1016%2Fj.bmcl.2004.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Towle, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maduakor, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlefield, B. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2553</span>– <span class="NLM_lpage">2559</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1993&pages=2553-2559&issue=11&author=M.+J.+Towleauthor=A.+Leeauthor=E.+C.+Maduakorauthor=C.+E.+Schwartzauthor=A.+J.+Bridgesauthor=B.+A.+Littlefield&title=Inhibition+of+urokinase+by+4-substituted+benzo%5Bb%5Dthiophene-2-carboxamidines%3A+an+important+new+class+of+selective+synthetic+urokinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTowle%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DMaduakor%26aufirst%3DE.%2BC.%26aulast%3DSchwartz%26aufirst%3DC.%2BE.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DLittlefield%26aufirst%3DB.%2BA.%26atitle%3DInhibition%2520of%2520urokinase%2520by%25204-substituted%2520benzo%255Bb%255Dthiophene-2-carboxamidines%253A%2520an%2520important%2520new%2520class%2520of%2520selective%2520synthetic%2520urokinase%2520inhibitor%26jtitle%3DCancer%2520Res.%26date%3D1993%26volume%3D53%26issue%3D11%26spage%3D2553%26epage%3D2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rockway, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the proteolytic activity of urokinase type plasminogen activator</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">1483</span>– <span class="NLM_lpage">1498</span>, <span class="refDoi"> DOI: 10.2174/1381612033454649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.2174%2F1381612033454649" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=1483-1498&issue=19&author=T.+W.+Rockwayauthor=V.+L.+Giranda&title=Inhibitors+of+the+proteolytic+activity+of+urokinase+type+plasminogen+activator&doi=10.2174%2F1381612033454649"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F1381612033454649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612033454649%26sid%3Dliteratum%253Aachs%26aulast%3DRockway%26aufirst%3DT.%2BW.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DInhibitors%2520of%2520the%2520proteolytic%2520activity%2520of%2520urokinase%2520type%2520plasminogen%2520activator%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2003%26volume%3D9%26issue%3D19%26spage%3D1483%26epage%3D1498%26doi%3D10.2174%2F1381612033454649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frederickson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaghan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chessari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinkovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, N. G.</span></span> <span> </span><span class="NLM_article-title">Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1021/jm701359z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701359z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=183-186&issue=2&author=M.+Fredericksonauthor=O.+Callaghanauthor=G.+Chessariauthor=M.+Congreveauthor=S.+R.+Cowanauthor=J.+E.+Matthewsauthor=R.+McMenaminauthor=D.+M.+Smithauthor=M.+Vinkovicauthor=N.+G.+Wallis&title=Fragment-based+discovery+of+mexiletine+derivatives+as+orally+bioavailable+inhibitors+of+urokinase-type+plasminogen+activator&doi=10.1021%2Fjm701359z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm701359z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701359z%26sid%3Dliteratum%253Aachs%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DCallaghan%26aufirst%3DO.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCowan%26aufirst%3DS.%2BR.%26aulast%3DMatthews%26aufirst%3DJ.%2BE.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DVinkovic%26aufirst%3DM.%26aulast%3DWallis%26aufirst%3DN.%2BG.%26atitle%3DFragment-based%2520discovery%2520of%2520mexiletine%2520derivatives%2520as%2520orally%2520bioavailable%2520inhibitors%2520of%2520urokinase-type%2520plasminogen%2520activator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D2%26spage%3D183%26epage%3D186%26doi%3D10.1021%2Fjm701359z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sturzebecher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieweg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetzer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweinitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renatus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrom, P.</span></span> <span> </span><span class="NLM_article-title">3-Amidinophenylalanine-based inhibitors of urokinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">3147</span>– <span class="NLM_lpage">3152</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(99)00541-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2FS0960-894X%2899%2900541-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10560742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaK1MXntlOmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=3147-3152&issue=21&author=J.+Sturzebecherauthor=H.+Viewegauthor=T.+Steinmetzerauthor=A.+Schweinitzauthor=M.+T.+Stubbsauthor=M.+Renatusauthor=P.+Wikstrom&title=3-Amidinophenylalanine-based+inhibitors+of+urokinase&doi=10.1016%2FS0960-894X%2899%2900541-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">3-Amidinophenylalanine-based inhibitors of urokinase</span></div><div class="casAuthors">Sturzebecher, Jorg; Vieweg, Helmut; Steinmetzer, Torsten; Schweinitz, Andrea; Stubbs, Milton T.; Renatus, Martin; Wikstrom, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3147-3152</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Synthesis and anti-uPA activity of a series of Nα-triisopropyl-phenylsulfonyl-protected 3-amidinophenylalanine amides are described.  We have explored SAR around the C-terminal amide part for inhibition of uPA, plasmin and trypsin.  Modification of the amide part has been found to affect potency but not selectivity.  With a Ki of 0.41 μM I is one of the most potent uPA inhibitors described so far.  The X-ray crystal structure of I was solved in complex with trypsin, superimposed with uPA and the results suggest an unique binding mode of this inhibitor type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5sBl6FqZ4RLVg90H21EOLACvtfcHk0ljPsyP0CorBlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntlOmu7g%253D&md5=f9df9988e3632bea96004b15beee04f2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2899%2900541-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252899%252900541-7%26sid%3Dliteratum%253Aachs%26aulast%3DSturzebecher%26aufirst%3DJ.%26aulast%3DVieweg%26aufirst%3DH.%26aulast%3DSteinmetzer%26aufirst%3DT.%26aulast%3DSchweinitz%26aufirst%3DA.%26aulast%3DStubbs%26aufirst%3DM.%2BT.%26aulast%3DRenatus%26aufirst%3DM.%26aulast%3DWikstrom%26aufirst%3DP.%26atitle%3D3-Amidinophenylalanine-based%2520inhibitors%2520of%2520urokinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26issue%3D21%26spage%3D3147%26epage%3D3152%26doi%3D10.1016%2FS0960-894X%2899%2900541-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinemann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubender, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bevan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mala, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeck, S.</span></span> <span> </span><span class="NLM_article-title">Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">766</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.1038/bjc.2013.62</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1038%2Fbjc.2013.62" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=23412098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslWmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2013&pages=766-770&issue=4&author=V.+Heinemannauthor=M.+P.+Ebertauthor=R.+P.+Laubenderauthor=P.+Bevanauthor=C.+Malaauthor=S.+Boeck&title=Phase+II+randomised+proof-of-concept+study+of+the+urokinase+inhibitor+upamostat+%28WX-671%29+in+combination+with+gemcitabine+compared+with+gemcitabine+alone+in+patients+with+non-resectable%2C+locally+advanced+pancreatic+cancer&doi=10.1038%2Fbjc.2013.62"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II randomized proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer</span></div><div class="casAuthors">Heinemann, V.; Ebert, M. P.; Laubender, R. P.; Bevan, P.; Mala, C.; Boeck, S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">766-770</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: To evaluate the efficacy and tolerability of the urokinase plasminogen activator (uPA) inhibitor upamostat in combination with gemcitabine in locally advanced pancreatic adenocarcinoma (LAPC).  Methods: Within a prospective multicenter study, LAPC patients were randomly assigned to receive 1000 mg m-2 of gemcitabine IV weekly either alone (arm A) or in combination with 200 mg (arm B) or 400 mg (arm C) oral upamostat daily.  Efficacy endpoints of this proof-of-concept study included response rate, time to first metastasis, progression-free and overall survival (OS).  Results: Of the 95 enrolled patients, 85 were evaluable for response and 93 for safety.  Median OS was 12.5 mo (95% CI 8.2-18.2) in arm C, 9.7 mo (95% CI 8.4-17.1) in arm B and 9.9 mo (95% CI 7.4-12.1) in arm A; corresponding 1-yr survival rates were 50.6%, 40.7% and 33.9%, resp.  More patients achieved a partial remission (confirmed responses by RECIST) with upamostat combination therapy (arm C: 12.9%; arm B: 7.1%; arm A: 3.8%).  Overall, only 12 patients progressed by developing detectable distant metastasis (arm A: 4, arm B: 6, arm C: 2).  The most common adverse events considered to be related to upamostat were asthenia, fever and nausea.  Conclusion: In this proof-of-concept study targeting the uPA system in LAPC, the addn. of upamostat to gemcitabine was tolerated well; similar survival results were obsd. for the three treatment arms.  British Journal of Cancer (2013) 108, 766-770; doi:10.1038/bjc.2013.62 www.bjcancer.com; published online 14 Feb. 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmZfmwPy6jILVg90H21EOLACvtfcHk0li2HqCQCPf8Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslWmtbo%253D&md5=8cb64bd2fb82944adeaec5327c8b7c47</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2013.62&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2013.62%26sid%3Dliteratum%253Aachs%26aulast%3DHeinemann%26aufirst%3DV.%26aulast%3DEbert%26aufirst%3DM.%2BP.%26aulast%3DLaubender%26aufirst%3DR.%2BP.%26aulast%3DBevan%26aufirst%3DP.%26aulast%3DMala%26aufirst%3DC.%26aulast%3DBoeck%26aufirst%3DS.%26atitle%3DPhase%2520II%2520randomised%2520proof-of-concept%2520study%2520of%2520the%2520urokinase%2520inhibitor%2520upamostat%2520%2528WX-671%2529%2520in%2520combination%2520with%2520gemcitabine%2520compared%2520with%2520gemcitabine%2520alone%2520in%2520patients%2520with%2520non-resectable%252C%2520locally%2520advanced%2520pancreatic%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2013%26volume%3D108%26issue%3D4%26spage%3D766%26epage%3D770%26doi%3D10.1038%2Fbjc.2013.62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit31"><span><span> </span><span class="NLM_article-title">Positive Phase II data for MESUPRON in breast
cancer</span>.  <i>WILEX Half-Yearly Financial Report
2012</i>; <span class="NLM_publisher-name">WILEX AG</span>: <span class="NLM_publisher-loc">Munich, Germany</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Positive+Phase+II+data+for+MESUPRON+in+breast%0Acancer.+WILEX+Half-Yearly+Financial+Report%0A2012%3B+WILEX+AG%3A+Munich%2C+Germany%2C+2012."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DPositive%2520Phase%2520II%2520data%2520for%2520MESUPRON%2520in%2520breast%250Acancer%26btitle%3DWILEX%2520Half-Yearly%2520Financial%2520Report%250A2012%26pub%3DWILEX%2520AG%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spinar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinarova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitovec, J.</span></span> <span> </span><span class="NLM_article-title">Diuretics in monotherapy and in combination with other diuretics and nondiuretics in the treatment of hypertension</span>. <i>Vnitr. Lek.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">494</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=23808745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A280%3ADC%252BC3sjnt1Ggtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2013&pages=486-494&issue=6&author=J.+Spinarauthor=L.+Spinarovaauthor=J.+Vitovec&title=Diuretics+in+monotherapy+and+in+combination+with+other+diuretics+and+nondiuretics+in+the+treatment+of+hypertension"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Diuretics in monotherapy and in combination with other diuretics and nondiuretics in the treatment of hypertension</span></div><div class="casAuthors">Spinar J; Spinarova L; Vitovec J</div><div class="citationInfo"><span class="NLM_cas:title">Vnitrni lekarstvi</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">486-94</span>
        ISSN:<span class="NLM_cas:issn">0042-773X</span>.
    </div><div class="casAbstract">Diuretics belong to the basic group of medicines for the treatment of hypertension and heart failure.  In the case of hypertension treatment, their main indication is higher age and isolated systolic hypertension.  In the case of heart failure they are used for the treatment of swellings and shortness of breath.  The most frequently prescribed group of diuretics is thiazides and similar products.  In patients with renal insufficiency, loop diuretics are administered.  In the case of hypertension, diuretics are mainly used in the combination treatment.  The most frequently used diuretic in combination is again hydrochlorothiazide, which is combined with reninangiotensin system blockers.  It is mainly the combination of an ACE inhibitor + indapamide that seems to be modern and promising, and it is, on the basis of large clinical trials, recommended also for diabetics (ADVANCE) or for secondary prevention following a cerebrovascular accident (PROGRESS) or for the elderly (HYVET).  Also a combination of two diuretics is popular -  mainly hydrochlorothiazide + amiloride.  A combination of a betablocker and diuretic is less suitable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyVpl0fjfBipp6t8nS6Nc3fW6udTcc2eZayMax-2PR8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjnt1Ggtg%253D%253D&md5=69b776e1eb688df6576268783fbc7d32</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSpinar%26aufirst%3DJ.%26aulast%3DSpinarova%26aufirst%3DL.%26aulast%3DVitovec%26aufirst%3DJ.%26atitle%3DDiuretics%2520in%2520monotherapy%2520and%2520in%2520combination%2520with%2520other%2520diuretics%2520and%2520nondiuretics%2520in%2520the%2520treatment%2520of%2520hypertension%26jtitle%3DVnitr.%2520Lek.%26date%3D2013%26volume%3D59%26issue%3D6%26spage%3D486%26epage%3D494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lant, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G. M.</span></span> <span> </span><span class="NLM_article-title">Clinical evaluation of amiloride, a potassium-sparing diuretic</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1002/cpt196910150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1002%2Fcpt196910150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=4884296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaF1MXms1OisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1969&pages=50-63&issue=1&author=A.+F.+Lantauthor=A.+J.+Smithauthor=G.+M.+Wilson&title=Clinical+evaluation+of+amiloride%2C+a+potassium-sparing+diuretic&doi=10.1002%2Fcpt196910150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical evaluation of amiloride, a potassium-sparing diuretic</span></div><div class="casAuthors">Lant, Ariel F.; Smith, Anthony J.; Wilson, Graham M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-63</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    </div><div class="casAbstract">Oral amiloride (5-60 mg.) when evaluated in 34 hospitalized patients with fluid retention increased the excretion of Na+, Cl-, and water but decreased K+ excretion.  The major natriuretic effects of amiloride were complete within 24 hrs., but in a few patients some K+-sparing lasted longer.  The natriuretic and K+-sparing efficacies of amiloride (40 mg.) were significantly greater than those of triamterene (200 mg.).  Amiloride at submax. dose of 10 mg. potentiated this natriuresis and reduced the K+ loss evoked by ethacrynic acid (Edecrin) (50 mg.).  The K+-retaining action of amiloride (40 mg.) was apparent even in the presence of a full dose of spironolactone (AldactoneA) (150 mg.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpetk-KxYogdbVg90H21EOLACvtfcHk0li2HqCQCPf8Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXms1OisQ%253D%253D&md5=593193195bebf647153811fe4c81dd9c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fcpt196910150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt196910150%26sid%3Dliteratum%253Aachs%26aulast%3DLant%26aufirst%3DA.%2BF.%26aulast%3DSmith%26aufirst%3DA.%2BJ.%26aulast%3DWilson%26aufirst%3DG.%2BM.%26atitle%3DClinical%2520evaluation%2520of%2520amiloride%252C%2520a%2520potassium-sparing%2520diuretic%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1969%26volume%3D10%26issue%3D1%26spage%3D50%26epage%3D63%26doi%3D10.1002%2Fcpt196910150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleyman, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cragoe, E. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">The mechanism of action of amiloride</span>. <i>Semin. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">242</span>– <span class="NLM_lpage">248</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=2849182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaL1MXisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1988&pages=242-248&issue=3&author=T.+R.+Kleymanauthor=E.+J.+Cragoe&title=The+mechanism+of+action+of+amiloride"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of action of amiloride</span></div><div class="casAuthors">Kleyman, Thomas R.; Cragoe, Edward J., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Nephrology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">242-8</span>CODEN:
                <span class="NLM_cas:coden">SNEPDJ</span>;
        ISSN:<span class="NLM_cas:issn">0270-9295</span>.
    </div><div class="casAbstract">A review with 43 refs.  Amiloride induces a mild natriuresis as well as antikaliuresis.  These changes in salt excretion are due to direct inhibition of the NA+ channel in the apical plasma membrane of the distal nephron.  Amiloride does not exert any direct or indirect inhibitory effect on apical K+ channels.  The antikaliuretic effect is most likely a result of hyperpolarization of the apical plasma membrane and decrease in the electrochem. driving force for K+ movement across the apical membrane into the urinary space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxpR6Af_OWorVg90H21EOLACvtfcHk0lhND2tSpC-MUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXisw%253D%253D&md5=5e5b42e31458db5fea185c6b6a4d94af</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKleyman%26aufirst%3DT.%2BR.%26aulast%3DCragoe%26aufirst%3DE.%2BJ.%26atitle%3DThe%2520mechanism%2520of%2520action%2520of%2520amiloride%26jtitle%3DSemin.%2520Nephrol.%26date%3D1988%26volume%3D8%26issue%3D3%26spage%3D242%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. F.</span></span> <span> </span><span class="NLM_article-title">Regulation of potassium homeostasis</span>. <i>Clin. J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1050</span>– <span class="NLM_lpage">1060</span>, <span class="refDoi"> DOI: 10.2215/CJN.08580813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.2215%2FCJN.08580813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=24721891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCmtb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1050-1060&issue=6&author=B.+F.+Palmer&title=Regulation+of+potassium+homeostasis&doi=10.2215%2FCJN.08580813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of potassium homeostasis</span></div><div class="casAuthors">Palmer, Biff F.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1050-1060</span>CODEN:
                <span class="NLM_cas:coden">CJASC7</span>;
        ISSN:<span class="NLM_cas:issn">1555-9041</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">Potassium is the most abundant cation in the intracellular fluid, and maintaining the proper distribution of potassium across the cell membrane is crit. for normal cell function.  Long-term maintenance of potassium homeostasis is achieved by alterations in renal excretion of potassium in response to variations in intake.  Understanding the mechanism and regulatory influences governing the internal distribution and renal clearance of potassium under normal circumstances can provide a framework for approaching disorders of potassium commonly encountered in clin. practice.  This paper reviews key aspects of the normal regulation of potassium metab. and is designed to serve as a readily accessible review for the well informed clinician as well as a resource for teaching trainees and medical students.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7OcchFIAWrrVg90H21EOLACvtfcHk0lhND2tSpC-MUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCmtb3E&md5=a61fc81e693ae19b82c1ef20d5d4262c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2215%2FCJN.08580813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2215%252FCJN.08580813%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DB.%2BF.%26atitle%3DRegulation%2520of%2520potassium%2520homeostasis%26jtitle%3DClin.%2520J.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2015%26volume%3D10%26issue%3D6%26spage%3D1050%26epage%3D1060%26doi%3D10.2215%2FCJN.08580813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jankun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skrzypczak-Jankun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiercz, R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">563</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=559-563&issue=4&author=J.+Jankunauthor=R.+W.+Keckauthor=E.+Skrzypczak-Jankunauthor=R.+Swiercz&title=Inhibitors+of+urokinase+reduce+size+of+prostate+cancer+xenografts+in+severe+combined+immunodeficient+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJankun%26aufirst%3DJ.%26aulast%3DKeck%26aufirst%3DR.%2BW.%26aulast%3DSkrzypczak-Jankun%26aufirst%3DE.%26aulast%3DSwiercz%26aufirst%3DR.%26atitle%3DInhibitors%2520of%2520urokinase%2520reduce%2520size%2520of%2520prostate%2520cancer%2520xenografts%2520in%2520severe%2520combined%2520immunodeficient%2520mice%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26issue%3D4%26spage%3D559%26epage%3D563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassalli, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belin, D.</span></span> <span> </span><span class="NLM_article-title">Amiloride selectively inhibits the urokinase-type plasminogen activator</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>214</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1016/0014-5793(87)80039-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2F0014-5793%2887%2980039-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=1987&pages=187-191&issue=1&author=J.+D.+Vassalliauthor=D.+Belin&title=Amiloride+selectively+inhibits+the+urokinase-type+plasminogen+activator&doi=10.1016%2F0014-5793%2887%2980039-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2887%2980039-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252887%252980039-X%26sid%3Dliteratum%253Aachs%26aulast%3DVassalli%26aufirst%3DJ.%2BD.%26aulast%3DBelin%26aufirst%3DD.%26atitle%3DAmiloride%2520selectively%2520inhibits%2520the%2520urokinase-type%2520plasminogen%2520activator%26jtitle%3DFEBS%2520Lett.%26date%3D1987%26volume%3D214%26issue%3D1%26spage%3D187%26epage%3D191%26doi%3D10.1016%2F0014-5793%2887%2980039-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perazella, M. A.</span></span> <span> </span><span class="NLM_article-title">Drug-induced hyperkalemia: old culprits and new offenders</span>. <i>Am. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1016/S0002-9343(00)00496-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2FS0002-9343%2800%2900496-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10996582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A280%3ADC%252BD3M%252FitlaktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2000&pages=307-314&issue=4&author=M.+A.+Perazella&title=Drug-induced+hyperkalemia%3A+old+culprits+and+new+offenders&doi=10.1016%2FS0002-9343%2800%2900496-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced hyperkalemia: old culprits and new offenders</span></div><div class="casAuthors">Perazella M A</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-14</span>
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    </div><div class="casAbstract">Prescribed medications, over-the-counter drugs, and nutritional supplements are used by many patients.  Although most of these products are well tolerated, drug-induced hyperkalemia may develop in patients with underlying renal impairment or other abnormalities in potassium handling.  Drug-induced hyperkalemia most often occurs from impaired renal potassium excretion.  However, disturbed cellular uptake of a potassium load as well as excessive ingestion or infusion of potassium-containing substances may also occur.  Physicians must be aware of medications that can precipitate hyperkalemia, how these drugs induce alterations in potassium homeostasis, and the patient characteristics that increase the risk of hyperkalemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjPHSCG9JrV2BAiYWy6n3SfW6udTcc2eaVQDhJ6W_UTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M%252FitlaktA%253D%253D&md5=7be68cf7ccc234b32c2f5e7c79c8fa99</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS0002-9343%2800%2900496-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9343%252800%252900496-4%26sid%3Dliteratum%253Aachs%26aulast%3DPerazella%26aufirst%3DM.%2BA.%26atitle%3DDrug-induced%2520hyperkalemia%253A%2520old%2520culprits%2520and%2520new%2520offenders%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2000%26volume%3D109%26issue%3D4%26spage%3D307%26epage%3D314%26doi%3D10.1016%2FS0002-9343%2800%2900496-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wermuth, C. G.</span></span> <span> </span><span class="NLM_article-title">Selective optimization of side activities: another way for drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1303</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1021/jm030480f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030480f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1303-1314&issue=6&author=C.+G.+Wermuth&title=Selective+optimization+of+side+activities%3A+another+way+for+drug+discovery&doi=10.1021%2Fjm030480f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm030480f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030480f%26sid%3Dliteratum%253Aachs%26aulast%3DWermuth%26aufirst%3DC.%2BG.%26atitle%3DSelective%2520optimization%2520of%2520side%2520activities%253A%2520another%2520way%2520for%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D6%26spage%3D1303%26epage%3D1314%26doi%3D10.1021%2Fjm030480f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndall, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelso, M. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6760</span>– <span class="NLM_lpage">6766</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.09.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.bmcl.2011.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=21978672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKktrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6760-6766&issue=22&author=H.+Matthewsauthor=M.+Ransonauthor=J.+D.+Tyndallauthor=M.+J.+Kelso&title=Synthesis+and+preliminary+evaluation+of+amiloride+analogs+as+inhibitors+of+the+urokinase-type+plasminogen+activator+%28uPA%29&doi=10.1016%2Fj.bmcl.2011.09.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA)</span></div><div class="casAuthors">Matthews, Hayden; Ranson, Marie; Tyndall, Joel D. A.; Kelso, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6760-6766</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A known side-activity of the oral potassium-sparing diuretic drug amiloride is inhibition of the enzyme urokinase-type plasminogen activator (uPA, K i = 7 μM), a promising anticancer target.  Several studies have demonstrated significant antitumor/metastasis properties for amiloride in animal cancer models and it would appear that these arise, at least in part, through inhibition of uPA.  Selective optimization of amiloride's structure for more potent inhibition of uPA and loss of diuretic effects would thus appear as an attractive strategy towards novel anticancer agents.  A preliminary structure-activity exploration of amiloride analogs as inhibitors of uPA is reported.  A key finding was that the well-studied 5-substituted analogs ethylisopropyl amiloride (EIPA) and hexamethylene amiloride (HMA) are approx. twofold more potent than amiloride as uPA inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpor1thS6CQxLVg90H21EOLACvtfcHk0lj-5PgcvfWXWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKktrzJ&md5=3e4a6b17900bcf16f1d1829c83686116</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DMatthews%26aufirst%3DH.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DTyndall%26aufirst%3DJ.%2BD.%26aulast%3DKelso%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%2520and%2520preliminary%2520evaluation%2520of%2520amiloride%2520analogs%2520as%2520inhibitors%2520of%2520the%2520urokinase-type%2520plasminogen%2520activator%2520%2528uPA%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D22%26spage%3D6760%26epage%3D6766%26doi%3D10.1016%2Fj.bmcl.2011.09.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleyman, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cragoe, E. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Amiloride and its analogs as tools in the study of ion transport</span>. <i>J. Membr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1007/BF01871102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1007%2FBF01871102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=2852254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaL1MXjvVKj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=1988&pages=1-21&issue=1&author=T.+R.+Kleymanauthor=E.+J.+Cragoe&title=Amiloride+and+its+analogs+as+tools+in+the+study+of+ion+transport&doi=10.1007%2FBF01871102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Amiloride and its analogs as tools in the study of ion transport</span></div><div class="casAuthors">Kleyman, Thomas R.; Cragoe, Edward J., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Membrane Biology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">JMBBBO</span>;
        ISSN:<span class="NLM_cas:issn">0022-2631</span>.
    </div><div class="casAbstract">This review with 86 refs. addresses the structure-activity relationships of amiloride and its analogs on the large no. of ion transporters and other cellular processes that are inhibited by amiloride, and examines the use of these drugs as probes for the characterization of transport proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotq8xXQUzGTbVg90H21EOLACvtfcHk0lj-5PgcvfWXWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXjvVKj&md5=7d6c138698739364f288ea963cd2e5c4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2FBF01871102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01871102%26sid%3Dliteratum%253Aachs%26aulast%3DKleyman%26aufirst%3DT.%2BR.%26aulast%3DCragoe%26aufirst%3DE.%2BJ.%26atitle%3DAmiloride%2520and%2520its%2520analogs%2520as%2520tools%2520in%2520the%2520study%2520of%2520ion%2520transport%26jtitle%3DJ.%2520Membr.%2520Biol.%26date%3D1988%26volume%3D105%26issue%3D1%26spage%3D1%26epage%3D21%26doi%3D10.1007%2FBF01871102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makepeace, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cragoe, E. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Effects of HMA, an analog of amiloride, on the thermosensitivity of tumors in vivo</span>. <i>Int. J. Radiat. Oncol., Biol., Phys.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1016/0360-3016(94)90528-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2F0360-3016%2894%2990528-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=8083106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFaisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1994&pages=133-139&issue=1&author=C.+W.+Songauthor=J.+C.+Lyonsauthor=C.+M.+Makepeaceauthor=R.+J.+Griffinauthor=E.+J.+Cragoe&title=Effects+of+HMA%2C+an+analog+of+amiloride%2C+on+the+thermosensitivity+of+tumors+in+vivo&doi=10.1016%2F0360-3016%2894%2990528-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of HMA, an analog of amiloride, on the thermosensitivity of tumors in vivo</span></div><div class="casAuthors">Song, Chang W.; Lyons, John C.; Makepeace, Carol M.; Griffin, Robert J.; Cragoe, Edward J. Jr.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Radiation Oncology, Biology, Physics</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">133-9</span>CODEN:
                <span class="NLM_cas:coden">IOBPD3</span>;
        ISSN:<span class="NLM_cas:issn">0360-3016</span>.
    </div><div class="casAbstract">The effects of HMA (3-amino-6-chloro-5-(1-homopiperidyl)-N- (diaminomethylene)pyrazinecarboxamide), an analog of amiloride, on the intracellular pH (pHi) of SCK tumor cells in vitro and on the thermosensitivity of tumors in vivo were investigated.  The pHi of SCK tumor cells in vitro was measured with the BCECF fluorescence spectroscopy method.  The effect of HMA on the thermosensitivity of SCK tumors grown SC in the legs of A/J mice was assessed by the tumor growth delay method and the in vivo-in vitro excision assay method.  The pHi of SCK tumor cells in pH 7.5 and 6.6 medium was about 7.50 and 7.15, resp.  The presence of 10-50 μM of HMA lowered the pHi by 0.1-0.2 pH units both in pH 7.5 and 6.6 medium.  Heating at 43°C for 120 min lowered the pHi by 0.2 and 0.3 pH units in pH 7.5 and 6.6 medium, resp.  When the cells were heated in the presence of 10-50 μM HMA, a marked decline in pHi occurred and the decline in pHi resulting from the combination of heat and HMA was more pronounced in pH 6.6 medium than in pH 7.5 medium.  Heating the SCK tumors grown SC in the legs of A/J mice at 43.5°C for 1 h resulted in a growth delay of 3.7 days.  When the host mice were IV injected with 0.1 mg/kg of HMA and the tumors were heated 20 min later, the tumor growth was delayed by 8.2 days, which was 4.5 days longer than that by heating alone.  Heating the SCK tumor at 42.5°C for 1 h caused a tumor growth delay of 0.9 days.  An IV injection of 1 mg/kg or 10 mg/kg of HMA prior to heating at 42.5°C for 1 h caused a tumor growth delay 2.1 and 3.1 days longer, resp., than that by heating alone.  Such an enhancement of heat-induced tumor growth delay by HMA was due to increased cell killing, as detd. with the in vivo-in vitro excision assay of clonogenic cells in the tumors.  HMA is a potent thermosensitizer, particularly in an acidic environment.  Thermosensitization by HMA may occur preferentially in tumors relative to normal tissues since the intratumor environment is acidic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd3SFCokawJbVg90H21EOLACvtfcHk0lj-5PgcvfWXWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFaisbs%253D&md5=0ad7cd50c1caf2f3dd4456cb309631a8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2F0360-3016%2894%2990528-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0360-3016%252894%252990528-2%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DC.%2BW.%26aulast%3DLyons%26aufirst%3DJ.%2BC.%26aulast%3DMakepeace%26aufirst%3DC.%2BM.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DCragoe%26aufirst%3DE.%2BJ.%26atitle%3DEffects%2520of%2520HMA%252C%2520an%2520analog%2520of%2520amiloride%252C%2520on%2520the%2520thermosensitivity%2520of%2520tumors%2520in%2520vivo%26jtitle%3DInt.%2520J.%2520Radiat.%2520Oncol.%252C%2520Biol.%252C%2520Phys.%26date%3D1994%26volume%3D30%26issue%3D1%26spage%3D133%26epage%3D139%26doi%3D10.1016%2F0360-3016%2894%2990528-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tannock, I. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>70</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">617</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1038/bjc.1994.360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1038%2Fbjc.1994.360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=7917906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaK2MXitVWmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1994&pages=617-624&issue=4&author=J.+Luoauthor=I.+F.+Tannock&title=Inhibition+of+the+regulation+of+intracellular+pH%3A+potential+of+5-%28N%2CN-hexamethylene%29+amiloride+in+tumour-selective+therapy&doi=10.1038%2Fbjc.1994.360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the regulation of intracellular pH: Potential of 5-(N,N-hexamethylene)amiloride in tumor-selective therapy</span></div><div class="casAuthors">Luo, J.; Tannock, I. F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">617-24</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    </div><div class="casAbstract">The viability of cells within the acidic microenvironment found in solid tumors is expected to depend on the regulation of intracellular pH (pHi).  5-(N,N-hexamethylene)amiloride (HMA) is a potent inhibitor of the Na+/H+ antiport, a major mechanism for the regulation of pHi.  The authors have therefore studied the cytotoxicity of HMA in combination with nigericin, a cell-acidifying agent, for EMT-6 cells in monolayer cell culture, in spheroids and in a murine tumor model.  The combination of nigericin and HMA was toxic to cells in tissue culture at extracellular pH (pHe) ≤ 6.8 (as may be found in tumors) but not at pH 7.0 or above (as in most normal tissues).  Compared with amiloride, the relative potency of HMA in causing in vitro cytotoxicity (∼100-fold) was similar to that for inhibition of the Na+/H+ antiport.  The fluorescent probe Hoechst 33342 was used with flow cytometry to study the cytotoxicity of HMA and nigericin at different depths in multicellular tumor spheroids.  Only small differences in the level of cell survival were obsd., but higher concns. of HMA were required as compared with those giving equal levels of survival in monolayer culture.  The pharmacokinetics of HMA in mice was studied by using high-performance liq. chromatog.: after i.p. injection of 20 μg g-1, the plasma level of HMA peaked at 8 μM after about 15 min and decreased to 1 μM at 120 min; the half-life was 35 min.  Nigericin and HMA, at doses of 1.25 μg g-1 and 10 μg g-1 resp., failed to cause significant cell killing in the EMT-6 murine tumor, but the surviving fraction was reduced to ∼0.004 when hydralazine was administered with nigericin and HMA.  Local tumor irradn. (15 Gy), followed by treatment with these drugs, led to cell killing that was additive to the effects of drugs and radiation alone, so that hypoxic cells which survived radiation did not appear more sensitive to pH-dependent drug treatment.  Acid-mediated therapy can lead to cell death in murine solid tumors, but further measures will be required before the strategy can be exploited clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxQajsBgCzT7Vg90H21EOLACvtfcHk0lj-5PgcvfWXWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXitVWmtLY%253D&md5=2d687828c2ff7c90e4846c8001a85300</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1994.360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1994.360%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTannock%26aufirst%3DI.%2BF.%26atitle%3DInhibition%2520of%2520the%2520regulation%2520of%2520intracellular%2520pH%253A%2520potential%2520of%25205-%2528N%252CN-hexamethylene%2529%2520amiloride%2520in%2520tumour-selective%2520therapy%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1994%26volume%3D70%26issue%3D4%26spage%3D617%26epage%3D624%26doi%3D10.1038%2Fbjc.1994.360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rich, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worthington-White, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garden, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musk, P.</span></span> <span> </span><span class="NLM_article-title">Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na(+)/H(+) exchanger</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1427</span>– <span class="NLM_lpage">1434</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10666221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtFKitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2000&pages=1427-1434&issue=4&author=I.+N.+Richauthor=D.+Worthington-Whiteauthor=O.+A.+Gardenauthor=P.+Musk&title=Apoptosis+of+leukemic+cells+accompanies+reduction+in+intracellular+pH+after+targeted+inhibition+of+the+Na%28%2B%29%2FH%28%2B%29+exchanger"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na+/H+ exchanger</span></div><div class="casAuthors">Rich, Ivan N.; Worthington-White, Diana; Garden, Oliver A.; Musk, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1427-1434</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The Na+/H+ exchanger isoform 1 (NHE1) is primarily responsible for the regulation of intracellular pH (pHi).  It is a ubiquitous, amiloride-sensitive, growth factor-activatable exchanger whose role has been implicated in cell-cycle regulation, apoptosis, and neoplasia.  Here we demonstrate that leukemic cell lines and peripheral blood from primary patient leukemic samples exhibit a constitutively and statistically higher pHi than normal hematopoietic tissue.  We then show that a direct correlation exists between pHi and cell-cycle status of normal hematopoietic and leukemic cells.  Advantage was taken of this relationship by treating leukemic cells with the Na+/H+ exchanger inhibitor, 5-(N, N-hexamethylene)-amiloride (HMA), which decreases the pHi and induces apoptosis.  By incubating patient leukemic cells in vitro with pharmacol. doses of HMA for up to 5 h, we show, using flow cytometry and fluorescent ratio imaging microscopy, that when the pHi decreases, apoptosis-measured by annexin-V and TUNEL methodologies-rapidly increases so that more than 90% of the leukemic cells are killed.  The differential sensitivity exhibited between normal and leukemic cells allows consideration of NHE1 inhibitors as potential antileukemic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo86ZFcUKdn77Vg90H21EOLACvtfcHk0ljjUXOAqZSN0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtFKitLY%253D&md5=df9ec526fa033d2f2a48876d0d5a7645</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRich%26aufirst%3DI.%2BN.%26aulast%3DWorthington-White%26aufirst%3DD.%26aulast%3DGarden%26aufirst%3DO.%2BA.%26aulast%3DMusk%26aufirst%3DP.%26atitle%3DApoptosis%2520of%2520leukemic%2520cells%2520accompanies%2520reduction%2520in%2520intracellular%2520pH%2520after%2520targeted%2520inhibition%2520of%2520the%2520Na%2528%252B%2529%252FH%2528%252B%2529%2520exchanger%26jtitle%3DBlood%26date%3D2000%26volume%3D95%26issue%3D4%26spage%3D1427%26epage%3D1434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Man, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, A. Y.</span></span> <span> </span><span class="NLM_article-title">A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>123</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">2530</span>– <span class="NLM_lpage">2539</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-07-512194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1182%2Fblood-2013-07-512194" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=2530-2539&issue=16&author=C.+H.+Manauthor=S.+S.+Lamauthor=M.+K.+Sunauthor=H.+C.+Chowauthor=H.+Gillauthor=Y.+L.+Kwongauthor=A.+Y.+Leung&title=A+novel+tescalcin-sodium%2Fhydrogen+exchange+axis+underlying+sorafenib+resistance+in+FLT3-ITD%2B+AML&doi=10.1182%2Fblood-2013-07-512194"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-07-512194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-07-512194%26sid%3Dliteratum%253Aachs%26aulast%3DMan%26aufirst%3DC.%2BH.%26aulast%3DLam%26aufirst%3DS.%2BS.%26aulast%3DSun%26aufirst%3DM.%2BK.%26aulast%3DChow%26aufirst%3DH.%2BC.%26aulast%3DGill%26aufirst%3DH.%26aulast%3DKwong%26aufirst%3DY.%2BL.%26aulast%3DLeung%26aufirst%3DA.%2BY.%26atitle%3DA%2520novel%2520tescalcin-sodium%252Fhydrogen%2520exchange%2520axis%2520underlying%2520sorafenib%2520resistance%2520in%2520FLT3-ITD%252B%2520AML%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26issue%3D16%26spage%3D2530%26epage%3D2539%26doi%3D10.1182%2Fblood-2013-07-512194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T. L.</span></span> <span> </span><span class="NLM_article-title">Identification of acid-sensing ion channels in adenoid cystic carcinomas</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>355</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">986</span>– <span class="NLM_lpage">992</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2007.02.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.bbrc.2007.02.061" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2007&pages=986-992&issue=4&author=J.+H.+Yeauthor=J.+Gaoauthor=Y.+N.+Wuauthor=Y.+J.+Huauthor=C.+P.+Zhangauthor=T.+L.+Xu&title=Identification+of+acid-sensing+ion+channels+in+adenoid+cystic+carcinomas&doi=10.1016%2Fj.bbrc.2007.02.061"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2007.02.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2007.02.061%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DJ.%2BH.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%2BN.%26aulast%3DHu%26aufirst%3DY.%2BJ.%26aulast%3DZhang%26aufirst%3DC.%2BP.%26aulast%3DXu%26aufirst%3DT.%2BL.%26atitle%3DIdentification%2520of%2520acid-sensing%2520ion%2520channels%2520in%2520adenoid%2520cystic%2520carcinomas%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2007%26volume%3D355%26issue%3D4%26spage%3D986%26epage%3D992%26doi%3D10.1016%2Fj.bbrc.2007.02.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowson-Hodel, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wald, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanderVorst, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curiel, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carraway, K. L.</span></span> <span> </span><span class="NLM_article-title">Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.02.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.canlet.2016.02.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=26944316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjslygs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=62-72&issue=1&author=A.+R.+Rowson-Hodelauthor=A.+L.+Bergauthor=J.+H.+Waldauthor=J.+Hatakeyamaauthor=K.+VanderVorstauthor=D.+A.+Curielauthor=L.+J.+Leonauthor=C.+Sweeneyauthor=K.+L.+Carraway&title=Hexamethylene+amiloride+engages+a+novel+reactive+oxygen+species-+and+lysosome-dependent+programmed+necrotic+mechanism+to+selectively+target+breast+cancer+cells&doi=10.1016%2Fj.canlet.2016.02.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells</span></div><div class="casAuthors">Rowson-Hodel, Ashley R.; Berg, Anastasia L.; Wald, Jessica H.; Hatakeyama, Jason; VanderVorst, Kacey; Curiel, Daniel A.; Leon, Leonardo J.; Sweeney, Colleen; Carraway, Kermit L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-72</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Anticancer chemotherapeutics often rely on induction of apoptosis in rapidly dividing cells.  While these treatment strategies are generally effective in debulking the primary tumor, post-therapeutic recurrence and metastasis are pervasive concerns with potentially devastating consequences.  We demonstrate that the amiloride deriv. 5-(N,N-hexamethylene) amiloride (HMA) harbors cytotoxic properties particularly attractive for a novel class of therapeutic agent.  HMA is potently and specifically cytotoxic toward breast cancer cells, with remarkable selectivity for transformed cells relative to non-transformed or primary cells.  Nonetheless, HMA is similarly cytotoxic to breast cancer cells irresp. of their mol. profile, proliferative status, or species of origin, suggesting that it engages a cell death mechanism common to all breast tumor subtypes.  We obsd. that HMA induces a novel form of caspase- and autophagy-independent programmed necrosis relying on the orchestration of mitochondrial and lysosomal pro-death mechanisms, where its cytotoxicity was attenuated with ROS-scavengers or lysosomal cathepsin inhibition.  Overall, our findings suggest HMA may efficiently target the heterogeneous populations of cancer cells known to reside within a single breast tumor by induction of a ROS- and lysosome-mediated form of programmed necrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoArlIWBoHhCLVg90H21EOLACvtfcHk0ljjUXOAqZSN0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjslygs7c%253D&md5=2985012c2d32a10d9b8c8830955f84e8</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.02.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.02.042%26sid%3Dliteratum%253Aachs%26aulast%3DRowson-Hodel%26aufirst%3DA.%2BR.%26aulast%3DBerg%26aufirst%3DA.%2BL.%26aulast%3DWald%26aufirst%3DJ.%2BH.%26aulast%3DHatakeyama%26aufirst%3DJ.%26aulast%3DVanderVorst%26aufirst%3DK.%26aulast%3DCuriel%26aufirst%3DD.%2BA.%26aulast%3DLeon%26aufirst%3DL.%2BJ.%26aulast%3DSweeney%26aufirst%3DC.%26aulast%3DCarraway%26aufirst%3DK.%2BL.%26atitle%3DHexamethylene%2520amiloride%2520engages%2520a%2520novel%2520reactive%2520oxygen%2520species-%2520and%2520lysosome-dependent%2520programmed%2520necrotic%2520mechanism%2520to%2520selectively%2520target%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D375%26issue%3D1%26spage%3D62%26epage%3D72%26doi%3D10.1016%2Fj.canlet.2016.02.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleyman, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cragoe, E. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Cation transport probes: the amiloride series</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.1016/0076-6879(90)91045-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2F0076-6879%2890%2991045-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=1990&pages=739-755&author=T.+R.+Kleymanauthor=E.+J.+Cragoe&title=Cation+transport+probes%3A+the+amiloride+series&doi=10.1016%2F0076-6879%2890%2991045-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2F0076-6879%2890%2991045-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0076-6879%252890%252991045-8%26sid%3Dliteratum%253Aachs%26aulast%3DKleyman%26aufirst%3DT.%2BR.%26aulast%3DCragoe%26aufirst%3DE.%2BJ.%26atitle%3DCation%2520transport%2520probes%253A%2520the%2520amiloride%2520series%26jtitle%3DMethods%2520Enzymol.%26date%3D1990%26volume%3D191%26spage%3D739%26epage%3D755%26doi%3D10.1016%2F0076-6879%2890%2991045-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cragoe, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woltersdorf, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicking, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. H.</span></span> <span> </span><span class="NLM_article-title">Pyrazine Diuretics. II. N-Amidino-3-amino-5-substituted 6-Halopyrazinecarboxamides</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1021/jm00313a014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00313a014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1967&pages=66-75&issue=1&author=E.+J.+Cragoeauthor=O.+W.+Woltersdorfauthor=J.+B.+Bickingauthor=S.+F.+Kwongauthor=J.+H.+Jones&title=Pyrazine+Diuretics.+II.+N-Amidino-3-amino-5-substituted+6-Halopyrazinecarboxamides&doi=10.1021%2Fjm00313a014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm00313a014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00313a014%26sid%3Dliteratum%253Aachs%26aulast%3DCragoe%26aufirst%3DE.%2BJ.%26aulast%3DWoltersdorf%26aufirst%3DO.%2BW.%26aulast%3DBicking%26aufirst%3DJ.%2BB.%26aulast%3DKwong%26aufirst%3DS.%2BF.%26aulast%3DJones%26aufirst%3DJ.%2BH.%26atitle%3DPyrazine%2520Diuretics.%2520II.%2520N-Amidino-3-amino-5-substituted%25206-Halopyrazinecarboxamides%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1967%26volume%3D10%26issue%3D1%26spage%3D66%26epage%3D75%26doi%3D10.1021%2Fjm00313a014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patwardhan, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathyamoorthy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Hashimi, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrove, A. E.</span></span> <span> </span><span class="NLM_article-title">Amiloride as a new RNA-binding scaffold with activity against HIV-1 TAR</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1022</span>– <span class="NLM_lpage">1036</span>, <span class="refDoi"> DOI: 10.1039/C6MD00729E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1039%2FC6MD00729E" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1022-1036&issue=5&author=N.+N.+Patwardhanauthor=L.+R.+Ganserauthor=G.+J.+Kapralauthor=C.+S.+Eubanksauthor=J.+Leeauthor=B.+Sathyamoorthyauthor=H.+M.+Al-Hashimiauthor=A.+E.+Hargrove&title=Amiloride+as+a+new+RNA-binding+scaffold+with+activity+against+HIV-1+TAR&doi=10.1039%2FC6MD00729E"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1039%2FC6MD00729E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00729E%26sid%3Dliteratum%253Aachs%26aulast%3DPatwardhan%26aufirst%3DN.%2BN.%26aulast%3DGanser%26aufirst%3DL.%2BR.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DEubanks%26aufirst%3DC.%2BS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DSathyamoorthy%26aufirst%3DB.%26aulast%3DAl-Hashimi%26aufirst%3DH.%2BM.%26aulast%3DHargrove%26aufirst%3DA.%2BE.%26atitle%3DAmiloride%2520as%2520a%2520new%2520RNA-binding%2520scaffold%2520with%2520activity%2520against%2520HIV-1%2520TAR%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26issue%3D5%26spage%3D1022%26epage%3D1036%26doi%3D10.1039%2FC6MD00729E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeslawska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweinitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karcher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondermann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturzebecher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, U.</span></span> <span> </span><span class="NLM_article-title">Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>301</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">475</span>, <span class="refDoi"> DOI: 10.1006/jmbi.2000.3966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1006%2Fjmbi.2000.3966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10926521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltlCjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2000&pages=465-475&issue=2&author=E.+Zeslawskaauthor=A.+Schweinitzauthor=A.+Karcherauthor=P.+Sondermannauthor=S.+Sperlauthor=J.+Sturzebecherauthor=U.+Jacob&title=Crystals+of+the+urokinase+type+plasminogen+activator+variant+beta%28c%29-uPAin+complex+with+small+molecule+inhibitors+open+the+way+towards+structure-based+drug+design&doi=10.1006%2Fjmbi.2000.3966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Crystals of the Urokinase Type Plasminogen Activator Variant βc-uPA in Complex with Small Molecule Inhibitors Open the Way towards Structure-based Drug Design</span></div><div class="casAuthors">Zeslawska, Ewa; Schweinitz, Andrea; Karcher, Annette; Sondermann, Peter; Sperl, Stefan; Sturzebecher, Jorg; Jacob, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">465-475</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Urokinase is a serine protease involved in cancer growth and metastasis.  Here the authors present the first urokinase crystal structure in complex with reversible inhibitors at 2.1 and 2.6 Å resoln.  These inhibitor complex structures have been obtained from crystals of engineered urokinase type plasminogen activator designed to obtain a crystal form open for inhibitor soaking.  The mutant C122S loses its flexible A-chain upon activation cleavage and crystallizes in the presence of benzamidine, which was later displaced by the desired inhibitor.  This new soakable crystal form turned out to be of great value in the process of structure-based drug design.  The evaluated binding mode of amiloride, and UKI-1D revealed a new subsite of the primary specificity pocket of urokinase that will be employed in the future ligand optimization process.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWO6L7KKfXq7Vg90H21EOLACvtfcHk0lgV7u--4nIFRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltlCjsLo%253D&md5=d67810ed0e2ea6ba1f4a601687883926</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.2000.3966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.2000.3966%26sid%3Dliteratum%253Aachs%26aulast%3DZeslawska%26aufirst%3DE.%26aulast%3DSchweinitz%26aufirst%3DA.%26aulast%3DKarcher%26aufirst%3DA.%26aulast%3DSondermann%26aufirst%3DP.%26aulast%3DSperl%26aufirst%3DS.%26aulast%3DSturzebecher%26aufirst%3DJ.%26aulast%3DJacob%26aufirst%3DU.%26atitle%3DCrystals%2520of%2520the%2520urokinase%2520type%2520plasminogen%2520activator%2520variant%2520beta%2528c%2529-uPAin%2520complex%2520with%2520small%2520molecule%2520inhibitors%2520open%2520the%2520way%2520towards%2520structure-based%2520drug%2520design%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2000%26volume%3D301%26issue%3D2%26spage%3D465%26epage%3D475%26doi%3D10.1006%2Fjmbi.2000.3966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S.-e.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span> <span> </span><span class="NLM_article-title">(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2882</span>– <span class="NLM_lpage">2891</span>, <span class="refDoi"> DOI: 10.1021/jm0492305</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0492305" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2882-2891&issue=8&author=S.+Leeauthor=K.+Y.+Yiauthor=S.+K.+Hwangauthor=B.+H.+Leeauthor=S.-e.+Yooauthor=K.+Lee&title=%285-Arylfuran-2-ylcarbonyl%29guanidines+as+cardioprotectives+through+the+inhibition+of+Na%2B%2FH%2B+exchanger+isoform-1&doi=10.1021%2Fjm0492305"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm0492305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0492305%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%26aulast%3DYi%26aufirst%3DK.%2BY.%26aulast%3DHwang%26aufirst%3DS.%2BK.%26aulast%3DLee%26aufirst%3DB.%2BH.%26aulast%3DYoo%26aufirst%3DS.-e.%26aulast%3DLee%26aufirst%3DK.%26atitle%3D%25285-Arylfuran-2-ylcarbonyl%2529guanidines%2520as%2520cardioprotectives%2520through%2520the%2520inhibition%2520of%2520Na%252B%252FH%252B%2520exchanger%2520isoform-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D8%26spage%3D2882%26epage%3D2891%26doi%3D10.1021%2Fjm0492305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawardhana, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vine, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span> <span> </span><span class="NLM_article-title">The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity</span>. <i>BMC Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">43</span>, <span class="refDoi"> DOI: 10.1186/1472-6750-9-43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1186%2F1472-6750-9-43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=19442270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A280%3ADC%252BD1Mvgt1CksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=43&author=B.+J.+Cochranauthor=L.+P.+Gunawardhanaauthor=K.+L.+Vineauthor=J.+A.+Leeauthor=S.+Lobovauthor=M.+Ranson&title=The+CD-loop+of+PAI-2+%28SERPINB2%29+is+redundant+in+the+targeting%2C+inhibition+and+clearance+of+cell+surface+uPA+activity&doi=10.1186%2F1472-6750-9-43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity</span></div><div class="casAuthors">Cochran Blake J; Gunawardhana Lakshitha P; Vine Kara L; Lee Jodi A; Lobov Sergei; Ranson Marie</div><div class="citationInfo"><span class="NLM_cas:title">BMC biotechnology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Plasminogen activator inhibitor type-2 (PAI-2, SERPINB2) is an irreversible, specific inhibitor of the urokinase plasminogen activator (uPA).  Since overexpression of uPA at the surface of cancer cells is linked to malignancy, targeting of uPA by exogenous recombinant PAI-2 has been proposed as the basis of potential cancer therapies.  To this end, reproducible yields of high purity protein that maintains this targeting ability is required.  Herein we validate the use in vitro of recombinant 6 x His-tagged-PAI-2 lacking the intrahelical loop between C and D alpha-helices (PAI-2 Delta CD-loop) for these purposes.  RESULTS:  We show that PAI-2 Delta CD-loop expressed and purified from the pQE9 vector system presents an easier purification target than the previously used pET15b system.  Additionally, PAI-2 Delta CD-loop gave both higher yield and purity than wild-type PAI-2 expressed and purified under identical conditions.  Importantly, absence of the CD-loop had no impact on the inhibition of both solution phase and cell surface uPA or on the clearance of receptor bound uPA from the cell surface.  Furthermore, uPA:PAI-2 Delta CD-loop complexes had similar binding kinetics (KD approximately 5 nM) with the endocytosis receptor Very Low Density Lipoprotein Receptor (VLDLR) to that previously published for uPA:PAI-2 complexes.  CONCLUSION:  We demonstrate that the CD-loop is redundant for the purposes of cellular uPA inhibition and cell surface clearance (endocytosis) and is thus suitable for the development of anti-uPA targeted cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSS-Sk6_th3hp0d-O_J5C0AfW6udTcc2ebRFuN31t1o-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mvgt1CksA%253D%253D&md5=9319fe04e9a23728b814cd5fb9b09234</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1186%2F1472-6750-9-43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6750-9-43%26sid%3Dliteratum%253Aachs%26aulast%3DCochran%26aufirst%3DB.%2BJ.%26aulast%3DGunawardhana%26aufirst%3DL.%2BP.%26aulast%3DVine%26aufirst%3DK.%2BL.%26aulast%3DLee%26aufirst%3DJ.%2BA.%26aulast%3DLobov%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DThe%2520CD-loop%2520of%2520PAI-2%2520%2528SERPINB2%2529%2520is%2520redundant%2520in%2520the%2520targeting%252C%2520inhibition%2520and%2520clearance%2520of%2520cell%2520surface%2520uPA%2520activity%26jtitle%3DBMC%2520Biotechnol.%26date%3D2009%26volume%3D9%26spage%3D43%26doi%3D10.1186%2F1472-6750-9-43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yung-Chi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">3099</span>– <span class="NLM_lpage">3108</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=4202581" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&issue=23&author=C.+Yung-Chiauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28KI%29+and+the+concentration+of+inhibitor+which+causes+50%25+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DYung-Chi%26aufirst%3DC.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528KI%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2525%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26issue%3D23%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nienaber, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkin, J.</span></span> <span> </span><span class="NLM_article-title">Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">7239</span>– <span class="NLM_lpage">7248</span>, <span class="refDoi"> DOI: 10.1074/jbc.275.10.7239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1074%2Fjbc.275.10.7239" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=7239-7248&issue=10&author=V.+Nienaberauthor=J.+Wangauthor=D.+Davidsonauthor=J.+Henkin&title=Re-engineering+of+human+urokinase+provides+a+system+for+structure-based+drug+design+at+high+resolution+and+reveals+a+novel+structural+subsite&doi=10.1074%2Fjbc.275.10.7239"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1074%2Fjbc.275.10.7239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.275.10.7239%26sid%3Dliteratum%253Aachs%26aulast%3DNienaber%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDavidson%26aufirst%3DD.%26aulast%3DHenkin%26aufirst%3DJ.%26atitle%3DRe-engineering%2520of%2520human%2520urokinase%2520provides%2520a%2520system%2520for%2520structure-based%2520drug%2520design%2520at%2520high%2520resolution%2520and%2520reveals%2520a%2520novel%2520structural%2520subsite%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26issue%3D10%26spage%3D7239%26epage%3D7248%26doi%3D10.1074%2Fjbc.275.10.7239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachovchin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblan, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woznica, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poplawski, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiritsy, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMare, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanford, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munford, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachovchin, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span> <span> </span><span class="NLM_article-title">A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">656</span>– <span class="NLM_lpage">663</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1038%2Fnchembio.1578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=24997602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSlsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=656-663&issue=8&author=D.+A.+Bachovchinauthor=L.+W.+Koblanauthor=W.+Wuauthor=Y.+Liuauthor=Y.+Liauthor=P.+Zhaoauthor=I.+Woznicaauthor=Y.+Shuauthor=J.+H.+Laiauthor=S.+E.+Poplawskiauthor=C.+P.+Kiritsyauthor=S.+E.+Healeyauthor=M.+DiMareauthor=D.+G.+Sanfordauthor=R.+S.+Munfordauthor=W.+W.+Bachovchinauthor=T.+R.+Golub&title=A+high-throughput%2C+multiplexed+assay+for+superfamily-wide+profiling+of+enzyme+activity&doi=10.1038%2Fnchembio.1578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity</span></div><div class="casAuthors">Bachovchin, Daniel A.; Koblan, Luke W.; Wu, Wengen; Liu, Yuxin; Li, Youhua; Zhao, Peng; Woznica, Iwona; Shu, Ying; Lai, Jack H.; Poplawski, Sarah E.; Kiritsy, Christopher P.; Healey, Sarah E.; Di Mare, Matthew; Sanford, David G.; Munford, Robert S.; Bachovchin, William W.; Golub, Todd R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">656-663</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The selectivity of an enzyme inhibitor is a key determinant of its usefulness as a tool compd. or its safety as a drug.  Yet selectivity is never assessed comprehensively in the early stages of the drug discovery process, and only rarely in the later stages, because tech. limitations prohibit doing otherwise.  Here, we report EnPlex, an efficient, high-throughput method for simultaneously assessing inhibitor potency and specificity, and pilot its application to 96 serine hydrolases.  EnPlex anal. of widely used serine hydrolase inhibitors revealed numerous previously unrecognized off-target interactions, some of which may help to explain previously confounding adverse effects.  In addn., EnPlex screening of a hydrolase-directed library of boronic acid- and nitrile-contg. compds. provided structure-activity relationships in both potency and selectivity dimensions from which lead candidates could be more effectively prioritized.  Follow-up of a series of dipeptidyl peptidase 4 inhibitors showed that EnPlex indeed predicted efficacy and safety in animal models.  These results demonstrate the feasibility and value of high-throughput, superfamily-wide selectivity profiling and suggest that such profiling can be incorporated into the earliest stages of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxvrqyTuuh07Vg90H21EOLACvtfcHk0lhoFmepNSbZCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSlsLrI&md5=a047ea0af874967ae10296e4ab5fbdad</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1578%26sid%3Dliteratum%253Aachs%26aulast%3DBachovchin%26aufirst%3DD.%2BA.%26aulast%3DKoblan%26aufirst%3DL.%2BW.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DWoznica%26aufirst%3DI.%26aulast%3DShu%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DJ.%2BH.%26aulast%3DPoplawski%26aufirst%3DS.%2BE.%26aulast%3DKiritsy%26aufirst%3DC.%2BP.%26aulast%3DHealey%26aufirst%3DS.%2BE.%26aulast%3DDiMare%26aufirst%3DM.%26aulast%3DSanford%26aufirst%3DD.%2BG.%26aulast%3DMunford%26aufirst%3DR.%2BS.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26atitle%3DA%2520high-throughput%252C%2520multiplexed%2520assay%2520for%2520superfamily-wide%2520profiling%2520of%2520enzyme%2520activity%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26issue%3D8%26spage%3D656%26epage%3D663%26doi%3D10.1038%2Fnchembio.1578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soisson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abeywickrema, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickert, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumb, K. J.</span></span> <span> </span><span class="NLM_article-title">Structural definition and substrate specificity of the S28 protease family: the crystal structure of human prolylcarboxypeptidase</span>. <i>BMC Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">16</span>, <span class="refDoi"> DOI: 10.1186/1472-6807-10-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1186%2F1472-6807-10-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=20540760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A280%3ADC%252BC3cnjsV2lsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=16&issue=16&author=S.+M.+Soissonauthor=S.+B.+Patelauthor=P.+D.+Abeywickremaauthor=N.+J.+Byrneauthor=R.+E.+Diehlauthor=D.+L.+Hallauthor=R.+E.+Fordauthor=J.+C.+Reidauthor=K.+W.+Rickertauthor=J.+M.+Shipmanauthor=S.+Sharmaauthor=K.+J.+Lumb&title=Structural+definition+and+substrate+specificity+of+the+S28+protease+family%3A+the+crystal+structure+of+human+prolylcarboxypeptidase&doi=10.1186%2F1472-6807-10-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Structural definition and substrate specificity of the S28 protease family: the crystal structure of human prolylcarboxypeptidase</span></div><div class="casAuthors">Soisson Stephen M; Patel Sangita B; Abeywickrema Pravien D; Byrne Noel J; Diehl Ronald E; Hall Dawn L; Ford Rachael E; Reid John C; Rickert Keith W; Shipman Jennifer M; Sharma Sujata; Lumb Kevin J</div><div class="citationInfo"><span class="NLM_cas:title">BMC structural biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The unique S28 family of proteases is comprised of the carboxypeptidase PRCP and the aminopeptidase DPP7.  The structural basis of the different substrate specificities of the two enzymes is not understood nor has the structure of the S28 fold been described.  RESULTS:  The experimentally phased 2.8 A crystal structure is presented for human PRCP.  PRCP contains an alpha/beta hydrolase domain harboring the catalytic Asp-His-Ser triad and a novel helical structural domain that caps the active site.  Structural comparisons with prolylendopeptidase and DPP4 identify the S1 proline binding site of PRCP.  A structure-based alignment with the previously undescribed structure of DPP7 illuminates the mechanism of orthogonal substrate specificity of PRCP and DPP7.  PRCP has an extended active-site cleft that can accommodate proline substrates with multiple N-terminal residues.  In contrast, the substrate binding groove of DPP7 is occluded by a short amino-acid insertion unique to DPP7 that creates a truncated active site selective for dipeptidyl proteolysis of N-terminal substrates.  CONCLUSION:  The results define the structure of the S28 family of proteases, provide the structural basis of PRCP and DPP7 substrate specificity and enable the rational design of selective PRCP modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0lIMBqBv6-ROk4JA3soTqfW6udTcc2eYAJ6OzInZuZLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnjsV2lsw%253D%253D&md5=994545a9e7ce68d57dc6e7377d64f019</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1186%2F1472-6807-10-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6807-10-16%26sid%3Dliteratum%253Aachs%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DAbeywickrema%26aufirst%3DP.%2BD.%26aulast%3DByrne%26aufirst%3DN.%2BJ.%26aulast%3DDiehl%26aufirst%3DR.%2BE.%26aulast%3DHall%26aufirst%3DD.%2BL.%26aulast%3DFord%26aufirst%3DR.%2BE.%26aulast%3DReid%26aufirst%3DJ.%2BC.%26aulast%3DRickert%26aufirst%3DK.%2BW.%26aulast%3DShipman%26aufirst%3DJ.%2BM.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26atitle%3DStructural%2520definition%2520and%2520substrate%2520specificity%2520of%2520the%2520S28%2520protease%2520family%253A%2520the%2520crystal%2520structure%2520of%2520human%2520prolylcarboxypeptidase%26jtitle%3DBMC%2520Struct.%2520Biol.%26date%3D2010%26volume%3D10%26issue%3D16%26spage%3D16%26doi%3D10.1186%2F1472-6807-10-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soudijn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Wijngaarden, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzermann, A. P.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of G protein-coupled receptors: perspectives and recent developments</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">752</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03220-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2FS1359-6446%2804%2903220-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=15450241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvFCruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=752-758&issue=17&author=W.+Soudijnauthor=I.+Van+Wijngaardenauthor=A.+P.+Ijzermann&title=Allosteric+modulation+of+G+protein-coupled+receptors%3A+perspectives+and+recent+developments&doi=10.1016%2FS1359-6446%2804%2903220-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of G protein-coupled receptors: perspectives and recent developments</span></div><div class="casAuthors">Soudijn, Willem; van Wijngaarden, Ineke; Ijzerman, Ad P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">752-758</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  'Allosteric' rather than 'orthosteric' modulation of G protein-coupled receptors is a more natural way of intervening in receptor function and, thus, could lead to superior therapeutics.  Allosteric modulation of G protein-coupled receptors has recently been recognized as an alternative approach to gain selectivity in drug action.  In this overview, allosteric modulators that enhance or diminish the effects of (endogenous) agonists or antagonists on a variety of G protein-coupled receptors are described.  Emphasis is placed on the latest developments in this research area, including data on the first clin. studies.  It appears that all 3 major classes of G protein-coupled receptors (A, B and C) are amenable to allosteric modulation by small mols.  This constitutes an attractive and novel means to identify new leads in the drug discovery process.  However, it requires a re-engineering of the majority of current assays.  Finally, it is suggested to introduce the term 'non-competitive agonism' or allosteric agonism' next to allosteric modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoumXxOTZcyg7Vg90H21EOLACvtfcHk0lgVfzsp44LDlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvFCruro%253D&md5=e7fbeb9d23cfc07c41eee979a3526de5</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903220-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903220-9%26sid%3Dliteratum%253Aachs%26aulast%3DSoudijn%26aufirst%3DW.%26aulast%3DVan%2BWijngaarden%26aufirst%3DI.%26aulast%3DIjzermann%26aufirst%3DA.%2BP.%26atitle%3DAllosteric%2520modulation%2520of%2520G%2520protein-coupled%2520receptors%253A%2520perspectives%2520and%2520recent%2520developments%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26issue%3D17%26spage%3D752%26epage%3D758%26doi%3D10.1016%2FS1359-6446%2804%2903220-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of A(2A) adenosine receptors by amiloride analogues and sodium ions</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1016/S0006-2952(00)00360-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2FS0006-2952%2800%2900360-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10927025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1Knsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=669-676&issue=5&author=Z.+G.+Gaoauthor=A.+P.+Ijzerman&title=Allosteric+modulation+of+A%282A%29+adenosine+receptors+by+amiloride+analogues+and+sodium+ions&doi=10.1016%2FS0006-2952%2800%2900360-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of A2A adenosine receptors by amiloride analogs and sodium ions</span></div><div class="casAuthors">Gao, Z.-G.; Ijzerman, A. P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">669-676</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Allosteric regulation of rat A2A adenosine receptors by amiloride, amiloride analogs, and sodium ions was studied by investigating their ability to influence the dissocn. of [3H]4-{2-[7-amino-2-(2-furyl)-1,2,4-triazolo[1,5-a][1,3,5]triazin-5-yl-amino]ethyl}phenol ([3H]ZM241385) from receptors in rat striatal membranes.  Both amiloride and its analogs accelerated the dissocn., the analogs being more potent than amiloride itself.  In contrast, sodium ions decreased the rate of [3H]ZM241385 dissocn. in a concn.-dependent manner, and this rate was not influenced by guanosine triphosphate, N-ethylmaleimide, suramin, or the selective A2A adenosine receptor antagonist, 5-amino-2-(2-furyl)-7(2-phenylethyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH58261).  The effect of competition between the amiloride analog 5-(N,N-hexamethylene)amiloride (HMA) and sodium ions on [3H]ZM241385 dissocn. was also explored.  The addn. of sodium ions resulted in a concn.-dependent rightward shift of the HMA response curve.  The slopes of the HMA concn.-response curves in the presence and absence of sodium ions were not significantly different, which suggests that sodium ions and amiloride analogs act at a common allosteric site on the A2A adenosine receptor.  There was a lack of correlation between the displacement of ligand binding and the allosteric potencies of the amiloride analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDiF_W2jWd6bVg90H21EOLACvtfcHk0lgVfzsp44LDlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1Knsbk%253D&md5=c5bb422d0ebabf5924083a406c62c9a4</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2800%2900360-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252800%252900360-9%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DZ.%2BG.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26atitle%3DAllosteric%2520modulation%2520of%2520A%25282A%2529%2520adenosine%2520receptors%2520by%2520amiloride%2520analogues%2520and%2520sodium%2520ions%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2000%26volume%3D60%26issue%3D5%26spage%3D669%26epage%3D676%26doi%3D10.1016%2FS0006-2952%2800%2900360-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garritsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beukers, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soudijn, W.</span></span> <span> </span><span class="NLM_article-title">Recognition of adenosine receptors by amiloride and its analogues</span>. <i>Nucleosides Nucleotides</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1111</span>, <span class="refDoi"> DOI: 10.1080/07328319108047248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1080%2F07328319108047248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaK3MXlvF2gsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1991&pages=1107-1111&issue=5&author=A.+Garritsenauthor=M.+W.+Beukersauthor=A.+P.+Ijzermanauthor=W.+Soudijn&title=Recognition+of+adenosine+receptors+by+amiloride+and+its+analogues&doi=10.1080%2F07328319108047248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Recognition of adenosine receptors by amiloride and its analogs</span></div><div class="casAuthors">Garritsen, A.; Beukers, M. W.; IJzerman, A. P.; Soudijn, W.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleosides & Nucleotides</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1107-11</span>CODEN:
                <span class="NLM_cas:coden">NUNUD5</span>;
        ISSN:<span class="NLM_cas:issn">0732-8311</span>.
    </div><div class="casAbstract">Amiloride and its analogs displace the adenosine A1 receptor ligands 3H-labeled 8-cyclopentyl-1,3-dipropylxanthine ([3H]CPDPX) and 3H-labeled N6-R-1-phenyl-2-propyladenosine ([3H]PIA) from their binding sites in calf brain membranes in a GTP-insensitive manner.  High [NaCl] or low pH reduces the affinity of amiloride for A1 receptors, whereas the affinity of [3H]CPDPX is not affected.  Notwithstanding this difference in modulation, the interaction between amiloride and A1 receptors appears competitive in nature.  The structure-affinity relationships differ from those for classic amiloride-sensitive Na+ transport systems, indicating that a coupling between the A1 receptor and one of these systems is very unlikely.  Amiloride and its analogs may represent a novel class of A1 receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBkh90z_6bsbVg90H21EOLACvtfcHk0lgVfzsp44LDlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlvF2gsbg%253D&md5=4cedbaf2f0755d7e0d9d188ce0426d38</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1080%2F07328319108047248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07328319108047248%26sid%3Dliteratum%253Aachs%26aulast%3DGarritsen%26aufirst%3DA.%26aulast%3DBeukers%26aufirst%3DM.%2BW.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DSoudijn%26aufirst%3DW.%26atitle%3DRecognition%2520of%2520adenosine%2520receptors%2520by%2520amiloride%2520and%2520its%2520analogues%26jtitle%3DNucleosides%2520Nucleotides%26date%3D1991%26volume%3D10%26issue%3D5%26spage%3D1107%26epage%3D1111%26doi%3D10.1080%2F07328319108047248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garritsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulp, M. M. Th.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cragoe, E. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soudijn, W.</span></span> <span> </span><span class="NLM_article-title">Receptor binding profiles of amiloride analogues provide no evidence for a link between receptors and the Na+/H+ exchanger, but indicate a common structure on receptor proteins</span>. <i>J. Recept. Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">907</span>, <span class="refDoi"> DOI: 10.3109/10799899109064686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.3109%2F10799899109064686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1661335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaK38Xht1yr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1991&pages=891-907&issue=6&author=A.+Garritsenauthor=A.+P.+Ijzermanauthor=M.+M.+Th.+Tulpauthor=E.+J.+Cragoeauthor=W.+Soudijn&title=Receptor+binding+profiles+of+amiloride+analogues+provide+no+evidence+for+a+link+between+receptors+and+the+Na%2B%2FH%2B+exchanger%2C+but+indicate+a+common+structure+on+receptor+proteins&doi=10.3109%2F10799899109064686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor binding profiles of amiloride analogs provide no evidence for a link between receptors and the sodium/hydrogen ion exchanger, but indicate a common structure on receptor proteins</span></div><div class="casAuthors">Garritsen, Anja; IJzerman, Adriaan P.; Tulp, Martin T. M.; Cragoe, Edward J., Jr.; Soudijn, Willem</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Receptor Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">891-907</span>CODEN:
                <span class="NLM_cas:coden">JRERDM</span>;
        ISSN:<span class="NLM_cas:issn">0197-5110</span>.
    </div><div class="casAbstract">Amiloride and its analogs affect radioligand binding to the adenosine A1 receptor.  The specificity of this effect is investigated by generating receptor-binding profiles for amiloride and two of its analogs.  A limited structure-activity relationships study is performed to probe the relationship between inhibition of receptor binding by amiloride analogs and the effects of these compds. on Na+ transport, in particular Na+/H+ exchange.  The receptor-binding profiles of amiloride, benzamil, and 5'-(N,N-hexamethylene)amiloride (HMA) indicate that the compds. affect a variety of receptors and that none of the compds. is highly selective for any of them.  The structure-activity relationship study indicates that it is very unlikely that a direct coupling between receptors and Na+/H+ exchange or another amiloride-sensitive ion transport system is responsible for the inhibition of receptor binding.  A correlation between the signal transduction systems coupled to the receptors involved and the potency of the amiloride analogs is also absent.  The varying nature of the receptors affected by amiloride or its analogs suggests a wide-spread presence of an amiloride-binding site on receptors and other membrane proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodA698X-W10LVg90H21EOLACvtfcHk0lg6P9qEBfJMSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xht1yr&md5=7b58cec419bbfb4c3b7dc2e2aa0d50e0</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3109%2F10799899109064686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10799899109064686%26sid%3Dliteratum%253Aachs%26aulast%3DGarritsen%26aufirst%3DA.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DTulp%26aufirst%3DM.%2BM.%2BTh.%26aulast%3DCragoe%26aufirst%3DE.%2BJ.%26aulast%3DSoudijn%26aufirst%3DW.%26atitle%3DReceptor%2520binding%2520profiles%2520of%2520amiloride%2520analogues%2520provide%2520no%2520evidence%2520for%2520a%2520link%2520between%2520receptors%2520and%2520the%2520Na%252B%252FH%252B%2520exchanger%252C%2520but%2520indicate%2520a%2520common%2520structure%2520on%2520receptor%2520proteins%26jtitle%3DJ.%2520Recept.%2520Res.%26date%3D1991%26volume%3D11%26issue%3D6%26spage%3D891%26epage%3D907%26doi%3D10.3109%2F10799899109064686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Lera Ruiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptor as a drug discovery target</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3623</span>– <span class="NLM_lpage">3650</span>, <span class="refDoi"> DOI: 10.1021/jm4011669</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4011669" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yls7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3623-3650&issue=9&author=M.+de%0ALera+Ruizauthor=Y.-H.+Limauthor=J.+Zheng&title=Adenosine+A2A+receptor+as+a+drug+discovery+target&doi=10.1021%2Fjm4011669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor as a Drug Discovery Target</span></div><div class="casAuthors">de Lera Ruiz, Manuel; Lim, Yeon-Hee; Zheng, Junying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3623-3650</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The adenosine A2A receptor is a G-protein-coupled receptor (GPCR) that has been extensively studied during the past few decades because it offers numerous possibilities for therapeutic applications.  Herein the authors describe adenosine A2A receptor distribution, signaling pathways, pharmacol., and mol. structure, followed by a summary and SAR discussion of the most relevant series of adenosine A2A agonists and antagonists.  This review also provides an update of the A2A ligands that are undergoing or have undergone clin. studies, including the two currently marketed agonists adenosine and regadenoson.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQUPGC7zBCkbVg90H21EOLACvtfcHk0lg6P9qEBfJMSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yls7bJ&md5=846641d1ac3ad16b6335af6b4df15f08</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm4011669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4011669%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLera%2BRuiz%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DY.-H.%26aulast%3DZheng%26aufirst%3DJ.%26atitle%3DAdenosine%2520A2A%2520receptor%2520as%2520a%2520drug%2520discovery%2520target%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D9%26spage%3D3623%26epage%3D3650%26doi%3D10.1021%2Fjm4011669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louvel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adlere, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huisman, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijksteel, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenselink, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">5′-Substituted amiloride derivatives as allosteric modulators binding in the sodium ion pocket of the adenosine A2A receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4769</span>– <span class="NLM_lpage">4777</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00142</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00142" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFSis7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4769-4777&issue=10&author=A.+Massinkauthor=J.+Louvelauthor=I.+Adlereauthor=C.+van+Veenauthor=B.+J.+Huismanauthor=G.+S.+Dijksteelauthor=D.+Guoauthor=E.+B.+Lenselinkauthor=B.+J.+Buckleyauthor=H.+Matthewsauthor=M.+Ransonauthor=M.+Kelsoauthor=A.+P.+Ijzerman&title=5%E2%80%B2-Substituted+amiloride+derivatives+as+allosteric+modulators+binding+in+the+sodium+ion+pocket+of+the+adenosine+A2A+receptor&doi=10.1021%2Facs.jmedchem.6b00142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">5'-Substituted Amiloride Derivatives as Allosteric Modulators Binding in the Sodium Ion Pocket of the Adenosine A2A Receptor</span></div><div class="casAuthors">Massink, Arnault; Louvel, Julien; Adlere, Ilze; van Veen, Corine; Huisman, Berend J. H.; Dijksteel, Gabrielle S.; Guo, Dong; Lenselink, Eelke B.; Buckley, Benjamin J.; Matthews, Hayden; Ranson, Marie; Kelso, Michael; IJzerman, Adriaan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4769-4777</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The sodium ion site is an allosteric site conserved among many G protein-coupled receptors (GPCRs).  Amiloride and 5-(N,N-hexamethylene)amiloride (HMA) supposedly bind in this sodium ion site and can influence orthosteric ligand binding.  The availability of a high-resoln. X-ray crystal structure of the human adenosine A2A receptor (hA2AAR), in which the allosteric sodium ion site was elucidated, makes it an appropriate model receptor for investigating the allosteric site.  In this study, we report the synthesis and evaluation of novel 5'-substituted amiloride derivs. as hA2AAR allosteric antagonists.  The potency of the amiloride derivs. was assessed by their ability to displace orthosteric radioligand [3H]4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a]-[1,3,5]triazin-5-yl)amino)ethyl)phenol ([3H]ZM-241,385) from both the wild-type and sodium ion site W246A mutant hA2AAR. 4-Ethoxyphenethyl-substituted amiloride I was found to be more potent than both amiloride and HMA, and the shift in potency between the wild-type and mutated receptor confirmed its likely binding to the sodium ion site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCrEOabCZ6y7Vg90H21EOLACvtfcHk0lg6P9qEBfJMSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFSis7w%253D&md5=b6001778532001e01718898c3e527720</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00142%26sid%3Dliteratum%253Aachs%26aulast%3DMassink%26aufirst%3DA.%26aulast%3DLouvel%26aufirst%3DJ.%26aulast%3DAdlere%26aufirst%3DI.%26aulast%3Dvan%2BVeen%26aufirst%3DC.%26aulast%3DHuisman%26aufirst%3DB.%2BJ.%26aulast%3DDijksteel%26aufirst%3DG.%2BS.%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DLenselink%26aufirst%3DE.%2BB.%26aulast%3DBuckley%26aufirst%3DB.%2BJ.%26aulast%3DMatthews%26aufirst%3DH.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DKelso%26aufirst%3DM.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26atitle%3D5%25E2%2580%25B2-Substituted%2520amiloride%2520derivatives%2520as%2520allosteric%2520modulators%2520binding%2520in%2520the%2520sodium%2520ion%2520pocket%2520of%2520the%2520adenosine%2520A2A%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D10%26spage%3D4769%26epage%3D4777%26doi%3D10.1021%2Facs.jmedchem.6b00142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klinghofer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGonigal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarthy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nienaber, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorwin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockway, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulkower, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span> <span> </span><span class="NLM_article-title">Species specificity of amidine-based urokinase inhibitors</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">31</span>),  <span class="NLM_fpage">9125</span>– <span class="NLM_lpage">9131</span>, <span class="refDoi"> DOI: 10.1021/bi010186u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi010186u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=9125-9131&issue=31&author=V.+Klinghoferauthor=K.+Stewartauthor=T.+McGonigalauthor=R.+Smithauthor=A.+Sarthyauthor=V.+Nienaberauthor=C.+Butlerauthor=S.+Dorwinauthor=P.+Richardsonauthor=M.+Weitzbergauthor=M.+Wendtauthor=T.+Rockwayauthor=X.+Zhaoauthor=K.+I.+Hulkowerauthor=V.+L.+Giranda&title=Species+specificity+of+amidine-based+urokinase+inhibitors&doi=10.1021%2Fbi010186u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fbi010186u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi010186u%26sid%3Dliteratum%253Aachs%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DMcGonigal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DSarthy%26aufirst%3DA.%26aulast%3DNienaber%26aufirst%3DV.%26aulast%3DButler%26aufirst%3DC.%26aulast%3DDorwin%26aufirst%3DS.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DWeitzberg%26aufirst%3DM.%26aulast%3DWendt%26aufirst%3DM.%26aulast%3DRockway%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DHulkower%26aufirst%3DK.%2BI.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DSpecies%2520specificity%2520of%2520amidine-based%2520urokinase%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2001%26volume%3D40%26issue%3D31%26spage%3D9125%26epage%3D9131%26doi%3D10.1021%2Fbi010186u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McNay, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oran, E.</span></span> <span> </span><span class="NLM_article-title">Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)</span>. <i>Metab., Clin. Exp.</i> <span class="NLM_year" style="font-weight: bold;">1970</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/0026-0495(70)90118-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2F0026-0495%2870%2990118-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=5410663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaE3cXhtF2qu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1970&pages=58-70&issue=1&author=J.+L.+McNayauthor=E.+Oran&title=Possible+predisposition+of+diabetic+patients+to+hyperkalemia+following+administration+of+potassium-retaining+diuretic%2C+amiloride+%28MK+870%29&doi=10.1016%2F0026-0495%2870%2990118-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)</span></div><div class="casAuthors">McNay, John L.; Oran, Erdogan</div><div class="citationInfo"><span class="NLM_cas:title">Metabolism, Clinical and Experimental</span>
        (<span class="NLM_cas:date">1970</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-70</span>CODEN:
                <span class="NLM_cas:coden">METAAJ</span>;
        ISSN:<span class="NLM_cas:issn">0026-0495</span>.
    </div><div class="casAbstract">During the course of a study of the K-retaining diuretic amiloride (MK 870) as an agent for the therapy of mild hypertension accompanied by diabetes mellitus, 2 of 4 glycosuric patients developed serum K concns. of 6.3 mequiv/l. or greater, a 3rd glycosuric patients showed an increase of 1.1 mequiv K/l., and 2 patients with mildly depressed oral glucose tolerance showed increases of 1.5 and 0.4 mequiv K/l.  Generally, the hyperkalemia was accompanied by lowered serum Na.  In contrast 1 normal subject showed no change in serum K and a 2nd control showed an increase of only 0.3 mequiv/l.  During i.v. glucose tolerance tests without amiloride the 2 control subjects and the 2 patients with abnormal oral glucose tolerance tests showed the expected decrease in serum K levels; however, 2 of those with glycosuria developed increases in serum K, 1 showed no change, and 1 showed a decline.  When the glucose tolerance test was done during amiloride therapy, serum K increased in 7 of these 8 subjects, including the 4 with glycosuria.  The hyperkalemia was not clearly assocd. with impaired renal function or excessive K retention.  Diabetic patients may have an abnormality of electrolyte homeostasis which predisposes them to hyperkalemia during administration of K-retaining diuretics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkchNlzXY6frVg90H21EOLACvtfcHk0ljWffPz51My1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3cXhtF2qu7Y%253D&md5=85d2df4265c0b41bc20beb6d03f6faeb</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2F0026-0495%2870%2990118-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0026-0495%252870%252990118-6%26sid%3Dliteratum%253Aachs%26aulast%3DMcNay%26aufirst%3DJ.%2BL.%26aulast%3DOran%26aufirst%3DE.%26atitle%3DPossible%2520predisposition%2520of%2520diabetic%2520patients%2520to%2520hyperkalemia%2520following%2520administration%2520of%2520potassium-retaining%2520diuretic%252C%2520amiloride%2520%2528MK%2520870%2529%26jtitle%3DMetab.%252C%2520Clin.%2520Exp.%26date%3D1970%26volume%3D19%26issue%3D1%26spage%3D58%26epage%3D70%26doi%3D10.1016%2F0026-0495%2870%2990118-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baer, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, H. F.</span></span> <span> </span><span class="NLM_article-title">The potassium-sparing and natriuretic activity of N-amidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride dihydrate (amiloride hydrochloride)</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>157</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">472</span>– <span class="NLM_lpage">485</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=6039836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaF2sXksFamtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=1967&pages=472-485&issue=2&author=J.+E.+Baerauthor=C.+B.+Jonesauthor=S.+A.+Spitzerauthor=H.+F.+Russo&title=The+potassium-sparing+and+natriuretic+activity+of+N-amidino-3%2C5-diamino-6-chloropyrazinecarboxamide+hydrochloride+dihydrate+%28amiloride+hydrochloride%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Potassium-sparing and natriuretic activity of N-amidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride dihydrate (amiloride hydrochloride)</span></div><div class="casAuthors">Baer, John E.; Jones, C. B.; Spitzer, S. A.; Russo, H. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">472-85</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">N-Amidino-3-amino-6-chloropyrazinecarboxamide enhanced Na+ excretion and decreased K+ excretion in normal and adrenalectomized rats (Glitzer and Steelman, CA 64:4135c.  The 5-dimethylamino and 5-amino analogs are 3 and 15 times as potent natriuretics orally in normal rats.  The latter (amiloride) markedly enhanced Na+ excretion and depressed K+ excretion in acetazolamide- or hydrochlorothiazide-treated rats.  An i.v. dose of 1.0 mg./kg. of amiloride in dogs gave a modest (170 microequivs./min.) but sustained (up to 4 hrs.) natriuresis; in KCl- or thiazide-treated dogs, K+ excretion was inhibited by amiloride.  Orally, amiloride increased Na+ (but not K+) excretion at 0.016 to 4.0 mg./kg. in dogs; esp. at the higher doses, the action lasted more than 6 hrs.  Amiloride was slowly excreted unchanged by rat, dog, and man.  Stop-flow studies showed that amiloride increased concn. of Na+ and decreased K+ and pH of distal tubular samples, with no change in Cl-.  The mode of the K+-sparing action appears to differ from those of the aldosterone antagonists or organomercurial diuretics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgxDAb-ITQcrVg90H21EOLACvtfcHk0ljWffPz51My1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXksFamtLo%253D&md5=128f5415a68cd364b72a1afddf04abb9</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaer%26aufirst%3DJ.%2BE.%26aulast%3DJones%26aufirst%3DC.%2BB.%26aulast%3DSpitzer%26aufirst%3DS.%2BA.%26aulast%3DRusso%26aufirst%3DH.%2BF.%26atitle%3DThe%2520potassium-sparing%2520and%2520natriuretic%2520activity%2520of%2520N-amidino-3%252C5-diamino-6-chloropyrazinecarboxamide%2520hydrochloride%2520dihydrate%2520%2528amiloride%2520hydrochloride%2529%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1967%26volume%3D157%26issue%3D2%26spage%3D472%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="note"><p class="first last">Comprehensive pharmacokinetic profiling of compounds <b>18</b> and <b>26</b> will be reported elsewhere.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uhland, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siphos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetzer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweinitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetzer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van De Locht, A.</span></span> <span> </span><span class="NLM_article-title">Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.3892/ijo_00000346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.3892%2Fijo_00000346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=19578749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt12qtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=347-357&issue=2&author=K.+Uhlandauthor=B.+Siphosauthor=C.+Arkonaauthor=M.+Schusterauthor=B.+Petriauthor=P.+Steinmetzerauthor=F.+Muellerauthor=A.+Schweinitzauthor=T.+Steinmetzerauthor=A.+Van+De+Locht&title=Use+of+IHC+and+newly+designed+matriptase+inhibitors+to+elucidate+the+role+of+matriptase+in+pancreatic+ductal+adenocarcinoma&doi=10.3892%2Fijo_00000346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma</span></div><div class="casAuthors">Uhland, Kerstin; Siphos, Bence; Arkona, Christoph; Schuster, Maj; Petri, Bernhard; Steinmetzer, Peter; Mueller, Friedemann; Schweinitz, Andrea; Steinmetzer, Torsten; Van De Locht, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">347-357</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">Matriptase, also known as MT-SP1, is a type II transmembrane serine protease strongly implicated in both the development and progression of a variety of epithelial cancers.  Evidence comes from studies of its expression in human cancers and from mouse models of spontaneous cancer.  Matriptase is considered to be a major activator of two key stimulators of invasive growth, namely hepatocyte growth factor/scatter factor and urokinase-type plasminogen activator.  The aim of this study was to examine the role of matriptase in pancreatic ductal adenocarcinoma by expression anal. and functional assays in vitro.  Immunohistochem. anal. of matriptase performed on microtissue arrays and large samples of 55 pancreatic ductal adenocarcinomas and on 31 samples of normal pancreatic ducts revealed that although matriptase expression differed greatly in both malignant and normal ductal pancreatic tissue, matriptase scores were significantly (p = 0.02) elevated in pancreatic ductal adenocarcinoma compared to normal pancreatic ducts.  To evaluate the role of matriptase during development of pancreatic cancer, we studied the effects of newly designed matriptase inhibitors on the processing of the zymogen of urokinase-type plasminogen activator in the human adenocarcinoma cell lines AsPC-1 and BxPC-3.  In both cell lines, at 1 μM, all matriptase inhibitors completely prevented zymogen activation.  At lower inhibitor concns., the degree of inhibition of zymogen processing correlated with the affinities of the inhibitors towards matriptase indicating that this is a specific result of matriptase inhibition.  Furthermore, matriptase inhibitors reduced the phosphorylation of the HGF receptor/cMet and the overall cellular invasiveness of the human pancreatic adenocarcinoma cell line AsPC-1.  Our findings demonstrate for the first time that matriptase may be involved in the progression of pancreatic ductal adenocarcinoma and that matriptase inhibition may contribute to preventing the progression of this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3QUvu884Z37Vg90H21EOLACvtfcHk0ljWffPz51My1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt12qtbo%253D&md5=a857615f1ca9207d8f2ce884d7ae0b6a</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.3892%2Fijo_00000346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo_00000346%26sid%3Dliteratum%253Aachs%26aulast%3DUhland%26aufirst%3DK.%26aulast%3DSiphos%26aufirst%3DB.%26aulast%3DArkona%26aufirst%3DC.%26aulast%3DSchuster%26aufirst%3DM.%26aulast%3DPetri%26aufirst%3DB.%26aulast%3DSteinmetzer%26aufirst%3DP.%26aulast%3DMueller%26aufirst%3DF.%26aulast%3DSchweinitz%26aufirst%3DA.%26aulast%3DSteinmetzer%26aufirst%3DT.%26aulast%3DVan%2BDe%2BLocht%26aufirst%3DA.%26atitle%3DUse%2520of%2520IHC%2520and%2520newly%2520designed%2520matriptase%2520inhibitors%2520to%2520elucidate%2520the%2520role%2520of%2520matriptase%2520in%2520pancreatic%2520ductal%2520adenocarcinoma%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2009%26volume%3D35%26issue%3D2%26spage%3D347%26epage%3D357%26doi%3D10.3892%2Fijo_00000346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pothula, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biankin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirola, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apte, M. V.</span></span> <span> </span><span class="NLM_article-title">Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1038/bjc.2015.478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1038%2Fbjc.2015.478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=26766740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlKrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2016&pages=269-280&issue=3&author=S.+P.+Pothulaauthor=Z.+Xuauthor=D.+Goldsteinauthor=A.+V.+Biankinauthor=R.+C.+Pirolaauthor=J.+S.+Wilsonauthor=M.+V.+Apte&title=Hepatocyte+growth+factor+inhibition%3A+a+novel+therapeutic+approach+in+pancreatic+cancer&doi=10.1038%2Fbjc.2015.478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer</span></div><div class="casAuthors">Pothula, Srinivasa P.; Xu, Zhihong; Goldstein, David; Biankin, Andrew V.; Pirola, Romano C.; Wilson, Jeremy S.; Apte, Minoti V.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-280</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Pancreatic stellate cells (PSCs, which produce the stroma of pancreatic cancer (PC)) interact with cancer cells to facilitate PC growth.  A candidate growth factor pathway that may mediate this interaction is the HGF-c-MET pathway.  Methods: Effects of HGF inhibition (using a neutralizing antibody AMG102) alone or in combination with gemcitabine were assessed (i) in vivo using an orthotopic model of PC, and (ii) in vitro using cultured PC cells (AsPC-1) and human PSCs.  Results: We have shown that human PSCs (hPSCs) secrete HGF but do not express the receptor c-MET, which is present predominantly on cancer cells.  HGF inhibition was as effective as std. chemotherapy in inhibiting local tumor growth but was significantly more effective than gemcitabine in reducing tumor angiogenesis and metastasis.  HGF inhibition has resulted in reduced metastasis; however, interestingly this antimetastatic effect was lost when combined with gemcitabine.  This suggests that gemcitabine treatment selects out a subpopulation of cancer cells with increased epithelial-mesenchymal transition (EMT) and stem-cell characteristics, as supported by our findings of increased expression of EMT and stem-cell markers in tumor sections from our animal model.  In vitro studies showed that hPSC secretions induced proliferation and migration, but inhibited apoptosis, of cancer cells.  These effects were countered by pretreatment of hPSC secretions with a HGF-neutralising antibody but not by gemcitabine, indicating a key role for HGF in PSC-PC interactions.  Conclusions: Our studies suggest that targeted therapy to inhibit stromal-tumor interactions mediated by the HGF-c-MET pathway may represent a novel therapeutic approach in PC that will require careful modeling for optimal integration with existing treatment modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp40eRpjECkgLVg90H21EOLACvtfcHk0ljGtTA2Yc2MrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlKrsbY%253D&md5=a71d32e4e7c31104116559844f174423</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2015.478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2015.478%26sid%3Dliteratum%253Aachs%26aulast%3DPothula%26aufirst%3DS.%2BP.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DGoldstein%26aufirst%3DD.%26aulast%3DBiankin%26aufirst%3DA.%2BV.%26aulast%3DPirola%26aufirst%3DR.%2BC.%26aulast%3DWilson%26aufirst%3DJ.%2BS.%26aulast%3DApte%26aufirst%3DM.%2BV.%26atitle%3DHepatocyte%2520growth%2520factor%2520inhibition%253A%2520a%2520novel%2520therapeutic%2520approach%2520in%2520pancreatic%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2016%26volume%3D114%26issue%3D3%26spage%3D269%26epage%3D280%26doi%3D10.1038%2Fbjc.2015.478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikishkin, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huskens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verboom, W.</span></span> <span> </span><span class="NLM_article-title">Transition metal-catalyzed functionalization of pyrazines</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">3583</span>– <span class="NLM_lpage">3602</span>, <span class="refDoi"> DOI: 10.1039/c3ob40460a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1039%2Fc3ob40460a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=3583-3602&issue=22&author=N.+I.+Nikishkinauthor=J.+Huskensauthor=W.+Verboom&title=Transition+metal-catalyzed+functionalization+of+pyrazines&doi=10.1039%2Fc3ob40460a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1039%2Fc3ob40460a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3ob40460a%26sid%3Dliteratum%253Aachs%26aulast%3DNikishkin%26aufirst%3DN.%2BI.%26aulast%3DHuskens%26aufirst%3DJ.%26aulast%3DVerboom%26aufirst%3DW.%26atitle%3DTransition%2520metal-catalyzed%2520functionalization%2520of%2520pyrazines%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2013%26volume%3D11%26issue%3D22%26spage%3D3583%26epage%3D3602%26doi%3D10.1039%2Fc3ob40460a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chessell, I.
P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, P. P.</span></span> <span> </span><span class="NLM_article-title">Properties of the pore-forming P2 × 7 purinoceptor in mouse NTW8 microglial cells</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1429</span>– <span class="NLM_lpage">1437</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0701278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1038%2Fsj.bjp.0701278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=9257924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaK2sXlt1Wjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=1997&pages=1429-1437&issue=7&author=I.%0AP.+Chessellauthor=A.+D.+Michelauthor=P.+P.+Humphrey&title=Properties+of+the+pore-forming+P2+%C3%97+7+purinoceptor+in+mouse+NTW8+microglial+cells&doi=10.1038%2Fsj.bjp.0701278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Properties of the pore-forming P2X7 purinoceptor in mouse NTW8 microglial cells</span></div><div class="casAuthors">Chessell, I.P.; Michel, A.D.; Humphrey, P.P.A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1429-1437</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">The authors have used whole-cell patch clamping methods to study and characterize the cytolytic P2X7 (P2Z) receptor in the NTW8 mouse microglial cell line.  At room temp., in an extracellular soln. contg. 2 mM Ca2+ and 1 mM Mg2+, 2'- and 3'-O-(4-benzoylbenzoyl)-adenosine-5'-triphosphate (Bz-ATP; 300 μM), or ATP (3 mM), evoked peak whole cell inward currents, at a holding potential of -90 mV, of 549 and 644 pA, resp.  Current-voltage relationships generated with 3 mM ATP reversed at 4.6 mV and did not display strong rectification.  In an extracellular soln. contg. zero Mg2+ and 500 μM Ca2+ (low divalent soln.), brief (0.5 s) application of these agonists elicited larger maximal currents (909 and 1818 pA, Bz-ATP and ATP, resp.).  Longer application of ATP (1 mM for 30 s) produced larger, slowly developing, currents which reached a plateau after approx. 15-20 s and were reversible on washing.  Under these conditions, in the presence of ATP, ethidium bromide uptake could be demonstrated.  Further applications of 1 mM ATP produced rapid currents of the same magnitude as those obsd. during the 30 s application.  Subsequent detn. of concn.-effect curves to Bz-ATP, ATP and 2-methylthio-ATP yielded EC50 values of 58.3, 298 and 505 μM, resp.  These affects of ATP were antagonized by pyridoxal-phosphate-6-azophenyl- 2',4'-disulfonic acid (PPADS; 30 μM) but not suramin (100 μM).  In low divalent soln., repeated application of 1 mM ATP for 1 s produced successively larger currents which reached a plateau, after 8 applications, of 466% of the first application current.  PPADS (30 μM) prevented this augmentation, while 5-(N,N-hexamethylene)-amiloride (HMA) (100 μM) accelerated it such that maximal augmentation was obsd. after only one application of ATP in the presence of HMA.  At a bath temp. of 32°, current augmentation also occurred in normal divalent cation contg. soln.  These data demonstrate that mouse microglial NTW8 cells possess a purinoceptor with pharmacol. characteristics resembling the P2X, receptor.  The authors suggest that the current augmentation phenomenon obsd. reflects formation of the large cytolytic pore characteristic of this receptor.  The authors have demonstrated that pore formation can occur under normal physiol. conditions and can be modulated pharmacol., both pos. and neg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzcIn44XVAubVg90H21EOLACvtfcHk0ljGtTA2Yc2MrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlt1Wjtrw%253D&md5=6fae33db137981f78c45e34e9470dfb7</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0701278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0701278%26sid%3Dliteratum%253Aachs%26aulast%3DChessell%26aufirst%3DI.%2BP.%26aulast%3DMichel%26aufirst%3DA.%2BD.%26aulast%3DHumphrey%26aufirst%3DP.%2BP.%26atitle%3DProperties%2520of%2520the%2520pore-forming%2520P2%2520%25C3%2597%25207%2520purinoceptor%2520in%2520mouse%2520NTW8%2520microglial%2520cells%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D121%26issue%3D7%26spage%3D1429%26epage%3D1437%26doi%3D10.1038%2Fsj.bjp.0701278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amith, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fliegel, L.</span></span> <span> </span><span class="NLM_article-title">KR-33028, a potent inhibitor of the Na(+)/H(+) exchanger NHE1, suppresses metastatic potential of triple-negative breast cancer cells</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2016.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.bcp.2016.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=27521504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtleisr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2016&pages=31-39&author=S.+R.+Amithauthor=J.+M.+Wilkinsonauthor=L.+Fliegel&title=KR-33028%2C+a+potent+inhibitor+of+the+Na%28%2B%29%2FH%28%2B%29+exchanger+NHE1%2C+suppresses+metastatic+potential+of+triple-negative+breast+cancer+cells&doi=10.1016%2Fj.bcp.2016.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">KR-33028, a potent inhibitor of the Na+/H+ exchanger NHE1, suppresses metastatic potential of triple-negative breast cancer cells</span></div><div class="casAuthors">Amith, Schammim Ray; Wilkinson, Jodi Marie; Fliegel, Larry</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-39</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hyper-activation of the Na+/H+ exchanger NHE1 occurs at the onset of oncogenic transformation and plays a crit. role in breast cancer carcinogenesis.  Dysregulation of NHE1 activity results in intracellular alkalinization and the acidification of the extracellular tumor microenvironment that promotes metastasis.  Hence, the use of chem. inhibitors of NHE1 as chemotherapeutic agents is an alluring prospect.  We previously demonstrated that two structurally different NHE1 inhibitors, EMD87580 [(2-methyl-4,5-di-(methylsulfonyl)-benzoyl)-guanidine], and HMA [5-(N,N-hexamethylene)-amiloride], were effective as co-adjuvants to potentiate paclitaxel-mediated cytotoxic chemotherapy in triple-neg. breast cancer (TNBC) cells.  Both these drugs, however, had reduced or minimal anti-cancer effects when used alone.  Here, we tested KR-33028 (4-cyano (benzo[b]thiophene-2-carbonyl)guanidine), a potent and selective inhibitor of NHE1, to det. its efficacy in inhibition of metastatic potential of TNBC cells.  In highly invasive MDA-MB-231, moderately invasive MDA-MB-468, and lowly invasive Hs578T TNBC cells, KR-33028 considerably reduced rates of cell migration and anchorage-independent colony growth.  Invasion of MDA-MB-231 and MDA-MB-468 cells through extracellular matrix was also dramatically decreased in response to KR-33028.  We further tested the effect of KR-33028 on MDA-MB-231 cells lacking NHE1 expression (231koNHE1); no differences were obsd. between untreated control and KR-33028-treated 231koNHE1 cells.  Taken together, our results highlight the in vitro efficacy of KR-33028-mediated NHE1 inhibition on limiting cellular functions that are predictive of metastasis in vivo.  We suggest that targeting NHE1 in the development of novel chemotherapeutics could be highly effective in combating triple-neg. breast cancer and that KR-33028 is potentially useful in prevention of metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5F9yBhpgG87Vg90H21EOLACvtfcHk0ljGtTA2Yc2MrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtleisr3F&md5=12416b156b9e1e32cfdc604327c4112c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2016.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2016.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DAmith%26aufirst%3DS.%2BR.%26aulast%3DWilkinson%26aufirst%3DJ.%2BM.%26aulast%3DFliegel%26aufirst%3DL.%26atitle%3DKR-33028%252C%2520a%2520potent%2520inhibitor%2520of%2520the%2520Na%2528%252B%2529%252FH%2528%252B%2529%2520exchanger%2520NHE1%252C%2520suppresses%2520metastatic%2520potential%2520of%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2016%26volume%3D118%26spage%3D31%26epage%3D39%26doi%3D10.1016%2Fj.bcp.2016.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casarotto, M. G.</span></span> <span> </span><span class="NLM_article-title">Probing interactions of Vpu from HIV-1 with amiloride-based compounds</span>. <i>Biochim. Biophys. Acta, Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1858</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1016/j.bbamem.2015.12.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.bbamem.2015.12.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=26724207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1858&publication_year=2016&pages=733-739&issue=4&author=M.+R.+Rosenbergauthor=L.+M.+Weaverauthor=M.+G.+Casarotto&title=Probing+interactions+of+Vpu+from+HIV-1+with+amiloride-based+compounds&doi=10.1016%2Fj.bbamem.2015.12.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Probing interactions of Vpu from HIV-1 with amiloride-based compounds</span></div><div class="casAuthors">Rosenberg, Matthew R.; Weaver, Llara M.; Casarotto, Marco G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1858</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-739</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Viral ion channels or viroporins are short membrane proteins that participate in wide-ranging functions including virus replication and entry, assembly, and virus release.  One such viroporin is the 81 amino acid residue Vpu protein derived from HIV-1.  This protein consists of one transmembrane (TM) and two cytoplasmic helical domains, the former of which oligomerises to form cation-selective ion channels.  In this study, we investigate the binding properties of amiloride compds. to Vpu embedded into liposomes using surface plasmon resonance (SPR).  We explore the Vpu ion channel inhibitor, hexamethylene amiloride (HMA), as a mol. tool to examine the potential interactive role of key TM residues, Trp23, Ser24, and Glu29, in terms of positioning of these residues on the channel pore and the orientation of its constituent helixes.  The study provides exptl. support that a direct interaction between Ser24 and HMA occurs and that this residue is most likely located in the channel pore.  Mutation of Trp23 does not impact HMA affinity suggesting no direct involvement in binding and that this residue is lipid facing.  These findings indicate that small mols. such as amilorides are capable of specifically interacting with Vpu ion channels.  Although a correlation between ion channel and functional activity cannot be dismissed, alternative mechanisms involving protein-protein interactions may play an important role in the efficacy of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa6CgQ784t_LVg90H21EOLACvtfcHk0li7btAblmg5TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaruw%253D%253D&md5=dd3419c47e8e25f0dd7924ab0e0f5219</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2015.12.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2015.12.028%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DM.%2BR.%26aulast%3DWeaver%26aufirst%3DL.%2BM.%26aulast%3DCasarotto%26aufirst%3DM.%2BG.%26atitle%3DProbing%2520interactions%2520of%2520Vpu%2520from%2520HIV-1%2520with%2520amiloride-based%2520compounds%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2016%26volume%3D1858%26issue%3D4%26spage%3D733%26epage%3D739%26doi%3D10.1016%2Fj.bbamem.2015.12.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jalily, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldstrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, S. S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niikura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tietjen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedida, D.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of action of novel influenza A/M2 viroporin inhibitors derived from hexamethylene amiloride</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1124/mol.115.102731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1124%2Fmol.115.102731" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=80-95&issue=2&author=P.+H.+Jalilyauthor=J.+Eldstromauthor=S.+C.+Millerauthor=D.+C.+Kwanauthor=S.+S.-H.+Taiauthor=D.+Chouauthor=M.+Niikuraauthor=I.+Tietjenauthor=D.+Fedida&title=Mechanisms+of+action+of+novel+influenza+A%2FM2+viroporin+inhibitors+derived+from+hexamethylene+amiloride&doi=10.1124%2Fmol.115.102731"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.102731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.102731%26sid%3Dliteratum%253Aachs%26aulast%3DJalily%26aufirst%3DP.%2BH.%26aulast%3DEldstrom%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DS.%2BC.%26aulast%3DKwan%26aufirst%3DD.%2BC.%26aulast%3DTai%26aufirst%3DS.%2BS.-H.%26aulast%3DChou%26aufirst%3DD.%26aulast%3DNiikura%26aufirst%3DM.%26aulast%3DTietjen%26aufirst%3DI.%26aulast%3DFedida%26aufirst%3DD.%26atitle%3DMechanisms%2520of%2520action%2520of%2520novel%2520influenza%2520A%252FM2%2520viroporin%2520inhibitors%2520derived%2520from%2520hexamethylene%2520amiloride%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D90%26issue%3D2%26spage%3D80%26epage%3D95%26doi%3D10.1124%2Fmol.115.102731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oosterom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1808</span>– <span class="NLM_lpage">1815</span>, <span class="refDoi"> DOI: 10.1124/mol.107.043521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1124%2Fmol.107.043521" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=1808-1815&issue=6&author=L.+H.+Heitmanauthor=K.+Yeauthor=J.+Oosteromauthor=A.+P.+Ijzerman&title=Amiloride+derivatives+and+a+nonpeptidic+antagonist+bind+at+two+distinct+allosteric+sites+in+the+human+gonadotropin-releasing+hormone+receptor&doi=10.1124%2Fmol.107.043521"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.043521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.043521%26sid%3Dliteratum%253Aachs%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DYe%26aufirst%3DK.%26aulast%3DOosterom%26aufirst%3DJ.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26atitle%3DAmiloride%2520derivatives%2520and%2520a%2520nonpeptidic%2520antagonist%2520bind%2520at%2520two%2520distinct%2520allosteric%2520sites%2520in%2520the%2520human%2520gonadotropin-releasing%2520hormone%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D73%26issue%3D6%26spage%3D1808%26epage%3D1815%26doi%3D10.1124%2Fmol.107.043521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Snell, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, E. B.</span></span> <span> </span><span class="NLM_article-title">5-(N, N-Hexamethylene) amiloride is a GABA-A ρ1 receptor positive allosteric modulator</span>. <i>Channels</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">498</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1080/19336950.2016.1207021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1080%2F19336950.2016.1207021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=498-506&issue=6&author=H.+D.+Snellauthor=E.+B.+Gonzales&title=5-%28N%2C+N-Hexamethylene%29+amiloride+is+a+GABA-A+%CF%811+receptor+positive+allosteric+modulator&doi=10.1080%2F19336950.2016.1207021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1080%2F19336950.2016.1207021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F19336950.2016.1207021%26sid%3Dliteratum%253Aachs%26aulast%3DSnell%26aufirst%3DH.%2BD.%26aulast%3DGonzales%26aufirst%3DE.%2BB.%26atitle%3D5-%2528N%252C%2520N-Hexamethylene%2529%2520amiloride%2520is%2520a%2520GABA-A%2520%25CF%25811%2520receptor%2520positive%2520allosteric%2520modulator%26jtitle%3DChannels%26date%3D2016%26volume%3D10%26issue%3D6%26spage%3D498%26epage%3D506%26doi%3D10.1080%2F19336950.2016.1207021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leng, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Z. G.</span></span> <span> </span><span class="NLM_article-title">Amiloride analogs as ASIC1a inhibitors</span>. <i>CNS Neurosci. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">468</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1111/cns.12524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1111%2Fcns.12524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=26890278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVCrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=468-476&issue=6&author=T.+D.+Lengauthor=H.+F.+Siauthor=J.+Liauthor=T.+Yangauthor=M.+Zhuauthor=B.+Wangauthor=R.+P.+Simonauthor=Z.+G.+Xiong&title=Amiloride+analogs+as+ASIC1a+inhibitors&doi=10.1111%2Fcns.12524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Amiloride Analogs as ASIC1a Inhibitors</span></div><div class="casAuthors">Leng, Tian-Dong; Si, Hong-Fang; Li, Jun; Yang, Tao; Zhu, Mengyuan; Wang, Binghe; Simon, Roger P.; Xiong, Zhi-Gang</div><div class="citationInfo"><span class="NLM_cas:title">CNS Neuroscience & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">468-476</span>CODEN:
                <span class="NLM_cas:coden">CNTNAB</span>;
        ISSN:<span class="NLM_cas:issn">1755-5930</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : ASIC1a, the predominant acid-sensing ion channels (ASICs), is implicated in neurol. disorders including stroke, traumatic spinal cord injury, and ALS.  Potent ASIC1a inhibitors should have promising therapeutic potential for ASIC1a-related diseases.  Aims : We examd. the inhibitory effects of a no. of amiloride analogs on ASIC1a currents, aimed at understanding the structure-activity relationship and identifying potent ASIC1a inhibitors for stroke intervention.  Methods : Whole-cell patch-clamp techniques and a mouse model of middle cerebral artery occlusion (MCAO)-induced focal ischemia were used.  Surflex-Dock was used to dock the analogs into the pocket with default parameters.  Results : Amiloride and its analogs inhibit ASIC1a currents expressed in Chinese hamster ovary cells with a potency rank order of benzamil > phenamil > 5-(N,N-dimethyl)amiloride (DMA) > amiloride > 5-(N,N-hexamethylene)amiloride (HMA) ≥ 5-(N-methyl-N-isopropyl)amiloride (MIA) > 5-(N-ethyl-N-isopropyl)amiloride (EIPA).  In addn., amiloride and its analogs inhibit ASIC currents in cortical neurons with the same potency rank order.  In mice, benzamil and EIPA decreased MCAO-induced infarct vol.  Similar to its effect on the ASIC current, benzamil showed a much higher potency than EIPA.  Conclusion : Addn. of a benzyl group to the terminal guanidinyl group resulted in enhanced inhibitory activity on ASIC1a.  On the other hand, the bulky groups added to the 5-amino residues slightly decreased the activity.  Among the tested amiloride analogs, benzamil is the most potent ASIC1a inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprvommAdpu37Vg90H21EOLACvtfcHk0li7btAblmg5TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVCrtbg%253D&md5=531cb15375f06ef61bf9be7115a3e9b3</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1111%2Fcns.12524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcns.12524%26sid%3Dliteratum%253Aachs%26aulast%3DLeng%26aufirst%3DT.%2BD.%26aulast%3DSi%26aufirst%3DH.%2BF.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DSimon%26aufirst%3DR.%2BP.%26aulast%3DXiong%26aufirst%3DZ.%2BG.%26atitle%3DAmiloride%2520analogs%2520as%2520ASIC1a%2520inhibitors%26jtitle%3DCNS%2520Neurosci.%2520Ther.%26date%3D2016%26volume%3D22%26issue%3D6%26spage%3D468%26epage%3D476%26doi%3D10.1111%2Fcns.12524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, K. B.</span></span> <span> </span><span class="NLM_article-title">Targeting GIRK channels for the development of new therapeutic agents</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">64</span>, <span class="refDoi"> DOI: 10.3389/fphar.2011.00064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.3389%2Ffphar.2011.00064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=22059075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC38Xis1ahtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=64&author=K.+B.+Walsh&title=Targeting+GIRK+channels+for+the+development+of+new+therapeutic+agents&doi=10.3389%2Ffphar.2011.00064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting GIRK channels for the development of new therapeutic agents</span></div><div class="casAuthors">Walsh, Kenneth B.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology of Ion Channels and Channelopathies</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">Oct.</span>),
    <span class="NLM_cas:pages">64</span>CODEN:
                <span class="NLM_cas:coden">FPICA4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">G protein-coupled inward rectifier K+ (GIRK) channels represent novel targets for the development of new therapeutic agents.  GIRK channels are activated by a large no. of G protein-coupled receptors (GPCRs) and regulate the elec. activity of neurons, cardiac myocytes, and β-pancreatic cells.  Abnormalities in GIRK channel function have been implicated in the patho-physiol. of neuropathic pain, drug addiction, cardiac arrhythmias, and other disorders.  However, the pharmacol. of these channels remains largely unexplored.  In this paper we describe the development of a screening assay for identifying new modulators of neuronal and cardiac GIRK channels.  Pituitary (AtT20) and cardiac (HL-1) cell lines expressing GIRK channels were cultured in 96-well plates, loaded with oxonol membrane potential-sensitive dyes and measured using a fluorescent imaging plate reader.  Activation of the endogenous GPCRs in the cells caused a rapid, time-dependent decrease in the fluorescent signal; indicative of K+ efflux through the GIRK channels (GPCR stimulation vs. control, Z'-factor = 0.5-0.7).  As expected this signal was inhibited by addn. of Ba2+ and the GIRK channel toxin tertiapin-Q.  To test the utility of the assay for screening GIRK channel blockers, cells were incubated for 5 min with a compd. library of Na+ and K+ channel modulators.  Ion transporter inhibitors such as 5-(N,N-hexamethylene)-amiloride and SCH-28080 were identified as blockers of the GIRK channel at sub-micromolar concns.  Thus, the screening assay will be useful for expanding the limited pharmacol. of the GIRK channel and in developing new agents for the treatment of GIRK channelopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxjvoI-loMq7Vg90H21EOLACvtfcHk0lhwmqNYZmSivQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xis1ahtA%253D%253D&md5=f0e442266e636d5577e6a1972a6aa52f</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2011.00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2011.00064%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DK.%2BB.%26atitle%3DTargeting%2520GIRK%2520channels%2520for%2520the%2520development%2520of%2520new%2520therapeutic%2520agents%26jtitle%3DFront.%2520Pharmacol.%26date%3D2011%26volume%3D2%26spage%3D64%26doi%3D10.3389%2Ffphar.2011.00064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, G.</span>; <span class="NLM_string-name">Ewart, G.</span>; <span class="NLM_string-name">Gage, P.</span></span> <span> </span><span class="NLM_article-title">A Method of Modulating Ion Channel Functional Activity</span>. PCT Int. Appl. <span class="NLM_patent">WO2000021538 A1</span>, <span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=G.+Cox&author=G.+Ewart&author=P.+Gage&title=A+Method+of+Modulating+Ion+Channel+Functional+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DG.%26atitle%3DA%2520Method%2520of%2520Modulating%2520Ion%2520Channel%2520Functional%2520Activity%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreasen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span> <span> </span><span class="NLM_article-title">Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1</span>. <i>J. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>160</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.jsb.2007.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.jsb.2007.06.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2007&pages=1-10&issue=1&author=G.+Zhaoauthor=C.+Yuanauthor=T.+Windauthor=Z.+Huangauthor=P.+A.+Andreasenauthor=M.+Huang&title=Structural+basis+of+specificity+of+a+peptidyl+urokinase+inhibitor%2C+upain-1&doi=10.1016%2Fj.jsb.2007.06.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2007.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2007.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DWind%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAndreasen%26aufirst%3DP.%2BA.%26aulast%3DHuang%26aufirst%3DM.%26atitle%3DStructural%2520basis%2520of%2520specificity%2520of%2520a%2520peptidyl%2520urokinase%2520inhibitor%252C%2520upain-1%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2007%26volume%3D160%26issue%3D1%26spage%3D1%26epage%3D10%26doi%3D10.1016%2Fj.jsb.2007.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otwinowski, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minor, W.</span></span> <span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0lhwmqNYZmSivQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit81"><span><span> </span><span class="NLM_article-title">The CCP4 suite: Programs for protein crystallography.
Collaborative
Computational Project, Number 4</span>.  <i>Acta Crystallogr.,
Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume">50</span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1107/S0907444994003112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1107%2FS0907444994003112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+CCP4+suite%3A+Programs+for+protein+crystallography.%0ACollaborative%0AComputational+Project%2C+Number+4.+Acta+Crystallogr.%2C%0ASect.+D%3A+Biol.+Crystallogr.+1994%2C+50%2C+760%E2%80%93763%2C+10.1107%2FS0907444994003112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1107%2FS0907444994003112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444994003112%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520CCP4%2520suite%253A%2520Programs%2520for%2520protein%2520crystallography.%250ACollaborative%250AComputational%2520Project%252C%2520Number%25204%26jtitle%3DActa%2520Crystallogr.%252C%250ASect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1994%26volume%3D50%26spage%3D760%26epage%3D763%26doi%3D10.1107%2FS0907444994003112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botkjaer, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreasen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span> <span> </span><span class="NLM_article-title">Rezymogenation of active urokinase induced by an inhibitory antibody</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>449</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1042/BJ20121132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1042%2FBJ20121132" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=449&publication_year=2013&pages=161-166&issue=1&author=L.+Jiangauthor=K.+A.+Botkjaerauthor=L.+M.+Andersenauthor=C.+Yuanauthor=P.+A.+Andreasenauthor=M.+Huang&title=Rezymogenation+of+active+urokinase+induced+by+an+inhibitory+antibody&doi=10.1042%2FBJ20121132"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1042%2FBJ20121132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20121132%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DBotkjaer%26aufirst%3DK.%2BA.%26aulast%3DAndersen%26aufirst%3DL.%2BM.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DAndreasen%26aufirst%3DP.%2BA.%26aulast%3DHuang%26aufirst%3DM.%26atitle%3DRezymogenation%2520of%2520active%2520urokinase%2520induced%2520by%2520an%2520inhibitory%2520antibody%26jtitle%3DBiochem.%2520J.%26date%3D2013%26volume%3D449%26issue%3D1%26spage%3D161%26epage%3D166%26doi%3D10.1042%2FBJ20121132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0ljhQD8GUKi4_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echeverri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalabat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laita, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahan, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staszewski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimmich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patron, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, B. D.</span></span> <span> </span><span class="NLM_article-title">Small molecule activator of the human epithelial sodium channel</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">11981</span>– <span class="NLM_lpage">11994</span>, <span class="refDoi"> DOI: 10.1074/jbc.M708001200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1074%2Fjbc.M708001200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=18326490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltVyrsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=11981-11994&issue=18&author=M.+Luauthor=F.+Echeverriauthor=D.+Kalabatauthor=B.+Laitaauthor=D.+S.+Dahanauthor=R.+D.+Smithauthor=H.+Xuauthor=L.+Staszewskiauthor=J.+Yamamotoauthor=J.+Lingauthor=N.+Hwangauthor=R.+Kimmichauthor=P.+Liauthor=E.+Patronauthor=W.+Keungauthor=A.+Patronauthor=B.+D.+Moyer&title=Small+molecule+activator+of+the+human+epithelial+sodium+channel&doi=10.1074%2Fjbc.M708001200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Activator of the Human Epithelial Sodium Channel</span></div><div class="casAuthors">Lu, Min; Echeverri, Fernando; Kalabat, Dalia; Laita, Bianca; Dahan, David S.; Smith, Raymond D.; Xu, Hong; Staszewski, Lena; Yamamoto, Jeff; Ling, Jing; Hwang, Nancy; Kimmich, Rachel; Li, Peter; Patron, Erika; Keung, Walter; Patron, Andrew; Moyer, Bryan D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">11981-11994</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The epithelial sodium channel (ENaC), a heterotrimeric complex composed of α, β, and γ subunits, belongs to the ENaC/degenerin family of ion channels and forms the principal route for apical Na+ entry in many reabsorbing epithelia.  Although high affinity ENaC blockers, including amiloride and derivs., have been described, potent and specific small mol. ENaC activators have not been reported.  Here we describe compd. S3969 that fully and reversibly activates human ENaC (hENaC) in an amiloride-sensitive and dose-dependent manner in heterologous cells.  Mechanistically, S3969 increases hENaC open probability through interactions requiring the extracellular domain of the β subunit. hENaC activation by S3969 did not require cleavage by the furin protease, indicating that nonproteolyzed channels can be opened.  Function of αβG37Sγ hENaC, a channel defective in gating that leads to the salt-wasting disease pseudohypoaldosteronism type I, was rescued by S3969.  Small mol. activation of hENaC may find application in alleviating human disease, including pseudohypoaldosteronism type I, hypotension, and neonatal respiratory distress syndrome, when improved Na+ flux across epithelial membranes is clin. desirable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfnBYQQrO4z7Vg90H21EOLACvtfcHk0ljhQD8GUKi4_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltVyrsrg%253D&md5=02d23ef30f9cb7864e25c9ec8dd76930</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M708001200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M708001200%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DM.%26aulast%3DEcheverri%26aufirst%3DF.%26aulast%3DKalabat%26aufirst%3DD.%26aulast%3DLaita%26aufirst%3DB.%26aulast%3DDahan%26aufirst%3DD.%2BS.%26aulast%3DSmith%26aufirst%3DR.%2BD.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DStaszewski%26aufirst%3DL.%26aulast%3DYamamoto%26aufirst%3DJ.%26aulast%3DLing%26aufirst%3DJ.%26aulast%3DHwang%26aufirst%3DN.%26aulast%3DKimmich%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DPatron%26aufirst%3DE.%26aulast%3DKeung%26aufirst%3DW.%26aulast%3DPatron%26aufirst%3DA.%26aulast%3DMoyer%26aufirst%3DB.%2BD.%26atitle%3DSmall%2520molecule%2520activator%2520of%2520the%2520human%2520epithelial%2520sodium%2520channel%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26issue%3D18%26spage%3D11981%26epage%3D11994%26doi%3D10.1074%2Fjbc.M708001200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonlaufen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiala-Beer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biankin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirola, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apte, M. V.</span></span> <span> </span><span class="NLM_article-title">Role of pancreatic stellate cells in pancreatic cancer metastasis</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>177</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2585</span>– <span class="NLM_lpage">2596</span>, <span class="refDoi"> DOI: 10.2353/ajpath.2010.090899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.2353%2Fajpath.2010.090899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=20934972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A280%3ADC%252BC3cbksVejsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2010&pages=2585-2596&issue=5&author=Z.+Xuauthor=A.+Vonlaufenauthor=P.+A.+Phillipsauthor=E.+Fiala-Beerauthor=X.+Zhangauthor=L.+Yangauthor=A.+V.+Biankinauthor=D.+Goldsteinauthor=R.+C.+Pirolaauthor=J.+S.+Wilsonauthor=M.+V.+Apte&title=Role+of+pancreatic+stellate+cells+in+pancreatic+cancer+metastasis&doi=10.2353%2Fajpath.2010.090899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Role of pancreatic stellate cells in pancreatic cancer metastasis</span></div><div class="casAuthors">Xu Zhihong; Vonlaufen Alain; Phillips Phoebe A; Fiala-Beer Eva; Zhang Xuguo; Yang Lu; Biankin Andrew V; Goldstein David; Pirola Romano C; Wilson Jeremy S; Apte Minoti V</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of pathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2585-96</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pancreatic stellate cells (PSCs) produce the stromal reaction in pancreatic cancer (PC), and their interaction with cancer cells facilitates cancer progression.  This study investigated the role of human PSCs (hPSCs) in the metastatic process and tumor angiogenesis using both in vivo (orthotopic model) and in vitro (cultured PSC and PC cells) approaches.  A sex mismatch study (injection of male hPSCs plus female PC cells into the pancreas of female mice) was conducted to determine whether hPSCs accompany cancer cells to metastatic sites.  Metastatic nodules were examined by fluorescent in situ hybridization for the presence of the Y chromosome.  Angiogenesis was assessed by i) immunostaining tumors for CD31, an endothelial cell marker; and ii) quantifying human microvascular endothelial cell (HMEC-1) tube formation in vitro on exposure to conditioned media from hPSCs.  Transendothelial migration was assessed in vitro by examining the movement of fluorescently labeled hPSCs through an endothelial cell monolayer.  Human PSCs i) were found in multiple metastatic sites in each mouse injected with male hPSCs plus female PC cells; ii) increased CD31 expression in primary tumors from mice injected with MiaPaCa-2 and hPSCs and stimulated tube formation by HMEC-1 in vitro; and iii) exhibited transendothelial migration that was stimulated by cancer cells.  Human PSCs accompany cancer cells to metastatic sites, stimulate angiogenesis, and are able to intravasate/extravasate to and from blood vessels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2QMGV98SuTPxQvRxYU81tfW6udTcc2eanKdB9Vsu0Drntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbksVejsw%253D%253D&md5=89b066c4aabfb4290d1051eefc72921c</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2010.090899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2010.090899%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DVonlaufen%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DP.%2BA.%26aulast%3DFiala-Beer%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DBiankin%26aufirst%3DA.%2BV.%26aulast%3DGoldstein%26aufirst%3DD.%26aulast%3DPirola%26aufirst%3DR.%2BC.%26aulast%3DWilson%26aufirst%3DJ.%2BS.%26aulast%3DApte%26aufirst%3DM.%2BV.%26atitle%3DRole%2520of%2520pancreatic%2520stellate%2520cells%2520in%2520pancreatic%2520cancer%2520metastasis%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2010%26volume%3D177%26issue%3D5%26spage%3D2585%26epage%3D2596%26doi%3D10.2353%2Fajpath.2010.090899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref20':['cit20'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':[],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref99':['cit99'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 19 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Martin Juhás, <span class="NLM_string-name hlFld-ContribAuthor">Jan Zitko</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Interactions of Pyrazine-Based Compounds to Proteins. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 8901-8916. <a href="https://doi.org/10.1021/acs.jmedchem.9b02021" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02021%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMolecular%252BInteractions%252Bof%252BPyrazine-Based%252BCompounds%252Bto%252BProteins%26aulast%3DJuh%25C3%25A1s%26aufirst%3DMartin%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D05122019%26date%3D24042020%26date%3D10042020%26volume%3D63%26issue%3D17%26spage%3D8901%26epage%3D8916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kiem  Vu</span>, <span class="hlFld-ContribAuthor ">Eduardo  Blumwald</span>, <span class="hlFld-ContribAuthor ">Angie  Gelli</span>. </span><span class="cited-content_cbyCitation_article-title">The Antifungal Activity of HMA, an Amiloride Analog and Inhibitor of Na+/H+ Exchangers. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Microbiology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fmicb.2021.673035" title="DOI URL">https://doi.org/10.3389/fmicb.2021.673035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmicb.2021.673035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmicb.2021.673035%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Microbiology%26atitle%3DThe%252BAntifungal%252BActivity%252Bof%252BHMA%25252C%252Ban%252BAmiloride%252BAnalog%252Band%252BInhibitor%252Bof%252BNa%25252B%25252FH%25252B%252BExchangers%26aulast%3DVu%26aufirst%3DKiem%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benjamin J.  Buckley</span>, <span class="hlFld-ContribAuthor ">Ashraf  Aboelela</span>, <span class="hlFld-ContribAuthor ">Hiwa  Majed</span>, <span class="hlFld-ContribAuthor ">Richard S.  Bujaroski</span>, <span class="hlFld-ContribAuthor ">Karen L.  White</span>, <span class="hlFld-ContribAuthor ">Andrew K.  Powell</span>, <span class="hlFld-ContribAuthor ">Wen  Wang</span>, <span class="hlFld-ContribAuthor ">Kasiram  Katneni</span>, <span class="hlFld-ContribAuthor ">Jessica  Saunders</span>, <span class="hlFld-ContribAuthor ">David M.  Shackleford</span>, <span class="hlFld-ContribAuthor ">Susan A.  Charman</span>, <span class="hlFld-ContribAuthor ">Gregory M.  Cook</span>, <span class="hlFld-ContribAuthor ">Michael J.  Kelso</span>, <span class="hlFld-ContribAuthor ">Marie  Ranson</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic evaluation of structure–property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>37 </em>, 116116. <a href="https://doi.org/10.1016/j.bmc.2021.116116" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116116</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116116%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSystematic%252Bevaluation%252Bof%252Bstructure%2525E2%252580%252593property%252Brelationships%252Band%252Bpharmacokinetics%252Bin%252B6-%252528hetero%252529aryl-substituted%252Bmatched%252Bpair%252Banalogs%252Bof%252Bamiloride%252Band%252B5-%252528N%25252CN-hexamethylene%252529amiloride%26aulast%3DBuckley%26aufirst%3DBenjamin%2BJ.%26date%3D2021%26volume%3D37%26spage%3D116116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benjamin J.  Buckley</span>, <span class="hlFld-ContribAuthor ">Ashna  Kumar</span>, <span class="hlFld-ContribAuthor ">Ashraf  Aboelela</span>, <span class="hlFld-ContribAuthor ">Richard S.  Bujaroski</span>, <span class="hlFld-ContribAuthor ">Xiuju  Li</span>, <span class="hlFld-ContribAuthor ">Hiwa  Majed</span>, <span class="hlFld-ContribAuthor ">Larry  Fliegel</span>, <span class="hlFld-ContribAuthor ">Marie  Ranson</span>, <span class="hlFld-ContribAuthor ">Michael J.  Kelso</span>. </span><span class="cited-content_cbyCitation_article-title">Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA/NHE1 Active and Single Target-Selective Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (6)
                                     , 2999. <a href="https://doi.org/10.3390/ijms22062999" title="DOI URL">https://doi.org/10.3390/ijms22062999</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22062999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22062999%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DScreening%252Bof%252B5-%252Band%252B6-Substituted%252BAmiloride%252BLibraries%252BIdentifies%252BDual-uPA%25252FNHE1%252BActive%252Band%252BSingle%252BTarget-Selective%252BInhibitors%26aulast%3DBuckley%26aufirst%3DBenjamin%2BJ.%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D6%26spage%3D2999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roberto G. S.  Berlinck</span>, <span class="hlFld-ContribAuthor ">Darlon I.  Bernardi</span>, <span class="hlFld-ContribAuthor ">Taicia  Fill</span>, <span class="hlFld-ContribAuthor ">Alessandra A. G.  Fernandes</span>, <span class="hlFld-ContribAuthor ">Igor D.  Jurberg</span>. </span><span class="cited-content_cbyCitation_article-title">The chemistry and biology of guanidine secondary metabolites. </span><span class="cited-content_cbyCitation_journal-name">Natural Product Reports</span><span> <strong>2021,</strong> <em>66 </em><a href="https://doi.org/10.1039/D0NP00051E" title="DOI URL">https://doi.org/10.1039/D0NP00051E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0NP00051E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0NP00051E%26sid%3Dliteratum%253Aachs%26jtitle%3DNatural%2520Product%2520Reports%26atitle%3DThe%252Bchemistry%252Band%252Bbiology%252Bof%252Bguanidine%252Bsecondary%252Bmetabolites%26aulast%3DBerlinck%26aufirst%3DRoberto%2BG.%2BS.%26date%3D2021%26date%3D2021%26volume%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuliya O.  Kuchkovska</span>, <span class="hlFld-ContribAuthor ">Oleksandr O.  Grygorenko</span>. </span><span class="cited-content_cbyCitation_article-title">Azepines and Their Fused-Ring Derivatives. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00073-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00073-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00073-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00073-1%26sid%3Dliteratum%253Aachs%26atitle%3DAzepines%252Band%252BTheir%252BFused-Ring%252BDerivatives%26aulast%3DKuchkovska%26aufirst%3DYuliya%2BO.%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Srinivasa P.  Pothula</span>, <span class="hlFld-ContribAuthor ">Zhihong  Xu</span>, <span class="hlFld-ContribAuthor ">David  Goldstein</span>, <span class="hlFld-ContribAuthor ">Romano C.  Pirola</span>, <span class="hlFld-ContribAuthor ">Jeremy S.  Wilson</span>, <span class="hlFld-ContribAuthor ">Minoti V.  Apte</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting HGF/c-MET Axis in Pancreatic Cancer. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (23)
                                     , 9170. <a href="https://doi.org/10.3390/ijms21239170" title="DOI URL">https://doi.org/10.3390/ijms21239170</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21239170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21239170%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DTargeting%252BHGF%25252Fc-MET%252BAxis%252Bin%252BPancreatic%252BCancer%26aulast%3DPothula%26aufirst%3DSrinivasa%2BP.%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D23%26spage%3D9170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michala G.  Rolver</span>, <span class="hlFld-ContribAuthor ">Line O.  Elingaard-Larsen</span>, <span class="hlFld-ContribAuthor ">Anne P.  Andersen</span>, <span class="hlFld-ContribAuthor ">Laurent  Counillon</span>, <span class="hlFld-ContribAuthor ">Stine F.  Pedersen</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrazine ring-based Na+/H+ exchanger (NHE) inhibitors potently inhibit cancer cell growth in 3D culture, independent of NHE1. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-62430-z" title="DOI URL">https://doi.org/10.1038/s41598-020-62430-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-62430-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-62430-z%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DPyrazine%252Bring-based%252BNa%25252B%25252FH%25252B%252Bexchanger%252B%252528NHE%252529%252Binhibitors%252Bpotently%252Binhibit%252Bcancer%252Bcell%252Bgrowth%252Bin%252B3D%252Bculture%25252C%252Bindependent%252Bof%252BNHE1%26aulast%3DRolver%26aufirst%3DMichala%2BG.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amanda E.  Hargrove</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule–RNA targeting: starting with the fundamentals. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2020,</strong> <em>56 </em>
                                    (94)
                                     , 14744-14756. <a href="https://doi.org/10.1039/D0CC06796B" title="DOI URL">https://doi.org/10.1039/D0CC06796B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CC06796B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CC06796B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DSmall%252Bmolecule%2525E2%252580%252593RNA%252Btargeting%25253A%252Bstarting%252Bwith%252Bthe%252Bfundamentals%26aulast%3DHargrove%26aufirst%3DAmanda%2BE.%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D94%26spage%3D14744%26epage%3D14756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jay  Perry</span>, <span class="hlFld-ContribAuthor ">Elahe  Minaei</span>, <span class="hlFld-ContribAuthor ">Elette  Engels</span>, <span class="hlFld-ContribAuthor ">Bruce G  Ashford</span>, <span class="hlFld-ContribAuthor ">Luke  McAlary</span>, <span class="hlFld-ContribAuthor ">Jonathan R  Clark</span>, <span class="hlFld-ContribAuthor ">Ruta  Gupta</span>, <span class="hlFld-ContribAuthor ">Moeava  Tehei</span>, <span class="hlFld-ContribAuthor ">Stephanie  Corde</span>, <span class="hlFld-ContribAuthor ">Martin  Carolan</span>, <span class="hlFld-ContribAuthor ">Marie  Ranson</span>. </span><span class="cited-content_cbyCitation_article-title">Thulium oxide nanoparticles as radioenhancers for the treatment of metastatic cutaneous squamous cell carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Physics in Medicine & Biology</span><span> <strong>2020,</strong> <em>65 </em>
                                    (21)
                                     , 215018. <a href="https://doi.org/10.1088/1361-6560/abaa5d" title="DOI URL">https://doi.org/10.1088/1361-6560/abaa5d</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1088/1361-6560/abaa5d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1088%2F1361-6560%2Fabaa5d%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysics%2520in%2520Medicine%2520%2526%2520Biology%26atitle%3DThulium%252Boxide%252Bnanoparticles%252Bas%252Bradioenhancers%252Bfor%252Bthe%252Btreatment%252Bof%252Bmetastatic%252Bcutaneous%252Bsquamous%252Bcell%252Bcarcinoma%26aulast%3DPerry%26aufirst%3DJay%26date%3D2020%26date%3D2020%26volume%3D65%26issue%3D21%26spage%3D215018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nagaraja Reddy  Gangarapu</span>, <span class="hlFld-ContribAuthor ">Archakam  Ranganatham</span>, <span class="hlFld-ContribAuthor ">Eeda Koti  Reddy</span>, <span class="hlFld-ContribAuthor ">Shivaraj  Yellappa</span>, <span class="hlFld-ContribAuthor ">Kothapalli Bannoth  Chandrasekhar</span>. </span><span class="cited-content_cbyCitation_article-title">2‐Aminoaryl‐3,5‐diaryl pyrazines: Synthesis, biological evaluation against
              Mycobacterium tuberculosis
              and docking studies. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2020,</strong> <em>353 </em>
                                    (7)
                                     , 1900368. <a href="https://doi.org/10.1002/ardp.201900368" title="DOI URL">https://doi.org/10.1002/ardp.201900368</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201900368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201900368%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3D2%2525E2%252580%252590Aminoaryl%2525E2%252580%2525903%25252C5%2525E2%252580%252590diaryl%252Bpyrazines%25253A%252BSynthesis%25252C%252Bbiological%252Bevaluation%252Bagainst%252BMycobacterium%252Btuberculosis%252Band%252Bdocking%252Bstudies%26aulast%3DGangarapu%26aufirst%3DNagaraja%25C2%25A0Reddy%26date%3D2020%26date%3D2020%26volume%3D353%26issue%3D7%26spage%3D1900368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Ariens</span>, <span class="hlFld-ContribAuthor ">Cecilia  Becattini</span>, <span class="hlFld-ContribAuthor ">Markus  Bender</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Bergmeier</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Castoldi</span>, <span class="hlFld-ContribAuthor ">Katrien  Devreese</span>, <span class="hlFld-ContribAuthor ">Martin  Ellis</span>, <span class="hlFld-ContribAuthor ">David  Gailani</span>, <span class="hlFld-ContribAuthor ">Vera  Ignjatovic</span>, <span class="hlFld-ContribAuthor ">Paula D.  James</span>, <span class="hlFld-ContribAuthor ">Steven  Kerrigan</span>, <span class="hlFld-ContribAuthor ">Michele  Lambert</span>, <span class="hlFld-ContribAuthor ">Lai Heng  Lee</span>, <span class="hlFld-ContribAuthor ">Marcel  Levi</span>, <span class="hlFld-ContribAuthor ">Norma  Maugeri</span>, <span class="hlFld-ContribAuthor ">Joost  Meijers</span>, <span class="hlFld-ContribAuthor ">Juan  Melero‐Martin</span>, <span class="hlFld-ContribAuthor ">Alan D.  Michelson</span>, <span class="hlFld-ContribAuthor ">Federico  Mingozzi</span>, <span class="hlFld-ContribAuthor ">Keith  Neeves</span>, <span class="hlFld-ContribAuthor ">Heyu  Ni</span>, <span class="hlFld-ContribAuthor ">Anna‐Karin  Olsson</span>, <span class="hlFld-ContribAuthor ">Zoltán  Prohászka</span>, <span class="hlFld-ContribAuthor ">Marie  Ranson</span>, <span class="hlFld-ContribAuthor ">Nicoletta  Riva</span>, <span class="hlFld-ContribAuthor ">Yotis  Senis</span>, <span class="hlFld-ContribAuthor ">Cornelia H.  Ommen</span>, <span class="hlFld-ContribAuthor ">Douglas E.  Vaughan</span>, <span class="hlFld-ContribAuthor ">John  Weisel</span>. </span><span class="cited-content_cbyCitation_article-title">Illustrated State‐of‐the‐Art Capsules of the ISTH 2020 Congress. </span><span class="cited-content_cbyCitation_journal-name">Research and Practice in Thrombosis and Haemostasis</span><span> <strong>2020,</strong> <em>4 </em>
                                    (5)
                                     , 680-713. <a href="https://doi.org/10.1002/rth2.12368" title="DOI URL">https://doi.org/10.1002/rth2.12368</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/rth2.12368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Frth2.12368%26sid%3Dliteratum%253Aachs%26jtitle%3DResearch%2520and%2520Practice%2520in%2520Thrombosis%2520and%2520Haemostasis%26atitle%3DIllustrated%252BState%2525E2%252580%252590of%2525E2%252580%252590the%2525E2%252580%252590Art%252BCapsules%252Bof%252Bthe%252BISTH%252B2020%252BCongress%26aulast%3DAriens%26aufirst%3DRobert%26date%3D2020%26date%3D2020%26volume%3D4%26issue%3D5%26spage%3D680%26epage%3D713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Breanne H.Y.  Gibson</span>, <span class="hlFld-ContribAuthor ">Matthew T.  Duvernay</span>, <span class="hlFld-ContribAuthor ">Stephanie N.  Moore‐Lotridge</span>, <span class="hlFld-ContribAuthor ">Matthew J.  Flick</span>, <span class="hlFld-ContribAuthor ">Jonathan G.  Schoenecker</span>. </span><span class="cited-content_cbyCitation_article-title">Plasminogen activation in the musculoskeletal acute phase response: Injury, repair, and disease. </span><span class="cited-content_cbyCitation_journal-name">Research and Practice in Thrombosis and Haemostasis</span><span> <strong>2020,</strong> <em>4 </em>
                                    (4)
                                     , 469-480. <a href="https://doi.org/10.1002/rth2.12355" title="DOI URL">https://doi.org/10.1002/rth2.12355</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/rth2.12355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Frth2.12355%26sid%3Dliteratum%253Aachs%26jtitle%3DResearch%2520and%2520Practice%2520in%2520Thrombosis%2520and%2520Haemostasis%26atitle%3DPlasminogen%252Bactivation%252Bin%252Bthe%252Bmusculoskeletal%252Bacute%252Bphase%252Bresponse%25253A%252BInjury%25252C%252Brepair%25252C%252Band%252Bdisease%26aulast%3DGibson%26aufirst%3DBreanne%2BH.Y.%26date%3D2020%26date%3D2020%26volume%3D4%26issue%3D4%26spage%3D469%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haili  Lin</span>, <span class="hlFld-ContribAuthor ">Luning  Xu</span>, <span class="hlFld-ContribAuthor ">Shujuan  Yu</span>, <span class="hlFld-ContribAuthor ">Wanjin  Hong</span>, <span class="hlFld-ContribAuthor ">Mingdong  Huang</span>, <span class="hlFld-ContribAuthor ">Peng  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutics targeting the fibrinolytic system. </span><span class="cited-content_cbyCitation_journal-name">Experimental & Molecular Medicine</span><span> <strong>2020,</strong> <em>52 </em>
                                    (3)
                                     , 367-379. <a href="https://doi.org/10.1038/s12276-020-0397-x" title="DOI URL">https://doi.org/10.1038/s12276-020-0397-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s12276-020-0397-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs12276-020-0397-x%26sid%3Dliteratum%253Aachs%26jtitle%3DExperimental%2520%2526%2520Molecular%2520Medicine%26atitle%3DTherapeutics%252Btargeting%252Bthe%252Bfibrinolytic%252Bsystem%26aulast%3DLin%26aufirst%3DHaili%26date%3D2020%26date%3D2020%26volume%3D52%26issue%3D3%26spage%3D367%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Larry  Fliegel</span>. </span><span class="cited-content_cbyCitation_article-title">Role of pH Regulatory Proteins and Dysregulation of pH in Prostate Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1007/112_2020_18" title="DOI URL">https://doi.org/10.1007/112_2020_18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/112_2020_18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F112_2020_18%26sid%3Dliteratum%253Aachs%26atitle%3DRole%252Bof%252BpH%252BRegulatory%252BProteins%252Band%252BDysregulation%252Bof%252BpH%252Bin%252BProstate%252BCancer%26aulast%3DFliegel%26aufirst%3DLarry%26date%3D2020%26date%3D2020%26pub%3DSpringer%2520Berlin%2520Heidelberg%26date%3D2020%26date%3D2020%26volume%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benjamin J.  Buckley</span>, <span class="hlFld-ContribAuthor ">Hiwa  Majed</span>, <span class="hlFld-ContribAuthor ">Ashraf  Aboelela</span>, <span class="hlFld-ContribAuthor ">Elahe  Minaei</span>, <span class="hlFld-ContribAuthor ">Longguang  Jiang</span>, <span class="hlFld-ContribAuthor ">Karen  Fildes</span>, <span class="hlFld-ContribAuthor ">Chen-Yi  Cheung</span>, <span class="hlFld-ContribAuthor ">Darren  Johnson</span>, <span class="hlFld-ContribAuthor ">Daniel  Bachovchin</span>, <span class="hlFld-ContribAuthor ">Gregory M.  Cook</span>, <span class="hlFld-ContribAuthor ">Mingdong  Huang</span>, <span class="hlFld-ContribAuthor ">Marie  Ranson</span>, <span class="hlFld-ContribAuthor ">Michael J.  Kelso</span>. </span><span class="cited-content_cbyCitation_article-title">6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (24)
                                     , 126753. <a href="https://doi.org/10.1016/j.bmcl.2019.126753" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126753</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126753%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3D6-Substituted%252Bamiloride%252Bderivatives%252Bas%252Binhibitors%252Bof%252Bthe%252Burokinase-type%252Bplasminogen%252Bactivator%252Bfor%252Buse%252Bin%252Bmetastatic%252Bdisease%26aulast%3DBuckley%26aufirst%3DBenjamin%2BJ.%26date%3D2019%26volume%3D29%26issue%3D24%26spage%3D126753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kamal M  Dawood</span>. </span><span class="cited-content_cbyCitation_article-title">An update on benzofuran inhibitors: a patent review. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (11)
                                     , 841-870. <a href="https://doi.org/10.1080/13543776.2019.1673727" title="DOI URL">https://doi.org/10.1080/13543776.2019.1673727</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1673727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1673727%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DAn%252Bupdate%252Bon%252Bbenzofuran%252Binhibitors%25253A%252Ba%252Bpatent%252Breview%26aulast%3DDawood%26aufirst%3DKamal%2BM%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D11%26spage%3D841%26epage%3D870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neeraj N.  Patwardhan</span>, <span class="hlFld-ContribAuthor ">Zhengguo  Cai</span>, <span class="hlFld-ContribAuthor ">Aline  Umuhire Juru</span>, <span class="hlFld-ContribAuthor ">Amanda E.  Hargrove</span>. </span><span class="cited-content_cbyCitation_article-title">Driving factors in amiloride recognition of HIV RNA targets. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (42)
                                     , 9313-9320. <a href="https://doi.org/10.1039/C9OB01702J" title="DOI URL">https://doi.org/10.1039/C9OB01702J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB01702J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB01702J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DDriving%252Bfactors%252Bin%252Bamiloride%252Brecognition%252Bof%252BHIV%252BRNA%252Btargets%26aulast%3DPatwardhan%26aufirst%3DNeeraj%2BN.%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D42%26spage%3D9313%26epage%3D9320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benjamin J.  Buckley</span>, <span class="hlFld-ContribAuthor ">Umar  Ali</span>, <span class="hlFld-ContribAuthor ">Michael J.  Kelso</span>, <span class="hlFld-ContribAuthor ">Marie  Ranson</span>. </span><span class="cited-content_cbyCitation_article-title">The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets. </span><span class="cited-content_cbyCitation_journal-name">Current Drug Targets</span><span> <strong>2019,</strong> <em>20 </em>
                                    (9)
                                     , 970-981. <a href="https://doi.org/10.2174/1389450120666181204164140" title="DOI URL">https://doi.org/10.2174/1389450120666181204164140</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1389450120666181204164140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1389450120666181204164140%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Drug%2520Targets%26atitle%3DThe%252BUrokinase%252BPlasminogen%252BActivation%252BSystem%252Bin%252BRheumatoid%252BArthritis%25253A%252BPathophysiological%252BRoles%252Band%252BProspective%252BTherapeutic%252BTargets%26aulast%3DBuckley%26aufirst%3DBenjamin%2BJ.%26date%3D2019%26volume%3D20%26issue%3D9%26spage%3D970%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of reported uPA inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 6-(Hetero)aryl HMA Analogs <b>9</b>–<b>32</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (CH<sub>2</sub>)<sub>6</sub>NH, DIPEA, <i><sup>i</sup></i>PrOH, reflux, 2 h, 86%; (b) R-B(OH)<sub>2</sub> or R-B(pin), Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, toluene/MeOH (4:1), reflux, 0.5–18 h; (c) guanidine (2 M in MeOH), DMF, rt, 18 h.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 6-(2-(Alkylamino)pyrimidin-5-yl) Analogs <b>33</b>–<b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (2-chloropyrimidin-5-yl)boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, toluene/MeOH (4:1), reflux, 18 h, 64%; (b) (i) R-NH<sub>2</sub>, DIPEA, DMF, rt, 2 d or (ii) R-NH<sub>2</sub>, DIPEA, <i>i</i>-PrOH, reflux, 4 h, 83–87%; (c) guanidine (2 M in MeOH), DMF, rt, 18 h, 85–89%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 2-Aminopyrimidinyl Derivative <b>41</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (Boc)<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, DIPEA, DMAP, rt, 16 h, 85%; (b) Pd/C, H<sub>2</sub> (1 atm), MgO, MeOH, rt, 48 h, 92%; (c) <i>N</i>-bromosuccinimide, CH<sub>2</sub>Cl<sub>2</sub>, rt, 5 h, 60%; (d) 2-aminopyrimidine, Pd<sub>2</sub>(dba)<sub>3</sub>/Xantphos, 1,4-dioxane, Cs<sub>2</sub>CO<sub>3</sub>, 100 °C, 18 h, 30%; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 98%; (f) guanidine (2 M in MeOH), DMF, rt, 35%.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Inhibition of low molecular weight human uPA by <b>18</b> (black) and <b>27</b> (red). Data points represent the mean ± SEM (<i>n</i> = 3) from a single representative experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray cocrystal structures of (a) amiloride <b>4</b><a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(49)</a> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1F5L">1F5L</a>) and (b) HMA <b>5</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZA7">5ZA7</a>, 1.7 Å resolution) bound to uPA. Blue wire basket = 2<i>mF</i><sub>o</sub> – <i>DF</i><sub>C</sub> map contoured at 1.5σ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray cocrystal structures of: (a) <b>22</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAE">5ZAE</a>, 1.7 Å), (b) <b>23</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAF">5ZAF</a>, 1.7 Å), (c) <b>18</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZA9">5ZA9</a>, 1.6 Å), and (d) <b>19</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZC5">5ZC5</a>, 1.9 Å) bound to uPA. Blue wire baskets represent 2<i>mF</i><sub>o</sub> – <i>DF</i><sub>C</sub> maps contoured at 1.5σ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray cocrystal structures of (a) <b>25</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAG">5ZAG</a>, 2.0 Å), (b) <b>26</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAH">5ZAH</a>, 3.0 Å), (c) <b>27</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAJ">5ZAJ</a>, 1.7 Å), and (d) <b>14</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZA8">5ZA8</a>, 1.9 Å) bound to uPA. Blue wire baskets represent 2<i>mF</i><sub>o</sub> – <i>DF</i><sub>C</sub> maps contoured at 1.5σ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. EnPlex<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(54)</a> screening of amiloride <b>4</b>, HMA <b>5</b> and analogs <b>18</b>, <b>25</b>, and <b>26</b> for inhibition of 85 serine hydrolases. Gray boxes indicate wells in which no fluorescence was observed. The singular readouts suggesting activity of <b>4</b> and <b>26</b> against LIPE are artifacts. Black arrows indicate decreasing compound concentration from 33.3 μM to 10 nM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Single concentration screening (10 μM) of HMA <b>5</b> and 6-substituted HMA analogs as antagonists of the human adenosine A<sub>2A</sub> receptor (hA<sub>2A</sub>AR-WT). Radioligand [<sup>3</sup>H]ZM241385 was present at 2.5 nM. Total binding (TB, 100%) of [<sup>3</sup>H]ZM241385 was determined in the absence of inhibitors. Nonspecific binding (NSB, 0%) was determined in the presence of 100 μM A<sub>2A</sub> agonist 5′-(<i>N</i>-ethylcarboxamido)adenosine (NECA). Data represent the mean ± SEM from at least three independent experiments conducted in duplicate. Methods were as described in ref <a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(61)</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inhibition of ENaC activity by amiloride <b>4</b>, HMA <b>5</b> and 6-substituted analogs <b>11</b>, <b>18</b>, <b>25</b>, and <b>26</b> in transfected HEK-293 cells. All compounds were present at 10 μM. Data represent the mean ± SD (<i>n</i> = 4).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Effects of amiloride <b>4</b>, HMA <b>5</b>, and 6-substituted analogs <b>18</b> and <b>26</b> on urine flow and excretion of Na<sup>+</sup> and K<sup>+</sup> in Sprague Dawley rats. Rats were dosed with 25 mg/kg acetazolamide prior to administering 1.5 mg/kg of test compound. Data represent the mean ± SEM (<i>n</i> = 8): (∗∗) <i>p</i> < 0.001, (∗∗∗∗) <i>p</i> < 0.0001 relative to acetazolamide control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Effects of amiloride <b>4</b>, <b>18</b>, and <b>26</b> in experimental mouse model of late-stage lung metastasis. All compounds were administered once daily at 7.5 mg kg<sup>–1</sup> day<sup>–1</sup> for 21 days. Lung metastasis was quantified by end point luciferase assay of lung homogenates. Data represent the mean ± SEM (<b>18</b> and <b>26</b><i>n</i> = 6; vehicle and <b>4</b><i>n</i> = 4): (∗) <i>p</i> < 0.03; (∗∗∗) <i>p</i> < 0.001 relative to vehicle control, (∧) <i>p</i> < 0.03 relative to <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/medium/jm-2018-00838t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Effects of gemcitabine (Gem), <b>18</b>, and <b>26</b> on end point primary tumor volume in an orthotopic xenograft pancreatic cancer model. Mice received oral gemcitabine 75 mg/kg twice weekly or daily intraperitoneal injections of <b>18</b> or <b>26</b> (10 mg/kg) for 28 days. Data represent the mean ± SEM (<i>n</i> = 4 per group). (B) Number of mice with histologically confirmed liver metastases after receiving gemcitabine, <b>18</b>, and <b>26</b> (<i>n</i> = 4 per group): (∗) <i>p</i> = 0.0285 vs vehicle, χ<sup>2</sup> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00838/20180920/images/large/jm-2018-00838t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00838&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i100">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31445" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31445" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 84 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ulisse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrenti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Armiento, M.</span></span> <span> </span><span class="NLM_article-title">The urokinase plasminogen activator system: a target for anti-cancer therapy</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.2174/156800909787314002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.2174%2F156800909787314002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=19200050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1Wjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=32-71&issue=1&author=S.+Ulisseauthor=E.+Baldiniauthor=S.+Sorrentiauthor=M.+D%E2%80%99Armiento&title=The+urokinase+plasminogen+activator+system%3A+a+target+for+anti-cancer+therapy&doi=10.2174%2F156800909787314002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The urokinase plasminogen activator system: a target for anti-cancer therapy</span></div><div class="casAuthors">Ulisse, Salvatore; Baldini, Enke; Sorrenti, Salvatore; D'Armiento, Massimino</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-71</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The urokinase plasminogen activator (uPA) system (uPAS) consists of the uPA, its cognate receptor (uPAR) and two specific inhibitors, the plasminogen activator inhibitor 1 (PAI-1) and 2 (PAI-2).  The uPA converts the proenzyme plasminogen in the serine protease plasmin, involved in a no. of physiopathol. processes requiring basement membrane (BM) and/or extracellular matrix (ECM) remodelling, including tumor progression and metastasis.  Data accumulated over the past years have made increasingly clear that the uPAS has a multifunctional task in the neoplastic evolution, affecting tumor angiogenesis, malignant cell proliferation, adhesion and migration, intravasation and growth at the metastatic site.  In agreement with their role in cancer progression and metastasis, an increased expression of uPA, uPAR, and PAI-1 has been documented in several malignant tumors, and a pos. correlation between the levels of one or more uPAS members and a poor prognosis has been frequently reported.  This is particularly evident in breast cancer, for which uPA has been demonstrated to be the most potent independent prognostic factor described to date.  The involvement of the uPAS in cancer progression identifies its components as suitable targets for anti-cancer therapy.  Several therapeutical approaches aimed at inhibiting the uPA/uPAR functions have been shown to possess anti-tumor effects in xenograft models, including selective inhibitors of uPA activity, antagonist peptides, monoclonal antibodies able to prevent uPA binding to uPAR and gene therapy techniques silencing uPA/uPAR expression.  All these strategies, however, although promising, need definitive confirmation in humans as, up to now, only few uPA inhibitors entered clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra2dQsy6IUN7Vg90H21EOLACvtfcHk0lhBo1fXdn7cyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1Wjsr8%253D&md5=7fb917600d9bc1b0ec5751822c401e59</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F156800909787314002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156800909787314002%26sid%3Dliteratum%253Aachs%26aulast%3DUlisse%26aufirst%3DS.%26aulast%3DBaldini%26aufirst%3DE.%26aulast%3DSorrenti%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Armiento%26aufirst%3DM.%26atitle%3DThe%2520urokinase%2520plasminogen%2520activator%2520system%253A%2520a%2520target%2520for%2520anti-cancer%2520therapy%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2009%26volume%3D9%26issue%3D1%26spage%3D32%26epage%3D71%26doi%3D10.2174%2F156800909787314002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brungs, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghmesheh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vine, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carolan, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span> <span> </span><span class="NLM_article-title">The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">23099</span>– <span class="NLM_lpage">23109</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.15485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.18632%2Foncotarget.15485" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=23099-23109&issue=14&author=D.+Brungsauthor=J.+Chenauthor=M.+Aghmeshehauthor=K.+L.+Vineauthor=T.+M.+Beckerauthor=M.+G.+Carolanauthor=M.+Ranson&title=The+urokinase+plasminogen+activation+system+in+gastroesophageal+cancer%3A+A+systematic+review+and+meta-analysis&doi=10.18632%2Foncotarget.15485"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.15485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.15485%26sid%3Dliteratum%253Aachs%26aulast%3DBrungs%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DAghmesheh%26aufirst%3DM.%26aulast%3DVine%26aufirst%3DK.%2BL.%26aulast%3DBecker%26aufirst%3DT.%2BM.%26aulast%3DCarolan%26aufirst%3DM.%2BG.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DThe%2520urokinase%2520plasminogen%2520activation%2520system%2520in%2520gastroesophageal%2520cancer%253A%2520A%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D14%26spage%3D23099%26epage%3D23109%26doi%3D10.18632%2Foncotarget.15485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Croucher, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span> <span> </span><span class="NLM_article-title">Revisiting the biological roles of PAI2 (SERPINB2) in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1038/nrc2400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1038%2Fnrc2400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=18548086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFOkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=535-545&issue=7&author=D.+R.+Croucherauthor=D.+N.+Saundersauthor=S.+Lobovauthor=M.+Ranson&title=Revisiting+the+biological+roles+of+PAI2+%28SERPINB2%29+in+cancer&doi=10.1038%2Fnrc2400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting the biological roles of PAI2 (SERPINB2) in cancer</span></div><div class="casAuthors">Croucher, David R.; Saunders, Darren N.; Lobov, Sergei; Ranson, Marie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">535-545</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor expression of the urokinase plasminogen activator correlates with invasive capacity.  Consequently, inhibition of this serine protease by physiol. inhibitors should decrease invasion and metastasis.  However, of the two main urokinase inhibitors, high tumor levels of the type 1 inhibitor actually promote tumor progression, whereas high levels of the type 2 inhibitor decrease tumor growth and metastasis.  We propose that the basis of this apparently paradoxical action of two similar serine protease inhibitors lies in key structural differences controlling interactions with components of the extracellular matrix and endocytosis-signaling co-receptors.  Of the two main urokinase plasminogen activator inhibitors, high tumor levels of the type 1 inhibitor promote tumor progression, whereas high levels of the type 2 inhibitor decrease tumor growth and metastasis.  What might be the basis of this paradoxical action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi0c6ydaFqRrVg90H21EOLACvtfcHk0lhBo1fXdn7cyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFOkt7o%253D&md5=3e6a3c1e8760dc75f203540ba87f69f4</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2400%26sid%3Dliteratum%253Aachs%26aulast%3DCroucher%26aufirst%3DD.%2BR.%26aulast%3DSaunders%26aufirst%3DD.%2BN.%26aulast%3DLobov%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DRevisiting%2520the%2520biological%2520roles%2520of%2520PAI2%2520%2528SERPINB2%2529%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26issue%3D7%26spage%3D535%26epage%3D545%26doi%3D10.1038%2Fnrc2400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, N. L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vennin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, J. R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vine, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shearer, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allam, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pajic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, J. P.</span></span>; <span class="NLM_contrib-group">Australian Pancreatic Cancer Genome Initiative</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biankin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timpson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D. N.</span></span> <span> </span><span class="NLM_article-title">SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">4288</span>– <span class="NLM_lpage">4298</span>, <span class="refDoi"> DOI: 10.1038/onc.2017.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1038%2Fonc.2017.63" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=4288-4298&issue=30&author=N.+L.+E.+Harrisauthor=C.+Venninauthor=J.+R.+W.+Conwayauthor=K.+L.+Vineauthor=M.+Pineseauthor=M.+J.+Cowleyauthor=R.+F.+Shearerauthor=M.+C.+Lucasauthor=D.+Herrmannauthor=A.+H.+Allamauthor=M.+Pajicauthor=J.+P.+Mortonauthor=Australian+Pancreatic+Cancer+Genome+Initiativeauthor=A.+V.+Biankinauthor=M.+Ransonauthor=P.+Timpsonauthor=D.+N.+Saunders&title=SerpinB2+regulates+stromal+remodelling+and+local+invasion+in+pancreatic+cancer&doi=10.1038%2Fonc.2017.63"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fonc.2017.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2017.63%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DN.%2BL.%2BE.%26aulast%3DVennin%26aufirst%3DC.%26aulast%3DConway%26aufirst%3DJ.%2BR.%2BW.%26aulast%3DVine%26aufirst%3DK.%2BL.%26aulast%3DPinese%26aufirst%3DM.%26aulast%3DCowley%26aufirst%3DM.%2BJ.%26aulast%3DShearer%26aufirst%3DR.%2BF.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DHerrmann%26aufirst%3DD.%26aulast%3DAllam%26aufirst%3DA.%2BH.%26aulast%3DPajic%26aufirst%3DM.%26aulast%3DMorton%26aufirst%3DJ.%2BP.%26aulast%3D%26aulast%3DBiankin%26aufirst%3DA.%2BV.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DTimpson%26aufirst%3DP.%26aulast%3DSaunders%26aufirst%3DD.%2BN.%26atitle%3DSerpinB2%2520regulates%2520stromal%2520remodelling%2520and%2520local%2520invasion%2520in%2520pancreatic%2520cancer%26jtitle%3DOncogene%26date%3D2017%26volume%3D36%26issue%3D30%26spage%3D4288%26epage%3D4298%26doi%3D10.1038%2Fonc.2017.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seetoo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berney, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ham, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, P. J.</span></span> <span> </span><span class="NLM_article-title">Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1002/1097-0215(20000920)89:5<431::AID-IJC6>3.0.CO;2-V</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1002%2F1097-0215%2820000920%2989%3A5%3C431%3A%3AAID-IJC6%3E3.0.CO%3B2-V" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=11008205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnsFWmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2000&pages=431-439&issue=5&author=J.+L.+Yangauthor=D.+Seetooauthor=Y.+Wangauthor=M.+Ransonauthor=C.+R.+Berneyauthor=J.+M.+Hamauthor=P.+J.+Russellauthor=P.+J.+Crowe&title=Urokinase-type+plasminogen+activator+and+its+receptor+in+colorectal+cancer%3A+independent+prognostic+factors+of+metastasis+and+cancer-specific+survival+and+potential+therapeutic+targets&doi=10.1002%2F1097-0215%2820000920%2989%3A5%3C431%3A%3AAID-IJC6%3E3.0.CO%3B2-V"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets</span></div><div class="casAuthors">Yang, Jia-Lin; Seetoo, Da-qiang; Wang, Yao; Ranson, Marie; Berney, Christophe R.; Ham, John M.; Russell, Pamela J.; Crowe, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">431-439</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Urokinase-type plasminogen activator (uPA) and its receptor (uPAR), plasminogen (Plg), and plasminogen activator inhibitors-1 and -2 (PAI-1 and PAI-2) were obsd. in many cancers and may contribute to progression and metastasis.  In this study, the authors examd. the expression of the 5 proteins by immunohistochem. in 59 consecutive primary colorectal cancers (CRC) and correlated the protein expression with patient outcome.  In addn., the authors detd. the effect of down-regulation of uPAR on the invasive/metastatic capability of CRC cells, by measuring antisense-uPAR transfected HCT116 and control cell lines, in terms of uPAR expression, uPA-binding activity, invasiveness through Matrigel in vitro and metastasis after cecal orthotopic implantation in nude mice in vivo.  The authors found that higher expression of uPA or uPAR in primary tumor tissues was pos. correlated with distant metastasis of CRC (Mann-Whitney, p < 0.02) and neg. correlated with both patient overall survival (OS) and cancer-specific survival (CSS; Cox model, p < 0.04).  The prognostic value of uPA and uPAR for both OS and CSS was independent of other variables (multivariate Cox model, p < 0.007).  Antisense-uPAR transfected HCT116 cells, which expressed significantly lower levels of total cellular and cell surface uPAR proteins and uPA-binding activity compared with either wild-type or cells transfected with vector alone (Bonferroni, p < 0.05/3), consistently showed decreased invasiveness through Matrigel (Bonferroni, p < 0.05/3) and decreased metastasis formation in nude mice (Fisher, p < 0.05).  These data suggest that uPAR and uPA are independent prognostic factors in CRC; anti-uPAR treatment, which affects both uPAR and uPA levels, may have potential for new treatment of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBhJJx-EBpm7Vg90H21EOLACvtfcHk0ljwf0tMP45E6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnsFWmsrY%253D&md5=be98ec0cf73d21ec4744bca274a02364</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2F1097-0215%2820000920%2989%3A5%3C431%3A%3AAID-IJC6%3E3.0.CO%3B2-V&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0215%252820000920%252989%253A5%253C431%253A%253AAID-IJC6%253E3.0.CO%253B2-V%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%2BL.%26aulast%3DSeetoo%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DBerney%26aufirst%3DC.%2BR.%26aulast%3DHam%26aufirst%3DJ.%2BM.%26aulast%3DRussell%26aufirst%3DP.%2BJ.%26aulast%3DCrowe%26aufirst%3DP.%2BJ.%26atitle%3DUrokinase-type%2520plasminogen%2520activator%2520and%2520its%2520receptor%2520in%2520colorectal%2520cancer%253A%2520independent%2520prognostic%2520factors%2520of%2520metastasis%2520and%2520cancer-specific%2520survival%2520and%2520potential%2520therapeutic%2520targets%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2000%26volume%3D89%26issue%3D5%26spage%3D431%26epage%3D439%26doi%3D10.1002%2F1097-0215%2820000920%2989%3A5%3C431%3A%3AAID-IJC6%3E3.0.CO%3B2-V" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsche, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravdin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somerfield, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bast, R. C.,  Jr.</span></span> <span> </span><span class="NLM_article-title">American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">33</span>),  <span class="NLM_fpage">5287</span>– <span class="NLM_lpage">5312</span>, <span class="refDoi"> DOI: 10.1200/JCO.2007.14.2364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1200%2FJCO.2007.14.2364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=17954709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKnsbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=5287-5312&issue=33&author=L.+Harrisauthor=H.+Fritscheauthor=R.+Mennelauthor=L.+Nortonauthor=P.+Ravdinauthor=S.+Taubeauthor=M.+R.+Somerfieldauthor=D.+F.+Hayesauthor=R.+C.+Bast&title=American+society+of+clinical+oncology+2007+update+of+recommendations+for+the+use+of+tumor+markers+in+breast+cancer&doi=10.1200%2FJCO.2007.14.2364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer</span></div><div class="casAuthors">Harris, Lyndsay; Fritsche, Herbert; Mennel, Robert; Norton, Larry; Ravdin, Peter; Taube, Sheila; Somerfield, Mark R.; Hayes, Daniel F.; Bast, Robert C., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5287-5312</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Purpose: To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer.  Methods: For the 2007 update, an Update Committee composed of members from the full Panel was formed to complete the review and anal. of data published since 1999.  Computerized literature searches of MEDLINE and the Cochrane Collaboration Library were performed.  The Update Committee's literature review focused attention on available systematic reviews and meta analyses of published tumor marker studies.  In general, significant health outcomes (overall survival, disease-free survival, quality of life, lesser toxicity, and cost-effectiveness) were used for making recommendations.  Recommendations and Conclusions: Thirteen categories of breast tumor markers were considered, six of which were new for the guideline.  The following categories showed evidence of clin. utility and were recommended for use in practice: CA 15-3, CA 27.29, carcinoembryonic antigen, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, urokinase plasminogen activator, plasminogen activator inhibitor 1, and certain multiparameter gene expression assays.  Not all applications for these markers were supported, however.  The following categories demonstrated insufficient evidence to support routine use in clin. practice: DNA/ploidy by flow cytometry, p53, cathepsin D, cyclin E, proteomics, certain multiparameter assays, detection of bone marrow micrometastases, and circulating tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJw2_N7FeeLrVg90H21EOLACvtfcHk0ljwf0tMP45E6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKnsbzK&md5=194b8cd7564003cb9519cb7df2c54818</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.14.2364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.14.2364%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DL.%26aulast%3DFritsche%26aufirst%3DH.%26aulast%3DMennel%26aufirst%3DR.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DRavdin%26aufirst%3DP.%26aulast%3DTaube%26aufirst%3DS.%26aulast%3DSomerfield%26aufirst%3DM.%2BR.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DBast%26aufirst%3DR.%2BC.%26atitle%3DAmerican%2520society%2520of%2520clinical%2520oncology%25202007%2520update%2520of%2520recommendations%2520for%2520the%2520use%2520of%2520tumor%2520markers%2520in%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26issue%3D33%26spage%3D5287%26epage%3D5312%26doi%3D10.1200%2FJCO.2007.14.2364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Look, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Putten, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbeck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomssen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kates, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyratos, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eppenberger-Castori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweep, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrat, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magdelenat, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisboa, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendahl, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quillien, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricolleau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer-van Gelder, M.
E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manders, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiets, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blankenstein, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daxenbichler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windbichler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cufer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borstnar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kueng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beex, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klijn, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Higgins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eppenberger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janicke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foekens, J. A.</span></span> <span> </span><span class="NLM_article-title">Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients</span>. <i>J. Natl. Cancer. Inst.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1093/jnci/94.2.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1093%2Fjnci%2F94.2.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=11792750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD38Xit1amt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2002&pages=116-128&issue=2&author=M.+P.+Lookauthor=W.+L.+van+Puttenauthor=M.+J.+Duffyauthor=N.+Harbeckauthor=I.+J.+Christensenauthor=C.+Thomssenauthor=R.+Katesauthor=F.+Spyratosauthor=M.+Fernoauthor=S.+Eppenberger-Castoriauthor=C.+G.+Sweepauthor=K.+Ulmauthor=J.+P.+Peyratauthor=P.+M.+Martinauthor=H.+Magdelenatauthor=N.+Brunnerauthor=C.+Dugganauthor=B.+W.+Lisboaauthor=P.+O.+Bendahlauthor=V.+Quillienauthor=A.+Daverauthor=G.+Ricolleauauthor=M.%0AE.+Meijer-van+Gelderauthor=P.+Mandersauthor=W.+E.+Fietsauthor=M.+A.+Blankensteinauthor=P.+Broetauthor=S.+Romainauthor=G.+Daxenbichlerauthor=G.+Windbichlerauthor=T.+Cuferauthor=S.+Borstnarauthor=W.+Kuengauthor=L.+V.+Beexauthor=J.+G.+Klijnauthor=N.+O%E2%80%99Higginsauthor=U.+Eppenbergerauthor=F.+Janickeauthor=M.+Schmittauthor=J.+A.+Foekens&title=Pooled+analysis+of+prognostic+impact+of+urokinase-type+plasminogen+activator+and+its+inhibitor+PAI-1+in+8377+breast+cancer+patients&doi=10.1093%2Fjnci%2F94.2.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients</span></div><div class="casAuthors">Look, Maxime P.; van Putten, Wim L. J.; Duffy, Michael J.; Harbeck, Nadia; Christensen, Ib Jarle; Thomssen, Christoph; Kates, Ronald; Spyratos, Frederique; Ferno, Marten; Eppenberger-Castori, Serenella; Sweep, C. G. J.; Ulm, Kurt; Peyrat, Jean-Philippe; Martin, Pierre-Marie; Magdelenat, Henri; Brunner, Nils; Duggan, Catherine; Lisboa, Bjorn W.; Bendahl, Par-Ola; Quillien, Veronique; Daver, Alain; Ricolleau, Gabriel; Meijer-van Gelder, Marion E.; Manders, Peggy; Fiets, W. Edward; Blankenstein, Marinus A.; Broet, Philippe; Romain, Sylvie; Daxenbichler, Gunter; Windbichler, Gudrun; Cufer, Tanja; Borstnar, Simona; Kueng, Willy; Beex, Louk V. A. M.; Klijn, Jan G. M.; O'Higgins, Niall; Eppenberger, Urs; Janicke, Fritz; Schmitt, Manfred; Foekens, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-128</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) play essential roles in tumor invasion and metastasis.  High levels of both uPA and PAI-1 are assocd. with poor prognosis in breast cancer patients.  To confirm the prognostic value of uPA and PAI-1 in primary breast cancer, the authors reanalyzed individual patient data provided by members of the European Organization for Research and Treatment of Cancer-Receptor and Biomarker Group (EORTC-RBG).  The study included 18 datasets involving 8377 breast cancer patients.  During follow-up (median 79 mo), 35% of the patients relapsed and 27% died.  Levels of uPA and PAI-1 in tumor tissue exts. were detd. by different immunoassays; values were ranked within each dataset and divided by the no. of patients in that dataset to produce fractional ranks that could be compared directly across datasets.  Assocns. of ranks of uPA and PAI-1 levels with relapse-free survival (RFS) and overall survival (OS) were analyzed by Cox multivariable regression anal. stratified by dataset, including the following traditional prognostic variables: age, menopausal status, lymph node status, tumor size, histol. grade, and steroid hormone-receptor status.  All P values were two-sided.  Apart from lymph node status, high levels of uPA and PAI-1 were the strongest predictors of both poor RFS and poor OS in the analyses of all patients.  Moreover, in both lymph node-pos. and lymph node-neg. patients, higher uPA and PAI-1 values were independently assocd. with poor RFS and poor OS.  For (untreated) lymph node-neg. patients in particular, uPA and PAI-1 included together showed strong prognostic ability (all P<.001).  This pooled anal. of the EORTC-RBG datasets confirmed the strong and independent prognostic value of uPA and PAI-1 in primary breast cancer.  For patients with lymph node-neg. breast cancer, uPA and PAI-1 measurements in primary tumors may be esp. useful for designing individualized treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUHv67JMd3wbVg90H21EOLACvtfcHk0lj1Fo3w7u8mlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xit1amt7s%253D&md5=4a607778acf517db8947cf683122d741</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F94.2.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F94.2.116%26sid%3Dliteratum%253Aachs%26aulast%3DLook%26aufirst%3DM.%2BP.%26aulast%3Dvan%2BPutten%26aufirst%3DW.%2BL.%26aulast%3DDuffy%26aufirst%3DM.%2BJ.%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DChristensen%26aufirst%3DI.%2BJ.%26aulast%3DThomssen%26aufirst%3DC.%26aulast%3DKates%26aufirst%3DR.%26aulast%3DSpyratos%26aufirst%3DF.%26aulast%3DFerno%26aufirst%3DM.%26aulast%3DEppenberger-Castori%26aufirst%3DS.%26aulast%3DSweep%26aufirst%3DC.%2BG.%26aulast%3DUlm%26aufirst%3DK.%26aulast%3DPeyrat%26aufirst%3DJ.%2BP.%26aulast%3DMartin%26aufirst%3DP.%2BM.%26aulast%3DMagdelenat%26aufirst%3DH.%26aulast%3DBrunner%26aufirst%3DN.%26aulast%3DDuggan%26aufirst%3DC.%26aulast%3DLisboa%26aufirst%3DB.%2BW.%26aulast%3DBendahl%26aufirst%3DP.%2BO.%26aulast%3DQuillien%26aufirst%3DV.%26aulast%3DDaver%26aufirst%3DA.%26aulast%3DRicolleau%26aufirst%3DG.%26aulast%3DMeijer-van%2BGelder%26aufirst%3DM.%2BE.%26aulast%3DManders%26aufirst%3DP.%26aulast%3DFiets%26aufirst%3DW.%2BE.%26aulast%3DBlankenstein%26aufirst%3DM.%2BA.%26aulast%3DBroet%26aufirst%3DP.%26aulast%3DRomain%26aufirst%3DS.%26aulast%3DDaxenbichler%26aufirst%3DG.%26aulast%3DWindbichler%26aufirst%3DG.%26aulast%3DCufer%26aufirst%3DT.%26aulast%3DBorstnar%26aufirst%3DS.%26aulast%3DKueng%26aufirst%3DW.%26aulast%3DBeex%26aufirst%3DL.%2BV.%26aulast%3DKlijn%26aufirst%3DJ.%2BG.%26aulast%3DO%25E2%2580%2599Higgins%26aufirst%3DN.%26aulast%3DEppenberger%26aufirst%3DU.%26aulast%3DJanicke%26aufirst%3DF.%26aulast%3DSchmitt%26aufirst%3DM.%26aulast%3DFoekens%26aufirst%3DJ.%2BA.%26atitle%3DPooled%2520analysis%2520of%2520prognostic%2520impact%2520of%2520urokinase-type%2520plasminogen%2520activator%2520and%2520its%2520inhibitor%2520PAI-1%2520in%25208377%2520breast%2520cancer%2520patients%26jtitle%3DJ.%2520Natl.%2520Cancer.%2520Inst.%26date%3D2002%26volume%3D94%26issue%3D2%26spage%3D116%26epage%3D128%26doi%3D10.1093%2Fjnci%2F94.2.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foekens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portengen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janicke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer-van Gelder, M.
E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henzen-Logmans, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Putten, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klijn, J. G.</span></span> <span> </span><span class="NLM_article-title">The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients</span>. <i>Cancer. Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">636</span>– <span class="NLM_lpage">643</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10676647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht1GmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=636-643&issue=3&author=J.+A.+Foekensauthor=H.+A.+Petersauthor=M.+P.+Lookauthor=H.+Portengenauthor=M.+Schmittauthor=M.+D.+Kramerauthor=N.+Brunnerauthor=F.+Janickeauthor=M.%0AE.+Meijer-van+Gelderauthor=S.+C.+Henzen-Logmansauthor=W.+L.+van+Puttenauthor=J.+G.+Klijn&title=The+urokinase+system+of+plasminogen+activation+and+prognosis+in+2780+breast+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients</span></div><div class="casAuthors">Foekens, John A.; Peters, Harry A.; Look, Maxime P.; Portengen, Henk; Schmitt, Manfred; Kramer, Michael D.; Brunner, Nils; Janicke, Fritz; Gelder, Marion E. Meijer-Van; Henzen-Logmans, Sonja C.; Van Putten, Wim L. J.; Klijn, Jan G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">636-643</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">The antigen levels of components of the urokinase-type plasminogen activator (uPA) system of plasminogen activation are correlated with prognosis in several types of cancers, including breast cancer.  In the present study involving 2780 patients with primary invasive breast cancer, we have evaluated the prognostic importance of the four major components of the uPA system [uPA, the receptor uPAR (CD87), and the inhibitors PAI-1 and PAI-2].  The antigen levels were detd. by ELISA in cytosols prepd. from primary breast tumors.  The levels of the four factors significantly correlated with each other; the Spearman rank correlation coeffs. (rs) ranged from 0.32 (between PAI-2 and PAI-1 or uPAR) to 0.59 (between uPA and PAI-1).  The median duration of follow-up of patients still alive was 88 mo.  In the multivariate analyses for relapse-free survival (RFS) and overall survival (OS), we defined a basic model including age, menopausal status, tumor size and grade, lymph node status, adjuvant therapy, and steroid hormone receptor status.  UPA, uPAR, PAI-1, and PAI-2 were considered as categorical variables, each with two cut points that were established by isotonic regression anal.  Compared with tumors with low levels, those with intermediate and high levels showed a relative hazard rate (RHR) and 95% confidence interval (95% CI) of 1.22 (1.02-1.45) and 1.69 (1.39-2.05) for uPA, and 1.32 (1.14-1.54) and 2.17 (1.74-2.70) for PAI-1, resp., in multivariate anal. for RFS in all patients.  Compared with tumors with high PAI-2 levels, those with intermediate and low levels showed a poor RFS with a RHR (95% CI) of 1.30 (1.14-1.48) and 1.76 (1.38-2.24), resp.  Similar results were obtained in the multivariate anal. for OS in all patients.  Furthermore, uPA and PAI-1 were independent predictive factors of a poor RFS and OS in node-neg. and node-pos. patients.  PAI-2 also added to the multivariate models for RFS in node-neg. and node-pos. patients, and in the anal. for OS in node-neg. patients.  UPAR did not further contribute to any of the multivariate models.  A prognostic score was calcd. based on the ests. from the final multivariate model for RFS.  Using this score, the difference between the highest and lowest 10% risk groups was 66% in the anal. for RFS at 10 yr and 61% in the anal. for OS.  Moreover, sep. prognostic scores were calcd. for node-neg. and node-pos. patients.  In the 10% highest risk groups, the proportion of disease-free patients was only 27±6% and 9±3% at 10 yr for node-neg. and node-pos. patients, resp.  These proportions were 86±4% and 61±6% for the corresponding 10% lowest risk groups of relapse.  We conclude that several components of the uPA system are potential predictors of RFS and OS in patients with primary invasive breast cancer.  Knowledge of these factors could be helpful to assess the individual risk of patients, to select various types of adjuvant treatment and to identify patients who may benefit from targeted therapies that are currently being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLtE82O-8T47Vg90H21EOLACvtfcHk0lj1Fo3w7u8mlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht1GmtLk%253D&md5=ee7094ecddd28d8f0f0cf13efe9dbd9c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFoekens%26aufirst%3DJ.%2BA.%26aulast%3DPeters%26aufirst%3DH.%2BA.%26aulast%3DLook%26aufirst%3DM.%2BP.%26aulast%3DPortengen%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DM.%26aulast%3DKramer%26aufirst%3DM.%2BD.%26aulast%3DBrunner%26aufirst%3DN.%26aulast%3DJanicke%26aufirst%3DF.%26aulast%3DMeijer-van%2BGelder%26aufirst%3DM.%2BE.%26aulast%3DHenzen-Logmans%26aufirst%3DS.%2BC.%26aulast%3Dvan%2BPutten%26aufirst%3DW.%2BL.%26aulast%3DKlijn%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520urokinase%2520system%2520of%2520plasminogen%2520activation%2520and%2520prognosis%2520in%25202780%2520breast%2520cancer%2520patients%26jtitle%3DCancer.%2520Res.%26date%3D2000%26volume%3D60%26issue%3D3%26spage%3D636%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Grady, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devaney, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Siorain, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennelly, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lijnen, H. J.</span></span> <span> </span><span class="NLM_article-title">Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1002%2F1097-0142%2819880801%2962%3A3%3C531%3A%3AAID-CNCR2820620315%3E3.0.CO%3B2-B" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1988&pages=531-533&issue=3&author=M.+J.+Duffyauthor=P.+O%E2%80%99Gradyauthor=D.+Devaneyauthor=L.+O%E2%80%99Siorainauthor=J.+J.+Fennellyauthor=H.+J.+Lijnen&title=Urokinase-plasminogen+activator%2C+a+marker+for+aggressive+breast+carcinomas.+Preliminary+report&doi=10.1002%2F1097-0142%2819880801%2962%3A3%3C531%3A%3AAID-CNCR2820620315%3E3.0.CO%3B2-B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2F1097-0142%2819880801%2962%3A3%3C531%3A%3AAID-CNCR2820620315%3E3.0.CO%3B2-B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0142%252819880801%252962%253A3%253C531%253A%253AAID-CNCR2820620315%253E3.0.CO%253B2-B%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DM.%2BJ.%26aulast%3DO%25E2%2580%2599Grady%26aufirst%3DP.%26aulast%3DDevaney%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Siorain%26aufirst%3DL.%26aulast%3DFennelly%26aufirst%3DJ.%2BJ.%26aulast%3DLijnen%26aufirst%3DH.%2BJ.%26atitle%3DUrokinase-plasminogen%2520activator%252C%2520a%2520marker%2520for%2520aggressive%2520breast%2520carcinomas.%2520Preliminary%2520report%26jtitle%3DCancer%26date%3D1988%26volume%3D62%26issue%3D3%26spage%3D531%26epage%3D533%26doi%3D10.1002%2F1097-0142%2819880801%2962%3A3%3C531%3A%3AAID-CNCR2820620315%3E3.0.CO%3B2-B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Estreicher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhlhauser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpentier, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassalli, J. D.</span></span> <span> </span><span class="NLM_article-title">The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1083/jcb.111.2.783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1083%2Fjcb.111.2.783" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1990&pages=783-792&issue=2&author=A.+Estreicherauthor=J.+Muhlhauserauthor=J.+L.+Carpentierauthor=L.+Orciauthor=J.+D.+Vassalli&title=The+receptor+for+urokinase+type+plasminogen+activator+polarizes+expression+of+the+protease+to+the+leading+edge+of+migrating+monocytes+and+promotes+degradation+of+enzyme+inhibitor+complexes&doi=10.1083%2Fjcb.111.2.783"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1083%2Fjcb.111.2.783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.111.2.783%26sid%3Dliteratum%253Aachs%26aulast%3DEstreicher%26aufirst%3DA.%26aulast%3DMuhlhauser%26aufirst%3DJ.%26aulast%3DCarpentier%26aufirst%3DJ.%2BL.%26aulast%3DOrci%26aufirst%3DL.%26aulast%3DVassalli%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520receptor%2520for%2520urokinase%2520type%2520plasminogen%2520activator%2520polarizes%2520expression%2520of%2520the%2520protease%2520to%2520the%2520leading%2520edge%2520of%2520migrating%2520monocytes%2520and%2520promotes%2520degradation%2520of%2520enzyme%2520inhibitor%2520complexes%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1990%26volume%3D111%26issue%3D2%26spage%3D783%26epage%3D792%26doi%3D10.1083%2Fjcb.111.2.783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lund, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurison, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer-Hansen, G.</span></span> <span> </span><span class="NLM_article-title">uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1744</span>– <span class="NLM_lpage">1760</span>, <span class="refDoi"> DOI: 10.2174/138945011797635902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.2174%2F138945011797635902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=21707477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVSrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=1744-1760&issue=12&author=I.+K.+Lundauthor=M.+Illemannauthor=T.+Thurisonauthor=I.+J.+Christensenauthor=G.+Hoyer-Hansen&title=uPAR+as+anti-cancer+target%3A+evaluation+of+biomarker+potential%2C+histological+localization%2C+and+antibody-based+therapy&doi=10.2174%2F138945011797635902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy</span></div><div class="casAuthors">Lund, Ida K.; Illemann, Martin; Thurison, Tine; Christensen, Ib J.; Hoeyer-Hansen, Gunilla</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1744-1760</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Degrdn. of proteins in the extracellular matrix is crucial for the multistep process of cancer invasion and metastasis.  Compelling evidence has demonstrated the urokinase receptor (uPAR) and its cognate ligand, the urokinase plasminogen activator (uPA), to play crit. roles in the concerted action of several proteolytic systems in generation of a high proteolytic potential required for tissue remodeling processes.  UPAR is addnl. cleaved by uPA on the cell surface, liberating domain I, resulting in abrogated pericellular proteolysis.  The expression of both uPAR and uPA is significantly up-regulated during cancer progression and is primarily confined to the tumor-assocd. stromal compartment.  Furthermore, both uPAR and uPA have proven to be prognostic markers in several types of cancer; high levels indicating poor survival.  The cleaved forms of uPAR are also prognostic markers, and a potential diagnostic and predictive impact of the different uPAR forms has been reported.  Hence, pericellular proteolysis seems to be a suitable target for anti-cancer therapy and numerous approaches have been pursued.  Targeting of this process may be achieved by preventing the binding of uPA to uPAR on the cell surface and/or by direct inhibition of the catalytic activity of uPA.  Both strategies have been pursued and inhibition of these functions has shown effect in xenogenic cancer models.  Pericellular proteolysis has also been inhibited in vivo in mouse models of wound healing and hepatic fibrinolysis using mouse monoclonal antibodies (mAbs) against mouse uPA or uPAR.  These reagents will target uPA and uPAR in both stromal cells and cancer cells, and their therapeutic potential can now be assessed in syngenic mouse cancer models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-yFaxesgDvLVg90H21EOLACvtfcHk0lgol_KdumXeNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVSrtbo%253D&md5=07724bde3e8c999edff87d6c1d332c9a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F138945011797635902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945011797635902%26sid%3Dliteratum%253Aachs%26aulast%3DLund%26aufirst%3DI.%2BK.%26aulast%3DIllemann%26aufirst%3DM.%26aulast%3DThurison%26aufirst%3DT.%26aulast%3DChristensen%26aufirst%3DI.%2BJ.%26aulast%3DHoyer-Hansen%26aufirst%3DG.%26atitle%3DuPAR%2520as%2520anti-cancer%2520target%253A%2520evaluation%2520of%2520biomarker%2520potential%252C%2520histological%2520localization%252C%2520and%2520antibody-based%2520therapy%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2011%26volume%3D12%26issue%3D12%26spage%3D1744%26epage%3D1760%26doi%3D10.2174%2F138945011797635902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dohn, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Høyer-Hansen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hostmark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litlekalsoy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von der Maase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappot, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laerum, O. D.</span></span> <span> </span><span class="NLM_article-title">Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder</span>. <i>Urol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">165.e15</span>– <span class="NLM_lpage">165.e24</span>, <span class="refDoi"> DOI: 10.1016/j.urolonc.2014.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.urolonc.2014.12.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=165.e15-165.e24&issue=4&author=L.+H.+Dohnauthor=M.+Illemannauthor=G.+H%C3%B8yer-Hansenauthor=I.+J.+Christensenauthor=J.+Hostmarkauthor=J.+Litlekalsoyauthor=H.+von+der+Maaseauthor=H.+Pappotauthor=O.+D.+Laerum&title=Urokinase-type+plasminogen+activator+receptor+%28uPAR%29+expression+is+associated+with+T-stage+and+survival+in+urothelial+carcinoma+of+the+bladder&doi=10.1016%2Fj.urolonc.2014.12.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.urolonc.2014.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.urolonc.2014.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DDohn%26aufirst%3DL.%2BH.%26aulast%3DIllemann%26aufirst%3DM.%26aulast%3DH%25C3%25B8yer-Hansen%26aufirst%3DG.%26aulast%3DChristensen%26aufirst%3DI.%2BJ.%26aulast%3DHostmark%26aufirst%3DJ.%26aulast%3DLitlekalsoy%26aufirst%3DJ.%26aulast%3Dvon%2Bder%2BMaase%26aufirst%3DH.%26aulast%3DPappot%26aufirst%3DH.%26aulast%3DLaerum%26aufirst%3DO.%2BD.%26atitle%3DUrokinase-type%2520plasminogen%2520activator%2520receptor%2520%2528uPAR%2529%2520expression%2520is%2520associated%2520with%2520T-stage%2520and%2520survival%2520in%2520urothelial%2520carcinoma%2520of%2520the%2520bladder%26jtitle%3DUrol.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3D4%26spage%3D165.e15%26epage%3D165.e24%26doi%3D10.1016%2Fj.urolonc.2014.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ploug, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, V.</span></span> <span> </span><span class="NLM_article-title">Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>349</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1016/0014-5793(94)00674-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2F0014-5793%2894%2900674-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=8050560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaK2cXlvF2jsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=1994&pages=163-168&issue=2&author=M.+Plougauthor=V.+Ellis&title=Structure-function+relationships+in+the+receptor+for+urokinase-type+plasminogen+activator.+Comparison+to+other+members+of+the+Ly-6+family+and+snake+venom+alpha-neurotoxins&doi=10.1016%2F0014-5793%2894%2900674-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom α-neurotoxins</span></div><div class="casAuthors">Ploug, Michael; Ellis, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-8</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    </div><div class="casAbstract">A review with 50 refs. Plasminogen activation is regulated by the interaction between urokinase-type plasminogen activator (uPA) and its specific glycolipid-anchored cell surface receptor (uPAR).  UPAR is composed of three homologous domains and is the only multi-domain member of the Ly-6 family of glycolipid-anchored membrane proteins.  Recent evidence has highlighted similarities between the individual domains of uPAR and the large family of secreted, single domain snake venom α-neurotoxins, suggesting that uPAR may adopt the same gross folding pattern as these structurally well characterized proteins.  Structural aspects of the binding between α-neurotoxins and the acetylcholine receptor may have a major influence on future studies of the interaction between uPA and uPAR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaboUKtl143LVg90H21EOLACvtfcHk0lgol_KdumXeNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlvF2jsL0%253D&md5=4c56931f332e53a5cae9836b7e97bf32</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2894%2900674-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252894%252900674-1%26sid%3Dliteratum%253Aachs%26aulast%3DPloug%26aufirst%3DM.%26aulast%3DEllis%26aufirst%3DV.%26atitle%3DStructure-function%2520relationships%2520in%2520the%2520receptor%2520for%2520urokinase-type%2520plasminogen%2520activator.%2520Comparison%2520to%2520other%2520members%2520of%2520the%2520Ly-6%2520family%2520and%2520snake%2520venom%2520alpha-neurotoxins%26jtitle%3DFEBS%2520Lett.%26date%3D1994%26volume%3D349%26issue%3D2%26spage%3D163%26epage%3D168%26doi%3D10.1016%2F0014-5793%2894%2900674-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, C.</span></span> <span> </span><span class="NLM_article-title">The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer</span>. <i>Clin. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1016/j.clinbiochem.2004.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.clinbiochem.2004.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=15234235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltl2gtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2004&pages=541-548&issue=7&author=M.+J.+Duffyauthor=C.+Duggan&title=The+urokinase+plasminogen+activator+system%3A+a+rich+source+of+tumour+markers+for+the+individualised+management+of+patients+with+cancer&doi=10.1016%2Fj.clinbiochem.2004.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The urokinase plasminogen activator system: a rich source of tumor markers for the individualised management of patients with cancer</span></div><div class="casAuthors">Duffy, M. J.; Duggan, C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">541-548</span>CODEN:
                <span class="NLM_cas:coden">CLBIAS</span>;
        ISSN:<span class="NLM_cas:issn">0009-9120</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The urokinase plasminogen activator (uPA) system consists of the serine protease uPA, the glycolipid-anchored receptor, uPAR, and the 2 serpin inhibitors, plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2).  Recent findings suggest that uPA, uPAR and PAI-1 play a crit. role in cancer invasion and metastasis.  Consistent with their role in cancer dissemination, high levels of uPA, PAI-1 and uPAR in multiple cancer types correlate with adverse patient outcome.  The prognostic value of uPA/PAI-1 in axillary node-neg. breast cancer patients was recently validated using both a prospective randomized trial and a pooled anal.  Assay of uPA and PAI-1 may thus help identify low-risk node-neg. patients for whom adjuvant chemotherapy is unnecessary.  Finally, emerging data suggest that high levels of uPA and PAI-1 in breast cancer are assocd. with a preferential response to adjuvant chemotherapy but relative resistance to hormone therapy.  The measurement of uPA components, esp. in breast cancer, thus has the potential to help with individualised patient management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSGX_RwBqQxLVg90H21EOLACvtfcHk0lg7cdA0A73aMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltl2gtb4%253D&md5=69b7627e184196fa2fac01785e496df2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.clinbiochem.2004.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinbiochem.2004.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DM.%2BJ.%26aulast%3DDuggan%26aufirst%3DC.%26atitle%3DThe%2520urokinase%2520plasminogen%2520activator%2520system%253A%2520a%2520rich%2520source%2520of%2520tumour%2520markers%2520for%2520the%2520individualised%2520management%2520of%2520patients%2520with%2520cancer%26jtitle%3DClin.%2520Biochem.%26date%3D2004%26volume%3D37%26issue%3D7%26spage%3D541%26epage%3D548%26doi%3D10.1016%2Fj.clinbiochem.2004.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S. J.</span></span> <span> </span><span class="NLM_article-title">Navigating ECM barriers at the invasive front: the cancer cell-stroma interface</span>. <i>Annu. Rev. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1146/annurev.cellbio.24.110707.175315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1146%2Fannurev.cellbio.24.110707.175315" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2009&pages=567-595&author=R.+G.+Roweauthor=S.+J.+Weiss&title=Navigating+ECM+barriers+at+the+invasive+front%3A+the+cancer+cell-stroma+interface&doi=10.1146%2Fannurev.cellbio.24.110707.175315"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1146%2Fannurev.cellbio.24.110707.175315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.cellbio.24.110707.175315%26sid%3Dliteratum%253Aachs%26aulast%3DRowe%26aufirst%3DR.%2BG.%26aulast%3DWeiss%26aufirst%3DS.%2BJ.%26atitle%3DNavigating%2520ECM%2520barriers%2520at%2520the%2520invasive%2520front%253A%2520the%2520cancer%2520cell-stroma%2520interface%26jtitle%3DAnnu.%2520Rev.%2520Cell%2520Dev.%2520Biol.%26date%3D2009%26volume%3D25%26spage%3D567%26epage%3D595%26doi%3D10.1146%2Fannurev.cellbio.24.110707.175315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelso, M. J.</span></span> <span> </span><span class="NLM_article-title">Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2061</span>, <span class="refDoi"> DOI: 10.1002/ijc.26156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1002%2Fijc.26156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=21544803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSjsb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=2051-2061&issue=9&author=H.+Matthewsauthor=M.+Ransonauthor=M.+J.+Kelso&title=Anti-tumour%2Fmetastasis+effects+of+the+potassium-sparing+diuretic+amiloride%3A+an+orally+active+anti-cancer+drug+waiting+for+its+call-of-duty%3F&doi=10.1002%2Fijc.26156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor/metastasis effects of the potassium-sparing diuretic amiloride: An orally active anti-cancer drug waiting for its call-of-duty?</span></div><div class="casAuthors">Matthews, Hayden; Ranson, Marie; Kelso, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2051-2061</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Amiloride.HCl is clin. used as an oral potassium-sparing diuretic, but multiple studies in biochem., cellular and animal models have shown that the drug also possesses anti-tumor and anti-metastasis activities.  The addnl. effects appear to arise through inhibition of two discrete targets: (i) the sodium-hydrogen exchanger 1 (NHE1), a membrane protein responsible for the characteristically low extracellular pH of tumors and (ii) the urokinase-type plasminogen activator (uPA), a serine protease mediator of cell migration, invasion and metastasis and well-known marker of poor prognosis in cancer.  This mini-review summarizes for the first time the reported anti-tumor/metastasis effects of amiloride in exptl. models, discusses the putative mol. mechanisms responsible for these effects and concludes by commenting on the pros and cons of trialling amiloride or one of its structural analogs as potential new anti-tumor/metastasis drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohvJl1aiKpW7Vg90H21EOLACvtfcHk0lg7cdA0A73aMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSjsb%252FK&md5=97a98cebb32a4052f03c0f7d8391b1c6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fijc.26156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.26156%26sid%3Dliteratum%253Aachs%26aulast%3DMatthews%26aufirst%3DH.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DKelso%26aufirst%3DM.%2BJ.%26atitle%3DAnti-tumour%252Fmetastasis%2520effects%2520of%2520the%2520potassium-sparing%2520diuretic%2520amiloride%253A%2520an%2520orally%2520active%2520anti-cancer%2520drug%2520waiting%2520for%2520its%2520call-of-duty%253F%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26issue%3D9%26spage%3D2051%26epage%3D2061%26doi%3D10.1002%2Fijc.26156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andronicos, N. M.</span></span> <span> </span><span class="NLM_article-title">Plasminogen binding and cancer: promises and pitfalls</span>. <i>Front. Biosci., Landmark Ed.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">s294</span>– <span class="NLM_lpage">304</span>, <span class="refDoi"> DOI: 10.2741/1044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.2741%2F1044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=12700073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvVenurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=s294-304&author=M.+Ransonauthor=N.+M.+Andronicos&title=Plasminogen+binding+and+cancer%3A+promises+and+pitfalls&doi=10.2741%2F1044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Plasminogen binding and cancer: promises and pitfalls</span></div><div class="casAuthors">Ranson, Marie; Andronicos, Nicholas M.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">S294-S304</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  The urokinase plasminogen activation system is a key modulator of the tissue remodeling processes required for tumor cell invasion and metastasis.  Malignant progression is characterized by inappropriately high cell surface levels of receptor-bound active urokinase.  This enhances the rate of plasminogen activation resulting in markedly increased levels of cell surface plasmin.  The repercussions of this are significant and include the activation of growth factors and signaling pathways, and the degrdn. of extracellular matrixes, either directly or indirectly, via the activation of matrix metalloproteinases.  Native, circulating plasminogen binds in a lysine- and/or carbohydrate-dependent manner to tumor and endothelial cells with low affinity but high capacity and a heterogeneous group of plasminogen receptors have been identified.  This heterogeneity underscores the complexity of the mechanisms responsible for the regulation of cell-surface plasminogen binding.  This review summarizes the literature on known plasminogen receptor candidates and shows that they can be subdivided into three classes based on their mode of interaction with plasminogen.  We also aim to emphasize the notion that in the tumor environment the known intrinsic functional relationship between plasminogen conformation and activation is essentially connected to cellular binding.  This allows plasminogen to be co-localized in an activation-susceptible form with the enhanced uPA levels seen in malignancy and together furnishes tumor cells with elevated tissue remodeling capacity.  In addn., some of the pitfalls and strategies encountered when conducting plasminogen receptor expts. are also addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjGwsfozeOFrVg90H21EOLACvtfcHk0lg7cdA0A73aMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvVenurc%253D&md5=f99ad18e97eeb71b4a6b9311849a3cb9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2741%2F1044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F1044%26sid%3Dliteratum%253Aachs%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DAndronicos%26aufirst%3DN.%2BM.%26atitle%3DPlasminogen%2520binding%2520and%2520cancer%253A%2520promises%2520and%2520pitfalls%26jtitle%3DFront.%2520Biosci.%252C%2520Landmark%2520Ed.%26date%3D2003%26volume%3D8%26spage%3Ds294%26epage%3D304%26doi%3D10.2741%2F1044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, J. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span> <span> </span><span class="NLM_article-title">Structural basis for therapeutic intervention of uPA/uPAR system</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1729</span>– <span class="NLM_lpage">1743</span>, <span class="refDoi"> DOI: 10.2174/138945011797635911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.2174%2F138945011797635911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=21707478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVSrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=1729-1743&issue=12&author=J.+C.+K.+Ngoauthor=L.+Jiangauthor=Z.+Linauthor=C.+Yuanauthor=Z.+Chenauthor=X.+Zhangauthor=H.+Yuauthor=J.+Wangauthor=L.+Linauthor=M.+Huang&title=Structural+basis+for+therapeutic+intervention+of+uPA%2FuPAR+system&doi=10.2174%2F138945011797635911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for therapeutic intervention of uPA/uPAR system</span></div><div class="casAuthors">Ngo, Jacky Chi Ki; Jiang, Longguang; Lin, Zhonghui; Yuan, Cai; Chen, Zhuo; Zhang, Xu; Yu, Haiyang; Wang, Jundong; Lin, Lin; Huang, Mingdong</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1729-1743</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Urokinase-type plasminogen activator (uPA) is one of the two physiol. serine proteases responsible for the activation of plasminongen to plasmin.  UPA activity is regulated by its inhibitors (PAI-1 and PAI-2) and its receptor (uPAR), and an expanding list of their interacting proteins.  In addn. to plasminogen activation, this system also plays important roles in the regulation of many cellular processes including cell proliferation, adhesion and migration.  It is beyond reasonable doubt that this enzyme system plays a central role in tumor biol. and represents a high potential target for therapeutic intervention of tumor growth and metastasis.  During the past fifteen years, crystal structures of uPA and its inhibitors have facilitated the development of uPA inhibitors.  Many crystal structures of proteins in the uPA/uPAR system have also been reported recently, esp. a series of structures of uPAR and its complexes with vitronectin and uPA, facilitating the development and evaluation of uPAR inhibitors.  Recent progress on uPA inhibitors will be summarized in this article.  The unique structural features and the druggable potentials of these new structures will also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqxQduyMhtsbVg90H21EOLACvtfcHk0lg7cdA0A73aMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVSrtb0%253D&md5=d3f068f16db2bc1582af43cdd7977049</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F138945011797635911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945011797635911%26sid%3Dliteratum%253Aachs%26aulast%3DNgo%26aufirst%3DJ.%2BC.%2BK.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DM.%26atitle%3DStructural%2520basis%2520for%2520therapeutic%2520intervention%2520of%2520uPA%252FuPAR%2520system%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2011%26volume%3D12%26issue%3D12%26spage%3D1729%26epage%3D1743%26doi%3D10.2174%2F138945011797635911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tyndall, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelso, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clingan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span> <span> </span><span class="NLM_article-title">Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancer</span>. <i>Recent Pat. Anti-Cancer Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.2174/157489208783478711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.2174%2F157489208783478711" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1-13&issue=1&author=J.+D.+Tyndallauthor=M.+J.+Kelsoauthor=P.+Clinganauthor=M.+Ranson&title=Peptides+and+small+molecules+targeting+the+plasminogen+activation+system%3A+towards+prophylactic+anti-metastasis+drugs+for+breast+cancer&doi=10.2174%2F157489208783478711"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F157489208783478711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157489208783478711%26sid%3Dliteratum%253Aachs%26aulast%3DTyndall%26aufirst%3DJ.%2BD.%26aulast%3DKelso%26aufirst%3DM.%2BJ.%26aulast%3DClingan%26aufirst%3DP.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DPeptides%2520and%2520small%2520molecules%2520targeting%2520the%2520plasminogen%2520activation%2520system%253A%2520towards%2520prophylactic%2520anti-metastasis%2520drugs%2520for%2520breast%2520cancer%26jtitle%3DRecent%2520Pat.%2520Anti-Cancer%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26issue%3D1%26spage%3D1%26epage%3D13%26doi%3D10.2174%2F157489208783478711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nienaber, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edalji, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinghofer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magdalinos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockway, T.</span></span> <span> </span><span class="NLM_article-title">Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">563</span>, <span class="refDoi"> DOI: 10.1016/S0969-2126(00)00136-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2FS0969-2126%2800%2900136-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2000&pages=553-563&issue=5&author=V.+L.+Nienaberauthor=D.+Davidsonauthor=R.+Edaljiauthor=V.+L.+Girandaauthor=V.+Klinghoferauthor=J.+Henkinauthor=P.+Magdalinosauthor=R.+Manteiauthor=S.+Merrickauthor=J.+M.+Severinauthor=R.+A.+Smithauthor=K.+Stewartauthor=K.+Walterauthor=J.+Wangauthor=M.+Wendtauthor=M.+Weitzbergauthor=X.+Zhaoauthor=T.+Rockway&title=Structure-directed+discovery+of+potent+non-peptidic+inhibitors+of+human+urokinase+that+access+a+novel+binding+subsite&doi=10.1016%2FS0969-2126%2800%2900136-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2800%2900136-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252800%252900136-2%26sid%3Dliteratum%253Aachs%26aulast%3DNienaber%26aufirst%3DV.%2BL.%26aulast%3DDavidson%26aufirst%3DD.%26aulast%3DEdalji%26aufirst%3DR.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DHenkin%26aufirst%3DJ.%26aulast%3DMagdalinos%26aufirst%3DP.%26aulast%3DMantei%26aufirst%3DR.%26aulast%3DMerrick%26aufirst%3DS.%26aulast%3DSeverin%26aufirst%3DJ.%2BM.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DWalter%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWendt%26aufirst%3DM.%26aulast%3DWeitzberg%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DRockway%26aufirst%3DT.%26atitle%3DStructure-directed%2520discovery%2520of%2520potent%2520non-peptidic%2520inhibitors%2520of%2520human%2520urokinase%2520that%2520access%2520a%2520novel%2520binding%2520subsite%26jtitle%3DStructure%26date%3D2000%26volume%3D8%26issue%3D5%26spage%3D553%26epage%3D563%26doi%3D10.1016%2FS0969-2126%2800%2900136-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClellan, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockway, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nienaber, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinghofer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span> <span> </span><span class="NLM_article-title">Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3063</span>– <span class="NLM_lpage">3068</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.bmcl.2004.04.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=3063-3068&issue=12&author=M.+D.+Wendtauthor=A.+Geyerauthor=W.+J.+McClellanauthor=T.+W.+Rockwayauthor=M.+Weitzbergauthor=X.+Zhaoauthor=R.+Manteiauthor=K.+Stewartauthor=V.+Nienaberauthor=V.+Klinghoferauthor=V.+L.+Giranda&title=Interaction+with+the+S1+beta-pocket+of+urokinase%3A+8-heterocycle+substituted+and+6%2C8-disubstituted+2-naphthamidine+urokinase+inhibitors&doi=10.1016%2Fj.bmcl.2004.04.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DGeyer%26aufirst%3DA.%26aulast%3DMcClellan%26aufirst%3DW.%2BJ.%26aulast%3DRockway%26aufirst%3DT.%2BW.%26aulast%3DWeitzberg%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DMantei%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DNienaber%26aufirst%3DV.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DInteraction%2520with%2520the%2520S1%2520beta-pocket%2520of%2520urokinase%253A%25208-heterocycle%2520substituted%2520and%25206%252C8-disubstituted%25202-naphthamidine%2520urokinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26issue%3D12%26spage%3D3063%26epage%3D3068%26doi%3D10.1016%2Fj.bmcl.2004.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockway, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClellan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nienaber, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinghofer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span> <span> </span><span class="NLM_article-title">Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1021/jm0300072</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0300072" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=303-324&issue=2&author=M.+D.+Wendtauthor=T.+W.+Rockwayauthor=A.+Geyerauthor=W.+McClellanauthor=M.+Weitzbergauthor=X.+Zhaoauthor=R.+Manteiauthor=V.+L.+Nienaberauthor=K.+Stewartauthor=V.+Klinghoferauthor=V.+L.+Giranda&title=Identification+of+novel+binding+interactions+in+the+development+of+potent%2C+selective+2-naphthamidine+inhibitors+of+urokinase.+Synthesis%2C+structural+analysis%2C+and+SAR+of+N-phenyl+amide+6-substitution&doi=10.1021%2Fjm0300072"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm0300072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0300072%26sid%3Dliteratum%253Aachs%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DRockway%26aufirst%3DT.%2BW.%26aulast%3DGeyer%26aufirst%3DA.%26aulast%3DMcClellan%26aufirst%3DW.%26aulast%3DWeitzberg%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DMantei%26aufirst%3DR.%26aulast%3DNienaber%26aufirst%3DV.%2BL.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DIdentification%2520of%2520novel%2520binding%2520interactions%2520in%2520the%2520development%2520of%2520potent%252C%2520selective%25202-naphthamidine%2520inhibitors%2520of%2520urokinase.%2520Synthesis%252C%2520structural%2520analysis%252C%2520and%2520SAR%2520of%2520N-phenyl%2520amide%25206-substitution%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D2%26spage%3D303%26epage%3D324%26doi%3D10.1021%2Fjm0300072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruncko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClellan, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellaria, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nienaber, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinghofer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockway, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span> <span> </span><span class="NLM_article-title">Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.bmcl.2004.10.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=93-98&issue=1&author=M.+Brunckoauthor=W.+J.+McClellanauthor=M.+D.+Wendtauthor=D.+R.+Sauerauthor=A.+Geyerauthor=C.+R.+Daltonauthor=M.+A.+Kaminskiauthor=M.+Weitzbergauthor=J.+Gongauthor=J.+F.+Dellariaauthor=R.+Manteiauthor=X.+Zhaoauthor=V.+L.+Nienaberauthor=K.+Stewartauthor=V.+Klinghoferauthor=J.+Bouskaauthor=T.+W.+Rockwayauthor=V.+L.+Giranda&title=Naphthamidine+urokinase+plasminogen+activator+inhibitors+with+improved+pharmacokinetic+properties&doi=10.1016%2Fj.bmcl.2004.10.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DBruncko%26aufirst%3DM.%26aulast%3DMcClellan%26aufirst%3DW.%2BJ.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DSauer%26aufirst%3DD.%2BR.%26aulast%3DGeyer%26aufirst%3DA.%26aulast%3DDalton%26aufirst%3DC.%2BR.%26aulast%3DKaminski%26aufirst%3DM.%2BA.%26aulast%3DWeitzberg%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DDellaria%26aufirst%3DJ.%2BF.%26aulast%3DMantei%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DNienaber%26aufirst%3DV.%2BL.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%26aulast%3DRockway%26aufirst%3DT.%2BW.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DNaphthamidine%2520urokinase%2520plasminogen%2520activator%2520inhibitors%2520with%2520improved%2520pharmacokinetic%2520properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26issue%3D1%26spage%3D93%26epage%3D98%26doi%3D10.1016%2Fj.bmcl.2004.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Towle, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maduakor, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlefield, B. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2553</span>– <span class="NLM_lpage">2559</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1993&pages=2553-2559&issue=11&author=M.+J.+Towleauthor=A.+Leeauthor=E.+C.+Maduakorauthor=C.+E.+Schwartzauthor=A.+J.+Bridgesauthor=B.+A.+Littlefield&title=Inhibition+of+urokinase+by+4-substituted+benzo%5Bb%5Dthiophene-2-carboxamidines%3A+an+important+new+class+of+selective+synthetic+urokinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTowle%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DMaduakor%26aufirst%3DE.%2BC.%26aulast%3DSchwartz%26aufirst%3DC.%2BE.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DLittlefield%26aufirst%3DB.%2BA.%26atitle%3DInhibition%2520of%2520urokinase%2520by%25204-substituted%2520benzo%255Bb%255Dthiophene-2-carboxamidines%253A%2520an%2520important%2520new%2520class%2520of%2520selective%2520synthetic%2520urokinase%2520inhibitor%26jtitle%3DCancer%2520Res.%26date%3D1993%26volume%3D53%26issue%3D11%26spage%3D2553%26epage%3D2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rockway, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the proteolytic activity of urokinase type plasminogen activator</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">1483</span>– <span class="NLM_lpage">1498</span>, <span class="refDoi"> DOI: 10.2174/1381612033454649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.2174%2F1381612033454649" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=1483-1498&issue=19&author=T.+W.+Rockwayauthor=V.+L.+Giranda&title=Inhibitors+of+the+proteolytic+activity+of+urokinase+type+plasminogen+activator&doi=10.2174%2F1381612033454649"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F1381612033454649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612033454649%26sid%3Dliteratum%253Aachs%26aulast%3DRockway%26aufirst%3DT.%2BW.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DInhibitors%2520of%2520the%2520proteolytic%2520activity%2520of%2520urokinase%2520type%2520plasminogen%2520activator%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2003%26volume%3D9%26issue%3D19%26spage%3D1483%26epage%3D1498%26doi%3D10.2174%2F1381612033454649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frederickson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaghan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chessari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinkovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, N. G.</span></span> <span> </span><span class="NLM_article-title">Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1021/jm701359z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701359z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=183-186&issue=2&author=M.+Fredericksonauthor=O.+Callaghanauthor=G.+Chessariauthor=M.+Congreveauthor=S.+R.+Cowanauthor=J.+E.+Matthewsauthor=R.+McMenaminauthor=D.+M.+Smithauthor=M.+Vinkovicauthor=N.+G.+Wallis&title=Fragment-based+discovery+of+mexiletine+derivatives+as+orally+bioavailable+inhibitors+of+urokinase-type+plasminogen+activator&doi=10.1021%2Fjm701359z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm701359z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701359z%26sid%3Dliteratum%253Aachs%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DCallaghan%26aufirst%3DO.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCowan%26aufirst%3DS.%2BR.%26aulast%3DMatthews%26aufirst%3DJ.%2BE.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DVinkovic%26aufirst%3DM.%26aulast%3DWallis%26aufirst%3DN.%2BG.%26atitle%3DFragment-based%2520discovery%2520of%2520mexiletine%2520derivatives%2520as%2520orally%2520bioavailable%2520inhibitors%2520of%2520urokinase-type%2520plasminogen%2520activator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D2%26spage%3D183%26epage%3D186%26doi%3D10.1021%2Fjm701359z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sturzebecher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieweg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetzer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweinitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renatus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrom, P.</span></span> <span> </span><span class="NLM_article-title">3-Amidinophenylalanine-based inhibitors of urokinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">3147</span>– <span class="NLM_lpage">3152</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(99)00541-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2FS0960-894X%2899%2900541-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10560742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaK1MXntlOmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=3147-3152&issue=21&author=J.+Sturzebecherauthor=H.+Viewegauthor=T.+Steinmetzerauthor=A.+Schweinitzauthor=M.+T.+Stubbsauthor=M.+Renatusauthor=P.+Wikstrom&title=3-Amidinophenylalanine-based+inhibitors+of+urokinase&doi=10.1016%2FS0960-894X%2899%2900541-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">3-Amidinophenylalanine-based inhibitors of urokinase</span></div><div class="casAuthors">Sturzebecher, Jorg; Vieweg, Helmut; Steinmetzer, Torsten; Schweinitz, Andrea; Stubbs, Milton T.; Renatus, Martin; Wikstrom, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3147-3152</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Synthesis and anti-uPA activity of a series of Nα-triisopropyl-phenylsulfonyl-protected 3-amidinophenylalanine amides are described.  We have explored SAR around the C-terminal amide part for inhibition of uPA, plasmin and trypsin.  Modification of the amide part has been found to affect potency but not selectivity.  With a Ki of 0.41 μM I is one of the most potent uPA inhibitors described so far.  The X-ray crystal structure of I was solved in complex with trypsin, superimposed with uPA and the results suggest an unique binding mode of this inhibitor type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5sBl6FqZ4RLVg90H21EOLACvtfcHk0lhogloMdx5_XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntlOmu7g%253D&md5=f9df9988e3632bea96004b15beee04f2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2899%2900541-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252899%252900541-7%26sid%3Dliteratum%253Aachs%26aulast%3DSturzebecher%26aufirst%3DJ.%26aulast%3DVieweg%26aufirst%3DH.%26aulast%3DSteinmetzer%26aufirst%3DT.%26aulast%3DSchweinitz%26aufirst%3DA.%26aulast%3DStubbs%26aufirst%3DM.%2BT.%26aulast%3DRenatus%26aufirst%3DM.%26aulast%3DWikstrom%26aufirst%3DP.%26atitle%3D3-Amidinophenylalanine-based%2520inhibitors%2520of%2520urokinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26issue%3D21%26spage%3D3147%26epage%3D3152%26doi%3D10.1016%2FS0960-894X%2899%2900541-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinemann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubender, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bevan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mala, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeck, S.</span></span> <span> </span><span class="NLM_article-title">Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">766</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.1038/bjc.2013.62</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1038%2Fbjc.2013.62" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=23412098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslWmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2013&pages=766-770&issue=4&author=V.+Heinemannauthor=M.+P.+Ebertauthor=R.+P.+Laubenderauthor=P.+Bevanauthor=C.+Malaauthor=S.+Boeck&title=Phase+II+randomised+proof-of-concept+study+of+the+urokinase+inhibitor+upamostat+%28WX-671%29+in+combination+with+gemcitabine+compared+with+gemcitabine+alone+in+patients+with+non-resectable%2C+locally+advanced+pancreatic+cancer&doi=10.1038%2Fbjc.2013.62"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II randomized proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer</span></div><div class="casAuthors">Heinemann, V.; Ebert, M. P.; Laubender, R. P.; Bevan, P.; Mala, C.; Boeck, S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">766-770</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: To evaluate the efficacy and tolerability of the urokinase plasminogen activator (uPA) inhibitor upamostat in combination with gemcitabine in locally advanced pancreatic adenocarcinoma (LAPC).  Methods: Within a prospective multicenter study, LAPC patients were randomly assigned to receive 1000 mg m-2 of gemcitabine IV weekly either alone (arm A) or in combination with 200 mg (arm B) or 400 mg (arm C) oral upamostat daily.  Efficacy endpoints of this proof-of-concept study included response rate, time to first metastasis, progression-free and overall survival (OS).  Results: Of the 95 enrolled patients, 85 were evaluable for response and 93 for safety.  Median OS was 12.5 mo (95% CI 8.2-18.2) in arm C, 9.7 mo (95% CI 8.4-17.1) in arm B and 9.9 mo (95% CI 7.4-12.1) in arm A; corresponding 1-yr survival rates were 50.6%, 40.7% and 33.9%, resp.  More patients achieved a partial remission (confirmed responses by RECIST) with upamostat combination therapy (arm C: 12.9%; arm B: 7.1%; arm A: 3.8%).  Overall, only 12 patients progressed by developing detectable distant metastasis (arm A: 4, arm B: 6, arm C: 2).  The most common adverse events considered to be related to upamostat were asthenia, fever and nausea.  Conclusion: In this proof-of-concept study targeting the uPA system in LAPC, the addn. of upamostat to gemcitabine was tolerated well; similar survival results were obsd. for the three treatment arms.  British Journal of Cancer (2013) 108, 766-770; doi:10.1038/bjc.2013.62 www.bjcancer.com; published online 14 Feb. 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmZfmwPy6jILVg90H21EOLACvtfcHk0lhogloMdx5_XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslWmtbo%253D&md5=8cb64bd2fb82944adeaec5327c8b7c47</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2013.62&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2013.62%26sid%3Dliteratum%253Aachs%26aulast%3DHeinemann%26aufirst%3DV.%26aulast%3DEbert%26aufirst%3DM.%2BP.%26aulast%3DLaubender%26aufirst%3DR.%2BP.%26aulast%3DBevan%26aufirst%3DP.%26aulast%3DMala%26aufirst%3DC.%26aulast%3DBoeck%26aufirst%3DS.%26atitle%3DPhase%2520II%2520randomised%2520proof-of-concept%2520study%2520of%2520the%2520urokinase%2520inhibitor%2520upamostat%2520%2528WX-671%2529%2520in%2520combination%2520with%2520gemcitabine%2520compared%2520with%2520gemcitabine%2520alone%2520in%2520patients%2520with%2520non-resectable%252C%2520locally%2520advanced%2520pancreatic%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2013%26volume%3D108%26issue%3D4%26spage%3D766%26epage%3D770%26doi%3D10.1038%2Fbjc.2013.62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span> </span><span class="NLM_article-title">Positive Phase II data for MESUPRON in breast
cancer</span>.  <i>WILEX Half-Yearly Financial Report
2012</i>; <span class="NLM_publisher-name">WILEX AG</span>: <span class="NLM_publisher-loc">Munich, Germany</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Positive+Phase+II+data+for+MESUPRON+in+breast%0Acancer.+WILEX+Half-Yearly+Financial+Report%0A2012%3B+WILEX+AG%3A+Munich%2C+Germany%2C+2012."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DPositive%2520Phase%2520II%2520data%2520for%2520MESUPRON%2520in%2520breast%250Acancer%26btitle%3DWILEX%2520Half-Yearly%2520Financial%2520Report%250A2012%26pub%3DWILEX%2520AG%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spinar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinarova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitovec, J.</span></span> <span> </span><span class="NLM_article-title">Diuretics in monotherapy and in combination with other diuretics and nondiuretics in the treatment of hypertension</span>. <i>Vnitr. Lek.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">494</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=23808745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A280%3ADC%252BC3sjnt1Ggtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2013&pages=486-494&issue=6&author=J.+Spinarauthor=L.+Spinarovaauthor=J.+Vitovec&title=Diuretics+in+monotherapy+and+in+combination+with+other+diuretics+and+nondiuretics+in+the+treatment+of+hypertension"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Diuretics in monotherapy and in combination with other diuretics and nondiuretics in the treatment of hypertension</span></div><div class="casAuthors">Spinar J; Spinarova L; Vitovec J</div><div class="citationInfo"><span class="NLM_cas:title">Vnitrni lekarstvi</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">486-94</span>
        ISSN:<span class="NLM_cas:issn">0042-773X</span>.
    </div><div class="casAbstract">Diuretics belong to the basic group of medicines for the treatment of hypertension and heart failure.  In the case of hypertension treatment, their main indication is higher age and isolated systolic hypertension.  In the case of heart failure they are used for the treatment of swellings and shortness of breath.  The most frequently prescribed group of diuretics is thiazides and similar products.  In patients with renal insufficiency, loop diuretics are administered.  In the case of hypertension, diuretics are mainly used in the combination treatment.  The most frequently used diuretic in combination is again hydrochlorothiazide, which is combined with reninangiotensin system blockers.  It is mainly the combination of an ACE inhibitor + indapamide that seems to be modern and promising, and it is, on the basis of large clinical trials, recommended also for diabetics (ADVANCE) or for secondary prevention following a cerebrovascular accident (PROGRESS) or for the elderly (HYVET).  Also a combination of two diuretics is popular -  mainly hydrochlorothiazide + amiloride.  A combination of a betablocker and diuretic is less suitable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyVpl0fjfBipp6t8nS6Nc3fW6udTcc2eZg3JMjAGf6Zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjnt1Ggtg%253D%253D&md5=69b776e1eb688df6576268783fbc7d32</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSpinar%26aufirst%3DJ.%26aulast%3DSpinarova%26aufirst%3DL.%26aulast%3DVitovec%26aufirst%3DJ.%26atitle%3DDiuretics%2520in%2520monotherapy%2520and%2520in%2520combination%2520with%2520other%2520diuretics%2520and%2520nondiuretics%2520in%2520the%2520treatment%2520of%2520hypertension%26jtitle%3DVnitr.%2520Lek.%26date%3D2013%26volume%3D59%26issue%3D6%26spage%3D486%26epage%3D494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lant, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G. M.</span></span> <span> </span><span class="NLM_article-title">Clinical evaluation of amiloride, a potassium-sparing diuretic</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1002/cpt196910150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1002%2Fcpt196910150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=4884296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaF1MXms1OisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1969&pages=50-63&issue=1&author=A.+F.+Lantauthor=A.+J.+Smithauthor=G.+M.+Wilson&title=Clinical+evaluation+of+amiloride%2C+a+potassium-sparing+diuretic&doi=10.1002%2Fcpt196910150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical evaluation of amiloride, a potassium-sparing diuretic</span></div><div class="casAuthors">Lant, Ariel F.; Smith, Anthony J.; Wilson, Graham M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-63</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    </div><div class="casAbstract">Oral amiloride (5-60 mg.) when evaluated in 34 hospitalized patients with fluid retention increased the excretion of Na+, Cl-, and water but decreased K+ excretion.  The major natriuretic effects of amiloride were complete within 24 hrs., but in a few patients some K+-sparing lasted longer.  The natriuretic and K+-sparing efficacies of amiloride (40 mg.) were significantly greater than those of triamterene (200 mg.).  Amiloride at submax. dose of 10 mg. potentiated this natriuresis and reduced the K+ loss evoked by ethacrynic acid (Edecrin) (50 mg.).  The K+-retaining action of amiloride (40 mg.) was apparent even in the presence of a full dose of spironolactone (AldactoneA) (150 mg.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpetk-KxYogdbVg90H21EOLACvtfcHk0ljgcK7vUbxwIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXms1OisQ%253D%253D&md5=593193195bebf647153811fe4c81dd9c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fcpt196910150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt196910150%26sid%3Dliteratum%253Aachs%26aulast%3DLant%26aufirst%3DA.%2BF.%26aulast%3DSmith%26aufirst%3DA.%2BJ.%26aulast%3DWilson%26aufirst%3DG.%2BM.%26atitle%3DClinical%2520evaluation%2520of%2520amiloride%252C%2520a%2520potassium-sparing%2520diuretic%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1969%26volume%3D10%26issue%3D1%26spage%3D50%26epage%3D63%26doi%3D10.1002%2Fcpt196910150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleyman, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cragoe, E. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">The mechanism of action of amiloride</span>. <i>Semin. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">242</span>– <span class="NLM_lpage">248</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=2849182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaL1MXisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1988&pages=242-248&issue=3&author=T.+R.+Kleymanauthor=E.+J.+Cragoe&title=The+mechanism+of+action+of+amiloride"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of action of amiloride</span></div><div class="casAuthors">Kleyman, Thomas R.; Cragoe, Edward J., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Nephrology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">242-8</span>CODEN:
                <span class="NLM_cas:coden">SNEPDJ</span>;
        ISSN:<span class="NLM_cas:issn">0270-9295</span>.
    </div><div class="casAbstract">A review with 43 refs.  Amiloride induces a mild natriuresis as well as antikaliuresis.  These changes in salt excretion are due to direct inhibition of the NA+ channel in the apical plasma membrane of the distal nephron.  Amiloride does not exert any direct or indirect inhibitory effect on apical K+ channels.  The antikaliuretic effect is most likely a result of hyperpolarization of the apical plasma membrane and decrease in the electrochem. driving force for K+ movement across the apical membrane into the urinary space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxpR6Af_OWorVg90H21EOLACvtfcHk0ljgcK7vUbxwIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXisw%253D%253D&md5=5e5b42e31458db5fea185c6b6a4d94af</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKleyman%26aufirst%3DT.%2BR.%26aulast%3DCragoe%26aufirst%3DE.%2BJ.%26atitle%3DThe%2520mechanism%2520of%2520action%2520of%2520amiloride%26jtitle%3DSemin.%2520Nephrol.%26date%3D1988%26volume%3D8%26issue%3D3%26spage%3D242%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. F.</span></span> <span> </span><span class="NLM_article-title">Regulation of potassium homeostasis</span>. <i>Clin. J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1050</span>– <span class="NLM_lpage">1060</span>, <span class="refDoi"> DOI: 10.2215/CJN.08580813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.2215%2FCJN.08580813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=24721891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCmtb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1050-1060&issue=6&author=B.+F.+Palmer&title=Regulation+of+potassium+homeostasis&doi=10.2215%2FCJN.08580813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of potassium homeostasis</span></div><div class="casAuthors">Palmer, Biff F.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1050-1060</span>CODEN:
                <span class="NLM_cas:coden">CJASC7</span>;
        ISSN:<span class="NLM_cas:issn">1555-9041</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">Potassium is the most abundant cation in the intracellular fluid, and maintaining the proper distribution of potassium across the cell membrane is crit. for normal cell function.  Long-term maintenance of potassium homeostasis is achieved by alterations in renal excretion of potassium in response to variations in intake.  Understanding the mechanism and regulatory influences governing the internal distribution and renal clearance of potassium under normal circumstances can provide a framework for approaching disorders of potassium commonly encountered in clin. practice.  This paper reviews key aspects of the normal regulation of potassium metab. and is designed to serve as a readily accessible review for the well informed clinician as well as a resource for teaching trainees and medical students.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7OcchFIAWrrVg90H21EOLACvtfcHk0ljgcK7vUbxwIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCmtb3E&md5=a61fc81e693ae19b82c1ef20d5d4262c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2215%2FCJN.08580813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2215%252FCJN.08580813%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DB.%2BF.%26atitle%3DRegulation%2520of%2520potassium%2520homeostasis%26jtitle%3DClin.%2520J.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2015%26volume%3D10%26issue%3D6%26spage%3D1050%26epage%3D1060%26doi%3D10.2215%2FCJN.08580813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jankun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skrzypczak-Jankun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiercz, R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">563</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=559-563&issue=4&author=J.+Jankunauthor=R.+W.+Keckauthor=E.+Skrzypczak-Jankunauthor=R.+Swiercz&title=Inhibitors+of+urokinase+reduce+size+of+prostate+cancer+xenografts+in+severe+combined+immunodeficient+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJankun%26aufirst%3DJ.%26aulast%3DKeck%26aufirst%3DR.%2BW.%26aulast%3DSkrzypczak-Jankun%26aufirst%3DE.%26aulast%3DSwiercz%26aufirst%3DR.%26atitle%3DInhibitors%2520of%2520urokinase%2520reduce%2520size%2520of%2520prostate%2520cancer%2520xenografts%2520in%2520severe%2520combined%2520immunodeficient%2520mice%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26issue%3D4%26spage%3D559%26epage%3D563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassalli, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belin, D.</span></span> <span> </span><span class="NLM_article-title">Amiloride selectively inhibits the urokinase-type plasminogen activator</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>214</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1016/0014-5793(87)80039-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2F0014-5793%2887%2980039-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=1987&pages=187-191&issue=1&author=J.+D.+Vassalliauthor=D.+Belin&title=Amiloride+selectively+inhibits+the+urokinase-type+plasminogen+activator&doi=10.1016%2F0014-5793%2887%2980039-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2887%2980039-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252887%252980039-X%26sid%3Dliteratum%253Aachs%26aulast%3DVassalli%26aufirst%3DJ.%2BD.%26aulast%3DBelin%26aufirst%3DD.%26atitle%3DAmiloride%2520selectively%2520inhibits%2520the%2520urokinase-type%2520plasminogen%2520activator%26jtitle%3DFEBS%2520Lett.%26date%3D1987%26volume%3D214%26issue%3D1%26spage%3D187%26epage%3D191%26doi%3D10.1016%2F0014-5793%2887%2980039-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perazella, M. A.</span></span> <span> </span><span class="NLM_article-title">Drug-induced hyperkalemia: old culprits and new offenders</span>. <i>Am. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1016/S0002-9343(00)00496-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2FS0002-9343%2800%2900496-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10996582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A280%3ADC%252BD3M%252FitlaktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2000&pages=307-314&issue=4&author=M.+A.+Perazella&title=Drug-induced+hyperkalemia%3A+old+culprits+and+new+offenders&doi=10.1016%2FS0002-9343%2800%2900496-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced hyperkalemia: old culprits and new offenders</span></div><div class="casAuthors">Perazella M A</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-14</span>
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    </div><div class="casAbstract">Prescribed medications, over-the-counter drugs, and nutritional supplements are used by many patients.  Although most of these products are well tolerated, drug-induced hyperkalemia may develop in patients with underlying renal impairment or other abnormalities in potassium handling.  Drug-induced hyperkalemia most often occurs from impaired renal potassium excretion.  However, disturbed cellular uptake of a potassium load as well as excessive ingestion or infusion of potassium-containing substances may also occur.  Physicians must be aware of medications that can precipitate hyperkalemia, how these drugs induce alterations in potassium homeostasis, and the patient characteristics that increase the risk of hyperkalemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjPHSCG9JrV2BAiYWy6n3SfW6udTcc2eYYXPXKoepnNbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M%252FitlaktA%253D%253D&md5=7be68cf7ccc234b32c2f5e7c79c8fa99</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS0002-9343%2800%2900496-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9343%252800%252900496-4%26sid%3Dliteratum%253Aachs%26aulast%3DPerazella%26aufirst%3DM.%2BA.%26atitle%3DDrug-induced%2520hyperkalemia%253A%2520old%2520culprits%2520and%2520new%2520offenders%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2000%26volume%3D109%26issue%3D4%26spage%3D307%26epage%3D314%26doi%3D10.1016%2FS0002-9343%2800%2900496-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wermuth, C. G.</span></span> <span> </span><span class="NLM_article-title">Selective optimization of side activities: another way for drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1303</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1021/jm030480f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030480f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1303-1314&issue=6&author=C.+G.+Wermuth&title=Selective+optimization+of+side+activities%3A+another+way+for+drug+discovery&doi=10.1021%2Fjm030480f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm030480f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030480f%26sid%3Dliteratum%253Aachs%26aulast%3DWermuth%26aufirst%3DC.%2BG.%26atitle%3DSelective%2520optimization%2520of%2520side%2520activities%253A%2520another%2520way%2520for%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D6%26spage%3D1303%26epage%3D1314%26doi%3D10.1021%2Fjm030480f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndall, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelso, M. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6760</span>– <span class="NLM_lpage">6766</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.09.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.bmcl.2011.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=21978672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKktrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6760-6766&issue=22&author=H.+Matthewsauthor=M.+Ransonauthor=J.+D.+Tyndallauthor=M.+J.+Kelso&title=Synthesis+and+preliminary+evaluation+of+amiloride+analogs+as+inhibitors+of+the+urokinase-type+plasminogen+activator+%28uPA%29&doi=10.1016%2Fj.bmcl.2011.09.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA)</span></div><div class="casAuthors">Matthews, Hayden; Ranson, Marie; Tyndall, Joel D. A.; Kelso, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6760-6766</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A known side-activity of the oral potassium-sparing diuretic drug amiloride is inhibition of the enzyme urokinase-type plasminogen activator (uPA, K i = 7 μM), a promising anticancer target.  Several studies have demonstrated significant antitumor/metastasis properties for amiloride in animal cancer models and it would appear that these arise, at least in part, through inhibition of uPA.  Selective optimization of amiloride's structure for more potent inhibition of uPA and loss of diuretic effects would thus appear as an attractive strategy towards novel anticancer agents.  A preliminary structure-activity exploration of amiloride analogs as inhibitors of uPA is reported.  A key finding was that the well-studied 5-substituted analogs ethylisopropyl amiloride (EIPA) and hexamethylene amiloride (HMA) are approx. twofold more potent than amiloride as uPA inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpor1thS6CQxLVg90H21EOLACvtfcHk0lhcXxpq_lYPTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKktrzJ&md5=3e4a6b17900bcf16f1d1829c83686116</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DMatthews%26aufirst%3DH.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DTyndall%26aufirst%3DJ.%2BD.%26aulast%3DKelso%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%2520and%2520preliminary%2520evaluation%2520of%2520amiloride%2520analogs%2520as%2520inhibitors%2520of%2520the%2520urokinase-type%2520plasminogen%2520activator%2520%2528uPA%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D22%26spage%3D6760%26epage%3D6766%26doi%3D10.1016%2Fj.bmcl.2011.09.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleyman, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cragoe, E. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Amiloride and its analogs as tools in the study of ion transport</span>. <i>J. Membr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1007/BF01871102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1007%2FBF01871102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=2852254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaL1MXjvVKj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=1988&pages=1-21&issue=1&author=T.+R.+Kleymanauthor=E.+J.+Cragoe&title=Amiloride+and+its+analogs+as+tools+in+the+study+of+ion+transport&doi=10.1007%2FBF01871102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Amiloride and its analogs as tools in the study of ion transport</span></div><div class="casAuthors">Kleyman, Thomas R.; Cragoe, Edward J., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Membrane Biology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">JMBBBO</span>;
        ISSN:<span class="NLM_cas:issn">0022-2631</span>.
    </div><div class="casAbstract">This review with 86 refs. addresses the structure-activity relationships of amiloride and its analogs on the large no. of ion transporters and other cellular processes that are inhibited by amiloride, and examines the use of these drugs as probes for the characterization of transport proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotq8xXQUzGTbVg90H21EOLACvtfcHk0lijWqE5a13JVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXjvVKj&md5=7d6c138698739364f288ea963cd2e5c4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2FBF01871102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01871102%26sid%3Dliteratum%253Aachs%26aulast%3DKleyman%26aufirst%3DT.%2BR.%26aulast%3DCragoe%26aufirst%3DE.%2BJ.%26atitle%3DAmiloride%2520and%2520its%2520analogs%2520as%2520tools%2520in%2520the%2520study%2520of%2520ion%2520transport%26jtitle%3DJ.%2520Membr.%2520Biol.%26date%3D1988%26volume%3D105%26issue%3D1%26spage%3D1%26epage%3D21%26doi%3D10.1007%2FBF01871102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makepeace, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cragoe, E. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Effects of HMA, an analog of amiloride, on the thermosensitivity of tumors in vivo</span>. <i>Int. J. Radiat. Oncol., Biol., Phys.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1016/0360-3016(94)90528-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2F0360-3016%2894%2990528-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=8083106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFaisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1994&pages=133-139&issue=1&author=C.+W.+Songauthor=J.+C.+Lyonsauthor=C.+M.+Makepeaceauthor=R.+J.+Griffinauthor=E.+J.+Cragoe&title=Effects+of+HMA%2C+an+analog+of+amiloride%2C+on+the+thermosensitivity+of+tumors+in+vivo&doi=10.1016%2F0360-3016%2894%2990528-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of HMA, an analog of amiloride, on the thermosensitivity of tumors in vivo</span></div><div class="casAuthors">Song, Chang W.; Lyons, John C.; Makepeace, Carol M.; Griffin, Robert J.; Cragoe, Edward J. Jr.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Radiation Oncology, Biology, Physics</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">133-9</span>CODEN:
                <span class="NLM_cas:coden">IOBPD3</span>;
        ISSN:<span class="NLM_cas:issn">0360-3016</span>.
    </div><div class="casAbstract">The effects of HMA (3-amino-6-chloro-5-(1-homopiperidyl)-N- (diaminomethylene)pyrazinecarboxamide), an analog of amiloride, on the intracellular pH (pHi) of SCK tumor cells in vitro and on the thermosensitivity of tumors in vivo were investigated.  The pHi of SCK tumor cells in vitro was measured with the BCECF fluorescence spectroscopy method.  The effect of HMA on the thermosensitivity of SCK tumors grown SC in the legs of A/J mice was assessed by the tumor growth delay method and the in vivo-in vitro excision assay method.  The pHi of SCK tumor cells in pH 7.5 and 6.6 medium was about 7.50 and 7.15, resp.  The presence of 10-50 μM of HMA lowered the pHi by 0.1-0.2 pH units both in pH 7.5 and 6.6 medium.  Heating at 43°C for 120 min lowered the pHi by 0.2 and 0.3 pH units in pH 7.5 and 6.6 medium, resp.  When the cells were heated in the presence of 10-50 μM HMA, a marked decline in pHi occurred and the decline in pHi resulting from the combination of heat and HMA was more pronounced in pH 6.6 medium than in pH 7.5 medium.  Heating the SCK tumors grown SC in the legs of A/J mice at 43.5°C for 1 h resulted in a growth delay of 3.7 days.  When the host mice were IV injected with 0.1 mg/kg of HMA and the tumors were heated 20 min later, the tumor growth was delayed by 8.2 days, which was 4.5 days longer than that by heating alone.  Heating the SCK tumor at 42.5°C for 1 h caused a tumor growth delay of 0.9 days.  An IV injection of 1 mg/kg or 10 mg/kg of HMA prior to heating at 42.5°C for 1 h caused a tumor growth delay 2.1 and 3.1 days longer, resp., than that by heating alone.  Such an enhancement of heat-induced tumor growth delay by HMA was due to increased cell killing, as detd. with the in vivo-in vitro excision assay of clonogenic cells in the tumors.  HMA is a potent thermosensitizer, particularly in an acidic environment.  Thermosensitization by HMA may occur preferentially in tumors relative to normal tissues since the intratumor environment is acidic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd3SFCokawJbVg90H21EOLACvtfcHk0lijWqE5a13JVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFaisbs%253D&md5=0ad7cd50c1caf2f3dd4456cb309631a8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2F0360-3016%2894%2990528-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0360-3016%252894%252990528-2%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DC.%2BW.%26aulast%3DLyons%26aufirst%3DJ.%2BC.%26aulast%3DMakepeace%26aufirst%3DC.%2BM.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DCragoe%26aufirst%3DE.%2BJ.%26atitle%3DEffects%2520of%2520HMA%252C%2520an%2520analog%2520of%2520amiloride%252C%2520on%2520the%2520thermosensitivity%2520of%2520tumors%2520in%2520vivo%26jtitle%3DInt.%2520J.%2520Radiat.%2520Oncol.%252C%2520Biol.%252C%2520Phys.%26date%3D1994%26volume%3D30%26issue%3D1%26spage%3D133%26epage%3D139%26doi%3D10.1016%2F0360-3016%2894%2990528-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tannock, I. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>70</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">617</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1038/bjc.1994.360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1038%2Fbjc.1994.360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=7917906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaK2MXitVWmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1994&pages=617-624&issue=4&author=J.+Luoauthor=I.+F.+Tannock&title=Inhibition+of+the+regulation+of+intracellular+pH%3A+potential+of+5-%28N%2CN-hexamethylene%29+amiloride+in+tumour-selective+therapy&doi=10.1038%2Fbjc.1994.360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the regulation of intracellular pH: Potential of 5-(N,N-hexamethylene)amiloride in tumor-selective therapy</span></div><div class="casAuthors">Luo, J.; Tannock, I. F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">617-24</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    </div><div class="casAbstract">The viability of cells within the acidic microenvironment found in solid tumors is expected to depend on the regulation of intracellular pH (pHi).  5-(N,N-hexamethylene)amiloride (HMA) is a potent inhibitor of the Na+/H+ antiport, a major mechanism for the regulation of pHi.  The authors have therefore studied the cytotoxicity of HMA in combination with nigericin, a cell-acidifying agent, for EMT-6 cells in monolayer cell culture, in spheroids and in a murine tumor model.  The combination of nigericin and HMA was toxic to cells in tissue culture at extracellular pH (pHe) ≤ 6.8 (as may be found in tumors) but not at pH 7.0 or above (as in most normal tissues).  Compared with amiloride, the relative potency of HMA in causing in vitro cytotoxicity (∼100-fold) was similar to that for inhibition of the Na+/H+ antiport.  The fluorescent probe Hoechst 33342 was used with flow cytometry to study the cytotoxicity of HMA and nigericin at different depths in multicellular tumor spheroids.  Only small differences in the level of cell survival were obsd., but higher concns. of HMA were required as compared with those giving equal levels of survival in monolayer culture.  The pharmacokinetics of HMA in mice was studied by using high-performance liq. chromatog.: after i.p. injection of 20 μg g-1, the plasma level of HMA peaked at 8 μM after about 15 min and decreased to 1 μM at 120 min; the half-life was 35 min.  Nigericin and HMA, at doses of 1.25 μg g-1 and 10 μg g-1 resp., failed to cause significant cell killing in the EMT-6 murine tumor, but the surviving fraction was reduced to ∼0.004 when hydralazine was administered with nigericin and HMA.  Local tumor irradn. (15 Gy), followed by treatment with these drugs, led to cell killing that was additive to the effects of drugs and radiation alone, so that hypoxic cells which survived radiation did not appear more sensitive to pH-dependent drug treatment.  Acid-mediated therapy can lead to cell death in murine solid tumors, but further measures will be required before the strategy can be exploited clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxQajsBgCzT7Vg90H21EOLACvtfcHk0lijWqE5a13JVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXitVWmtLY%253D&md5=2d687828c2ff7c90e4846c8001a85300</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1994.360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1994.360%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTannock%26aufirst%3DI.%2BF.%26atitle%3DInhibition%2520of%2520the%2520regulation%2520of%2520intracellular%2520pH%253A%2520potential%2520of%25205-%2528N%252CN-hexamethylene%2529%2520amiloride%2520in%2520tumour-selective%2520therapy%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1994%26volume%3D70%26issue%3D4%26spage%3D617%26epage%3D624%26doi%3D10.1038%2Fbjc.1994.360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rich, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worthington-White, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garden, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musk, P.</span></span> <span> </span><span class="NLM_article-title">Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na(+)/H(+) exchanger</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1427</span>– <span class="NLM_lpage">1434</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10666221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtFKitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2000&pages=1427-1434&issue=4&author=I.+N.+Richauthor=D.+Worthington-Whiteauthor=O.+A.+Gardenauthor=P.+Musk&title=Apoptosis+of+leukemic+cells+accompanies+reduction+in+intracellular+pH+after+targeted+inhibition+of+the+Na%28%2B%29%2FH%28%2B%29+exchanger"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na+/H+ exchanger</span></div><div class="casAuthors">Rich, Ivan N.; Worthington-White, Diana; Garden, Oliver A.; Musk, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1427-1434</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The Na+/H+ exchanger isoform 1 (NHE1) is primarily responsible for the regulation of intracellular pH (pHi).  It is a ubiquitous, amiloride-sensitive, growth factor-activatable exchanger whose role has been implicated in cell-cycle regulation, apoptosis, and neoplasia.  Here we demonstrate that leukemic cell lines and peripheral blood from primary patient leukemic samples exhibit a constitutively and statistically higher pHi than normal hematopoietic tissue.  We then show that a direct correlation exists between pHi and cell-cycle status of normal hematopoietic and leukemic cells.  Advantage was taken of this relationship by treating leukemic cells with the Na+/H+ exchanger inhibitor, 5-(N, N-hexamethylene)-amiloride (HMA), which decreases the pHi and induces apoptosis.  By incubating patient leukemic cells in vitro with pharmacol. doses of HMA for up to 5 h, we show, using flow cytometry and fluorescent ratio imaging microscopy, that when the pHi decreases, apoptosis-measured by annexin-V and TUNEL methodologies-rapidly increases so that more than 90% of the leukemic cells are killed.  The differential sensitivity exhibited between normal and leukemic cells allows consideration of NHE1 inhibitors as potential antileukemic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo86ZFcUKdn77Vg90H21EOLACvtfcHk0lijWqE5a13JVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtFKitLY%253D&md5=df9ec526fa033d2f2a48876d0d5a7645</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRich%26aufirst%3DI.%2BN.%26aulast%3DWorthington-White%26aufirst%3DD.%26aulast%3DGarden%26aufirst%3DO.%2BA.%26aulast%3DMusk%26aufirst%3DP.%26atitle%3DApoptosis%2520of%2520leukemic%2520cells%2520accompanies%2520reduction%2520in%2520intracellular%2520pH%2520after%2520targeted%2520inhibition%2520of%2520the%2520Na%2528%252B%2529%252FH%2528%252B%2529%2520exchanger%26jtitle%3DBlood%26date%3D2000%26volume%3D95%26issue%3D4%26spage%3D1427%26epage%3D1434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Man, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, A. Y.</span></span> <span> </span><span class="NLM_article-title">A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>123</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">2530</span>– <span class="NLM_lpage">2539</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-07-512194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1182%2Fblood-2013-07-512194" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=2530-2539&issue=16&author=C.+H.+Manauthor=S.+S.+Lamauthor=M.+K.+Sunauthor=H.+C.+Chowauthor=H.+Gillauthor=Y.+L.+Kwongauthor=A.+Y.+Leung&title=A+novel+tescalcin-sodium%2Fhydrogen+exchange+axis+underlying+sorafenib+resistance+in+FLT3-ITD%2B+AML&doi=10.1182%2Fblood-2013-07-512194"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-07-512194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-07-512194%26sid%3Dliteratum%253Aachs%26aulast%3DMan%26aufirst%3DC.%2BH.%26aulast%3DLam%26aufirst%3DS.%2BS.%26aulast%3DSun%26aufirst%3DM.%2BK.%26aulast%3DChow%26aufirst%3DH.%2BC.%26aulast%3DGill%26aufirst%3DH.%26aulast%3DKwong%26aufirst%3DY.%2BL.%26aulast%3DLeung%26aufirst%3DA.%2BY.%26atitle%3DA%2520novel%2520tescalcin-sodium%252Fhydrogen%2520exchange%2520axis%2520underlying%2520sorafenib%2520resistance%2520in%2520FLT3-ITD%252B%2520AML%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26issue%3D16%26spage%3D2530%26epage%3D2539%26doi%3D10.1182%2Fblood-2013-07-512194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T. L.</span></span> <span> </span><span class="NLM_article-title">Identification of acid-sensing ion channels in adenoid cystic carcinomas</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>355</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">986</span>– <span class="NLM_lpage">992</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2007.02.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.bbrc.2007.02.061" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2007&pages=986-992&issue=4&author=J.+H.+Yeauthor=J.+Gaoauthor=Y.+N.+Wuauthor=Y.+J.+Huauthor=C.+P.+Zhangauthor=T.+L.+Xu&title=Identification+of+acid-sensing+ion+channels+in+adenoid+cystic+carcinomas&doi=10.1016%2Fj.bbrc.2007.02.061"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2007.02.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2007.02.061%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DJ.%2BH.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%2BN.%26aulast%3DHu%26aufirst%3DY.%2BJ.%26aulast%3DZhang%26aufirst%3DC.%2BP.%26aulast%3DXu%26aufirst%3DT.%2BL.%26atitle%3DIdentification%2520of%2520acid-sensing%2520ion%2520channels%2520in%2520adenoid%2520cystic%2520carcinomas%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2007%26volume%3D355%26issue%3D4%26spage%3D986%26epage%3D992%26doi%3D10.1016%2Fj.bbrc.2007.02.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowson-Hodel, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wald, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanderVorst, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curiel, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carraway, K. L.</span></span> <span> </span><span class="NLM_article-title">Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.02.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.canlet.2016.02.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=26944316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjslygs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=62-72&issue=1&author=A.+R.+Rowson-Hodelauthor=A.+L.+Bergauthor=J.+H.+Waldauthor=J.+Hatakeyamaauthor=K.+VanderVorstauthor=D.+A.+Curielauthor=L.+J.+Leonauthor=C.+Sweeneyauthor=K.+L.+Carraway&title=Hexamethylene+amiloride+engages+a+novel+reactive+oxygen+species-+and+lysosome-dependent+programmed+necrotic+mechanism+to+selectively+target+breast+cancer+cells&doi=10.1016%2Fj.canlet.2016.02.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells</span></div><div class="casAuthors">Rowson-Hodel, Ashley R.; Berg, Anastasia L.; Wald, Jessica H.; Hatakeyama, Jason; VanderVorst, Kacey; Curiel, Daniel A.; Leon, Leonardo J.; Sweeney, Colleen; Carraway, Kermit L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-72</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Anticancer chemotherapeutics often rely on induction of apoptosis in rapidly dividing cells.  While these treatment strategies are generally effective in debulking the primary tumor, post-therapeutic recurrence and metastasis are pervasive concerns with potentially devastating consequences.  We demonstrate that the amiloride deriv. 5-(N,N-hexamethylene) amiloride (HMA) harbors cytotoxic properties particularly attractive for a novel class of therapeutic agent.  HMA is potently and specifically cytotoxic toward breast cancer cells, with remarkable selectivity for transformed cells relative to non-transformed or primary cells.  Nonetheless, HMA is similarly cytotoxic to breast cancer cells irresp. of their mol. profile, proliferative status, or species of origin, suggesting that it engages a cell death mechanism common to all breast tumor subtypes.  We obsd. that HMA induces a novel form of caspase- and autophagy-independent programmed necrosis relying on the orchestration of mitochondrial and lysosomal pro-death mechanisms, where its cytotoxicity was attenuated with ROS-scavengers or lysosomal cathepsin inhibition.  Overall, our findings suggest HMA may efficiently target the heterogeneous populations of cancer cells known to reside within a single breast tumor by induction of a ROS- and lysosome-mediated form of programmed necrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoArlIWBoHhCLVg90H21EOLACvtfcHk0lg5UHJ3R2uESQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjslygs7c%253D&md5=2985012c2d32a10d9b8c8830955f84e8</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.02.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.02.042%26sid%3Dliteratum%253Aachs%26aulast%3DRowson-Hodel%26aufirst%3DA.%2BR.%26aulast%3DBerg%26aufirst%3DA.%2BL.%26aulast%3DWald%26aufirst%3DJ.%2BH.%26aulast%3DHatakeyama%26aufirst%3DJ.%26aulast%3DVanderVorst%26aufirst%3DK.%26aulast%3DCuriel%26aufirst%3DD.%2BA.%26aulast%3DLeon%26aufirst%3DL.%2BJ.%26aulast%3DSweeney%26aufirst%3DC.%26aulast%3DCarraway%26aufirst%3DK.%2BL.%26atitle%3DHexamethylene%2520amiloride%2520engages%2520a%2520novel%2520reactive%2520oxygen%2520species-%2520and%2520lysosome-dependent%2520programmed%2520necrotic%2520mechanism%2520to%2520selectively%2520target%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D375%26issue%3D1%26spage%3D62%26epage%3D72%26doi%3D10.1016%2Fj.canlet.2016.02.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleyman, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cragoe, E. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Cation transport probes: the amiloride series</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.1016/0076-6879(90)91045-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2F0076-6879%2890%2991045-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=1990&pages=739-755&author=T.+R.+Kleymanauthor=E.+J.+Cragoe&title=Cation+transport+probes%3A+the+amiloride+series&doi=10.1016%2F0076-6879%2890%2991045-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2F0076-6879%2890%2991045-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0076-6879%252890%252991045-8%26sid%3Dliteratum%253Aachs%26aulast%3DKleyman%26aufirst%3DT.%2BR.%26aulast%3DCragoe%26aufirst%3DE.%2BJ.%26atitle%3DCation%2520transport%2520probes%253A%2520the%2520amiloride%2520series%26jtitle%3DMethods%2520Enzymol.%26date%3D1990%26volume%3D191%26spage%3D739%26epage%3D755%26doi%3D10.1016%2F0076-6879%2890%2991045-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cragoe, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woltersdorf, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicking, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. H.</span></span> <span> </span><span class="NLM_article-title">Pyrazine Diuretics. II. N-Amidino-3-amino-5-substituted 6-Halopyrazinecarboxamides</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1021/jm00313a014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00313a014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1967&pages=66-75&issue=1&author=E.+J.+Cragoeauthor=O.+W.+Woltersdorfauthor=J.+B.+Bickingauthor=S.+F.+Kwongauthor=J.+H.+Jones&title=Pyrazine+Diuretics.+II.+N-Amidino-3-amino-5-substituted+6-Halopyrazinecarboxamides&doi=10.1021%2Fjm00313a014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm00313a014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00313a014%26sid%3Dliteratum%253Aachs%26aulast%3DCragoe%26aufirst%3DE.%2BJ.%26aulast%3DWoltersdorf%26aufirst%3DO.%2BW.%26aulast%3DBicking%26aufirst%3DJ.%2BB.%26aulast%3DKwong%26aufirst%3DS.%2BF.%26aulast%3DJones%26aufirst%3DJ.%2BH.%26atitle%3DPyrazine%2520Diuretics.%2520II.%2520N-Amidino-3-amino-5-substituted%25206-Halopyrazinecarboxamides%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1967%26volume%3D10%26issue%3D1%26spage%3D66%26epage%3D75%26doi%3D10.1021%2Fjm00313a014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patwardhan, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathyamoorthy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Hashimi, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrove, A. E.</span></span> <span> </span><span class="NLM_article-title">Amiloride as a new RNA-binding scaffold with activity against HIV-1 TAR</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1022</span>– <span class="NLM_lpage">1036</span>, <span class="refDoi"> DOI: 10.1039/C6MD00729E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1039%2FC6MD00729E" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1022-1036&issue=5&author=N.+N.+Patwardhanauthor=L.+R.+Ganserauthor=G.+J.+Kapralauthor=C.+S.+Eubanksauthor=J.+Leeauthor=B.+Sathyamoorthyauthor=H.+M.+Al-Hashimiauthor=A.+E.+Hargrove&title=Amiloride+as+a+new+RNA-binding+scaffold+with+activity+against+HIV-1+TAR&doi=10.1039%2FC6MD00729E"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1039%2FC6MD00729E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00729E%26sid%3Dliteratum%253Aachs%26aulast%3DPatwardhan%26aufirst%3DN.%2BN.%26aulast%3DGanser%26aufirst%3DL.%2BR.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DEubanks%26aufirst%3DC.%2BS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DSathyamoorthy%26aufirst%3DB.%26aulast%3DAl-Hashimi%26aufirst%3DH.%2BM.%26aulast%3DHargrove%26aufirst%3DA.%2BE.%26atitle%3DAmiloride%2520as%2520a%2520new%2520RNA-binding%2520scaffold%2520with%2520activity%2520against%2520HIV-1%2520TAR%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26issue%3D5%26spage%3D1022%26epage%3D1036%26doi%3D10.1039%2FC6MD00729E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeslawska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweinitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karcher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondermann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturzebecher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, U.</span></span> <span> </span><span class="NLM_article-title">Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>301</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">475</span>, <span class="refDoi"> DOI: 10.1006/jmbi.2000.3966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1006%2Fjmbi.2000.3966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10926521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltlCjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2000&pages=465-475&issue=2&author=E.+Zeslawskaauthor=A.+Schweinitzauthor=A.+Karcherauthor=P.+Sondermannauthor=S.+Sperlauthor=J.+Sturzebecherauthor=U.+Jacob&title=Crystals+of+the+urokinase+type+plasminogen+activator+variant+beta%28c%29-uPAin+complex+with+small+molecule+inhibitors+open+the+way+towards+structure-based+drug+design&doi=10.1006%2Fjmbi.2000.3966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Crystals of the Urokinase Type Plasminogen Activator Variant βc-uPA in Complex with Small Molecule Inhibitors Open the Way towards Structure-based Drug Design</span></div><div class="casAuthors">Zeslawska, Ewa; Schweinitz, Andrea; Karcher, Annette; Sondermann, Peter; Sperl, Stefan; Sturzebecher, Jorg; Jacob, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">465-475</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Urokinase is a serine protease involved in cancer growth and metastasis.  Here the authors present the first urokinase crystal structure in complex with reversible inhibitors at 2.1 and 2.6 Å resoln.  These inhibitor complex structures have been obtained from crystals of engineered urokinase type plasminogen activator designed to obtain a crystal form open for inhibitor soaking.  The mutant C122S loses its flexible A-chain upon activation cleavage and crystallizes in the presence of benzamidine, which was later displaced by the desired inhibitor.  This new soakable crystal form turned out to be of great value in the process of structure-based drug design.  The evaluated binding mode of amiloride, and UKI-1D revealed a new subsite of the primary specificity pocket of urokinase that will be employed in the future ligand optimization process.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWO6L7KKfXq7Vg90H21EOLACvtfcHk0lg7JZUCFCW-eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltlCjsLo%253D&md5=d67810ed0e2ea6ba1f4a601687883926</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.2000.3966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.2000.3966%26sid%3Dliteratum%253Aachs%26aulast%3DZeslawska%26aufirst%3DE.%26aulast%3DSchweinitz%26aufirst%3DA.%26aulast%3DKarcher%26aufirst%3DA.%26aulast%3DSondermann%26aufirst%3DP.%26aulast%3DSperl%26aufirst%3DS.%26aulast%3DSturzebecher%26aufirst%3DJ.%26aulast%3DJacob%26aufirst%3DU.%26atitle%3DCrystals%2520of%2520the%2520urokinase%2520type%2520plasminogen%2520activator%2520variant%2520beta%2528c%2529-uPAin%2520complex%2520with%2520small%2520molecule%2520inhibitors%2520open%2520the%2520way%2520towards%2520structure-based%2520drug%2520design%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2000%26volume%3D301%26issue%3D2%26spage%3D465%26epage%3D475%26doi%3D10.1006%2Fjmbi.2000.3966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S.-e.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span> <span> </span><span class="NLM_article-title">(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2882</span>– <span class="NLM_lpage">2891</span>, <span class="refDoi"> DOI: 10.1021/jm0492305</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0492305" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2882-2891&issue=8&author=S.+Leeauthor=K.+Y.+Yiauthor=S.+K.+Hwangauthor=B.+H.+Leeauthor=S.-e.+Yooauthor=K.+Lee&title=%285-Arylfuran-2-ylcarbonyl%29guanidines+as+cardioprotectives+through+the+inhibition+of+Na%2B%2FH%2B+exchanger+isoform-1&doi=10.1021%2Fjm0492305"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm0492305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0492305%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%26aulast%3DYi%26aufirst%3DK.%2BY.%26aulast%3DHwang%26aufirst%3DS.%2BK.%26aulast%3DLee%26aufirst%3DB.%2BH.%26aulast%3DYoo%26aufirst%3DS.-e.%26aulast%3DLee%26aufirst%3DK.%26atitle%3D%25285-Arylfuran-2-ylcarbonyl%2529guanidines%2520as%2520cardioprotectives%2520through%2520the%2520inhibition%2520of%2520Na%252B%252FH%252B%2520exchanger%2520isoform-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D8%26spage%3D2882%26epage%3D2891%26doi%3D10.1021%2Fjm0492305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawardhana, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vine, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span> <span> </span><span class="NLM_article-title">The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity</span>. <i>BMC Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">43</span>, <span class="refDoi"> DOI: 10.1186/1472-6750-9-43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1186%2F1472-6750-9-43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=19442270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A280%3ADC%252BD1Mvgt1CksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=43&author=B.+J.+Cochranauthor=L.+P.+Gunawardhanaauthor=K.+L.+Vineauthor=J.+A.+Leeauthor=S.+Lobovauthor=M.+Ranson&title=The+CD-loop+of+PAI-2+%28SERPINB2%29+is+redundant+in+the+targeting%2C+inhibition+and+clearance+of+cell+surface+uPA+activity&doi=10.1186%2F1472-6750-9-43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity</span></div><div class="casAuthors">Cochran Blake J; Gunawardhana Lakshitha P; Vine Kara L; Lee Jodi A; Lobov Sergei; Ranson Marie</div><div class="citationInfo"><span class="NLM_cas:title">BMC biotechnology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Plasminogen activator inhibitor type-2 (PAI-2, SERPINB2) is an irreversible, specific inhibitor of the urokinase plasminogen activator (uPA).  Since overexpression of uPA at the surface of cancer cells is linked to malignancy, targeting of uPA by exogenous recombinant PAI-2 has been proposed as the basis of potential cancer therapies.  To this end, reproducible yields of high purity protein that maintains this targeting ability is required.  Herein we validate the use in vitro of recombinant 6 x His-tagged-PAI-2 lacking the intrahelical loop between C and D alpha-helices (PAI-2 Delta CD-loop) for these purposes.  RESULTS:  We show that PAI-2 Delta CD-loop expressed and purified from the pQE9 vector system presents an easier purification target than the previously used pET15b system.  Additionally, PAI-2 Delta CD-loop gave both higher yield and purity than wild-type PAI-2 expressed and purified under identical conditions.  Importantly, absence of the CD-loop had no impact on the inhibition of both solution phase and cell surface uPA or on the clearance of receptor bound uPA from the cell surface.  Furthermore, uPA:PAI-2 Delta CD-loop complexes had similar binding kinetics (KD approximately 5 nM) with the endocytosis receptor Very Low Density Lipoprotein Receptor (VLDLR) to that previously published for uPA:PAI-2 complexes.  CONCLUSION:  We demonstrate that the CD-loop is redundant for the purposes of cellular uPA inhibition and cell surface clearance (endocytosis) and is thus suitable for the development of anti-uPA targeted cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSS-Sk6_th3hp0d-O_J5C0AfW6udTcc2ea1QIEFyRupcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mvgt1CksA%253D%253D&md5=9319fe04e9a23728b814cd5fb9b09234</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1186%2F1472-6750-9-43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6750-9-43%26sid%3Dliteratum%253Aachs%26aulast%3DCochran%26aufirst%3DB.%2BJ.%26aulast%3DGunawardhana%26aufirst%3DL.%2BP.%26aulast%3DVine%26aufirst%3DK.%2BL.%26aulast%3DLee%26aufirst%3DJ.%2BA.%26aulast%3DLobov%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DThe%2520CD-loop%2520of%2520PAI-2%2520%2528SERPINB2%2529%2520is%2520redundant%2520in%2520the%2520targeting%252C%2520inhibition%2520and%2520clearance%2520of%2520cell%2520surface%2520uPA%2520activity%26jtitle%3DBMC%2520Biotechnol.%26date%3D2009%26volume%3D9%26spage%3D43%26doi%3D10.1186%2F1472-6750-9-43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yung-Chi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">3099</span>– <span class="NLM_lpage">3108</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=4202581" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&issue=23&author=C.+Yung-Chiauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28KI%29+and+the+concentration+of+inhibitor+which+causes+50%25+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DYung-Chi%26aufirst%3DC.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528KI%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2525%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26issue%3D23%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nienaber, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkin, J.</span></span> <span> </span><span class="NLM_article-title">Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">7239</span>– <span class="NLM_lpage">7248</span>, <span class="refDoi"> DOI: 10.1074/jbc.275.10.7239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1074%2Fjbc.275.10.7239" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=7239-7248&issue=10&author=V.+Nienaberauthor=J.+Wangauthor=D.+Davidsonauthor=J.+Henkin&title=Re-engineering+of+human+urokinase+provides+a+system+for+structure-based+drug+design+at+high+resolution+and+reveals+a+novel+structural+subsite&doi=10.1074%2Fjbc.275.10.7239"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1074%2Fjbc.275.10.7239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.275.10.7239%26sid%3Dliteratum%253Aachs%26aulast%3DNienaber%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDavidson%26aufirst%3DD.%26aulast%3DHenkin%26aufirst%3DJ.%26atitle%3DRe-engineering%2520of%2520human%2520urokinase%2520provides%2520a%2520system%2520for%2520structure-based%2520drug%2520design%2520at%2520high%2520resolution%2520and%2520reveals%2520a%2520novel%2520structural%2520subsite%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26issue%3D10%26spage%3D7239%26epage%3D7248%26doi%3D10.1074%2Fjbc.275.10.7239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachovchin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblan, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woznica, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poplawski, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiritsy, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMare, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanford, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munford, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachovchin, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span> <span> </span><span class="NLM_article-title">A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">656</span>– <span class="NLM_lpage">663</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1038%2Fnchembio.1578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=24997602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSlsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=656-663&issue=8&author=D.+A.+Bachovchinauthor=L.+W.+Koblanauthor=W.+Wuauthor=Y.+Liuauthor=Y.+Liauthor=P.+Zhaoauthor=I.+Woznicaauthor=Y.+Shuauthor=J.+H.+Laiauthor=S.+E.+Poplawskiauthor=C.+P.+Kiritsyauthor=S.+E.+Healeyauthor=M.+DiMareauthor=D.+G.+Sanfordauthor=R.+S.+Munfordauthor=W.+W.+Bachovchinauthor=T.+R.+Golub&title=A+high-throughput%2C+multiplexed+assay+for+superfamily-wide+profiling+of+enzyme+activity&doi=10.1038%2Fnchembio.1578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity</span></div><div class="casAuthors">Bachovchin, Daniel A.; Koblan, Luke W.; Wu, Wengen; Liu, Yuxin; Li, Youhua; Zhao, Peng; Woznica, Iwona; Shu, Ying; Lai, Jack H.; Poplawski, Sarah E.; Kiritsy, Christopher P.; Healey, Sarah E.; Di Mare, Matthew; Sanford, David G.; Munford, Robert S.; Bachovchin, William W.; Golub, Todd R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">656-663</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The selectivity of an enzyme inhibitor is a key determinant of its usefulness as a tool compd. or its safety as a drug.  Yet selectivity is never assessed comprehensively in the early stages of the drug discovery process, and only rarely in the later stages, because tech. limitations prohibit doing otherwise.  Here, we report EnPlex, an efficient, high-throughput method for simultaneously assessing inhibitor potency and specificity, and pilot its application to 96 serine hydrolases.  EnPlex anal. of widely used serine hydrolase inhibitors revealed numerous previously unrecognized off-target interactions, some of which may help to explain previously confounding adverse effects.  In addn., EnPlex screening of a hydrolase-directed library of boronic acid- and nitrile-contg. compds. provided structure-activity relationships in both potency and selectivity dimensions from which lead candidates could be more effectively prioritized.  Follow-up of a series of dipeptidyl peptidase 4 inhibitors showed that EnPlex indeed predicted efficacy and safety in animal models.  These results demonstrate the feasibility and value of high-throughput, superfamily-wide selectivity profiling and suggest that such profiling can be incorporated into the earliest stages of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxvrqyTuuh07Vg90H21EOLACvtfcHk0ljJSiRJYgqs4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSlsLrI&md5=a047ea0af874967ae10296e4ab5fbdad</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1578%26sid%3Dliteratum%253Aachs%26aulast%3DBachovchin%26aufirst%3DD.%2BA.%26aulast%3DKoblan%26aufirst%3DL.%2BW.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DWoznica%26aufirst%3DI.%26aulast%3DShu%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DJ.%2BH.%26aulast%3DPoplawski%26aufirst%3DS.%2BE.%26aulast%3DKiritsy%26aufirst%3DC.%2BP.%26aulast%3DHealey%26aufirst%3DS.%2BE.%26aulast%3DDiMare%26aufirst%3DM.%26aulast%3DSanford%26aufirst%3DD.%2BG.%26aulast%3DMunford%26aufirst%3DR.%2BS.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26atitle%3DA%2520high-throughput%252C%2520multiplexed%2520assay%2520for%2520superfamily-wide%2520profiling%2520of%2520enzyme%2520activity%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26issue%3D8%26spage%3D656%26epage%3D663%26doi%3D10.1038%2Fnchembio.1578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soisson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abeywickrema, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickert, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumb, K. J.</span></span> <span> </span><span class="NLM_article-title">Structural definition and substrate specificity of the S28 protease family: the crystal structure of human prolylcarboxypeptidase</span>. <i>BMC Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">16</span>, <span class="refDoi"> DOI: 10.1186/1472-6807-10-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1186%2F1472-6807-10-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=20540760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A280%3ADC%252BC3cnjsV2lsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=16&issue=16&author=S.+M.+Soissonauthor=S.+B.+Patelauthor=P.+D.+Abeywickremaauthor=N.+J.+Byrneauthor=R.+E.+Diehlauthor=D.+L.+Hallauthor=R.+E.+Fordauthor=J.+C.+Reidauthor=K.+W.+Rickertauthor=J.+M.+Shipmanauthor=S.+Sharmaauthor=K.+J.+Lumb&title=Structural+definition+and+substrate+specificity+of+the+S28+protease+family%3A+the+crystal+structure+of+human+prolylcarboxypeptidase&doi=10.1186%2F1472-6807-10-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Structural definition and substrate specificity of the S28 protease family: the crystal structure of human prolylcarboxypeptidase</span></div><div class="casAuthors">Soisson Stephen M; Patel Sangita B; Abeywickrema Pravien D; Byrne Noel J; Diehl Ronald E; Hall Dawn L; Ford Rachael E; Reid John C; Rickert Keith W; Shipman Jennifer M; Sharma Sujata; Lumb Kevin J</div><div class="citationInfo"><span class="NLM_cas:title">BMC structural biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The unique S28 family of proteases is comprised of the carboxypeptidase PRCP and the aminopeptidase DPP7.  The structural basis of the different substrate specificities of the two enzymes is not understood nor has the structure of the S28 fold been described.  RESULTS:  The experimentally phased 2.8 A crystal structure is presented for human PRCP.  PRCP contains an alpha/beta hydrolase domain harboring the catalytic Asp-His-Ser triad and a novel helical structural domain that caps the active site.  Structural comparisons with prolylendopeptidase and DPP4 identify the S1 proline binding site of PRCP.  A structure-based alignment with the previously undescribed structure of DPP7 illuminates the mechanism of orthogonal substrate specificity of PRCP and DPP7.  PRCP has an extended active-site cleft that can accommodate proline substrates with multiple N-terminal residues.  In contrast, the substrate binding groove of DPP7 is occluded by a short amino-acid insertion unique to DPP7 that creates a truncated active site selective for dipeptidyl proteolysis of N-terminal substrates.  CONCLUSION:  The results define the structure of the S28 family of proteases, provide the structural basis of PRCP and DPP7 substrate specificity and enable the rational design of selective PRCP modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0lIMBqBv6-ROk4JA3soTqfW6udTcc2eYKNkqPE2aLNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnjsV2lsw%253D%253D&md5=994545a9e7ce68d57dc6e7377d64f019</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1186%2F1472-6807-10-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6807-10-16%26sid%3Dliteratum%253Aachs%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DAbeywickrema%26aufirst%3DP.%2BD.%26aulast%3DByrne%26aufirst%3DN.%2BJ.%26aulast%3DDiehl%26aufirst%3DR.%2BE.%26aulast%3DHall%26aufirst%3DD.%2BL.%26aulast%3DFord%26aufirst%3DR.%2BE.%26aulast%3DReid%26aufirst%3DJ.%2BC.%26aulast%3DRickert%26aufirst%3DK.%2BW.%26aulast%3DShipman%26aufirst%3DJ.%2BM.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26atitle%3DStructural%2520definition%2520and%2520substrate%2520specificity%2520of%2520the%2520S28%2520protease%2520family%253A%2520the%2520crystal%2520structure%2520of%2520human%2520prolylcarboxypeptidase%26jtitle%3DBMC%2520Struct.%2520Biol.%26date%3D2010%26volume%3D10%26issue%3D16%26spage%3D16%26doi%3D10.1186%2F1472-6807-10-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soudijn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Wijngaarden, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzermann, A. P.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of G protein-coupled receptors: perspectives and recent developments</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">752</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03220-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2FS1359-6446%2804%2903220-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=15450241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvFCruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=752-758&issue=17&author=W.+Soudijnauthor=I.+Van+Wijngaardenauthor=A.+P.+Ijzermann&title=Allosteric+modulation+of+G+protein-coupled+receptors%3A+perspectives+and+recent+developments&doi=10.1016%2FS1359-6446%2804%2903220-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of G protein-coupled receptors: perspectives and recent developments</span></div><div class="casAuthors">Soudijn, Willem; van Wijngaarden, Ineke; Ijzerman, Ad P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">752-758</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  'Allosteric' rather than 'orthosteric' modulation of G protein-coupled receptors is a more natural way of intervening in receptor function and, thus, could lead to superior therapeutics.  Allosteric modulation of G protein-coupled receptors has recently been recognized as an alternative approach to gain selectivity in drug action.  In this overview, allosteric modulators that enhance or diminish the effects of (endogenous) agonists or antagonists on a variety of G protein-coupled receptors are described.  Emphasis is placed on the latest developments in this research area, including data on the first clin. studies.  It appears that all 3 major classes of G protein-coupled receptors (A, B and C) are amenable to allosteric modulation by small mols.  This constitutes an attractive and novel means to identify new leads in the drug discovery process.  However, it requires a re-engineering of the majority of current assays.  Finally, it is suggested to introduce the term 'non-competitive agonism' or allosteric agonism' next to allosteric modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoumXxOTZcyg7Vg90H21EOLACvtfcHk0ljJSiRJYgqs4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvFCruro%253D&md5=e7fbeb9d23cfc07c41eee979a3526de5</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903220-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903220-9%26sid%3Dliteratum%253Aachs%26aulast%3DSoudijn%26aufirst%3DW.%26aulast%3DVan%2BWijngaarden%26aufirst%3DI.%26aulast%3DIjzermann%26aufirst%3DA.%2BP.%26atitle%3DAllosteric%2520modulation%2520of%2520G%2520protein-coupled%2520receptors%253A%2520perspectives%2520and%2520recent%2520developments%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26issue%3D17%26spage%3D752%26epage%3D758%26doi%3D10.1016%2FS1359-6446%2804%2903220-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of A(2A) adenosine receptors by amiloride analogues and sodium ions</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1016/S0006-2952(00)00360-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2FS0006-2952%2800%2900360-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10927025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1Knsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=669-676&issue=5&author=Z.+G.+Gaoauthor=A.+P.+Ijzerman&title=Allosteric+modulation+of+A%282A%29+adenosine+receptors+by+amiloride+analogues+and+sodium+ions&doi=10.1016%2FS0006-2952%2800%2900360-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of A2A adenosine receptors by amiloride analogs and sodium ions</span></div><div class="casAuthors">Gao, Z.-G.; Ijzerman, A. P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">669-676</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Allosteric regulation of rat A2A adenosine receptors by amiloride, amiloride analogs, and sodium ions was studied by investigating their ability to influence the dissocn. of [3H]4-{2-[7-amino-2-(2-furyl)-1,2,4-triazolo[1,5-a][1,3,5]triazin-5-yl-amino]ethyl}phenol ([3H]ZM241385) from receptors in rat striatal membranes.  Both amiloride and its analogs accelerated the dissocn., the analogs being more potent than amiloride itself.  In contrast, sodium ions decreased the rate of [3H]ZM241385 dissocn. in a concn.-dependent manner, and this rate was not influenced by guanosine triphosphate, N-ethylmaleimide, suramin, or the selective A2A adenosine receptor antagonist, 5-amino-2-(2-furyl)-7(2-phenylethyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH58261).  The effect of competition between the amiloride analog 5-(N,N-hexamethylene)amiloride (HMA) and sodium ions on [3H]ZM241385 dissocn. was also explored.  The addn. of sodium ions resulted in a concn.-dependent rightward shift of the HMA response curve.  The slopes of the HMA concn.-response curves in the presence and absence of sodium ions were not significantly different, which suggests that sodium ions and amiloride analogs act at a common allosteric site on the A2A adenosine receptor.  There was a lack of correlation between the displacement of ligand binding and the allosteric potencies of the amiloride analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDiF_W2jWd6bVg90H21EOLACvtfcHk0lgA7fgyMgctXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1Knsbk%253D&md5=c5bb422d0ebabf5924083a406c62c9a4</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2800%2900360-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252800%252900360-9%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DZ.%2BG.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26atitle%3DAllosteric%2520modulation%2520of%2520A%25282A%2529%2520adenosine%2520receptors%2520by%2520amiloride%2520analogues%2520and%2520sodium%2520ions%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2000%26volume%3D60%26issue%3D5%26spage%3D669%26epage%3D676%26doi%3D10.1016%2FS0006-2952%2800%2900360-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garritsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beukers, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soudijn, W.</span></span> <span> </span><span class="NLM_article-title">Recognition of adenosine receptors by amiloride and its analogues</span>. <i>Nucleosides Nucleotides</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1111</span>, <span class="refDoi"> DOI: 10.1080/07328319108047248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1080%2F07328319108047248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaK3MXlvF2gsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1991&pages=1107-1111&issue=5&author=A.+Garritsenauthor=M.+W.+Beukersauthor=A.+P.+Ijzermanauthor=W.+Soudijn&title=Recognition+of+adenosine+receptors+by+amiloride+and+its+analogues&doi=10.1080%2F07328319108047248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Recognition of adenosine receptors by amiloride and its analogs</span></div><div class="casAuthors">Garritsen, A.; Beukers, M. W.; IJzerman, A. P.; Soudijn, W.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleosides & Nucleotides</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1107-11</span>CODEN:
                <span class="NLM_cas:coden">NUNUD5</span>;
        ISSN:<span class="NLM_cas:issn">0732-8311</span>.
    </div><div class="casAbstract">Amiloride and its analogs displace the adenosine A1 receptor ligands 3H-labeled 8-cyclopentyl-1,3-dipropylxanthine ([3H]CPDPX) and 3H-labeled N6-R-1-phenyl-2-propyladenosine ([3H]PIA) from their binding sites in calf brain membranes in a GTP-insensitive manner.  High [NaCl] or low pH reduces the affinity of amiloride for A1 receptors, whereas the affinity of [3H]CPDPX is not affected.  Notwithstanding this difference in modulation, the interaction between amiloride and A1 receptors appears competitive in nature.  The structure-affinity relationships differ from those for classic amiloride-sensitive Na+ transport systems, indicating that a coupling between the A1 receptor and one of these systems is very unlikely.  Amiloride and its analogs may represent a novel class of A1 receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBkh90z_6bsbVg90H21EOLACvtfcHk0lgA7fgyMgctXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlvF2gsbg%253D&md5=4cedbaf2f0755d7e0d9d188ce0426d38</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1080%2F07328319108047248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07328319108047248%26sid%3Dliteratum%253Aachs%26aulast%3DGarritsen%26aufirst%3DA.%26aulast%3DBeukers%26aufirst%3DM.%2BW.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DSoudijn%26aufirst%3DW.%26atitle%3DRecognition%2520of%2520adenosine%2520receptors%2520by%2520amiloride%2520and%2520its%2520analogues%26jtitle%3DNucleosides%2520Nucleotides%26date%3D1991%26volume%3D10%26issue%3D5%26spage%3D1107%26epage%3D1111%26doi%3D10.1080%2F07328319108047248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garritsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulp, M. M. Th.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cragoe, E. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soudijn, W.</span></span> <span> </span><span class="NLM_article-title">Receptor binding profiles of amiloride analogues provide no evidence for a link between receptors and the Na+/H+ exchanger, but indicate a common structure on receptor proteins</span>. <i>J. Recept. Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">907</span>, <span class="refDoi"> DOI: 10.3109/10799899109064686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.3109%2F10799899109064686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1661335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaK38Xht1yr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1991&pages=891-907&issue=6&author=A.+Garritsenauthor=A.+P.+Ijzermanauthor=M.+M.+Th.+Tulpauthor=E.+J.+Cragoeauthor=W.+Soudijn&title=Receptor+binding+profiles+of+amiloride+analogues+provide+no+evidence+for+a+link+between+receptors+and+the+Na%2B%2FH%2B+exchanger%2C+but+indicate+a+common+structure+on+receptor+proteins&doi=10.3109%2F10799899109064686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor binding profiles of amiloride analogs provide no evidence for a link between receptors and the sodium/hydrogen ion exchanger, but indicate a common structure on receptor proteins</span></div><div class="casAuthors">Garritsen, Anja; IJzerman, Adriaan P.; Tulp, Martin T. M.; Cragoe, Edward J., Jr.; Soudijn, Willem</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Receptor Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">891-907</span>CODEN:
                <span class="NLM_cas:coden">JRERDM</span>;
        ISSN:<span class="NLM_cas:issn">0197-5110</span>.
    </div><div class="casAbstract">Amiloride and its analogs affect radioligand binding to the adenosine A1 receptor.  The specificity of this effect is investigated by generating receptor-binding profiles for amiloride and two of its analogs.  A limited structure-activity relationships study is performed to probe the relationship between inhibition of receptor binding by amiloride analogs and the effects of these compds. on Na+ transport, in particular Na+/H+ exchange.  The receptor-binding profiles of amiloride, benzamil, and 5'-(N,N-hexamethylene)amiloride (HMA) indicate that the compds. affect a variety of receptors and that none of the compds. is highly selective for any of them.  The structure-activity relationship study indicates that it is very unlikely that a direct coupling between receptors and Na+/H+ exchange or another amiloride-sensitive ion transport system is responsible for the inhibition of receptor binding.  A correlation between the signal transduction systems coupled to the receptors involved and the potency of the amiloride analogs is also absent.  The varying nature of the receptors affected by amiloride or its analogs suggests a wide-spread presence of an amiloride-binding site on receptors and other membrane proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodA698X-W10LVg90H21EOLACvtfcHk0lgA7fgyMgctXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xht1yr&md5=7b58cec419bbfb4c3b7dc2e2aa0d50e0</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3109%2F10799899109064686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10799899109064686%26sid%3Dliteratum%253Aachs%26aulast%3DGarritsen%26aufirst%3DA.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DTulp%26aufirst%3DM.%2BM.%2BTh.%26aulast%3DCragoe%26aufirst%3DE.%2BJ.%26aulast%3DSoudijn%26aufirst%3DW.%26atitle%3DReceptor%2520binding%2520profiles%2520of%2520amiloride%2520analogues%2520provide%2520no%2520evidence%2520for%2520a%2520link%2520between%2520receptors%2520and%2520the%2520Na%252B%252FH%252B%2520exchanger%252C%2520but%2520indicate%2520a%2520common%2520structure%2520on%2520receptor%2520proteins%26jtitle%3DJ.%2520Recept.%2520Res.%26date%3D1991%26volume%3D11%26issue%3D6%26spage%3D891%26epage%3D907%26doi%3D10.3109%2F10799899109064686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Lera Ruiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptor as a drug discovery target</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3623</span>– <span class="NLM_lpage">3650</span>, <span class="refDoi"> DOI: 10.1021/jm4011669</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4011669" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yls7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3623-3650&issue=9&author=M.+de%0ALera+Ruizauthor=Y.-H.+Limauthor=J.+Zheng&title=Adenosine+A2A+receptor+as+a+drug+discovery+target&doi=10.1021%2Fjm4011669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor as a Drug Discovery Target</span></div><div class="casAuthors">de Lera Ruiz, Manuel; Lim, Yeon-Hee; Zheng, Junying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3623-3650</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The adenosine A2A receptor is a G-protein-coupled receptor (GPCR) that has been extensively studied during the past few decades because it offers numerous possibilities for therapeutic applications.  Herein the authors describe adenosine A2A receptor distribution, signaling pathways, pharmacol., and mol. structure, followed by a summary and SAR discussion of the most relevant series of adenosine A2A agonists and antagonists.  This review also provides an update of the A2A ligands that are undergoing or have undergone clin. studies, including the two currently marketed agonists adenosine and regadenoson.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQUPGC7zBCkbVg90H21EOLACvtfcHk0lgA7fgyMgctXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yls7bJ&md5=846641d1ac3ad16b6335af6b4df15f08</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm4011669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4011669%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLera%2BRuiz%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DY.-H.%26aulast%3DZheng%26aufirst%3DJ.%26atitle%3DAdenosine%2520A2A%2520receptor%2520as%2520a%2520drug%2520discovery%2520target%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D9%26spage%3D3623%26epage%3D3650%26doi%3D10.1021%2Fjm4011669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louvel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adlere, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huisman, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijksteel, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenselink, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">5′-Substituted amiloride derivatives as allosteric modulators binding in the sodium ion pocket of the adenosine A2A receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4769</span>– <span class="NLM_lpage">4777</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00142</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00142" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFSis7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4769-4777&issue=10&author=A.+Massinkauthor=J.+Louvelauthor=I.+Adlereauthor=C.+van+Veenauthor=B.+J.+Huismanauthor=G.+S.+Dijksteelauthor=D.+Guoauthor=E.+B.+Lenselinkauthor=B.+J.+Buckleyauthor=H.+Matthewsauthor=M.+Ransonauthor=M.+Kelsoauthor=A.+P.+Ijzerman&title=5%E2%80%B2-Substituted+amiloride+derivatives+as+allosteric+modulators+binding+in+the+sodium+ion+pocket+of+the+adenosine+A2A+receptor&doi=10.1021%2Facs.jmedchem.6b00142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">5'-Substituted Amiloride Derivatives as Allosteric Modulators Binding in the Sodium Ion Pocket of the Adenosine A2A Receptor</span></div><div class="casAuthors">Massink, Arnault; Louvel, Julien; Adlere, Ilze; van Veen, Corine; Huisman, Berend J. H.; Dijksteel, Gabrielle S.; Guo, Dong; Lenselink, Eelke B.; Buckley, Benjamin J.; Matthews, Hayden; Ranson, Marie; Kelso, Michael; IJzerman, Adriaan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4769-4777</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The sodium ion site is an allosteric site conserved among many G protein-coupled receptors (GPCRs).  Amiloride and 5-(N,N-hexamethylene)amiloride (HMA) supposedly bind in this sodium ion site and can influence orthosteric ligand binding.  The availability of a high-resoln. X-ray crystal structure of the human adenosine A2A receptor (hA2AAR), in which the allosteric sodium ion site was elucidated, makes it an appropriate model receptor for investigating the allosteric site.  In this study, we report the synthesis and evaluation of novel 5'-substituted amiloride derivs. as hA2AAR allosteric antagonists.  The potency of the amiloride derivs. was assessed by their ability to displace orthosteric radioligand [3H]4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a]-[1,3,5]triazin-5-yl)amino)ethyl)phenol ([3H]ZM-241,385) from both the wild-type and sodium ion site W246A mutant hA2AAR. 4-Ethoxyphenethyl-substituted amiloride I was found to be more potent than both amiloride and HMA, and the shift in potency between the wild-type and mutated receptor confirmed its likely binding to the sodium ion site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCrEOabCZ6y7Vg90H21EOLACvtfcHk0lhVuKECZ_HS0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFSis7w%253D&md5=b6001778532001e01718898c3e527720</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00142%26sid%3Dliteratum%253Aachs%26aulast%3DMassink%26aufirst%3DA.%26aulast%3DLouvel%26aufirst%3DJ.%26aulast%3DAdlere%26aufirst%3DI.%26aulast%3Dvan%2BVeen%26aufirst%3DC.%26aulast%3DHuisman%26aufirst%3DB.%2BJ.%26aulast%3DDijksteel%26aufirst%3DG.%2BS.%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DLenselink%26aufirst%3DE.%2BB.%26aulast%3DBuckley%26aufirst%3DB.%2BJ.%26aulast%3DMatthews%26aufirst%3DH.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DKelso%26aufirst%3DM.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26atitle%3D5%25E2%2580%25B2-Substituted%2520amiloride%2520derivatives%2520as%2520allosteric%2520modulators%2520binding%2520in%2520the%2520sodium%2520ion%2520pocket%2520of%2520the%2520adenosine%2520A2A%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D10%26spage%3D4769%26epage%3D4777%26doi%3D10.1021%2Facs.jmedchem.6b00142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klinghofer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGonigal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarthy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nienaber, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorwin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockway, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulkower, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span> <span> </span><span class="NLM_article-title">Species specificity of amidine-based urokinase inhibitors</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">31</span>),  <span class="NLM_fpage">9125</span>– <span class="NLM_lpage">9131</span>, <span class="refDoi"> DOI: 10.1021/bi010186u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi010186u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=9125-9131&issue=31&author=V.+Klinghoferauthor=K.+Stewartauthor=T.+McGonigalauthor=R.+Smithauthor=A.+Sarthyauthor=V.+Nienaberauthor=C.+Butlerauthor=S.+Dorwinauthor=P.+Richardsonauthor=M.+Weitzbergauthor=M.+Wendtauthor=T.+Rockwayauthor=X.+Zhaoauthor=K.+I.+Hulkowerauthor=V.+L.+Giranda&title=Species+specificity+of+amidine-based+urokinase+inhibitors&doi=10.1021%2Fbi010186u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fbi010186u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi010186u%26sid%3Dliteratum%253Aachs%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DMcGonigal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DSarthy%26aufirst%3DA.%26aulast%3DNienaber%26aufirst%3DV.%26aulast%3DButler%26aufirst%3DC.%26aulast%3DDorwin%26aufirst%3DS.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DWeitzberg%26aufirst%3DM.%26aulast%3DWendt%26aufirst%3DM.%26aulast%3DRockway%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DHulkower%26aufirst%3DK.%2BI.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DSpecies%2520specificity%2520of%2520amidine-based%2520urokinase%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2001%26volume%3D40%26issue%3D31%26spage%3D9125%26epage%3D9131%26doi%3D10.1021%2Fbi010186u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McNay, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oran, E.</span></span> <span> </span><span class="NLM_article-title">Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)</span>. <i>Metab., Clin. Exp.</i> <span class="NLM_year" style="font-weight: bold;">1970</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/0026-0495(70)90118-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2F0026-0495%2870%2990118-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=5410663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaE3cXhtF2qu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1970&pages=58-70&issue=1&author=J.+L.+McNayauthor=E.+Oran&title=Possible+predisposition+of+diabetic+patients+to+hyperkalemia+following+administration+of+potassium-retaining+diuretic%2C+amiloride+%28MK+870%29&doi=10.1016%2F0026-0495%2870%2990118-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)</span></div><div class="casAuthors">McNay, John L.; Oran, Erdogan</div><div class="citationInfo"><span class="NLM_cas:title">Metabolism, Clinical and Experimental</span>
        (<span class="NLM_cas:date">1970</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-70</span>CODEN:
                <span class="NLM_cas:coden">METAAJ</span>;
        ISSN:<span class="NLM_cas:issn">0026-0495</span>.
    </div><div class="casAbstract">During the course of a study of the K-retaining diuretic amiloride (MK 870) as an agent for the therapy of mild hypertension accompanied by diabetes mellitus, 2 of 4 glycosuric patients developed serum K concns. of 6.3 mequiv/l. or greater, a 3rd glycosuric patients showed an increase of 1.1 mequiv K/l., and 2 patients with mildly depressed oral glucose tolerance showed increases of 1.5 and 0.4 mequiv K/l.  Generally, the hyperkalemia was accompanied by lowered serum Na.  In contrast 1 normal subject showed no change in serum K and a 2nd control showed an increase of only 0.3 mequiv/l.  During i.v. glucose tolerance tests without amiloride the 2 control subjects and the 2 patients with abnormal oral glucose tolerance tests showed the expected decrease in serum K levels; however, 2 of those with glycosuria developed increases in serum K, 1 showed no change, and 1 showed a decline.  When the glucose tolerance test was done during amiloride therapy, serum K increased in 7 of these 8 subjects, including the 4 with glycosuria.  The hyperkalemia was not clearly assocd. with impaired renal function or excessive K retention.  Diabetic patients may have an abnormality of electrolyte homeostasis which predisposes them to hyperkalemia during administration of K-retaining diuretics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkchNlzXY6frVg90H21EOLACvtfcHk0lhVuKECZ_HS0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3cXhtF2qu7Y%253D&md5=85d2df4265c0b41bc20beb6d03f6faeb</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2F0026-0495%2870%2990118-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0026-0495%252870%252990118-6%26sid%3Dliteratum%253Aachs%26aulast%3DMcNay%26aufirst%3DJ.%2BL.%26aulast%3DOran%26aufirst%3DE.%26atitle%3DPossible%2520predisposition%2520of%2520diabetic%2520patients%2520to%2520hyperkalemia%2520following%2520administration%2520of%2520potassium-retaining%2520diuretic%252C%2520amiloride%2520%2528MK%2520870%2529%26jtitle%3DMetab.%252C%2520Clin.%2520Exp.%26date%3D1970%26volume%3D19%26issue%3D1%26spage%3D58%26epage%3D70%26doi%3D10.1016%2F0026-0495%2870%2990118-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baer, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, H. F.</span></span> <span> </span><span class="NLM_article-title">The potassium-sparing and natriuretic activity of N-amidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride dihydrate (amiloride hydrochloride)</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>157</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">472</span>– <span class="NLM_lpage">485</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=6039836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaF2sXksFamtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=1967&pages=472-485&issue=2&author=J.+E.+Baerauthor=C.+B.+Jonesauthor=S.+A.+Spitzerauthor=H.+F.+Russo&title=The+potassium-sparing+and+natriuretic+activity+of+N-amidino-3%2C5-diamino-6-chloropyrazinecarboxamide+hydrochloride+dihydrate+%28amiloride+hydrochloride%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Potassium-sparing and natriuretic activity of N-amidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride dihydrate (amiloride hydrochloride)</span></div><div class="casAuthors">Baer, John E.; Jones, C. B.; Spitzer, S. A.; Russo, H. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">472-85</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">N-Amidino-3-amino-6-chloropyrazinecarboxamide enhanced Na+ excretion and decreased K+ excretion in normal and adrenalectomized rats (Glitzer and Steelman, CA 64:4135c.  The 5-dimethylamino and 5-amino analogs are 3 and 15 times as potent natriuretics orally in normal rats.  The latter (amiloride) markedly enhanced Na+ excretion and depressed K+ excretion in acetazolamide- or hydrochlorothiazide-treated rats.  An i.v. dose of 1.0 mg./kg. of amiloride in dogs gave a modest (170 microequivs./min.) but sustained (up to 4 hrs.) natriuresis; in KCl- or thiazide-treated dogs, K+ excretion was inhibited by amiloride.  Orally, amiloride increased Na+ (but not K+) excretion at 0.016 to 4.0 mg./kg. in dogs; esp. at the higher doses, the action lasted more than 6 hrs.  Amiloride was slowly excreted unchanged by rat, dog, and man.  Stop-flow studies showed that amiloride increased concn. of Na+ and decreased K+ and pH of distal tubular samples, with no change in Cl-.  The mode of the K+-sparing action appears to differ from those of the aldosterone antagonists or organomercurial diuretics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgxDAb-ITQcrVg90H21EOLACvtfcHk0lhVuKECZ_HS0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXksFamtLo%253D&md5=128f5415a68cd364b72a1afddf04abb9</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaer%26aufirst%3DJ.%2BE.%26aulast%3DJones%26aufirst%3DC.%2BB.%26aulast%3DSpitzer%26aufirst%3DS.%2BA.%26aulast%3DRusso%26aufirst%3DH.%2BF.%26atitle%3DThe%2520potassium-sparing%2520and%2520natriuretic%2520activity%2520of%2520N-amidino-3%252C5-diamino-6-chloropyrazinecarboxamide%2520hydrochloride%2520dihydrate%2520%2528amiloride%2520hydrochloride%2529%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1967%26volume%3D157%26issue%3D2%26spage%3D472%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">65</a></strong><div class="note"><p class="first last">Comprehensive pharmacokinetic profiling of compounds <b>18</b> and <b>26</b> will be reported elsewhere.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uhland, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siphos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetzer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweinitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetzer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van De Locht, A.</span></span> <span> </span><span class="NLM_article-title">Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.3892/ijo_00000346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.3892%2Fijo_00000346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=19578749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt12qtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=347-357&issue=2&author=K.+Uhlandauthor=B.+Siphosauthor=C.+Arkonaauthor=M.+Schusterauthor=B.+Petriauthor=P.+Steinmetzerauthor=F.+Muellerauthor=A.+Schweinitzauthor=T.+Steinmetzerauthor=A.+Van+De+Locht&title=Use+of+IHC+and+newly+designed+matriptase+inhibitors+to+elucidate+the+role+of+matriptase+in+pancreatic+ductal+adenocarcinoma&doi=10.3892%2Fijo_00000346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma</span></div><div class="casAuthors">Uhland, Kerstin; Siphos, Bence; Arkona, Christoph; Schuster, Maj; Petri, Bernhard; Steinmetzer, Peter; Mueller, Friedemann; Schweinitz, Andrea; Steinmetzer, Torsten; Van De Locht, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">347-357</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">Matriptase, also known as MT-SP1, is a type II transmembrane serine protease strongly implicated in both the development and progression of a variety of epithelial cancers.  Evidence comes from studies of its expression in human cancers and from mouse models of spontaneous cancer.  Matriptase is considered to be a major activator of two key stimulators of invasive growth, namely hepatocyte growth factor/scatter factor and urokinase-type plasminogen activator.  The aim of this study was to examine the role of matriptase in pancreatic ductal adenocarcinoma by expression anal. and functional assays in vitro.  Immunohistochem. anal. of matriptase performed on microtissue arrays and large samples of 55 pancreatic ductal adenocarcinomas and on 31 samples of normal pancreatic ducts revealed that although matriptase expression differed greatly in both malignant and normal ductal pancreatic tissue, matriptase scores were significantly (p = 0.02) elevated in pancreatic ductal adenocarcinoma compared to normal pancreatic ducts.  To evaluate the role of matriptase during development of pancreatic cancer, we studied the effects of newly designed matriptase inhibitors on the processing of the zymogen of urokinase-type plasminogen activator in the human adenocarcinoma cell lines AsPC-1 and BxPC-3.  In both cell lines, at 1 μM, all matriptase inhibitors completely prevented zymogen activation.  At lower inhibitor concns., the degree of inhibition of zymogen processing correlated with the affinities of the inhibitors towards matriptase indicating that this is a specific result of matriptase inhibition.  Furthermore, matriptase inhibitors reduced the phosphorylation of the HGF receptor/cMet and the overall cellular invasiveness of the human pancreatic adenocarcinoma cell line AsPC-1.  Our findings demonstrate for the first time that matriptase may be involved in the progression of pancreatic ductal adenocarcinoma and that matriptase inhibition may contribute to preventing the progression of this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3QUvu884Z37Vg90H21EOLACvtfcHk0liTLpWVMMqq8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt12qtbo%253D&md5=a857615f1ca9207d8f2ce884d7ae0b6a</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.3892%2Fijo_00000346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo_00000346%26sid%3Dliteratum%253Aachs%26aulast%3DUhland%26aufirst%3DK.%26aulast%3DSiphos%26aufirst%3DB.%26aulast%3DArkona%26aufirst%3DC.%26aulast%3DSchuster%26aufirst%3DM.%26aulast%3DPetri%26aufirst%3DB.%26aulast%3DSteinmetzer%26aufirst%3DP.%26aulast%3DMueller%26aufirst%3DF.%26aulast%3DSchweinitz%26aufirst%3DA.%26aulast%3DSteinmetzer%26aufirst%3DT.%26aulast%3DVan%2BDe%2BLocht%26aufirst%3DA.%26atitle%3DUse%2520of%2520IHC%2520and%2520newly%2520designed%2520matriptase%2520inhibitors%2520to%2520elucidate%2520the%2520role%2520of%2520matriptase%2520in%2520pancreatic%2520ductal%2520adenocarcinoma%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2009%26volume%3D35%26issue%3D2%26spage%3D347%26epage%3D357%26doi%3D10.3892%2Fijo_00000346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pothula, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biankin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirola, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apte, M. V.</span></span> <span> </span><span class="NLM_article-title">Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1038/bjc.2015.478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1038%2Fbjc.2015.478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=26766740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlKrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2016&pages=269-280&issue=3&author=S.+P.+Pothulaauthor=Z.+Xuauthor=D.+Goldsteinauthor=A.+V.+Biankinauthor=R.+C.+Pirolaauthor=J.+S.+Wilsonauthor=M.+V.+Apte&title=Hepatocyte+growth+factor+inhibition%3A+a+novel+therapeutic+approach+in+pancreatic+cancer&doi=10.1038%2Fbjc.2015.478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer</span></div><div class="casAuthors">Pothula, Srinivasa P.; Xu, Zhihong; Goldstein, David; Biankin, Andrew V.; Pirola, Romano C.; Wilson, Jeremy S.; Apte, Minoti V.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-280</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Pancreatic stellate cells (PSCs, which produce the stroma of pancreatic cancer (PC)) interact with cancer cells to facilitate PC growth.  A candidate growth factor pathway that may mediate this interaction is the HGF-c-MET pathway.  Methods: Effects of HGF inhibition (using a neutralizing antibody AMG102) alone or in combination with gemcitabine were assessed (i) in vivo using an orthotopic model of PC, and (ii) in vitro using cultured PC cells (AsPC-1) and human PSCs.  Results: We have shown that human PSCs (hPSCs) secrete HGF but do not express the receptor c-MET, which is present predominantly on cancer cells.  HGF inhibition was as effective as std. chemotherapy in inhibiting local tumor growth but was significantly more effective than gemcitabine in reducing tumor angiogenesis and metastasis.  HGF inhibition has resulted in reduced metastasis; however, interestingly this antimetastatic effect was lost when combined with gemcitabine.  This suggests that gemcitabine treatment selects out a subpopulation of cancer cells with increased epithelial-mesenchymal transition (EMT) and stem-cell characteristics, as supported by our findings of increased expression of EMT and stem-cell markers in tumor sections from our animal model.  In vitro studies showed that hPSC secretions induced proliferation and migration, but inhibited apoptosis, of cancer cells.  These effects were countered by pretreatment of hPSC secretions with a HGF-neutralising antibody but not by gemcitabine, indicating a key role for HGF in PSC-PC interactions.  Conclusions: Our studies suggest that targeted therapy to inhibit stromal-tumor interactions mediated by the HGF-c-MET pathway may represent a novel therapeutic approach in PC that will require careful modeling for optimal integration with existing treatment modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp40eRpjECkgLVg90H21EOLACvtfcHk0liTLpWVMMqq8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlKrsbY%253D&md5=a71d32e4e7c31104116559844f174423</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2015.478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2015.478%26sid%3Dliteratum%253Aachs%26aulast%3DPothula%26aufirst%3DS.%2BP.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DGoldstein%26aufirst%3DD.%26aulast%3DBiankin%26aufirst%3DA.%2BV.%26aulast%3DPirola%26aufirst%3DR.%2BC.%26aulast%3DWilson%26aufirst%3DJ.%2BS.%26aulast%3DApte%26aufirst%3DM.%2BV.%26atitle%3DHepatocyte%2520growth%2520factor%2520inhibition%253A%2520a%2520novel%2520therapeutic%2520approach%2520in%2520pancreatic%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2016%26volume%3D114%26issue%3D3%26spage%3D269%26epage%3D280%26doi%3D10.1038%2Fbjc.2015.478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikishkin, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huskens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verboom, W.</span></span> <span> </span><span class="NLM_article-title">Transition metal-catalyzed functionalization of pyrazines</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">3583</span>– <span class="NLM_lpage">3602</span>, <span class="refDoi"> DOI: 10.1039/c3ob40460a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1039%2Fc3ob40460a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=3583-3602&issue=22&author=N.+I.+Nikishkinauthor=J.+Huskensauthor=W.+Verboom&title=Transition+metal-catalyzed+functionalization+of+pyrazines&doi=10.1039%2Fc3ob40460a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1039%2Fc3ob40460a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3ob40460a%26sid%3Dliteratum%253Aachs%26aulast%3DNikishkin%26aufirst%3DN.%2BI.%26aulast%3DHuskens%26aufirst%3DJ.%26aulast%3DVerboom%26aufirst%3DW.%26atitle%3DTransition%2520metal-catalyzed%2520functionalization%2520of%2520pyrazines%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2013%26volume%3D11%26issue%3D22%26spage%3D3583%26epage%3D3602%26doi%3D10.1039%2Fc3ob40460a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chessell, I.
P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, P. P.</span></span> <span> </span><span class="NLM_article-title">Properties of the pore-forming P2 × 7 purinoceptor in mouse NTW8 microglial cells</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1429</span>– <span class="NLM_lpage">1437</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0701278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1038%2Fsj.bjp.0701278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=9257924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaK2sXlt1Wjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=1997&pages=1429-1437&issue=7&author=I.%0AP.+Chessellauthor=A.+D.+Michelauthor=P.+P.+Humphrey&title=Properties+of+the+pore-forming+P2+%C3%97+7+purinoceptor+in+mouse+NTW8+microglial+cells&doi=10.1038%2Fsj.bjp.0701278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Properties of the pore-forming P2X7 purinoceptor in mouse NTW8 microglial cells</span></div><div class="casAuthors">Chessell, I.P.; Michel, A.D.; Humphrey, P.P.A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1429-1437</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">The authors have used whole-cell patch clamping methods to study and characterize the cytolytic P2X7 (P2Z) receptor in the NTW8 mouse microglial cell line.  At room temp., in an extracellular soln. contg. 2 mM Ca2+ and 1 mM Mg2+, 2'- and 3'-O-(4-benzoylbenzoyl)-adenosine-5'-triphosphate (Bz-ATP; 300 μM), or ATP (3 mM), evoked peak whole cell inward currents, at a holding potential of -90 mV, of 549 and 644 pA, resp.  Current-voltage relationships generated with 3 mM ATP reversed at 4.6 mV and did not display strong rectification.  In an extracellular soln. contg. zero Mg2+ and 500 μM Ca2+ (low divalent soln.), brief (0.5 s) application of these agonists elicited larger maximal currents (909 and 1818 pA, Bz-ATP and ATP, resp.).  Longer application of ATP (1 mM for 30 s) produced larger, slowly developing, currents which reached a plateau after approx. 15-20 s and were reversible on washing.  Under these conditions, in the presence of ATP, ethidium bromide uptake could be demonstrated.  Further applications of 1 mM ATP produced rapid currents of the same magnitude as those obsd. during the 30 s application.  Subsequent detn. of concn.-effect curves to Bz-ATP, ATP and 2-methylthio-ATP yielded EC50 values of 58.3, 298 and 505 μM, resp.  These affects of ATP were antagonized by pyridoxal-phosphate-6-azophenyl- 2',4'-disulfonic acid (PPADS; 30 μM) but not suramin (100 μM).  In low divalent soln., repeated application of 1 mM ATP for 1 s produced successively larger currents which reached a plateau, after 8 applications, of 466% of the first application current.  PPADS (30 μM) prevented this augmentation, while 5-(N,N-hexamethylene)-amiloride (HMA) (100 μM) accelerated it such that maximal augmentation was obsd. after only one application of ATP in the presence of HMA.  At a bath temp. of 32°, current augmentation also occurred in normal divalent cation contg. soln.  These data demonstrate that mouse microglial NTW8 cells possess a purinoceptor with pharmacol. characteristics resembling the P2X, receptor.  The authors suggest that the current augmentation phenomenon obsd. reflects formation of the large cytolytic pore characteristic of this receptor.  The authors have demonstrated that pore formation can occur under normal physiol. conditions and can be modulated pharmacol., both pos. and neg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzcIn44XVAubVg90H21EOLACvtfcHk0lip_0sB_0jwdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlt1Wjtrw%253D&md5=6fae33db137981f78c45e34e9470dfb7</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0701278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0701278%26sid%3Dliteratum%253Aachs%26aulast%3DChessell%26aufirst%3DI.%2BP.%26aulast%3DMichel%26aufirst%3DA.%2BD.%26aulast%3DHumphrey%26aufirst%3DP.%2BP.%26atitle%3DProperties%2520of%2520the%2520pore-forming%2520P2%2520%25C3%2597%25207%2520purinoceptor%2520in%2520mouse%2520NTW8%2520microglial%2520cells%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D121%26issue%3D7%26spage%3D1429%26epage%3D1437%26doi%3D10.1038%2Fsj.bjp.0701278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amith, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fliegel, L.</span></span> <span> </span><span class="NLM_article-title">KR-33028, a potent inhibitor of the Na(+)/H(+) exchanger NHE1, suppresses metastatic potential of triple-negative breast cancer cells</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2016.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.bcp.2016.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=27521504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtleisr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2016&pages=31-39&author=S.+R.+Amithauthor=J.+M.+Wilkinsonauthor=L.+Fliegel&title=KR-33028%2C+a+potent+inhibitor+of+the+Na%28%2B%29%2FH%28%2B%29+exchanger+NHE1%2C+suppresses+metastatic+potential+of+triple-negative+breast+cancer+cells&doi=10.1016%2Fj.bcp.2016.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">KR-33028, a potent inhibitor of the Na+/H+ exchanger NHE1, suppresses metastatic potential of triple-negative breast cancer cells</span></div><div class="casAuthors">Amith, Schammim Ray; Wilkinson, Jodi Marie; Fliegel, Larry</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-39</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hyper-activation of the Na+/H+ exchanger NHE1 occurs at the onset of oncogenic transformation and plays a crit. role in breast cancer carcinogenesis.  Dysregulation of NHE1 activity results in intracellular alkalinization and the acidification of the extracellular tumor microenvironment that promotes metastasis.  Hence, the use of chem. inhibitors of NHE1 as chemotherapeutic agents is an alluring prospect.  We previously demonstrated that two structurally different NHE1 inhibitors, EMD87580 [(2-methyl-4,5-di-(methylsulfonyl)-benzoyl)-guanidine], and HMA [5-(N,N-hexamethylene)-amiloride], were effective as co-adjuvants to potentiate paclitaxel-mediated cytotoxic chemotherapy in triple-neg. breast cancer (TNBC) cells.  Both these drugs, however, had reduced or minimal anti-cancer effects when used alone.  Here, we tested KR-33028 (4-cyano (benzo[b]thiophene-2-carbonyl)guanidine), a potent and selective inhibitor of NHE1, to det. its efficacy in inhibition of metastatic potential of TNBC cells.  In highly invasive MDA-MB-231, moderately invasive MDA-MB-468, and lowly invasive Hs578T TNBC cells, KR-33028 considerably reduced rates of cell migration and anchorage-independent colony growth.  Invasion of MDA-MB-231 and MDA-MB-468 cells through extracellular matrix was also dramatically decreased in response to KR-33028.  We further tested the effect of KR-33028 on MDA-MB-231 cells lacking NHE1 expression (231koNHE1); no differences were obsd. between untreated control and KR-33028-treated 231koNHE1 cells.  Taken together, our results highlight the in vitro efficacy of KR-33028-mediated NHE1 inhibition on limiting cellular functions that are predictive of metastasis in vivo.  We suggest that targeting NHE1 in the development of novel chemotherapeutics could be highly effective in combating triple-neg. breast cancer and that KR-33028 is potentially useful in prevention of metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5F9yBhpgG87Vg90H21EOLACvtfcHk0lip_0sB_0jwdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtleisr3F&md5=12416b156b9e1e32cfdc604327c4112c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2016.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2016.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DAmith%26aufirst%3DS.%2BR.%26aulast%3DWilkinson%26aufirst%3DJ.%2BM.%26aulast%3DFliegel%26aufirst%3DL.%26atitle%3DKR-33028%252C%2520a%2520potent%2520inhibitor%2520of%2520the%2520Na%2528%252B%2529%252FH%2528%252B%2529%2520exchanger%2520NHE1%252C%2520suppresses%2520metastatic%2520potential%2520of%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2016%26volume%3D118%26spage%3D31%26epage%3D39%26doi%3D10.1016%2Fj.bcp.2016.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casarotto, M. G.</span></span> <span> </span><span class="NLM_article-title">Probing interactions of Vpu from HIV-1 with amiloride-based compounds</span>. <i>Biochim. Biophys. Acta, Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1858</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1016/j.bbamem.2015.12.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.bbamem.2015.12.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=26724207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1858&publication_year=2016&pages=733-739&issue=4&author=M.+R.+Rosenbergauthor=L.+M.+Weaverauthor=M.+G.+Casarotto&title=Probing+interactions+of+Vpu+from+HIV-1+with+amiloride-based+compounds&doi=10.1016%2Fj.bbamem.2015.12.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Probing interactions of Vpu from HIV-1 with amiloride-based compounds</span></div><div class="casAuthors">Rosenberg, Matthew R.; Weaver, Llara M.; Casarotto, Marco G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1858</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-739</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Viral ion channels or viroporins are short membrane proteins that participate in wide-ranging functions including virus replication and entry, assembly, and virus release.  One such viroporin is the 81 amino acid residue Vpu protein derived from HIV-1.  This protein consists of one transmembrane (TM) and two cytoplasmic helical domains, the former of which oligomerises to form cation-selective ion channels.  In this study, we investigate the binding properties of amiloride compds. to Vpu embedded into liposomes using surface plasmon resonance (SPR).  We explore the Vpu ion channel inhibitor, hexamethylene amiloride (HMA), as a mol. tool to examine the potential interactive role of key TM residues, Trp23, Ser24, and Glu29, in terms of positioning of these residues on the channel pore and the orientation of its constituent helixes.  The study provides exptl. support that a direct interaction between Ser24 and HMA occurs and that this residue is most likely located in the channel pore.  Mutation of Trp23 does not impact HMA affinity suggesting no direct involvement in binding and that this residue is lipid facing.  These findings indicate that small mols. such as amilorides are capable of specifically interacting with Vpu ion channels.  Although a correlation between ion channel and functional activity cannot be dismissed, alternative mechanisms involving protein-protein interactions may play an important role in the efficacy of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa6CgQ784t_LVg90H21EOLACvtfcHk0lip_0sB_0jwdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaruw%253D%253D&md5=dd3419c47e8e25f0dd7924ab0e0f5219</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2015.12.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2015.12.028%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DM.%2BR.%26aulast%3DWeaver%26aufirst%3DL.%2BM.%26aulast%3DCasarotto%26aufirst%3DM.%2BG.%26atitle%3DProbing%2520interactions%2520of%2520Vpu%2520from%2520HIV-1%2520with%2520amiloride-based%2520compounds%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2016%26volume%3D1858%26issue%3D4%26spage%3D733%26epage%3D739%26doi%3D10.1016%2Fj.bbamem.2015.12.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jalily, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldstrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, S. S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niikura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tietjen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedida, D.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of action of novel influenza A/M2 viroporin inhibitors derived from hexamethylene amiloride</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1124/mol.115.102731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1124%2Fmol.115.102731" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=80-95&issue=2&author=P.+H.+Jalilyauthor=J.+Eldstromauthor=S.+C.+Millerauthor=D.+C.+Kwanauthor=S.+S.-H.+Taiauthor=D.+Chouauthor=M.+Niikuraauthor=I.+Tietjenauthor=D.+Fedida&title=Mechanisms+of+action+of+novel+influenza+A%2FM2+viroporin+inhibitors+derived+from+hexamethylene+amiloride&doi=10.1124%2Fmol.115.102731"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.102731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.102731%26sid%3Dliteratum%253Aachs%26aulast%3DJalily%26aufirst%3DP.%2BH.%26aulast%3DEldstrom%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DS.%2BC.%26aulast%3DKwan%26aufirst%3DD.%2BC.%26aulast%3DTai%26aufirst%3DS.%2BS.-H.%26aulast%3DChou%26aufirst%3DD.%26aulast%3DNiikura%26aufirst%3DM.%26aulast%3DTietjen%26aufirst%3DI.%26aulast%3DFedida%26aufirst%3DD.%26atitle%3DMechanisms%2520of%2520action%2520of%2520novel%2520influenza%2520A%252FM2%2520viroporin%2520inhibitors%2520derived%2520from%2520hexamethylene%2520amiloride%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D90%26issue%3D2%26spage%3D80%26epage%3D95%26doi%3D10.1124%2Fmol.115.102731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oosterom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1808</span>– <span class="NLM_lpage">1815</span>, <span class="refDoi"> DOI: 10.1124/mol.107.043521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1124%2Fmol.107.043521" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=1808-1815&issue=6&author=L.+H.+Heitmanauthor=K.+Yeauthor=J.+Oosteromauthor=A.+P.+Ijzerman&title=Amiloride+derivatives+and+a+nonpeptidic+antagonist+bind+at+two+distinct+allosteric+sites+in+the+human+gonadotropin-releasing+hormone+receptor&doi=10.1124%2Fmol.107.043521"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.043521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.043521%26sid%3Dliteratum%253Aachs%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DYe%26aufirst%3DK.%26aulast%3DOosterom%26aufirst%3DJ.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26atitle%3DAmiloride%2520derivatives%2520and%2520a%2520nonpeptidic%2520antagonist%2520bind%2520at%2520two%2520distinct%2520allosteric%2520sites%2520in%2520the%2520human%2520gonadotropin-releasing%2520hormone%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D73%26issue%3D6%26spage%3D1808%26epage%3D1815%26doi%3D10.1124%2Fmol.107.043521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Snell, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, E. B.</span></span> <span> </span><span class="NLM_article-title">5-(N, N-Hexamethylene) amiloride is a GABA-A ρ1 receptor positive allosteric modulator</span>. <i>Channels</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">498</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1080/19336950.2016.1207021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1080%2F19336950.2016.1207021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=498-506&issue=6&author=H.+D.+Snellauthor=E.+B.+Gonzales&title=5-%28N%2C+N-Hexamethylene%29+amiloride+is+a+GABA-A+%CF%811+receptor+positive+allosteric+modulator&doi=10.1080%2F19336950.2016.1207021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1080%2F19336950.2016.1207021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F19336950.2016.1207021%26sid%3Dliteratum%253Aachs%26aulast%3DSnell%26aufirst%3DH.%2BD.%26aulast%3DGonzales%26aufirst%3DE.%2BB.%26atitle%3D5-%2528N%252C%2520N-Hexamethylene%2529%2520amiloride%2520is%2520a%2520GABA-A%2520%25CF%25811%2520receptor%2520positive%2520allosteric%2520modulator%26jtitle%3DChannels%26date%3D2016%26volume%3D10%26issue%3D6%26spage%3D498%26epage%3D506%26doi%3D10.1080%2F19336950.2016.1207021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leng, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Z. G.</span></span> <span> </span><span class="NLM_article-title">Amiloride analogs as ASIC1a inhibitors</span>. <i>CNS Neurosci. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">468</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1111/cns.12524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1111%2Fcns.12524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=26890278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVCrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=468-476&issue=6&author=T.+D.+Lengauthor=H.+F.+Siauthor=J.+Liauthor=T.+Yangauthor=M.+Zhuauthor=B.+Wangauthor=R.+P.+Simonauthor=Z.+G.+Xiong&title=Amiloride+analogs+as+ASIC1a+inhibitors&doi=10.1111%2Fcns.12524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Amiloride Analogs as ASIC1a Inhibitors</span></div><div class="casAuthors">Leng, Tian-Dong; Si, Hong-Fang; Li, Jun; Yang, Tao; Zhu, Mengyuan; Wang, Binghe; Simon, Roger P.; Xiong, Zhi-Gang</div><div class="citationInfo"><span class="NLM_cas:title">CNS Neuroscience & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">468-476</span>CODEN:
                <span class="NLM_cas:coden">CNTNAB</span>;
        ISSN:<span class="NLM_cas:issn">1755-5930</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : ASIC1a, the predominant acid-sensing ion channels (ASICs), is implicated in neurol. disorders including stroke, traumatic spinal cord injury, and ALS.  Potent ASIC1a inhibitors should have promising therapeutic potential for ASIC1a-related diseases.  Aims : We examd. the inhibitory effects of a no. of amiloride analogs on ASIC1a currents, aimed at understanding the structure-activity relationship and identifying potent ASIC1a inhibitors for stroke intervention.  Methods : Whole-cell patch-clamp techniques and a mouse model of middle cerebral artery occlusion (MCAO)-induced focal ischemia were used.  Surflex-Dock was used to dock the analogs into the pocket with default parameters.  Results : Amiloride and its analogs inhibit ASIC1a currents expressed in Chinese hamster ovary cells with a potency rank order of benzamil > phenamil > 5-(N,N-dimethyl)amiloride (DMA) > amiloride > 5-(N,N-hexamethylene)amiloride (HMA) ≥ 5-(N-methyl-N-isopropyl)amiloride (MIA) > 5-(N-ethyl-N-isopropyl)amiloride (EIPA).  In addn., amiloride and its analogs inhibit ASIC currents in cortical neurons with the same potency rank order.  In mice, benzamil and EIPA decreased MCAO-induced infarct vol.  Similar to its effect on the ASIC current, benzamil showed a much higher potency than EIPA.  Conclusion : Addn. of a benzyl group to the terminal guanidinyl group resulted in enhanced inhibitory activity on ASIC1a.  On the other hand, the bulky groups added to the 5-amino residues slightly decreased the activity.  Among the tested amiloride analogs, benzamil is the most potent ASIC1a inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprvommAdpu37Vg90H21EOLACvtfcHk0lgac9eBVNjulA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVCrtbg%253D&md5=531cb15375f06ef61bf9be7115a3e9b3</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1111%2Fcns.12524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcns.12524%26sid%3Dliteratum%253Aachs%26aulast%3DLeng%26aufirst%3DT.%2BD.%26aulast%3DSi%26aufirst%3DH.%2BF.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DSimon%26aufirst%3DR.%2BP.%26aulast%3DXiong%26aufirst%3DZ.%2BG.%26atitle%3DAmiloride%2520analogs%2520as%2520ASIC1a%2520inhibitors%26jtitle%3DCNS%2520Neurosci.%2520Ther.%26date%3D2016%26volume%3D22%26issue%3D6%26spage%3D468%26epage%3D476%26doi%3D10.1111%2Fcns.12524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, K. B.</span></span> <span> </span><span class="NLM_article-title">Targeting GIRK channels for the development of new therapeutic agents</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">64</span>, <span class="refDoi"> DOI: 10.3389/fphar.2011.00064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.3389%2Ffphar.2011.00064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=22059075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BC38Xis1ahtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=64&author=K.+B.+Walsh&title=Targeting+GIRK+channels+for+the+development+of+new+therapeutic+agents&doi=10.3389%2Ffphar.2011.00064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting GIRK channels for the development of new therapeutic agents</span></div><div class="casAuthors">Walsh, Kenneth B.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology of Ion Channels and Channelopathies</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">Oct.</span>),
    <span class="NLM_cas:pages">64</span>CODEN:
                <span class="NLM_cas:coden">FPICA4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">G protein-coupled inward rectifier K+ (GIRK) channels represent novel targets for the development of new therapeutic agents.  GIRK channels are activated by a large no. of G protein-coupled receptors (GPCRs) and regulate the elec. activity of neurons, cardiac myocytes, and β-pancreatic cells.  Abnormalities in GIRK channel function have been implicated in the patho-physiol. of neuropathic pain, drug addiction, cardiac arrhythmias, and other disorders.  However, the pharmacol. of these channels remains largely unexplored.  In this paper we describe the development of a screening assay for identifying new modulators of neuronal and cardiac GIRK channels.  Pituitary (AtT20) and cardiac (HL-1) cell lines expressing GIRK channels were cultured in 96-well plates, loaded with oxonol membrane potential-sensitive dyes and measured using a fluorescent imaging plate reader.  Activation of the endogenous GPCRs in the cells caused a rapid, time-dependent decrease in the fluorescent signal; indicative of K+ efflux through the GIRK channels (GPCR stimulation vs. control, Z'-factor = 0.5-0.7).  As expected this signal was inhibited by addn. of Ba2+ and the GIRK channel toxin tertiapin-Q.  To test the utility of the assay for screening GIRK channel blockers, cells were incubated for 5 min with a compd. library of Na+ and K+ channel modulators.  Ion transporter inhibitors such as 5-(N,N-hexamethylene)-amiloride and SCH-28080 were identified as blockers of the GIRK channel at sub-micromolar concns.  Thus, the screening assay will be useful for expanding the limited pharmacol. of the GIRK channel and in developing new agents for the treatment of GIRK channelopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxjvoI-loMq7Vg90H21EOLACvtfcHk0lgac9eBVNjulA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xis1ahtA%253D%253D&md5=f0e442266e636d5577e6a1972a6aa52f</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2011.00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2011.00064%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DK.%2BB.%26atitle%3DTargeting%2520GIRK%2520channels%2520for%2520the%2520development%2520of%2520new%2520therapeutic%2520agents%26jtitle%3DFront.%2520Pharmacol.%26date%3D2011%26volume%3D2%26spage%3D64%26doi%3D10.3389%2Ffphar.2011.00064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, G.</span>; <span class="NLM_string-name">Ewart, G.</span>; <span class="NLM_string-name">Gage, P.</span></span> <span> </span><span class="NLM_article-title">A Method of Modulating Ion Channel Functional Activity</span>. PCT Int. Appl. <span class="NLM_patent">WO2000021538 A1</span>, <span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=G.+Cox&author=G.+Ewart&author=P.+Gage&title=A+Method+of+Modulating+Ion+Channel+Functional+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DG.%26atitle%3DA%2520Method%2520of%2520Modulating%2520Ion%2520Channel%2520Functional%2520Activity%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreasen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span> <span> </span><span class="NLM_article-title">Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1</span>. <i>J. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>160</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.jsb.2007.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2Fj.jsb.2007.06.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2007&pages=1-10&issue=1&author=G.+Zhaoauthor=C.+Yuanauthor=T.+Windauthor=Z.+Huangauthor=P.+A.+Andreasenauthor=M.+Huang&title=Structural+basis+of+specificity+of+a+peptidyl+urokinase+inhibitor%2C+upain-1&doi=10.1016%2Fj.jsb.2007.06.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2007.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2007.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DWind%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAndreasen%26aufirst%3DP.%2BA.%26aulast%3DHuang%26aufirst%3DM.%26atitle%3DStructural%2520basis%2520of%2520specificity%2520of%2520a%2520peptidyl%2520urokinase%2520inhibitor%252C%2520upain-1%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2007%26volume%3D160%26issue%3D1%26spage%3D1%26epage%3D10%26doi%3D10.1016%2Fj.jsb.2007.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otwinowski, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minor, W.</span></span> <span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0lgac9eBVNjulA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span> </span><span class="NLM_article-title">The CCP4 suite: Programs for protein crystallography.
Collaborative
Computational Project, Number 4</span>.  <i>Acta Crystallogr.,
Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume">50</span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1107/S0907444994003112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1107%2FS0907444994003112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+CCP4+suite%3A+Programs+for+protein+crystallography.%0ACollaborative%0AComputational+Project%2C+Number+4.+Acta+Crystallogr.%2C%0ASect.+D%3A+Biol.+Crystallogr.+1994%2C+50%2C+760%E2%80%93763%2C+10.1107%2FS0907444994003112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1107%2FS0907444994003112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444994003112%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520CCP4%2520suite%253A%2520Programs%2520for%2520protein%2520crystallography.%250ACollaborative%250AComputational%2520Project%252C%2520Number%25204%26jtitle%3DActa%2520Crystallogr.%252C%250ASect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1994%26volume%3D50%26spage%3D760%26epage%3D763%26doi%3D10.1107%2FS0907444994003112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botkjaer, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreasen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span> <span> </span><span class="NLM_article-title">Rezymogenation of active urokinase induced by an inhibitory antibody</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>449</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1042/BJ20121132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1042%2FBJ20121132" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=449&publication_year=2013&pages=161-166&issue=1&author=L.+Jiangauthor=K.+A.+Botkjaerauthor=L.+M.+Andersenauthor=C.+Yuanauthor=P.+A.+Andreasenauthor=M.+Huang&title=Rezymogenation+of+active+urokinase+induced+by+an+inhibitory+antibody&doi=10.1042%2FBJ20121132"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1042%2FBJ20121132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20121132%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DBotkjaer%26aufirst%3DK.%2BA.%26aulast%3DAndersen%26aufirst%3DL.%2BM.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DAndreasen%26aufirst%3DP.%2BA.%26aulast%3DHuang%26aufirst%3DM.%26atitle%3DRezymogenation%2520of%2520active%2520urokinase%2520induced%2520by%2520an%2520inhibitory%2520antibody%26jtitle%3DBiochem.%2520J.%26date%3D2013%26volume%3D449%26issue%3D1%26spage%3D161%26epage%3D166%26doi%3D10.1042%2FBJ20121132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0lglNhT7W9CPig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echeverri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalabat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laita, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahan, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staszewski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimmich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patron, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, B. D.</span></span> <span> </span><span class="NLM_article-title">Small molecule activator of the human epithelial sodium channel</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">11981</span>– <span class="NLM_lpage">11994</span>, <span class="refDoi"> DOI: 10.1074/jbc.M708001200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.1074%2Fjbc.M708001200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=18326490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltVyrsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=11981-11994&issue=18&author=M.+Luauthor=F.+Echeverriauthor=D.+Kalabatauthor=B.+Laitaauthor=D.+S.+Dahanauthor=R.+D.+Smithauthor=H.+Xuauthor=L.+Staszewskiauthor=J.+Yamamotoauthor=J.+Lingauthor=N.+Hwangauthor=R.+Kimmichauthor=P.+Liauthor=E.+Patronauthor=W.+Keungauthor=A.+Patronauthor=B.+D.+Moyer&title=Small+molecule+activator+of+the+human+epithelial+sodium+channel&doi=10.1074%2Fjbc.M708001200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Activator of the Human Epithelial Sodium Channel</span></div><div class="casAuthors">Lu, Min; Echeverri, Fernando; Kalabat, Dalia; Laita, Bianca; Dahan, David S.; Smith, Raymond D.; Xu, Hong; Staszewski, Lena; Yamamoto, Jeff; Ling, Jing; Hwang, Nancy; Kimmich, Rachel; Li, Peter; Patron, Erika; Keung, Walter; Patron, Andrew; Moyer, Bryan D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">11981-11994</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The epithelial sodium channel (ENaC), a heterotrimeric complex composed of α, β, and γ subunits, belongs to the ENaC/degenerin family of ion channels and forms the principal route for apical Na+ entry in many reabsorbing epithelia.  Although high affinity ENaC blockers, including amiloride and derivs., have been described, potent and specific small mol. ENaC activators have not been reported.  Here we describe compd. S3969 that fully and reversibly activates human ENaC (hENaC) in an amiloride-sensitive and dose-dependent manner in heterologous cells.  Mechanistically, S3969 increases hENaC open probability through interactions requiring the extracellular domain of the β subunit. hENaC activation by S3969 did not require cleavage by the furin protease, indicating that nonproteolyzed channels can be opened.  Function of αβG37Sγ hENaC, a channel defective in gating that leads to the salt-wasting disease pseudohypoaldosteronism type I, was rescued by S3969.  Small mol. activation of hENaC may find application in alleviating human disease, including pseudohypoaldosteronism type I, hypotension, and neonatal respiratory distress syndrome, when improved Na+ flux across epithelial membranes is clin. desirable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfnBYQQrO4z7Vg90H21EOLACvtfcHk0lglNhT7W9CPig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltVyrsrg%253D&md5=02d23ef30f9cb7864e25c9ec8dd76930</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M708001200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M708001200%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DM.%26aulast%3DEcheverri%26aufirst%3DF.%26aulast%3DKalabat%26aufirst%3DD.%26aulast%3DLaita%26aufirst%3DB.%26aulast%3DDahan%26aufirst%3DD.%2BS.%26aulast%3DSmith%26aufirst%3DR.%2BD.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DStaszewski%26aufirst%3DL.%26aulast%3DYamamoto%26aufirst%3DJ.%26aulast%3DLing%26aufirst%3DJ.%26aulast%3DHwang%26aufirst%3DN.%26aulast%3DKimmich%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DPatron%26aufirst%3DE.%26aulast%3DKeung%26aufirst%3DW.%26aulast%3DPatron%26aufirst%3DA.%26aulast%3DMoyer%26aufirst%3DB.%2BD.%26atitle%3DSmall%2520molecule%2520activator%2520of%2520the%2520human%2520epithelial%2520sodium%2520channel%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26issue%3D18%26spage%3D11981%26epage%3D11994%26doi%3D10.1074%2Fjbc.M708001200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonlaufen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiala-Beer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biankin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirola, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apte, M. V.</span></span> <span> </span><span class="NLM_article-title">Role of pancreatic stellate cells in pancreatic cancer metastasis</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>177</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2585</span>– <span class="NLM_lpage">2596</span>, <span class="refDoi"> DOI: 10.2353/ajpath.2010.090899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=10.2353%2Fajpath.2010.090899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=20934972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;key=1%3ACAS%3A280%3ADC%252BC3cbksVejsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2010&pages=2585-2596&issue=5&author=Z.+Xuauthor=A.+Vonlaufenauthor=P.+A.+Phillipsauthor=E.+Fiala-Beerauthor=X.+Zhangauthor=L.+Yangauthor=A.+V.+Biankinauthor=D.+Goldsteinauthor=R.+C.+Pirolaauthor=J.+S.+Wilsonauthor=M.+V.+Apte&title=Role+of+pancreatic+stellate+cells+in+pancreatic+cancer+metastasis&doi=10.2353%2Fajpath.2010.090899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Role of pancreatic stellate cells in pancreatic cancer metastasis</span></div><div class="casAuthors">Xu Zhihong; Vonlaufen Alain; Phillips Phoebe A; Fiala-Beer Eva; Zhang Xuguo; Yang Lu; Biankin Andrew V; Goldstein David; Pirola Romano C; Wilson Jeremy S; Apte Minoti V</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of pathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2585-96</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pancreatic stellate cells (PSCs) produce the stromal reaction in pancreatic cancer (PC), and their interaction with cancer cells facilitates cancer progression.  This study investigated the role of human PSCs (hPSCs) in the metastatic process and tumor angiogenesis using both in vivo (orthotopic model) and in vitro (cultured PSC and PC cells) approaches.  A sex mismatch study (injection of male hPSCs plus female PC cells into the pancreas of female mice) was conducted to determine whether hPSCs accompany cancer cells to metastatic sites.  Metastatic nodules were examined by fluorescent in situ hybridization for the presence of the Y chromosome.  Angiogenesis was assessed by i) immunostaining tumors for CD31, an endothelial cell marker; and ii) quantifying human microvascular endothelial cell (HMEC-1) tube formation in vitro on exposure to conditioned media from hPSCs.  Transendothelial migration was assessed in vitro by examining the movement of fluorescently labeled hPSCs through an endothelial cell monolayer.  Human PSCs i) were found in multiple metastatic sites in each mouse injected with male hPSCs plus female PC cells; ii) increased CD31 expression in primary tumors from mice injected with MiaPaCa-2 and hPSCs and stimulated tube formation by HMEC-1 in vitro; and iii) exhibited transendothelial migration that was stimulated by cancer cells.  Human PSCs accompany cancer cells to metastatic sites, stimulate angiogenesis, and are able to intravasate/extravasate to and from blood vessels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2QMGV98SuTPxQvRxYU81tfW6udTcc2eZBTcWoZXHT_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbksVejsw%253D%253D&md5=89b066c4aabfb4290d1051eefc72921c</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2010.090899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2010.090899%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DVonlaufen%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DP.%2BA.%26aulast%3DFiala-Beer%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DBiankin%26aufirst%3DA.%2BV.%26aulast%3DGoldstein%26aufirst%3DD.%26aulast%3DPirola%26aufirst%3DR.%2BC.%26aulast%3DWilson%26aufirst%3DJ.%2BS.%26aulast%3DApte%26aufirst%3DM.%2BV.%26atitle%3DRole%2520of%2520pancreatic%2520stellate%2520cells%2520in%2520pancreatic%2520cancer%2520metastasis%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2010%26volume%3D177%26issue%3D5%26spage%3D2585%26epage%3D2596%26doi%3D10.2353%2Fajpath.2010.090899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1F5L" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1F5L','PDB','1F5L'); return false;">PDB: 1F5L</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZA7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZA7','PDB','5ZA7'); return false;">PDB: 5ZA7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAE','PDB','5ZAE'); return false;">PDB: 5ZAE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAF','PDB','5ZAF'); return false;">PDB: 5ZAF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZA9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZA9','PDB','5ZA9'); return false;">PDB: 5ZA9</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZC5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZC5','PDB','5ZC5'); return false;">PDB: 5ZC5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAG','PDB','5ZAG'); return false;">PDB: 5ZAG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAH','PDB','5ZAH'); return false;">PDB: 5ZAH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZAJ','PDB','5ZAJ'); return false;">PDB: 5ZAJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZA8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZA8','PDB','5ZA8'); return false;">PDB: 5ZA8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DVA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DVA','PDB','4DVA'); return false;">PDB: 4DVA</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i97"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00838">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_48846"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00838">10.1021/acs.jmedchem.8b00838</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">X-ray crystallography refinement data and statistics, HT-1080 uPA and uPAR expression data, experimental late-stage metastasis model clinical score sheet (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00838/suppl_file/jm8b00838_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of all compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00838/suppl_file/jm8b00838_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00838/suppl_file/jm8b00838_si_001.pdf">jm8b00838_si_001.pdf (1.38 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00838/suppl_file/jm8b00838_si_002.csv">jm8b00838_si_002.csv (4.43 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00838&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-18%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00838%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00838" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                14MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67996ede29d13cc4","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
